%PDF-1.5 1 0 obj <> endobj 3 0 obj <> endobj 4 0 obj <> stream BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 0 rg BT 297.65 42.60 Td (- 1 -) Tj ET Q /GS0 gs q 77.00 0 0 44.00 54.00 694.00 cm /I1 Do Q BT /F1 11.00 Tf ET BT /F2 12.00 Tf ET q 0 0 0 rg BT 162.15 655.15 Td (PFIZER REPOR) Tj ET Q q 0 0 0 rg BT 250.73 655.15 Td (TS ) Tj ET Q BT /F2 12.00 Tf ET q 0 0 0 rg BT 268.41 655.15 Td (FIRST) Tj ET Q q 0 0 0 rg BT 302.65 655.15 Td (-QUAR) Tj ET Q q 0 0 0 rg BT 341.56 655.15 Td (TER) Tj ET Q BT /F2 12.00 Tf ET q 0 0 0 rg BT 366.23 655.15 Td ( ) Tj ET Q BT /F2 12.00 Tf ET q 0 0 0 rg BT 369.23 655.15 Td (2018) Tj ET Q BT /F2 12.00 Tf ET q 0 0 0 rg BT 393.23 655.15 Td ( RESUL) Tj ET Q q 0 0 0 rg BT 435.14 655.15 Td (TS) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 54.00 618.58 cm /I2 Do Q q 0 0 0 rg BT 58.00 620.95 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 72.00 620.95 Td (First-Quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 129.43 620.95 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 132.18 620.95 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 154.18 620.95 Td ( Revenues of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 214.36 620.95 Td ($12.9) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 239.11 620.95 Td ( Billion) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 54.00 593.38 cm /I3 Do Q q 0 0 0 rg BT 58.00 595.75 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 72.00 595.75 Td (First-Quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 129.43 595.75 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 132.18 595.75 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 154.18 595.75 Td ( Reported Diluted EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 254.70 600.73 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 263.03 595.75 Td ( of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 277.70 595.75 Td ($0.59) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 302.45 595.75 Td (, ) Tj ET Q q 0 0 0 rg BT 307.34 595.75 Td (Adjusted Diluted EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 404.51 600.73 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 412.85 595.75 Td ( of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 427.51 595.75 Td ($0.77) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 54.00 568.18 cm /I4 Do Q q 0 0 0 rg BT 58.00 570.55 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 72.00 570.55 Td (Reaf) Tj ET Q q 0 0 0 rg BT 92.57 570.55 Td (firmed ) Tj ET Q q 0 0 0 rg BT 124.03 570.55 Td (All Components of 2018 Financial Guidance) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 530.40 Td (NEW) Tj ET Q q 0 0 0 rg BT 78.85 530.40 Td ( ) Tj ET Q q 0 0 0 rg BT 81.19 530.40 Td (YORK, NY) Tj ET Q q 0 0 0 rg BT 132.33 530.40 Td (, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 137.63 530.40 Td (T) Tj ET Q q 0 0 0 rg BT 143.96 530.40 Td (uesday) Tj ET Q q 0 0 0 rg BT 173.79 530.40 Td (, May1, 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 235.20 530.40 Td ( Pfizer Inc. \(NYSE: PFE\) reported financial results for ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 486.00 530.40 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 538.53 530.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 511.25 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.00 511.25 Td ( and reaf) Tj ET Q q 0 0 0 rg BT 114.27 511.25 Td (firmed all components of 2018 financial guidance.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 486.15 Td (Results for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 120.91 486.15 Td (first quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 172.52 486.15 Td ( of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 187.19 486.15 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 209.19 486.15 Td ( and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 230.57 486.15 Td (2017) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 252.57 491.13 Td (\(3\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 260.91 486.15 Td ( are summarized below) Tj ET Q q 0 0 0 rg BT 362.51 486.15 Td (.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 453.75 Td (OVERALL) Tj ET Q q 0 0 0 rg BT 107.79 453.75 Td ( RESUL) Tj ET Q q 0 0 0 rg BT 146.21 453.75 Td (TS) Tj ET Q 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 447.65 m 174.5 447.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 447.65 m 240.5 447.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 240.5 447.65 m 306.5 447.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 447.65 m 372.5 447.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 423.65 m 240.5 423.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 408.65 m 240.5 408.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 240.5 423.65 m 306.5 423.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 240.5 408.65 m 306.5 408.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 423.65 m 372.5 423.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 408.65 m 372.5 408.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 334.65 m 174.5 334.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 334.65 m 240.5 334.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 240.5 334.65 m 306.5 334.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 334.65 m 372.5 334.65 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 57.00 434.91 Td (\($ in millions, except) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 57.00 425.96 Td (per share amounts\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 246.85 428.32 Td (First-Quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 413.77 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 197.00 413.77 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 263.00 413.77 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 323.70 413.77 Td (Change) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 399.22 Td (Revenues) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 199.15 399.22 Td ($ 12,906) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 265.15 399.22 Td ($ 12,779) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 332.30 399.22 Td (1%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 385.22 Td (Reported Net Income) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 143.08 389.75 Td (\(1\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 214.15 385.22 Td (3,561) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 280.15 385.22 Td (3,121) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 329.80 385.22 Td (14%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 371.22 Td (Reported Diluted EPS) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 145.88 375.75 Td (\(1\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 219.15 371.22 Td (0.59) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.15 371.22 Td (0.51) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 329.80 371.22 Td (15%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 357.22 Td (Adjusted Income) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 125.59 361.75 Td (\(2\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 214.15 357.22 Td (4,668) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 280.15 357.22 Td (4,192) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 329.80 357.22 Td (1) Tj ET Q q 0 0 0 rg BT 334.80 357.22 Td (1%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 343.22 Td (Adjusted Diluted EPS) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 145.33 347.75 Td (\(2\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 219.15 343.22 Td (0.77) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.15 343.22 Td (0.69) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 329.80 343.22 Td (12%) Tj ET Q BT /F1 11.00 Tf ET BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 302.75 Td (REVENUES) Tj ET Q 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 296.65 m 174.5 296.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 296.65 m 224.5 296.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 224.5 296.65 m 274.5 296.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 296.65 m 323.5 296.65 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 296.65 m 372.5 296.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 278.65 m 224.5 278.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 224.5 278.65 m 274.5 278.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 278.65 m 323.5 278.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 265.65 m 323.5 265.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 278.65 m 372.5 278.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 265.65 m 372.5 265.65 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 252.64999999999998 m 224.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 224.5 252.64999999999998 m 274.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 252.64999999999998 m 323.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 252.64999999999998 m 372.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 252.64999999999998 m 224.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 224.5 252.64999999999998 m 274.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 252.64999999999998 m 323.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 252.64999999999998 m 372.5 252.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 226.64999999999998 m 224.5 226.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 224.5 226.64999999999998 m 274.5 226.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 226.64999999999998 m 323.5 226.64999999999998 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 226.64999999999998 m 372.5 226.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 174.5 214.64999999999998 m 224.5 214.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 174.5 212.64999999999998 m 224.5 212.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 224.5 214.64999999999998 m 274.5 214.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 224.5 212.64999999999998 m 274.5 212.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 274.5 214.64999999999998 m 323.5 214.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 274.5 212.64999999999998 m 323.5 212.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 323.5 214.64999999999998 m 372.5 214.64999999999998 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 323.5 212.64999999999998 m 372.5 212.64999999999998 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 209.64999999999998 m 174.5 209.64999999999998 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 174.5 209.64999999999998 m 224.5 209.64999999999998 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 224.5 209.64999999999998 m 274.5 209.64999999999998 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 274.5 209.64999999999998 m 323.5 209.64999999999998 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 323.5 209.64999999999998 m 372.5 209.64999999999998 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 283.22 Td (\($ in millions\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 246.85 283.22 Td (First-Quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 269.22 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 189.00 263.27 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 239.00 263.27 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 302.30 269.22 Td (% Change) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 256.22 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 288.25 256.22 Td (T) Tj ET Q q 0 0 0 rg BT 294.01 256.22 Td (otal) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 336.50 256.22 Td (Oper) Tj ET Q q 0 0 0 rg BT 355.94 256.22 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 243.22 Td (Innovative Health) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 188.10 243.22 Td ($ 7,829) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 238.10 243.22 Td ($ 7,415) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 291.80 243.22 Td (6%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 340.80 243.22 Td (3%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 230.22 Td (Essential Health) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 198.15 230.22 Td (5,077) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 248.15 230.22 Td (5,364) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 288.50 230.22 Td (\(5%\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 337.50 230.22 Td (\(9%\)) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 63.00 217.38 Td (T) Tj ET Q q 0 0 0 rg BT 68.75 217.38 Td (otal Company) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 183.10 217.38 Td ($ 12,906) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 233.10 217.38 Td ($ 12,779) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 291.00 217.38 Td (1%) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 336.65 217.38 Td (\(2%\)) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 185.00 Td (On February 3, 2017, Pfizer completed the sale of its global infusion therapy net assets, Hospira Infusion Systems ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 165.85 Td (\(HIS\). ) Tj ET Q q 0 0 0 rg BT 84.35 165.85 Td (Therefore, financial results for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 237.67 165.85 Td (first quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 289.29 165.85 Td ( of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 303.95 165.85 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 325.95 165.85 Td ( do not reflect any contribution from legacy HIS ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 146.70 Td (operations, while the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 148.70 146.70 Td (first quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 200.31 146.70 Td ( of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 214.98 146.70 Td (2017) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 236.98 146.70 Td ( reflects approximately one month of legacy HIS domestic operations ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 127.55 Td (and approximately two months of legacy HIS international operations) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 361.31 132.53 Td (\(3\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 369.65 127.55 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 102.45 Td (Some amounts in this press release may not add due to rounding. ) Tj ET Q q 0 0 0 rg BT 342.09 102.45 Td (All percentages have been calculated using ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 83.30 Td (unrounded amounts. References to operational variances pertain to period-over) Tj ET Q q 0 0 0 rg BT 401.68 83.30 Td (-period growth rates that exclude ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 64.15 Td (the impact of foreign exchange) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 190.83 69.13 Td (\(4\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 199.17 64.15 Td (.) Tj ET Q endstream endobj 5 0 obj <> endobj 6 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 42.60 Td (- 2 -) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 730.60 Td (2018) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.00 730.60 Td ( FINANCIAL) Tj ET Q q 0 0 0 rg BT 140.48 730.60 Td ( GUIDANCE) Tj ET Q BT /F2 11.00 Tf ET BT /F2 7.15 Tf ET q 0 0 0 rg BT 203.12 735.58 Td (\(5\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 702.45 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 80.67 702.45 Td () Tj ET Q q 0 0 0 rg BT 83.73 702.45 Td (s reaf) Tj ET Q q 0 0 0 rg BT 107.65 702.45 Td (firmed 2018 financial guidance is presented below) Tj ET Q q 0 0 0 rg BT 329.31 702.45 Td (.) Tj ET Q 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 685.95 m 306.5 685.95 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 685.95 m 558.5 685.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 681.95 m 306.5 659.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 659.95 m 306.5 659.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 659.95 m 306.5 637.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 659.95 m 558.5 659.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 637.95 m 306.5 637.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 637.95 m 306.5 615.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 637.95 m 558.5 637.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 615.95 m 306.5 615.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 615.95 m 306.5 593.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 615.95 m 558.5 615.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 593.95 m 306.5 593.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 593.95 m 306.5 571.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 593.95 m 558.5 593.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 571.95 m 306.5 571.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 549.95 m 306.5 549.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 571.95 m 306.5 549.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 571.95 m 558.5 571.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 549.95 m 558.5 549.95 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 549.95 m 306.5 527.95 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 523.95 m 306.5 523.95 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 523.95 m 558.5 523.95 l s BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 668.37 Td (Revenues) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 384.45 668.37 Td ($53.5 to $55.5 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 646.37 Td (Adjusted Cost of Sales) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 157.53 651.36 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 165.86 646.37 Td ( as a Percentage of Revenues) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 396.55 646.37 Td (20.5% to 21.5%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 624.37 Td (Adjusted SI&A) Tj ET Q q 0 0 0 rg BT 125.14 624.37 Td ( Expenses) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 169.44 629.36 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 384.45 624.37 Td ($14.0 to $15.0 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 602.37 Td (Adjusted R&D Expenses) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 167.60 607.36 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 389.95 602.37 Td ($7.4 to $7.9 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 580.37 Td (Adjusted Other \(Income\)/Deductions) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 220.73 585.36 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 345.50 580.37 Td (Approximately $400 million of income) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 558.37 Td (Ef) Tj ET Q q 0 0 0 rg BT 67.18 558.37 Td (fective ) Tj ET Q q 0 0 0 rg BT 99.66 558.37 Td (T) Tj ET Q q 0 0 0 rg BT 105.61 558.37 Td (ax Rate on ) Tj ET Q q 0 0 0 rg BT 154.79 558.37 Td (Adjusted Income) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 230.24 563.36 Td (\(2\),\(6\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 383.10 558.37 Td (Approximately 17.0%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 57.00 536.37 Td (Adjusted Diluted EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 154.17 541.36 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 400.20 536.37 Td ($2.90 to $3.00) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 499.30 Td (Financial guidance for ) Tj ET Q q 0 0 0 rg BT 155.11 499.30 Td (Adjusted diluted EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 249.83 504.28 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 258.17 499.30 Td ( now anticipates share repurchases totaling approximately ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 515.66 499.30 Td ($6.1 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 480.15 Td (billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 82.72 480.15 Td ( in 2018, which includes shares repurchased during first-quarter 2018. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 393.69 480.15 Td (Dilution related to share-based ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 461.00 Td (employee compensation programs is expected to of) Tj ET Q q 0 0 0 rg BT 279.84 461.00 Td (fset by approximately half the reduction in shares associated ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 441.90 Td (with these share repurchases. ) Tj ET Q BT /F1 11.00 Tf ET BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 398.75 Td (CAPIT) Tj ET Q q 0 0 0 rg BT 87.41 398.75 Td (AL) Tj ET Q q 0 0 0 rg BT 102.08 398.75 Td ( ) Tj ET Q q 0 0 0 rg BT 104.23 398.75 Td (ALLOCA) Tj ET Q q 0 0 0 rg BT 150.47 398.75 Td (TION) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 365.23 cm /I5 Do Q q 0 0 0 rg BT 62.50 367.60 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 367.60 Td (During ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 110.41 367.60 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 162.94 367.60 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 165.69 367.60 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 187.69 367.60 Td (, Pfizer returned ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 261.60 367.60 Td ($8.1 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 312.33 367.60 Td ( directly to shareholders, through a combination of:) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 342.45 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 342.45 Td ($2.0 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 149.72 342.45 Td ( of dividends, or $0.34 per share of common stock; and) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 317.30 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 317.30 Td ($6.1 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 149.72 317.30 Td ( of share repurchases, composed of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 307.03 317.30 Td ($2.1 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 357.75 317.30 Td ( of open-market share repurchases and a ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 537.64 317.30 Td ($4.0 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 298.20 Td (billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 127.72 298.20 Td ( accelerated share repurchase agreement executed in March 2018.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 264.68 cm /I6 Do Q q 0 0 0 rg BT 62.50 267.05 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 267.05 Td (As of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 103.39 267.05 Td (May1, 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 159.30 267.05 Td (, Pfizer) Tj ET Q q 0 0 0 rg BT 191.47 267.05 Td () Tj ET Q q 0 0 0 rg BT 194.53 267.05 Td (s remaining share repurchase authorization was $10.3 billion.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 223.90 Td (EXECUTIVE COMMENT) Tj ET Q q 0 0 0 rg BT 181.22 223.90 Td (AR) Tj ET Q q 0 0 0 rg BT 196.72 223.90 Td (Y) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 195.75 Td (Ian Read, Chairman and Chief Executive Of) Tj ET Q q 0 0 0 rg BT 248.98 195.75 Td (ficer) Tj ET Q q 0 0 0 rg BT 268.69 195.75 Td (, stated, Our first-quarter 2018 financial results were solid, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 176.60 Td (driven by continued strength from our anchor brands, primarily Ibrance, Eliquis and Xeljanz. ) Tj ET Q q 0 0 0 rg BT 466.18 176.60 Td (The Essential Health ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 157.50 Td (business delivered strong growth in emer) Tj ET Q q 0 0 0 rg BT 234.96 157.50 Td (ging markets and biosimilars but was negatively impacted by continued ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 138.35 Td (legacy Hospira product supply shortages in the U.S. as well as product losses of exclusivity) Tj ET Q q 0 0 0 rg BT 455.94 138.35 Td (. ) Tj ET Q q 0 0 0 rg BT 461.24 138.35 Td (W) Tj ET Q q 0 0 0 rg BT 470.74 138.35 Td (e remain focused ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 119.20 Td (on executing our commercial strategies, managing expenses, advancing our pipeline and prudently allocating our ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 100.05 Td (capital to position Pfizer for sustainable success. ) Tj ET Q endstream endobj 7 0 obj <> endobj 8 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 42.60 Td (- 3 -) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 730.40 Td (Our pipeline today) Tj ET Q q 0 0 0 rg BT 140.65 730.40 Td (, with a range of tar) Tj ET Q q 0 0 0 rg BT 226.58 730.40 Td (geted compounds, biologics and vaccines, is as deep and focused as it has ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 711.25 Td (ever been. ) Tj ET Q q 0 0 0 rg BT 101.74 711.25 Td (W) Tj ET Q q 0 0 0 rg BT 111.69 711.25 Td (ith several potential near) Tj ET Q q 0 0 0 rg BT 219.89 711.25 Td (-term opportunities in core therapeutic areas, I believe our pipeline presents ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 692.10 Td (an unprecedented opportunity to deliver a life-changing impact on a growing number of patients while creating ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 673.00 Td (enhanced value for all of our stakeholders, Mr) Tj ET Q q 0 0 0 rg BT 261.70 673.00 Td (. Read concluded.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 644.85 Td (Frank DAmelio, Executive ) Tj ET Q q 0 0 0 rg BT 179.04 644.85 Td (V) Tj ET Q q 0 0 0 rg BT 186.33 644.85 Td (ice President, Business Operations and Chief Financial Of) Tj ET Q q 0 0 0 rg BT 442.13 644.85 Td (ficer) Tj ET Q q 0 0 0 rg BT 461.84 644.85 Td (, stated, First-) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 625.70 Td (quarter 2018 results were in-line with our expectations and we remain on track to deliver a solid financial ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 606.55 Td (performance in 2018. ) Tj ET Q q 0 0 0 rg BT 150.93 606.55 Td (W) Tj ET Q q 0 0 0 rg BT 160.43 606.55 Td (e reaf) Tj ET Q q 0 0 0 rg BT 184.96 606.55 Td (firmed all components of our 2018 financial guidance, reflecting our performance to ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 587.40 Td (date as well as our confidence in the business going forward. ) Tj ET Q q 0 0 0 rg BT 324.04 587.40 Td (Additionally) Tj ET Q q 0 0 0 rg BT 378.93 587.40 Td (, in first-quarter 2018, we returned ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 533.49 587.40 Td ($8.1 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 568.30 Td (billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 82.72 568.30 Td ( directly to shareholders through dividends and share repurchases, demonstrating our continued ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 549.15 Td (commitment to returning capital to our shareholders.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 506.00 Td (QUAR) Tj ET Q q 0 0 0 rg BT 86.00 506.00 Td (TERL) Tj ET Q q 0 0 0 rg BT 114.95 506.00 Td (Y) Tj ET Q q 0 0 0 rg BT 122.48 506.00 Td ( FINANCIAL) Tj ET Q q 0 0 0 rg BT 186.96 506.00 Td ( HIGHLIGHTS \() Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 268.26 506.00 Td (First-Quarter) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 332.81 506.00 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 335.56 506.00 Td (2018) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 357.56 506.00 Td ( vs. ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 375.59 506.00 Td (First-Quarter) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 440.14 506.00 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 442.89 506.00 Td (2017) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 464.89 506.00 Td (\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 477.85 Td (First-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.98 477.85 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 111.73 477.85 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 133.73 477.85 Td ( revenues totaled ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 211.01 477.85 Td ($12.9 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 267.23 477.85 Td (, an increase of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 336.56 477.85 Td ($127 million) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 393.09 477.85 Td (, or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 410.50 477.85 Td (1%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 425.16 477.85 Td (, compared to the prior) Tj ET Q q 0 0 0 rg BT 525.44 477.85 Td (-year ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 458.70 Td (quarter) Tj ET Q q 0 0 0 rg BT 84.71 458.70 Td (, reflecting the favorable impact of foreign exchange of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 330.87 458.70 Td ($430 million) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 387.40 458.70 Td (, or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 404.81 458.70 Td (3%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 419.48 458.70 Td (, partially of) Tj ET Q q 0 0 0 rg BT 473.34 458.70 Td (fset by an ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 439.60 Td (operational decline of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 152.65 439.60 Td ($302 million) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 209.18 439.60 Td (, or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 226.59 439.60 Td (2%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 241.26 439.60 Td (.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 408.45 Td (Innovative Health Highlights) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 374.93 cm /I7 Do Q q 0 0 0 rg BT 62.50 377.30 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 377.30 Td (IH revenues increased ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 176.98 377.30 Td (3%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 191.64 377.30 Td ( operationally in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 266.48 377.30 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 319.01 377.30 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 321.76 377.30 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 343.76 377.30 Td (, primarily driven by continued growth from key ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 358.15 Td (brands including Ibrance, Eliquis and Xeljanz. Global operational revenue growth for Ibrance, Eliquis and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 339.00 Td (Xeljanz was ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 133.31 339.00 Td (35%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 153.47 339.00 Td (, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 158.97 339.00 Td (30%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 179.14 339.00 Td ( and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 200.52 339.00 Td (29%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 220.68 339.00 Td (, respectively) Tj ET Q q 0 0 0 rg BT 278.61 339.00 Td (.) Tj ET Q BT /F1 11.00 Tf ET 1 1 1 rg /GS0 gs 58.50 315.53 18.00 -10.00 re f /GS0 gs /GS0 gs q 4.00 0 0 11.00 58.50 305.53 cm /I8 Do Q q 0 0 0 rg BT 62.50 307.90 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 307.90 Td (First-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 131.48 307.90 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 134.23 307.90 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 156.23 307.90 Td ( IH operational revenue growth was negatively impacted primarily by the loss of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 288.75 Td (exclusivity of ) Tj ET Q q 0 0 0 rg BT 139.23 288.75 Td (V) Tj ET Q q 0 0 0 rg BT 146.52 288.75 Td (iagra in the U.S. in December 2017 and the resulting shift in the reporting of U.S. and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 269.60 Td (Canada ) Tj ET Q q 0 0 0 rg BT 112.04 269.60 Td (V) Tj ET Q q 0 0 0 rg BT 119.32 269.60 Td (iagra revenues to the Essential Health business at the beginning of 2018) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 435.49 274.58 Td (\(3\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 443.82 269.60 Td (. IH operational revenue ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 250.45 Td (growth was also negatively impacted by lower revenues for Enbrel in most developed Europe markets due to ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 231.30 Td (continued biosimilar competition. In the U.S., revenue for Ibrance, Xeljanz and certain other products was ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 212.20 Td (negatively impacted by customer buying patterns.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 178.68 cm /I9 Do Q q 0 0 0 rg BT 62.50 181.05 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 181.05 Td (Global Prevnar 13/Prevenar 13 revenues declined ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 297.64 181.05 Td (3%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 312.31 181.05 Td ( operationally in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 387.15 181.05 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 439.68 181.05 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 442.43 181.05 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 464.43 181.05 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 155.90 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 155.90 Td (Prevenar 13 revenues in international markets increased ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 347.93 155.90 Td (16%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 368.09 155.90 Td ( operationally) Tj ET Q q 0 0 0 rg BT 428.16 155.90 Td (, primarily due to the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 136.75 Td (favorable impact of the inclusion of Prevenar 13 in additional national immunization programs in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 117.60 Td (certain emer) Tj ET Q q 0 0 0 rg BT 153.46 117.60 Td (ging markets for the adult indication as well as higher volumes for the pediatric indication ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 98.50 Td (resulting from the second-quarter 2017 launch of Prevenar 13 in China and increased shipments ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 79.35 Td (associated with Gavi, the) Tj ET Q q 0 0 0 rg BT 212.13 79.35 Td (V) Tj ET Q q 0 0 0 rg BT 218.86 79.35 Td (accine ) Tj ET Q q 0 0 0 rg BT 249.08 79.35 Td (Alliance, partially of) Tj ET Q q 0 0 0 rg BT 340.21 79.35 Td (fset by the overall unfavorable impact of timing ) Tj ET Q endstream endobj 9 0 obj <> endobj 10 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 42.60 Td (- 4 -) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 730.40 Td (associated with government purchases in certain international markets compared with the prior) Tj ET Q q 0 0 0 rg BT 516.33 730.40 Td (-year ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 711.25 Td (quarter) Tj ET Q q 0 0 0 rg BT 129.54 711.25 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 686.10 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 686.10 Td (In the U.S., Prevnar 13 revenues declined ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 284.72 686.10 Td (12%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 304.88 686.10 Td (, primarily due to lower government purchases in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 524.52 686.10 Td (first-) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 667.00 Td (quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 130.15 667.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 132.90 667.00 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 154.90 667.00 Td ( compared to ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 215.07 667.00 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 267.60 667.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 270.35 667.00 Td (2017) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 292.35 667.00 Td ( for the pediatric indication due to a change in ordering ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 647.85 Td (patterns and, to a lesser extent, the continued decline in revenues for the adult indication due to a ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 628.70 Td (smaller remaining catch up opportunity compared to the prior) Tj ET Q q 0 0 0 rg BT 379.80 628.70 Td (-year quarter) Tj ET Q q 0 0 0 rg BT 435.68 628.70 Td (.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 597.55 Td (Essential Health Highlights) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 564.03 cm /I10 Do Q q 0 0 0 rg BT 62.50 566.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 566.40 Td (First-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 131.48 566.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 134.23 566.40 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 156.23 566.40 Td ( EH revenues declined ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 258.25 566.40 Td (9%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 272.91 566.40 Td ( operationally) Tj ET Q q 0 0 0 rg BT 332.98 566.40 Td (, negatively impacted primarily by a ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 495.18 566.40 Td (15%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 515.34 566.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 547.30 Td (operational decline from the Sterile Injectable Pharmaceuticals \(SIP\) portfolio, primarily due to continued ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 528.15 Td (legacy Hospira product shortages in the U.S. EH operational revenue growth was also negatively impacted ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 509.00 Td (by a ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 97.88 509.00 Td (15%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 118.05 509.00 Td ( operational decline from the Peri-LOE Products portfolio, primarily due to expected declines in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 489.85 Td (L) Tj ET Q q 0 0 0 rg BT 82.61 489.85 Td (yrica in developed Europe and Pristiq in the U.S., partially of) Tj ET Q q 0 0 0 rg BT 352.16 489.85 Td (fset by the addition of ) Tj ET Q q 0 0 0 rg BT 451.24 489.85 Td (V) Tj ET Q q 0 0 0 rg BT 458.52 489.85 Td (iagra U.S. revenues ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 470.70 Td (previously recorded in the IH business. ) Tj ET Q q 0 0 0 rg BT 251.35 470.70 Td (These declines were partially of) Tj ET Q q 0 0 0 rg BT 391.64 470.70 Td (fset primarily by ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 467.70 470.70 Td (12%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 487.87 470.70 Td ( operational ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 451.60 Td (growth in emer) Tj ET Q q 0 0 0 rg BT 143.50 451.60 Td (ging markets and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 222.01 451.60 Td (53%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 242.18 451.60 Td ( operational growth from Biosimilars, primarily from Inflectra in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 432.45 Td (certain channels in the U.S. as well as in developed Europe.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 401.30 Td (GAAP) Tj ET Q q 0 0 0 rg BT 84.56 401.30 Td ( Reported) Tj ET Q BT /F2 11.00 Tf ET BT /F2 7.15 Tf ET q 0 0 0 rg BT 131.30 406.28 Td (\(1\)) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 139.63 401.30 Td ( Income Statement Highlights) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 374.90 Td (SELECTED ) Tj ET Q q 0 0 0 rg BT 115.24 374.90 Td (T) Tj ET Q q 0 0 0 rg BT 122.38 374.90 Td (OT) Tj ET Q q 0 0 0 rg BT 137.46 374.90 Td (AL) Tj ET Q q 0 0 0 rg BT 152.13 374.90 Td ( COMP) Tj ET Q q 0 0 0 rg BT 187.67 374.90 Td (ANY) Tj ET Q q 0 0 0 rg BT 211.09 374.90 Td ( REPOR) Tj ET Q q 0 0 0 rg BT 251.95 374.90 Td (TED COSTS ) Tj ET Q q 0 0 0 rg BT 315.53 374.90 Td (AND EXPENSES) Tj ET Q BT /F2 11.00 Tf ET BT /F2 7.15 Tf ET q 0 0 0 rg BT 398.97 379.88 Td (\(1\)) Tj ET Q 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 368.79999999999995 m 161.5 368.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 161.5 368.79999999999995 m 223.5 368.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 223.5 368.79999999999995 m 285.5 368.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 285.5 368.79999999999995 m 347.5 368.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 347.5 368.79999999999995 m 409.5 368.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 161.5 338.79999999999995 m 223.5 338.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 223.5 338.79999999999995 m 285.5 338.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 285.5 338.79999999999995 m 347.5 338.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347.5 338.79999999999995 m 409.5 338.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 285.5 323.79999999999995 m 347.5 323.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347.5 323.79999999999995 m 409.5 323.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 161.5 308.79999999999995 m 223.5 308.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 223.5 308.79999999999995 m 285.5 308.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 285.5 308.79999999999995 m 347.5 308.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347.5 308.79999999999995 m 409.5 308.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 161.5 248.79999999999995 m 223.5 248.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 161.5 234.79999999999995 m 223.5 234.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 161.5 232.79999999999995 m 223.5 232.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 223.5 248.79999999999995 m 285.5 248.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 223.5 234.79999999999995 m 285.5 234.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 223.5 232.79999999999995 m 285.5 232.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 285.5 248.79999999999995 m 347.5 248.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 285.5 234.79999999999995 m 347.5 234.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 285.5 232.79999999999995 m 347.5 232.79999999999995 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347.5 248.79999999999995 m 409.5 248.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 347.5 234.79999999999995 m 409.5 234.79999999999995 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 347.5 232.79999999999995 m 409.5 232.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 176.79999999999995 m 161.5 176.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 161.5 176.79999999999995 m 223.5 176.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 223.5 176.79999999999995 m 285.5 176.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 285.5 176.79999999999995 m 347.5 176.79999999999995 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 347.5 176.79999999999995 m 409.5 176.79999999999995 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 354.42 Td (\($ in millions\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 344.42 Td (\(Favorable\)/Unfavorable) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 258.85 343.47 Td (First-Quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 328.92 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 182.00 321.42 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 244.00 321.42 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 326.30 328.92 Td (% Change) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 313.92 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 305.75 313.92 Td (T) Tj ET Q q 0 0 0 rg BT 311.51 313.92 Td (otal) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 367.00 313.92 Td (Oper) Tj ET Q q 0 0 0 rg BT 386.71 313.92 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 298.92 Td (Cost of Sales) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 109.78 303.45 Td (\(1\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 182.15 298.92 Td ($ 2,563) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 244.15 298.92 Td ($ 2,468) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 309.30 298.92 Td (4%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 368.00 298.92 Td (\(6%\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 70.50 283.92 Td (Percent of Revenues) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 197.15 283.92 Td (19.9) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 214.65 283.92 Td (%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 259.15 283.92 Td (19.3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 276.65 283.92 Td (%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 307.65 283.92 Td (N/A) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 369.65 283.92 Td (N/A) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 268.92 Td (SI&A) Tj ET Q q 0 0 0 rg BT 80.34 268.92 Td ( Expenses) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 120.61 273.45 Td (\(1\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 189.65 268.92 Td ( 3,412) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 251.65 268.92 Td ( 3,315) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 309.30 268.92 Td (3%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 373.00 268.92 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 253.92 Td (R&D Expenses) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 118.94 258.45 Td (\(1\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 189.65 253.92 Td ( 1,743) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 251.65 253.92 Td ( 1,716) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 309.30 253.92 Td (2%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 371.30 253.92 Td (1%) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 57.00 239.03 Td (T) Tj ET Q q 0 0 0 rg BT 62.75 239.03 Td (otal) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 182.15 239.03 Td ($ 7,718) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 244.15 239.03 Td ($ 7,498) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 308.50 239.03 Td (3%) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 367.15 239.03 Td (\(2%\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 218.37 Td (Other \(Income\)/) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 208.37 Td (Deductionsnet) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 124.76 212.90 Td (\(1\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 191.30 213.42 Td (\($178) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 214.65 213.42 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 256.65 213.42 Td ($ 60) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 313.50 213.42 Td (*) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 375.50 213.42 Td (*) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 194.37 Td (Ef) Tj ET Q q 0 0 0 rg BT 66.26 194.37 Td (fective ) Tj ET Q q 0 0 0 rg BT 95.78 194.37 Td (T) Tj ET Q q 0 0 0 rg BT 101.19 194.37 Td (ax Rate on ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 184.37 Td (Reported Income) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 126.14 188.90 Td (\(1\),\(6\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 197.15 189.92 Td (13.5) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 214.65 189.92 Td (%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 259.15 189.92 Td (20.8) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 276.65 189.92 Td (%) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 149.15 Td (* Indicates calculation not meaningful or result is equal to or greater than 100%.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 121.00 Td (Pfizer recorded other incomenet) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 206.40 125.98 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 214.74 121.00 Td ( in) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 226.05 125.98 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 227.83 121.00 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 280.36 121.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 283.11 121.00 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 305.11 121.00 Td ( compared with ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 376.29 121.00 Td (other deductionsnet) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 473.73 125.98 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 482.07 121.00 Td ( in) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 493.38 125.98 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 495.16 121.00 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 547.69 121.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 101.90 Td (2017) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.00 101.90 Td ( primarily due to:) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 71.38 cm /I11 Do Q q 0 0 0 rg BT 62.50 73.75 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 73.75 Td (higher income from collaborations, out-licensing arrangements and sale of compound/product rights; and) Tj ET Q endstream endobj 11 0 obj <> endobj 12 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 42.60 Td (- 5 -) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 728.03 cm /I12 Do Q q 0 0 0 rg BT 62.50 730.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 730.40 Td (unrealized net gains on equity securities, reflecting the adoption of a new accounting standard in first-quarter ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 711.25 Td (2018. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all readily ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 692.10 Td (tradeable equity securities were reported in ) Tj ET Q q 0 0 0 rg BT 268.31 692.10 Td (Accumulated other comprehensive income.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 667.00 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 80.67 667.00 Td () Tj ET Q q 0 0 0 rg BT 83.73 667.00 Td (s ef) Tj ET Q q 0 0 0 rg BT 99.11 667.00 Td (fective tax rate on Reported income) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 256.40 671.98 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 264.74 667.00 Td ( for ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 283.06 667.00 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 335.59 667.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 338.34 667.00 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 360.34 667.00 Td ( was favorably impacted by the December ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 647.85 Td (2017 enactment of the ) Tj ET Q q 0 0 0 rg BT 154.60 647.85 Td (T) Tj ET Q q 0 0 0 rg BT 160.55 647.85 Td (ax Cuts and Jobs ) Tj ET Q q 0 0 0 rg BT 236.94 647.85 Td (Act \(TCJA\)) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 289.18 652.83 Td (\(6\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 297.52 647.85 Td (.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 616.70 Td (Adjusted) Tj ET Q BT /F2 11.00 Tf ET BT /F2 7.15 Tf ET q 0 0 0 rg BT 96.79 621.68 Td (\(2\)) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 105.12 616.70 Td ( Income Statement Highlights) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 590.30 Td (SELECTED ) Tj ET Q q 0 0 0 rg BT 115.24 590.30 Td (T) Tj ET Q q 0 0 0 rg BT 122.38 590.30 Td (OT) Tj ET Q q 0 0 0 rg BT 137.46 590.30 Td (AL) Tj ET Q q 0 0 0 rg BT 152.13 590.30 Td ( COMP) Tj ET Q q 0 0 0 rg BT 187.67 590.30 Td (ANY) Tj ET Q q 0 0 0 rg BT 211.09 590.30 Td ( ) Tj ET Q q 0 0 0 rg BT 213.23 590.30 Td (ADJUSTED COSTS ) Tj ET Q q 0 0 0 rg BT 312.26 590.30 Td (AND EXPENSES) Tj ET Q BT /F2 11.00 Tf ET BT /F2 7.15 Tf ET q 0 0 0 rg BT 395.70 595.28 Td (\(2\)) Tj ET Q 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 584.2 m 170.5 584.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 170.5 584.2 m 232.5 584.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 232.5 584.2 m 294.5 584.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 584.2 m 356.5 584.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 584.2 m 418.5 584.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 170.5 554.2 m 232.5 554.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 232.5 554.2 m 294.5 554.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 554.2 m 356.5 554.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 554.2 m 418.5 554.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 539.2 m 356.5 539.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 539.2 m 418.5 539.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 170.5 524.2 m 232.5 524.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 232.5 524.2 m 294.5 524.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 524.2 m 356.5 524.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 524.2 m 418.5 524.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 524.2 m 356.5 524.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 524.2 m 418.5 524.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 464.2 m 356.5 464.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 170.5 464.2 m 232.5 464.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 170.5 450.2 m 232.5 450.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 170.5 448.2 m 232.5 448.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 232.5 464.2 m 294.5 464.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 232.5 450.2 m 294.5 450.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 232.5 448.2 m 294.5 448.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 464.2 m 356.5 464.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 294.5 450.2 m 356.5 450.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 294.5 448.2 m 356.5 448.2 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 464.2 m 418.5 464.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 356.5 450.2 m 418.5 450.2 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 356.5 448.2 m 418.5 448.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 54.5 391.2 m 170.5 391.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 170.5 391.2 m 232.5 391.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 232.5 391.2 m 294.5 391.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 294.5 391.2 m 356.5 391.2 l s 0 0 0 RG /GS0 gs 1.50 w 0 i [] 0 d 0 J 0 j 3 M 356.5 391.2 m 418.5 391.2 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 569.82 Td (\($ in millions\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 559.82 Td (\(Favorable\)/Unfavorable) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 267.85 558.87 Td (First-Quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 544.32 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 191.00 536.82 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 253.00 536.82 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 335.30 544.32 Td (% Change) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 529.32 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 314.75 529.32 Td (T) Tj ET Q q 0 0 0 rg BT 320.51 529.32 Td (otal) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 376.00 529.32 Td (Oper) Tj ET Q q 0 0 0 rg BT 395.71 529.32 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 514.32 Td (Adjusted Cost of Sales) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 148.39 518.85 Td (\(2\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 191.15 514.32 Td ($ 2,536) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 253.15 514.32 Td ($ 2,432) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 318.30 514.32 Td (4%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 377.00 514.32 Td (\(6%\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 70.50 499.32 Td (Percent of Revenues) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 206.15 499.32 Td (19.7) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 223.65 499.32 Td (%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 268.15 499.32 Td (19.0) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.65 499.32 Td (%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 316.65 499.32 Td (N/A) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 378.65 499.32 Td (N/A) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 484.32 Td (Adjusted SI&A) Tj ET Q q 0 0 0 rg BT 118.95 484.32 Td ( Expenses) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 159.22 488.85 Td (\(2\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 198.65 484.32 Td ( 3,286) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 260.65 484.32 Td ( 3,295) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 320.00 484.32 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 377.00 484.32 Td (\(3%\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 469.32 Td (Adjusted R&D Expenses) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 157.55 473.85 Td (\(2\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 198.65 469.32 Td ( 1,739) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 260.65 469.32 Td ( 1,713) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 318.30 469.32 Td (1%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 380.30 469.32 Td (1%) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 57.00 454.43 Td (T) Tj ET Q q 0 0 0 rg BT 62.75 454.43 Td (otal) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 191.15 454.43 Td ($ 7,561) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 253.15 454.43 Td ($ 7,440) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 317.50 454.43 Td (2%) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 376.15 454.43 Td (\(3%\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 433.77 Td (Adjusted Other \(Income\)/) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 423.77 Td (Deductionsnet) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 124.76 428.30 Td (\(2\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 200.30 428.82 Td (\($322) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 223.65 428.82 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 262.30 428.82 Td (\($100) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.65 428.82 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 322.50 428.82 Td (*) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 384.50 428.82 Td (*) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 409.77 Td (Ef) Tj ET Q q 0 0 0 rg BT 66.26 409.77 Td (fective ) Tj ET Q q 0 0 0 rg BT 95.78 409.77 Td (T) Tj ET Q q 0 0 0 rg BT 101.19 409.77 Td (ax Rate on ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 399.77 Td (Adjusted Income) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 125.59 404.30 Td (\(2\),\(6\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 206.15 404.82 Td (16.4) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 223.65 404.82 Td (%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 268.15 404.82 Td (22.3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.65 404.82 Td (%) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 363.55 Td (* Indicates calculation not meaningful or result is equal to or greater than 100%.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 335.40 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 80.67 335.40 Td () Tj ET Q q 0 0 0 rg BT 83.73 335.40 Td (s ef) Tj ET Q q 0 0 0 rg BT 99.11 335.40 Td (fective tax rate on ) Tj ET Q q 0 0 0 rg BT 180.34 335.40 Td (Adjusted income) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 255.19 340.38 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 263.53 335.40 Td ( for ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 281.85 335.40 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 334.38 335.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 337.13 335.40 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 359.13 335.40 Td ( was favorably impacted by the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 316.30 Td (aforementioned December 2017 enactment of the ) Tj ET Q q 0 0 0 rg BT 274.32 316.30 Td (TCJA) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 300.60 321.28 Td (\(6\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 308.93 316.30 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 285.15 Td (First-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.98 285.15 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 111.73 285.15 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 133.73 285.15 Td ( diluted weighted-average shares outstanding used to calculate Reported) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 451.40 290.13 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 459.74 285.15 Td ( and ) Tj ET Q q 0 0 0 rg BT 480.51 285.15 Td (Adjusted) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 520.23 290.13 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 528.57 285.15 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 266.00 Td (diluted EPS declined by ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 162.76 266.00 Td (35 million) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 208.30 266.00 Td ( shares compared to the prior) Tj ET Q q 0 0 0 rg BT 336.06 266.00 Td (-year quarter due to Pfizer) Tj ET Q q 0 0 0 rg BT 451.91 266.00 Td () Tj ET Q q 0 0 0 rg BT 454.96 266.00 Td (s ongoing share ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 246.85 Td (repurchase program, reflecting the impact of the $5 billion accelerated share repurchase agreement executed in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 227.70 Td (February 2017 and completed in May 2017 and, to a lesser extent, share repurchases during first-quarter 2018, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 208.60 Td (partially of) Tj ET Q q 0 0 0 rg BT 102.37 208.60 Td (fset by dilution related to share-based employee compensation programs.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 177.45 Td (A) Tj ET Q q 0 0 0 rg BT 61.34 177.45 Td ( full reconciliation of Reported) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 197.57 182.43 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 205.91 177.45 Td ( to ) Tj ET Q q 0 0 0 rg BT 219.35 177.45 Td (Adjusted) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 259.07 182.43 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 267.41 177.45 Td ( financial measures and associated footnotes can be found starting ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 158.30 Td (on page 18 of this press release.) Tj ET Q endstream endobj 13 0 obj <> endobj 14 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 29.10 Td (- 6 -) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 730.60 Td (RECENT) Tj ET Q q 0 0 0 rg BT 99.64 730.60 Td ( NOT) Tj ET Q q 0 0 0 rg BT 125.41 730.60 Td (ABLE DEVELOPMENTS \(Since ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 284.63 730.60 Td (January30, 2018) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 365.00 730.60 Td (\)) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 699.45 Td (Pr) Tj ET Q q 0 0 0 rg BT 65.40 699.45 Td (oduct Developments) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 671.93 cm /I13 Do Q q 0 0 0 rg BT 62.50 674.30 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 674.30 Td (Bavencio \(avelumab\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 175.19 674.30 Td ( -- In February 2018, Merck KGaA, Darmstadt, Germany) Tj ET Q q 0 0 0 rg BT 427.09 674.30 Td (, which operates its ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 655.15 Td (biopharmaceutical business as EMD Serono in the U.S. and Canada \(Merck KGaA\), and Pfizer announced ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 636.00 Td (results from the Phase 3 JA) Tj ET Q q 0 0 0 rg BT 195.76 636.00 Td (VELIN Lung 200 trial comparing avelumab to docetaxel in patients with ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 616.90 Td (unresectable, recurrent or metastatic non-small cell lung cancer \(NSCLC\) whose disease progressed after ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 597.75 Td (treatment with a platinum-containing doublet therapy) Tj ET Q q 0 0 0 rg BT 310.69 597.75 Td (. ) Tj ET Q q 0 0 0 rg BT 315.99 597.75 Td (While the trial did not meet its pre-specified endpoint ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 578.60 Td (of improving overall survival \(OS\) in patients with programmed death ligand-1-positive \(PD-L1+\) \(1% or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 559.45 Td (higher\) tumors, the proportion of patients in the chemotherapy arm crossing over to immune checkpoint ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 540.30 Td (inhibitors outside the study was higher than previously reported in post-platinum immunotherapy clinical ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 521.20 Td (trials, which may have confounded this trial outcome \(percentage of patients receiving subsequent ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 502.05 Td (checkpoint inhibitor therapy: docetaxel arm 26.4%; avelumab arm 5.7%\). Improvements in OS versus the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 482.90 Td (control arm were observed in the moderate-to-high PD-L1+ expression \(50% or greater) Tj ET Q q 0 0 0 rg BT 460.72 482.90 Td (, which represented ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 463.75 Td (approximately 40% of the study population\) and high PD-L1+ expression \(PD-L1+ expression 80% or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 444.60 Td (greater) Tj ET Q q 0 0 0 rg BT 106.59 444.60 Td (, which represented approximately 30% of the study population\) population subsets. ) Tj ET Q q 0 0 0 rg BT 479.40 444.60 Td (The safety profile ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 425.50 Td (for avelumab in this trial was consistent with that observed in the overall JA) Tj ET Q q 0 0 0 rg BT 410.20 425.50 Td (VELIN clinical development ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 406.35 Td (program; no new safety signals were identified.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 378.83 cm /I14 Do Q q 0 0 0 rg BT 62.50 381.20 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 381.20 Td (Bosulif \(bosutinib\)) Tj ET Q BT /F2 11.00 Tf ET BT /F2 7.15 Tf ET q 0 0 0 rg BT 163.61 386.18 Td (\(7\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 171.95 381.20 Td ( -- In ) Tj ET Q q 0 0 0 rg BT 196.08 381.20 Td (April 2018, Pfizer announced that the European Commission \(EC\) approved an ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 362.05 Td (indication extension for Bosulif for the treatment of adults with newly diagnosed chronic phase Philadelphia ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 342.90 Td (chromosome-positive chronic myelogenous leukemia \(Ph+ CML\). Bosulif previously received conditional ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 323.80 Td (marketing authorization from the EC in March 2013 for the treatment of adult patients with chronic phase, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 304.65 Td (accelerated phase and blast phase Ph+ CML) Tj ET Q q 0 0 0 rg BT 270.45 304.65 Td ( previously treated with one or more tyrosine kinase inhibitors ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 285.50 Td (\(TKIs\) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 257.98 cm /I15 Do Q q 0 0 0 rg BT 62.50 260.35 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 260.35 Td (Chantix/Champix \(var) Tj ET Q q 0 0 0 rg BT 182.95 260.35 Td (enicline\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 225.41 260.35 Td (-- In March 2018, Pfizer announced results from a Phase 4 study ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 241.20 Td (evaluating the ef) Tj ET Q q 0 0 0 rg BT 149.60 241.20 Td (ficacy and safety of Chantix/Champix for smoking cessation in nicotine dependent ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 222.10 Td (adolescents 12-19 years of age. ) Tj ET Q q 0 0 0 rg BT 216.80 222.10 Td (The study did not meet its primary endpoint of the four) Tj ET Q q 0 0 0 rg BT 459.15 222.10 Td (-week continuous ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 202.95 Td (abstinence rate at weeks 9 through 12 for Chantix/Champix compared to placebo. ) Tj ET Q q 0 0 0 rg BT 438.28 202.95 Td (The study is a regulatory ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 183.80 Td (post-marketing commitment for Chantix/Champix in the U.S. and the European Union \(EU\) for adolescents ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 164.65 Td (12-16 years and 12-17 years of age, respectively) Tj ET Q q 0 0 0 rg BT 288.98 164.65 Td (. ) Tj ET Q q 0 0 0 rg BT 293.87 164.65 Td (As part of planned regulatory interactions in the U.S. and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 145.50 Td (EU, these data will be submitted to the U.S. Food and Drug ) Tj ET Q q 0 0 0 rg BT 340.77 145.50 Td (Administration \(FDA\) for pediatric exclusivity ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 126.40 Td (determination.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 98.88 cm /I16 Do Q q 0 0 0 rg BT 62.50 101.25 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 101.25 Td (Inlyta \(axitinib\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 150.76 101.25 Td ( -- In ) Tj ET Q q 0 0 0 rg BT 174.89 101.25 Td (April 2018, Pfizer announced that the independent Data Monitoring Committee for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 82.10 Td (Phase 3 ) Tj ET Q q 0 0 0 rg BT 112.56 82.10 Td (A) Tj ET Q q 0 0 0 rg BT 119.28 82.10 Td (TLAS trial evaluating Inlyta as adjuvant therapy for patients at high risk of recurrent renal cell ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 62.95 Td (carcinoma \(RCC\) after nephrectomy recommended stopping the trial at a planned interim analysis due to ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 43.80 Td (futility) Tj ET Q q 0 0 0 rg BT 105.73 43.80 Td (. ) Tj ET Q q 0 0 0 rg BT 111.03 43.80 Td (The recommendation was based on the study failing to demonstrate a clear improvement in the ) Tj ET Q endstream endobj 15 0 obj <> endobj 16 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 29.10 Td (- 7 -) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 730.40 Td (primary endpoint of extending disease-free survival for patients treated with Inlyta compared with patients ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 711.25 Td (treated with placebo. No new safety signals were observed, and the safety profile was consistent with the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 692.10 Td (known profile of Inlyta in advanced RCC.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 664.63 cm /I17 Do Q q 0 0 0 rg BT 62.50 667.00 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 667.00 Td (Mylotarg \(gemtuzumab ozogamicin\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 247.57 667.00 Td ( -- In ) Tj ET Q q 0 0 0 rg BT 271.71 667.00 Td (April 2018, Pfizer announced that the EC approved Mylotar) Tj ET Q q 0 0 0 rg BT 535.74 667.00 Td (g in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 647.85 Td (combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 628.70 Td (previously untreated, de novo, CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia. ) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 601.18 cm /I18 Do Q q 0 0 0 rg BT 62.50 603.55 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 603.55 Td (Steglatr) Tj ET Q q 0 0 0 rg BT 113.57 603.55 Td (o \(ertugliflozin\), Steglujan \(ertugliflozin and sitagliptin\) and Seglur) Tj ET Q q 0 0 0 rg BT 428.10 603.55 Td (omet \(ertugliflozin and ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 584.40 Td (metformin hydr) Tj ET Q q 0 0 0 rg BT 151.76 584.40 Td (ochloride\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 199.42 584.40 Td ( -- In March 2018, the EC approved the oral sodium-glucose cotransporter 2 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 565.30 Td (\(SGL) Tj ET Q q 0 0 0 rg BT 99.93 565.30 Td (T2\) inhibitor Steglatro \(ertugliflozin\) and the two fixed-dose combinations Steglujan \(ertugliflozin and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 546.15 Td (sitagliptin\) and Segluromet \(ertugliflozin and metformin hydrochloride\) for use in adults aged 18 years and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 527.00 Td (older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. ) Tj ET Q q 0 0 0 rg BT 509.45 527.00 Td (These ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 507.85 Td (products will be exclusively promoted by Merck, known as MSD outside the U.S. and Canada, in the EU.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 480.33 cm /I19 Do Q q 0 0 0 rg BT 62.50 482.70 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 482.70 Td (Sutent \(sunitinib malate\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 193.24 482.70 Td ( -- In February 2018, Pfizer announced that the Committee for Medicinal Products ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 463.60 Td (for Human Use \(CHMP\) of the European Medicines ) Tj ET Q q 0 0 0 rg BT 309.28 463.60 Td (Agency \(EMA\) has recommended against expanding ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 444.45 Td (use of Sutent to include the adjuvant treatment of adult patients at a high risk of recurrent RCC following ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 425.30 Td (nephrectomy) Tj ET Q q 0 0 0 rg BT 133.21 425.30 Td (. ) Tj ET Q q 0 0 0 rg BT 138.51 425.30 Td (The CHMP) Tj ET Q q 0 0 0 rg BT 192.60 425.30 Td (s recommendation is not binding but will now be taken into consideration by the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 406.15 Td (EC. ) Tj ET Q q 0 0 0 rg BT 95.86 406.15 Td (There is currently no approved adjuvant treatment option available for patients with non-metastatic RCC ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 387.00 Td (at high risk for recurrence in the EU.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 359.53 cm /I20 Do Q q 0 0 0 rg BT 62.50 361.90 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 361.90 Td (T) Tj ET Q q 0 0 0 rg BT 83.02 361.90 Td (rumenba \(Meningococcal Ser) Tj ET Q q 0 0 0 rg BT 220.91 361.90 Td (ogr) Tj ET Q q 0 0 0 rg BT 236.59 361.90 Td (oup B Bivalent Recombinant Lipopr) Tj ET Q q 0 0 0 rg BT 407.53 361.90 Td (otein vaccine\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 471.98 361.90 Td ( -- In ) Tj ET Q q 0 0 0 rg BT 496.12 361.90 Td (April 2018, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 342.75 Td (Pfizer announced that ) Tj ET Q q 0 0 0 rg BT 174.96 342.75 Td (T) Tj ET Q q 0 0 0 rg BT 181.29 342.75 Td (rumenba received Breakthrough ) Tj ET Q q 0 0 0 rg BT 325.56 342.75 Td (Therapy designation from the FDA) Tj ET Q q 0 0 0 rg BT 480.14 342.75 Td ( for active ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 323.60 Td (immunization to prevent invasive disease caused by ) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 307.74 323.60 Td (Neisseria meningitidis) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 406.44 323.60 Td ( group B \(MenB\) in children ages ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 304.45 Td (1 through 9 years. ) Tj ET Q q 0 0 0 rg BT 158.48 304.45 Td (This is the first Breakthrough ) Tj ET Q q 0 0 0 rg BT 290.56 304.45 Td (Therapy designation for a MenB vaccine to help protect ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 285.30 Td (children as young as 1 year of age. ) Tj ET Q q 0 0 0 rg BT 231.77 285.30 Td (T) Tj ET Q q 0 0 0 rg BT 238.11 285.30 Td (rumenba previously received Breakthrough ) Tj ET Q q 0 0 0 rg BT 431.56 285.30 Td (Therapy designation in 2014 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 266.20 Td (for the prevention of MenB in adolescents and young adults ages 10 through 25 years, and later the same ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 247.05 Td (year received FDA) Tj ET Q q 0 0 0 rg BT 159.57 247.05 Td ( approval as the first MenB vaccine approved in the U.S.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 219.53 cm /I21 Do Q q 0 0 0 rg BT 62.50 221.90 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 221.90 Td (V) Tj ET Q q 0 0 0 rg BT 83.43 221.90 Td (yndaqel \(tafamidis\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 174.80 221.90 Td ( -- In March 2018, Pfizer announced that the ) Tj ET Q q 0 0 0 rg BT 373.15 221.90 Td (T) Tj ET Q q 0 0 0 rg BT 379.10 221.90 Td (afamidis Phase 3 ) Tj ET Q q 0 0 0 rg BT 456.19 221.90 Td (T) Tj ET Q q 0 0 0 rg BT 462.52 221.90 Td (ransthyretin ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 202.75 Td (Cardiomyopathy \(A) Tj ET Q q 0 0 0 rg BT 163.57 202.75 Td (TTR-ACT\) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 183.60 Td (\(TTR-CM\) met its primary endpoint, demonstrating a statistically significant reduction in the combination of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 164.50 Td (all-cause mortality and frequency of cardiovascular) Tj ET Q q 0 0 0 rg BT 302.59 164.50 Td (-related hospitalizations compared to placebo at 30 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 145.35 Td (months. ) Tj ET Q q 0 0 0 rg BT 114.19 145.35 Td (The preliminary safety data showed that tafamidis was generally well tolerated in this population ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 126.20 Td (and no new safety signals were identified. ) Tj ET Q q 0 0 0 rg BT 263.85 126.20 Td (V) Tj ET Q q 0 0 0 rg BT 270.58 126.20 Td (yndaqel is approved in 40 countries for the treatment of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 107.05 Td (transthyretin amyloid polyneuropathy \(TTR-F) Tj ET Q q 0 0 0 rg BT 278.84 107.05 Td (AP\) in adult patients with early-stage symptomatic ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 87.90 Td (polyneuropathy to delay peripheral neurologic impairment. ) Tj ET Q q 0 0 0 rg BT 339.30 87.90 Td (T) Tj ET Q q 0 0 0 rg BT 345.25 87.90 Td (afamidis is an investigational treatment for ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 68.80 Td (TTR-CM and is not approved for this indication.) Tj ET Q endstream endobj 17 0 obj <> endobj 18 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 29.10 Td (- 8 -) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 728.03 cm /I22 Do Q q 0 0 0 rg BT 62.50 730.40 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 730.40 Td (Xeljanz \(tofacitinib\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 705.25 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 705.25 Td (In ) Tj ET Q q 0 0 0 rg BT 110.31 705.25 Td (April 2018, the CHMP) Tj ET Q q 0 0 0 rg BT 210.73 705.25 Td ( of the EMA) Tj ET Q q 0 0 0 rg BT 265.42 705.25 Td ( adopted a positive opinion recommending a change to the terms ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 686.10 Td (of the marketing authorization for Xeljanz to include Xeljanz in combination with methotrexate for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 667.00 Td (treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 647.85 Td (been intolerant to a prior disease-modifying antirheumatic drug therapy) Tj ET Q q 0 0 0 rg BT 412.90 647.85 Td (. ) Tj ET Q q 0 0 0 rg BT 418.20 647.85 Td (The CHMP) Tj ET Q q 0 0 0 rg BT 472.29 647.85 Td (s opinion will now ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 628.70 Td (be reviewed by the EC, which has the authority to approve medicines for the EU.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 603.55 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 603.55 Td (In March 2018, Pfizer announced a positive outcome from an FDA) Tj ET Q q 0 0 0 rg BT 393.79 603.55 Td ( Gastrointestinal Drugs ) Tj ET Q q 0 0 0 rg BT 497.97 603.55 Td (Advisory ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 584.40 Td (Committee \(GIDAC\) meeting. ) Tj ET Q q 0 0 0 rg BT 236.27 584.40 Td (The GIDAC met to discuss Pfizer) Tj ET Q q 0 0 0 rg BT 385.46 584.40 Td () Tj ET Q q 0 0 0 rg BT 388.52 584.40 Td (s supplemental New Drug ) Tj ET Q q 0 0 0 rg BT 505.22 584.40 Td (Application ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 565.30 Td (\(sNDA\) for Xeljanz, which is currently under review by the FDA, for the treatment of adult patients ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 546.15 Td (with moderately to severely active ulcerative colitis \(UC\). ) Tj ET Q q 0 0 0 rg BT 356.90 546.15 Td (The role of the GIDAC is to provide ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 527.00 Td (recommendations to the FDA; however) Tj ET Q q 0 0 0 rg BT 272.69 527.00 Td (, the recommendations are not binding. ) Tj ET Q q 0 0 0 rg BT 447.22 527.00 Td (The FDA) Tj ET Q q 0 0 0 rg BT 487.86 527.00 Td () Tj ET Q q 0 0 0 rg BT 490.91 527.00 Td (s decision on ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 507.85 Td (whether or not to approve Xeljanz for UC is expected by the Prescription Drug User Fee ) Tj ET Q q 0 0 0 rg BT 490.61 507.85 Td (Act \(PDUF) Tj ET Q q 0 0 0 rg BT 540.21 507.85 Td (A\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 488.70 Td (date in June 2018.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 461.23 cm /I23 Do Q q 0 0 0 rg BT 62.50 463.60 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 463.60 Td (Xtandi \(enzalutamide\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 438.45 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 438.45 Td (In March 2018, Pfizer and ) Tj ET Q q 0 0 0 rg BT 216.91 438.45 Td (Astellas Pharma Inc. \(Astellas\) announced that a sNDA) Tj ET Q q 0 0 0 rg BT 461.29 438.45 Td ( for Xtandi was ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 419.30 Td (accepted for filing and granted Priority Review designation by the FDA. If approved, the sNDA) Tj ET Q q 0 0 0 rg BT 520.56 419.30 Td ( would ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 400.15 Td (expand the indication of Xtandi to include men with non-metastatic \(M0\) Castration-Resistant Prostate ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 381.00 Td (Cancer \(CRPC\), based on data from the Phase 3 PROSPER trial. Xtandi is currently indicated for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 361.90 Td (treatment of patients with metastatic CRPC. ) Tj ET Q q 0 0 0 rg BT 295.24 361.90 Td (The PDUF) Tj ET Q q 0 0 0 rg BT 342.40 361.90 Td (A) Tj ET Q q 0 0 0 rg BT 349.73 361.90 Td ( goal date assigned by the FDA) Tj ET Q q 0 0 0 rg BT 487.21 361.90 Td ( is in July 2018. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 342.75 Td (In addition, the EMA) Tj ET Q q 0 0 0 rg BT 192.49 342.75 Td ( validated the ) Tj ET Q q 0 0 0 rg BT 254.29 342.75 Td (T) Tj ET Q q 0 0 0 rg BT 260.25 342.75 Td (ype II ) Tj ET Q q 0 0 0 rg BT 288.76 342.75 Td (V) Tj ET Q q 0 0 0 rg BT 295.48 342.75 Td (ariation for Xtandi seeking to expand the current indication ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 323.60 Td (to the same patient population.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 81.00 298.45 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 298.45 Td (In February 2018, Pfizer and ) Tj ET Q q 0 0 0 rg BT 227.91 298.45 Td (Astellas announced results from the Phase 3 PROSPER trial in patients ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 279.30 Td (with M0 CRPC. ) Tj ET Q q 0 0 0 rg BT 172.77 279.30 Td (The results show that the use of Xtandi plus androgen deprivation therapy \(ADT\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 260.20 Td (significantly reduced the risk of developing metastases or death by 71% compared to ) Tj ET Q q 0 0 0 rg BT 475.03 260.20 Td (ADT) Tj ET Q q 0 0 0 rg BT 497.44 260.20 Td ( alone. ) Tj ET Q q 0 0 0 rg BT 529.31 260.20 Td (The ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 241.05 Td (median for the primary endpoint, metastasis-free survival, was 36.6 months for men who received ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 221.90 Td (Xtandi compared to 14.7 months with ) Tj ET Q q 0 0 0 rg BT 267.95 221.90 Td (ADT) Tj ET Q q 0 0 0 rg BT 290.36 221.90 Td ( alone. Full results were presented at the 2018 Genitourinary ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 99.00 202.75 Td (Cancers Symposium in San Francisco.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 171.60 Td (Pipeline Developments) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 143.50 Td (A) Tj ET Q q 0 0 0 rg BT 61.34 143.50 Td ( comprehensive update of Pfizer) Tj ET Q q 0 0 0 rg BT 204.08 143.50 Td () Tj ET Q q 0 0 0 rg BT 207.14 143.50 Td (s development pipeline was published today and is now available at ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 124.35 Td (www) Tj ET Q q 0 0 0 rg BT 77.12 124.35 Td (.pfizer) Tj ET Q q 0 0 0 rg BT 104.91 124.35 Td (.com/science/drug-product-pipeline. It includes an overview of Pfizer) Tj ET Q q 0 0 0 rg BT 411.37 124.35 Td () Tj ET Q q 0 0 0 rg BT 414.43 124.35 Td (s research and a list of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 105.20 Td (compounds in development with tar) Tj ET Q q 0 0 0 rg BT 212.05 105.20 Td (geted indication and phase of development, as well as mechanism of action ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 54.00 86.05 Td (for some candidates in Phase 1 and all candidates from Phase 2 through registration.) Tj ET Q endstream endobj 19 0 obj <> endobj 20 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.65 42.60 Td (- 9 -) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 728.03 cm /I24 Do Q q 0 0 0 rg BT 62.50 730.40 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 730.40 Td (Dacomitinib \(PF-00299804\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 208.48 730.40 Td (-- In ) Tj ET Q q 0 0 0 rg BT 229.87 730.40 Td (April 2018, Pfizer announced that the FDA) Tj ET Q q 0 0 0 rg BT 419.58 730.40 Td ( accepted and granted Priority ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 711.25 Td (Review for the company) Tj ET Q q 0 0 0 rg BT 187.99 711.25 Td (s New Drug ) Tj ET Q q 0 0 0 rg BT 243.29 711.25 Td (Application \(NDA\) for dacomitinib, a pan-human epidermal growth ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 692.10 Td (factor receptor \(EGFR\) ) Tj ET Q q 0 0 0 rg BT 181.67 692.10 Td (TKI, for the first-line treatment of patients with locally advanced or metastatic ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 673.00 Td (NSCLC with EGFR-activating mutations. ) Tj ET Q q 0 0 0 rg BT 263.60 673.00 Td (The PDUF) Tj ET Q q 0 0 0 rg BT 310.76 673.00 Td (A) Tj ET Q q 0 0 0 rg BT 318.10 673.00 Td ( goal date assigned by the FDA) Tj ET Q q 0 0 0 rg BT 455.58 673.00 Td ( is in September 2018. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 653.85 Td (The EMA) Tj ET Q q 0 0 0 rg BT 120.19 653.85 Td ( has also accepted the Marketing ) Tj ET Q q 0 0 0 rg BT 266.19 653.85 Td (Authorization ) Tj ET Q q 0 0 0 rg BT 329.43 653.85 Td (Application for dacomitinib for the same ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 634.70 Td (indication.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 604.18 cm /I25 Do Q q 0 0 0 rg BT 62.50 606.55 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 606.55 Td (Lorlatinib \(PF-06463922\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 198.71 606.55 Td (-- In February 2018, Pfizer announced that the FDA) Tj ET Q q 0 0 0 rg BT 426.90 606.55 Td ( accepted and granted ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 587.40 Td (Priority Review for the company) Tj ET Q q 0 0 0 rg BT 224.36 587.40 Td (s NDA) Tj ET Q q 0 0 0 rg BT 254.61 587.40 Td ( for lorlatinib, an investigational, anaplastic lymphoma kinase ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 568.30 Td (\(ALK\) ) Tj ET Q q 0 0 0 rg BT 108.98 568.30 Td (TKI for the treatment of patients with ) Tj ET Q q 0 0 0 rg BT 276.69 568.30 Td (ALK-positive metastatic NSCLC, in patients previously treated ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 549.15 Td (with one or more ) Tj ET Q q 0 0 0 rg BT 154.10 549.15 Td (ALK ) Tj ET Q q 0 0 0 rg BT 179.25 549.15 Td (TKIs. ) Tj ET Q q 0 0 0 rg BT 207.16 549.15 Td (The PDUF) Tj ET Q q 0 0 0 rg BT 254.32 549.15 Td (A) Tj ET Q q 0 0 0 rg BT 261.66 549.15 Td ( goal date assigned by the FDA) Tj ET Q q 0 0 0 rg BT 399.14 549.15 Td ( is in ) Tj ET Q q 0 0 0 rg BT 422.67 549.15 Td (August 2018. ) Tj ET Q q 0 0 0 rg BT 484.50 549.15 Td (The EMA) Tj ET Q q 0 0 0 rg BT 528.19 549.15 Td ( and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 530.00 Td (the Japan Pharmaceutical and Medical Devices ) Tj ET Q q 0 0 0 rg BT 286.03 530.00 Td (Agency have also accepted marketing applications for the use ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 510.85 Td (of lorlatinib.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 480.33 cm /I26 Do Q q 0 0 0 rg BT 62.50 482.70 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 482.70 Td (PF-04965842) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 137.60 482.70 Td ( -- In February 2018, Pfizer announced that its once-daily oral Janus kinase 1 \(JAK1\) inhibitor ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 463.60 Td (PF-04965842 received Breakthrough ) Tj ET Q q 0 0 0 rg BT 242.18 463.60 Td (Therapy designation from the FDA) Tj ET Q q 0 0 0 rg BT 396.76 463.60 Td ( for the treatment of patients with ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 444.45 Td (moderate-to-severe atopic dermatitis \(AD\). ) Tj ET Q q 0 0 0 rg BT 269.03 444.45 Td (The Phase 3 program for PF-04965842 initiated in December ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 425.30 Td (2017 and is the first trial in the JAK1 ) Tj ET Q q 0 0 0 rg BT 242.40 425.30 Td (Atopic Dermatitis Ef) Tj ET Q q 0 0 0 rg BT 334.45 425.30 Td (ficacy and Safety \(JADE\) global development ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 406.15 Td (program.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 375.63 cm /I27 Do Q q 0 0 0 rg BT 62.50 378.00 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 378.00 Td (PF-05280014 \(pr) Tj ET Q q 0 0 0 rg BT 154.82 378.00 Td (oposed biosimilar) Tj ET Q q 0 0 0 rg BT 237.43 378.00 Td ( trastuzumab\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 303.73 378.00 Td ( -- In ) Tj ET Q q 0 0 0 rg BT 327.87 378.00 Td (April 2018, Pfizer announced that it received a ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 358.90 Td (Complete Response Letter \(CRL\) from the FDA) Tj ET Q q 0 0 0 rg BT 289.13 358.90 Td ( in response to the Biologics License ) Tj ET Q q 0 0 0 rg BT 453.19 358.90 Td (Application for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 339.75 Td (company) Tj ET Q q 0 0 0 rg BT 119.88 339.75 Td (s proposed trastuzumab biosimilar) Tj ET Q q 0 0 0 rg BT 270.49 339.75 Td (. In the CRL, the FDA) Tj ET Q q 0 0 0 rg BT 368.57 339.75 Td ( highlighted the need for additional ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 320.60 Td (technical information. ) Tj ET Q q 0 0 0 rg BT 176.18 320.60 Td (The additional requested information does not relate to safety or clinical data ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 301.45 Td (submitted in the application. Pfizer is working closely with the FDA) Tj ET Q q 0 0 0 rg BT 376.82 301.45 Td ( to address the contents of the letter and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 282.30 Td (remains committed to bringing this important medicine to patients in the U.S.) Tj ET Q BT /F2 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 251.83 cm /I28 Do Q q 0 0 0 rg BT 62.50 254.20 Td ( ) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 76.50 254.20 Td (PF-06939926) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 137.60 254.20 Td ( -- In ) Tj ET Q q 0 0 0 rg BT 161.73 254.20 Td (April 2018, Pfizer announced that a Phase 1b clinical trial for its mini-dystrophin gene ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 235.05 Td (therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy \(DMD\) was initiated. ) Tj ET Q q 0 0 0 rg BT 516.53 235.05 Td (The first ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 215.90 Td (boy received an infusion of the mini-dystrophin gene on March 22) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 369.15 220.88 Td (nd) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 376.30 215.90 Td (, administered under the supervision of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 196.75 Td (principal investigator) Tj ET Q q 0 0 0 rg BT 169.84 196.75 Td (, Edward Smith, MD, ) Tj ET Q q 0 0 0 rg BT 266.70 196.75 Td (Associate Professor of Pediatrics and Neurology at Duke ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 177.60 Td (University Medical Center) Tj ET Q q 0 0 0 rg BT 193.19 177.60 Td (. Screening and enrollment of patients is expected to continue at up to four clinical ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 158.50 Td (research sites in the U.S. Early data from this trial are expected in the first half of 2019, once the first patient ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 139.35 Td (has been evaluated for one full year post-treatment. ) Tj ET Q q 0 0 0 rg BT 305.07 139.35 Td (The multi-center) Tj ET Q q 0 0 0 rg BT 378.23 139.35 Td (, open-label, non-randomized, ascending ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 120.20 Td (dose study of a single intravenous infusion of PF-06939926 will enroll approximately 12 ambulatory boys ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 101.05 Td (aged 5 to 12 years with DMD. In addition to evaluating safety and tolerability) Tj ET Q q 0 0 0 rg BT 418.54 101.05 Td (, the study will evaluate ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 81.90 Td (measurements of dystrophin expression and distribution, as well as assessments of muscle strength, quality ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 62.80 Td (and function. ) Tj ET Q q 0 0 0 rg BT 136.68 62.80 Td (As part of the screening process, potential candidates for treatment will be tested to confirm a ) Tj ET Q endstream endobj 21 0 obj <> endobj 22 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 42.60 Td (- 10 -) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 730.40 Td (negative result for antibodies against the adeno-associated virus serotype 9 \(AA) Tj ET Q q 0 0 0 rg BT 426.36 730.40 Td (V9\) capsid and for a ) Tj ET Q q 0 0 0 rg BT 518.71 730.40 Td (T) Tj ET Q q 0 0 0 rg BT 524.42 730.40 Td (-cell ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 711.25 Td (\(immune\) response to dystrophin.) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 680.10 Td (Corporate Developments) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 655.63 cm /I29 Do Q q 0 0 0 rg BT 62.50 658.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 658.00 Td (In ) Tj ET Q q 0 0 0 rg BT 87.81 658.00 Td (April 2018, Pfizer and ) Tj ET Q q 0 0 0 rg BT 188.32 658.00 Td (Allogene ) Tj ET Q q 0 0 0 rg BT 231.19 658.00 Td (Therapeutics, Inc. \(Allogene\) announced that the two companies entered ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 638.85 Td (into an asset contribution agreement for Pfizer) Tj ET Q q 0 0 0 rg BT 280.95 638.85 Td () Tj ET Q q 0 0 0 rg BT 284.01 638.85 Td (s portfolio of assets related to allogeneic chimeric antigen ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 619.70 Td (receptor ) Tj ET Q q 0 0 0 rg BT 115.08 619.70 Td (T) Tj ET Q q 0 0 0 rg BT 121.60 619.70 Td ( cell \(CAR ) Tj ET Q q 0 0 0 rg BT 171.81 619.70 Td (T\) therapy) Tj ET Q q 0 0 0 rg BT 217.21 619.70 Td (, an investigational immune cell therapy approach to treating cancer) Tj ET Q q 0 0 0 rg BT 515.32 619.70 Td (. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 600.55 Td (Allogene is co-founded and led by former executives of Kite Pharma. Pfizer views this agreement as an ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 581.40 Td (attractive opportunity to support the continued development of allogeneic CAR ) Tj ET Q q 0 0 0 rg BT 428.22 581.40 Td (T) Tj ET Q q 0 0 0 rg BT 434.74 581.40 Td ( therapy in a highly focused ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 562.30 Td (and skilled manner) Tj ET Q q 0 0 0 rg BT 159.59 562.30 Td (. Pfizer will continue to participate financially in the development of the CAR ) Tj ET Q q 0 0 0 rg BT 505.18 562.30 Td (T) Tj ET Q q 0 0 0 rg BT 511.70 562.30 Td ( portfolio ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 543.15 Td (through a 25% ownership stake in ) Tj ET Q q 0 0 0 rg BT 228.64 543.15 Td (Allogene. Separately) Tj ET Q q 0 0 0 rg BT 320.17 543.15 Td (, Pfizer maintains its approximate 8% ownership ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 524.00 Td (stake in Cellectis through an equity agreement entered into in 2014 by which Pfizer obtained exclusive rights ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 504.85 Td (to pursue the development and commercialization of certain Cellectis CAR ) Tj ET Q q 0 0 0 rg BT 409.86 504.85 Td (T) Tj ET Q q 0 0 0 rg BT 416.38 504.85 Td ( therapies. ) Tj ET Q q 0 0 0 rg BT 464.14 504.85 Td (These CAR ) Tj ET Q q 0 0 0 rg BT 518.32 504.85 Td (T) Tj ET Q q 0 0 0 rg BT 524.84 504.85 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 485.70 Td (therapy development programs obtained from Cellectis comprise the assets contributed to ) Tj ET Q q 0 0 0 rg BT 473.31 485.70 Td (Allogene.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 58.50 455.23 cm /I30 Do Q q 0 0 0 rg BT 62.50 457.60 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 457.60 Td (On March 12, 2018, Pfizer entered into an accelerated share repurchase agreement with Citibank N.A. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 438.45 Td (\(Citibank\) to repurchase $4.0 billion of Pfizer) Tj ET Q q 0 0 0 rg BT 278.22 438.45 Td () Tj ET Q q 0 0 0 rg BT 281.27 438.45 Td (s common stock. Pursuant to the terms of the agreement, on ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 419.30 Td (March 14, 2018, Pfizer paid $4.0 billion to Citibank and received an initial delivery of approximately ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 525.24 419.30 Td (87 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 400.15 Td (million) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.28 400.15 Td ( shares of Pfizer common stock from Citibank. ) Tj ET Q q 0 0 0 rg BT 316.32 400.15 Td (At settlement of the agreement, which is expected to ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 381.00 Td (occur during or prior to the third quarter of 2018, Citibank may be required to deliver additional shares of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 361.90 Td (common stock to Pfizer) Tj ET Q q 0 0 0 rg BT 180.84 361.90 Td (, or) Tj ET Q q 0 0 0 rg BT 195.07 361.90 Td (, under certain circumstances, Pfizer may be required to deliver shares of its ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 342.75 Td (common stock or may elect to make a cash payment to Citibank, with the number of shares to be delivered ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 323.60 Td (or the amount of such payment based on the volume-weighted average price of Pfizer) Tj ET Q q 0 0 0 rg BT 453.52 323.60 Td () Tj ET Q q 0 0 0 rg BT 456.58 323.60 Td (s common stock ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 76.50 304.45 Td (during the term of the transaction.) Tj ET Q endstream endobj 23 0 obj <> endobj 24 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.35 42.60 Td (- 1) Tj ET Q q 0 0 0 rg BT 305.81 42.60 Td (1 -) Tj ET Q BT /F2 11.00 Tf ET q 0 0 0 rg BT 54.00 739.60 Td (For) Tj ET Q q 0 0 0 rg BT 70.90 739.60 Td ( additional details, see the attached financial schedules, pr) Tj ET Q q 0 0 0 rg BT 342.05 739.60 Td (oduct r) Tj ET Q q 0 0 0 rg BT 375.76 739.60 Td (evenue tables and disclosur) Tj ET Q q 0 0 0 rg BT 503.60 739.60 Td (e notice.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 708.45 Td (\(1\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 708.45 Td (Revenues is defined as revenues in accordance with U.S. generally accepted accounting principles ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 689.30 Td (\(GAAP\).) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 128.28 689.30 Td (Reported net income is defined as net income attributable to Pfizer Inc. in accordance with U.S. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 670.15 Td (GAAP) Tj ET Q q 0 0 0 rg BT 114.23 670.15 Td (.Reported diluted earnings per share \(EPS\) is defined as reported diluted EPS attributable to Pfizer ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 651.00 Td (Inc. common shareholders in accordance with U.S. GAAP) Tj ET Q q 0 0 0 rg BT 341.49 651.00 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 344.24 651.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 619.90 Td (\(2\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 619.90 Td (Adjusted income and its components and ) Tj ET Q q 0 0 0 rg BT 268.80 619.90 Td (Adjusted diluted EPS are defined as reported U.S. GAAP) Tj ET Q q 0 0 0 rg BT 521.35 619.90 Td ( net ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 600.75 Td (income) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 117.88 605.73 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 126.21 600.75 Td ( and its components and reported diluted EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 326.93 605.73 Td (\(1\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 335.27 600.75 Td ( excluding purchase accounting adjustments, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 581.60 Td (acquisition-related costs, discontinued operations and certain significant items \(some of which may recur) Tj ET Q q 0 0 0 rg BT 547.23 581.60 Td (, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 562.45 Td (such as restructuring or legal char) Tj ET Q q 0 0 0 rg BT 234.05 562.45 Td (ges, but which management does not believe are reflective of ongoing ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 543.30 Td (core operations\).) Tj ET Q q 0 0 0 rg BT 161.55 543.30 Td (Adjusted cost of sales, ) Tj ET Q q 0 0 0 rg BT 262.68 543.30 Td (Adjusted selling, informational and administrative \(SI&A\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 524.20 Td (expenses, ) Tj ET Q q 0 0 0 rg BT 130.10 524.20 Td (Adjusted research and development \(R&D\) expenses and ) Tj ET Q q 0 0 0 rg BT 384.55 524.20 Td (Adjusted other \(income\)/deductions ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 505.05 Td (are income statement line items prepared on the same basis as, and therefore components of, the overall ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 485.90 Td (Adjusted income measure.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 202.49 485.90 Td () Tj ET Q q 0 0 0 rg BT 204.64 485.90 Td (As described in the ) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 292.00 485.90 Td (Financial ReviewNon-GAAP) Tj ET Q q 0 0 0 rg BT 430.18 485.90 Td ( Financial Measur) Tj ET Q q 0 0 0 rg BT 511.65 485.90 Td (e ) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 85.50 466.75 Td (\(Adjusted Income\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 166.44 466.75 Td ( section of Pfizer) Tj ET Q q 0 0 0 rg BT 241.69 466.75 Td () Tj ET Q q 0 0 0 rg BT 244.74 466.75 Td (s 2017 Financial Report, which was filed as Exhibit 13 to Pfizer) Tj ET Q q 0 0 0 rg BT 526.82 466.75 Td () Tj ET Q q 0 0 0 rg BT 529.88 466.75 Td (s ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 447.60 Td (Annual Report on Form 10-K for the fiscal year ended December 31, 2017, management uses ) Tj ET Q q 0 0 0 rg BT 500.02 447.60 Td (Adjusted ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 428.50 Td (income, among other factors, to set performance goals and to measure the performance of the overall ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 409.35 Td (company) Tj ET Q q 0 0 0 rg BT 125.11 409.35 Td (.Because ) Tj ET Q q 0 0 0 rg BT 169.40 409.35 Td (Adjusted income is an important internal measurement for Pfizer) Tj ET Q q 0 0 0 rg BT 454.87 409.35 Td (, management believes ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 390.20 Td (that investors) Tj ET Q q 0 0 0 rg BT 147.31 390.20 Td ( understanding of our performance is enhanced by disclosing this performance ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 371.05 Td (measure.Pfizer reports ) Tj ET Q q 0 0 0 rg BT 189.35 371.05 Td (Adjusted income, certain components of ) Tj ET Q q 0 0 0 rg BT 369.58 371.05 Td (Adjusted income, and ) Tj ET Q q 0 0 0 rg BT 467.95 371.05 Td (Adjusted diluted ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 351.90 Td (EPS in order to portray the results of the company) Tj ET Q q 0 0 0 rg BT 309.43 351.90 Td (s major operationsthe discovery) Tj ET Q q 0 0 0 rg BT 459.92 351.90 Td (, development, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 332.80 Td (manufacture, marketing and sale of prescription medicines, vaccines and consumer healthcare \(OTC\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 313.65 Td (productsprior to considering certain income statement elements.See the accompanying reconciliations ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 294.50 Td (of certain GAAP) Tj ET Q q 0 0 0 rg BT 159.63 294.50 Td ( Reported to Non-GAAP) Tj ET Q q 0 0 0 rg BT 268.90 294.50 Td ( ) Tj ET Q q 0 0 0 rg BT 271.04 294.50 Td (Adjusted information for the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 399.96 294.50 Td (first quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 451.58 294.50 Td ( of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 466.24 294.50 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 488.24 294.50 Td ( and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 509.62 294.50 Td (2017) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 531.62 294.50 Td (. ) Tj ET Q q 0 0 0 rg BT 536.92 294.50 Td (The ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 275.35 Td (Adjusted income and its components and ) Tj ET Q q 0 0 0 rg BT 268.80 275.35 Td (Adjusted diluted EPS measures are not, and should not be ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 256.20 Td (viewed as, substitutes for U.S. GAAP) Tj ET Q q 0 0 0 rg BT 251.31 256.20 Td ( net income and its components and diluted EPS.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 225.10 Td (\(3\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 225.10 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 112.17 225.10 Td () Tj ET Q q 0 0 0 rg BT 115.23 225.10 Td (s fiscal year) Tj ET Q q 0 0 0 rg BT 167.54 225.10 Td (-end for international subsidiaries is November 30 while Pfizer) Tj ET Q q 0 0 0 rg BT 445.31 225.10 Td () Tj ET Q q 0 0 0 rg BT 448.37 225.10 Td (s fiscal year) Tj ET Q q 0 0 0 rg BT 500.68 225.10 Td (-end for ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 205.95 Td (U.S. subsidiaries is December 31. ) Tj ET Q q 0 0 0 rg BT 236.83 205.95 Td (Therefore, Pfizer) Tj ET Q q 0 0 0 rg BT 312.36 205.95 Td () Tj ET Q q 0 0 0 rg BT 315.42 205.95 Td (s ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 322.45 205.95 Td (first quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 374.06 205.95 Td ( for U.S. subsidiaries reflect the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 516.41 205.95 Td (three ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 186.80 Td (months) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 117.89 186.80 Td ( ending on ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 166.47 186.80 Td (April1, 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 225.44 186.80 Td ( and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 246.22 186.80 Td (April2, 2017) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 305.19 186.80 Td ( while Pfizer) Tj ET Q q 0 0 0 rg BT 361.80 186.80 Td () Tj ET Q q 0 0 0 rg BT 364.86 186.80 Td (s ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 371.89 186.80 Td (first quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 423.50 186.80 Td ( for subsidiaries operating ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 167.65 Td (outside the U.S. reflect the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 205.55 167.65 Td (three months) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 262.68 167.65 Td ( ending on ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 311.86 167.65 Td (February25, 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 392.82 167.65 Td ( and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 414.21 167.65 Td (February26, 2017) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 495.16 167.65 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 136.50 Td (\(4\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 136.50 Td (References to operational variances in this press release pertain to period-over) Tj ET Q q 0 0 0 rg BT 429.19 136.50 Td (-period growth rates that ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 117.40 Td (exclude the impact of foreign exchange. ) Tj ET Q q 0 0 0 rg BT 264.58 117.40 Td (The operational variances are determined by multiplying or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 98.25 Td (dividing, as appropriate, the current period U.S. dollar results by the current period average foreign ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 79.10 Td (exchange rates and then multiplying or dividing, as appropriate, those amounts by the prior) Tj ET Q q 0 0 0 rg BT 486.38 79.10 Td (-year period ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 59.95 Td (average foreign exchange rates. ) Tj ET Q q 0 0 0 rg BT 226.89 59.95 Td (Although exchange rate changes are part of Pfizer) Tj ET Q q 0 0 0 rg BT 447.51 59.95 Td () Tj ET Q q 0 0 0 rg BT 450.56 59.95 Td (s business, they are not ) Tj ET Q endstream endobj 25 0 obj <> endobj 26 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 42.60 Td (- 12 -) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 739.40 Td (within Pfizer) Tj ET Q q 0 0 0 rg BT 143.04 739.40 Td () Tj ET Q q 0 0 0 rg BT 146.09 739.40 Td (s control. Exchange rate changes, however) Tj ET Q q 0 0 0 rg BT 333.49 739.40 Td (, can mask positive or negative trends in the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 720.25 Td (business; therefore, Pfizer believes presenting operational variances provides useful information in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 701.10 Td (evaluating the results of its business.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 670.00 Td (\(5\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 670.00 Td (The 2018 financial guidance reflects the following:) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 636.48 cm /I31 Do Q q 0 0 0 rg BT 94.00 638.85 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 638.85 Td (Pfizer does not provide guidance for GAAP) Tj ET Q q 0 0 0 rg BT 300.66 638.85 Td ( Reported financial measures \(other than revenues\) or a ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 619.70 Td (reconciliation of forward-looking non-GAAP) Tj ET Q q 0 0 0 rg BT 307.68 619.70 Td ( financial measures to the most directly comparable ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 600.55 Td (GAAP) Tj ET Q q 0 0 0 rg BT 137.54 600.55 Td ( Reported financial measures on a forward-looking basis because it is unable to predict with ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 581.40 Td (reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 562.30 Td (related expenses and potential future asset impairments without unreasonable ef) Tj ET Q q 0 0 0 rg BT 459.38 562.30 Td (fort. ) Tj ET Q q 0 0 0 rg BT 480.56 562.30 Td (These items are ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 543.15 Td (uncertain, depend on various factors, and could have a material impact on GAAP) Tj ET Q q 0 0 0 rg BT 464.97 543.15 Td ( Reported results for ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 524.00 Td (the guidance period.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 197.49 524.00 Td ( ) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 493.48 cm /I32 Do Q q 0 0 0 rg BT 94.00 495.85 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 495.85 Td (Does not assume the completion of any business development transactionsnot completed as of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 476.70 Td (April1, 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 166.97 476.70 Td (, including any one-time upfront payments associated with such transactions) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 503.00 476.70 Td (.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 446.23 cm /I33 Do Q q 0 0 0 rg BT 94.00 448.60 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 448.60 Td (Guidance for ) Tj ET Q q 0 0 0 rg BT 167.87 448.60 Td (Adjusted other \(income\)/deductions) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 326.10 453.58 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 334.44 448.60 Td ( does not attempt to forecast unrealized net gains ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 429.45 Td (or losses on equity securities. Pfizer is unable to predict with reasonable certainty unrealized gains or ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 410.30 Td (losses on equity securities in a given period. Net unrealized gains and losses on equity securities are ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 391.15 Td (now recorded in ) Tj ET Q q 0 0 0 rg BT 181.62 391.15 Td (Adjusted other \(income\)/deductions) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 339.85 396.13 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 348.19 391.15 Td ( during each quarter) Tj ET Q q 0 0 0 rg BT 436.01 391.15 Td (, reflecting the adoption of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 372.00 Td (a new accounting standard in the first quarter of 2018. Prior to the adoption of the new standard, net ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 352.90 Td (unrealized gains and losses on virtually all readily tradeable equity securities were reported in ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 333.75 Td (Accumulated other comprehensive income.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 303.23 cm /I34 Do Q q 0 0 0 rg BT 94.00 305.60 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 305.60 Td (Exchange rates assumed are a blend of the actual exchange rates in ef) Tj ET Q q 0 0 0 rg BT 413.82 305.60 Td (fect through first-quarter 2018 ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 286.45 Td (and mid-April 2018 exchange rates for the remainder of the year) Tj ET Q q 0 0 0 rg BT 391.44 286.45 Td (.) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 255.93 cm /I35 Do Q q 0 0 0 rg BT 94.00 258.30 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 258.30 Td (Reflects an anticipated negative revenue impact of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 333.09 258.30 Td ($2.0 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 383.82 258.30 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 386.57 258.30 Td (due to recent and expected generic and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 239.20 Td (biosimilar competition for certain products that have recently lost or are anticipated to soon lose ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 220.05 Td (patent protection. ) Tj ET Q q 0 0 0 rg BT 187.12 220.05 Td (Assumes no generic competition for L) Tj ET Q q 0 0 0 rg BT 355.44 220.05 Td (yrica in the U.S. until June 2019, which is ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 200.90 Td (contingent upon a six-month patent-term extension granted by the FDA) Tj ET Q q 0 0 0 rg BT 422.35 200.90 Td ( for pediatric exclusivity) Tj ET Q q 0 0 0 rg BT 529.46 200.90 Td (, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 181.75 Td (which the company is currently pursuing.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 290.68 181.75 Td ( ) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 151.23 cm /I36 Do Q q 0 0 0 rg BT 94.00 153.60 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 153.60 Td (Reflects a full year contribution from Consumer Healthcare. Pfizer continues to expect that any ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 134.50 Td (decision regarding strategic alternatives for Consumer Healthcare will be made during 2018.) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 103.98 cm /I37 Do Q q 0 0 0 rg BT 94.00 106.35 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 106.35 Td (Reflects the anticipated favorable impact of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 302.86 106.35 Td ($1.3 billion) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 353.58 106.35 Td ( on revenues and ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 430.56 106.35 Td ($0.09) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 455.31 106.35 Td ( on ) Tj ET Q q 0 0 0 rg BT 471.20 106.35 Td (Adjusted diluted ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 87.20 Td (EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 126.95 92.18 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 135.29 87.20 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 138.04 87.20 Td (as a result of favorable changes in foreign exchange rates relative to the U.S. dollar compared ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 68.05 Td (to foreign exchange rates from 2017.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 270.50 68.05 Td ( ) Tj ET Q endstream endobj 27 0 obj <> endobj 28 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 42.60 Td (- 13 -) Tj ET Q BT /F1 11.00 Tf ET /GS0 gs q 4.00 0 0 11.00 90.00 737.03 cm /I38 Do Q q 0 0 0 rg BT 94.00 739.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 739.40 Td (Guidance for ) Tj ET Q q 0 0 0 rg BT 167.87 739.40 Td (Adjusted diluted EPS) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.15 Tf ET q 0 0 0 rg BT 262.59 744.38 Td (\(2\)) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 270.93 739.40 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 273.68 739.40 Td (assumes diluted weighted-average shares outstanding of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 720.25 Td (approximately) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 171.53 720.25 Td ( ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 174.28 720.25 Td (6.0) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 188.03 720.25 Td ( billion shares, ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 255.25 720.25 Td (which reflects share repurchases totaling approximately $6.1 billion ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 701.10 Td (in 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 141.31 701.10 Td (. ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 146.81 701.10 Td (Dilution related to share-based employee compensation programs is expected to of) Tj ET Q q 0 0 0 rg BT 510.71 701.10 Td (fset by ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 108.00 682.00 Td (approximately half the reduction in shares associated with these share repurchases. ) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 650.85 Td (\(6\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 650.85 Td (Given the significant changes resulting from and complexities associated with the ) Tj ET Q q 0 0 0 rg BT 447.90 650.85 Td (T) Tj ET Q q 0 0 0 rg BT 453.85 650.85 Td (ax Cuts and Jobs ) Tj ET Q q 0 0 0 rg BT 530.24 650.85 Td (Act ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 631.70 Td (\(TCJA\), the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 140.80 631.70 Td (estimated financial impacts associated with the ) Tj ET Q q 0 0 0 rg BT 350.14 631.70 Td (TCJA) Tj ET Q q 0 0 0 rg BT 375.81 631.70 Td ( that were recorded in fourth-quarter ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 612.55 Td (2017 are provisional and subject to further analysis, interpretation and clarification of the ) Tj ET Q q 0 0 0 rg BT 480.56 612.55 Td (TCJA, which ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 593.40 Td (could result in changes to these estimates during 2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 323.17 593.40 Td (.) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 58.50 562.30 Td (\(7\) ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 562.30 Td (Pfizer and ) Tj ET Q q 0 0 0 rg BT 132.54 562.30 Td (A) Tj ET Q q 0 0 0 rg BT 139.67 562.30 Td (villion entered into an exclusive collaborative development agreement in 2014 to conduct the ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 543.15 Td (BFORE trial, which supported the approval of the indication extension for Bosulif for the treatment of ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 524.00 Td (adults with newly diagnosed chronic phase Ph+ CML. Under the terms of the agreement, ) Tj ET Q q 0 0 0 rg BT 479.67 524.00 Td (A) Tj ET Q q 0 0 0 rg BT 486.80 524.00 Td (villion ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 504.85 Td (operationalized and funded the trial to generate the clinical data used to support this application and other ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 485.70 Td (potential regulatory filings for marketing authorization for Bosulif as first-line treatment for patients with ) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 85.50 466.60 Td (chronic phase Ph+ CML. Pfizer retains all rights to commercialize Bosulif globally) Tj ET Q q 0 0 0 rg BT 450.85 466.60 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 433.72 Td (Contacts:) Tj ET Q BT /F3 10.00 Tf ET 0 0 0 RG /GS0 gs 0.49 w 0 i [] 0 d 1 J 1 j 3 M 160 432.42363281250005 m 185.546875 432.42363281250005 l s q 0 0 0 rg BT 160.00 433.76 Td (Media) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 263.00 433.72 Td () Tj ET Q BT /F3 10.00 Tf ET 0 0 0 RG /GS0 gs 0.49 w 0 i [] 0 d 1 J 1 j 3 M 366 432.42363281250005 m 402.66015625 432.42363281250005 l s q 0 0 0 rg BT 366.00 433.76 Td (Investors) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 469.00 433.72 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 417.72 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.00 417.72 Td (Joan Campion) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 263.00 417.72 Td (212.733.2798) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 366.00 417.72 Td (Chuck ) Tj ET Q q 0 0 0 rg BT 394.52 417.72 Td (T) Tj ET Q q 0 0 0 rg BT 400.36 417.72 Td (riano) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 469.00 417.72 Td (212.733.3901) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 401.72 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.00 401.72 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 263.00 401.72 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 366.00 401.72 Td (R) Tj ET Q q 0 0 0 rg BT 372.47 401.72 Td (yan Crowe) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 469.00 401.72 Td (212.733.8160) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 366.00 385.72 Td (Bryan Dunn) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 469.00 385.72 Td (212.733.8917) Tj ET Q BT /F1 11.00 Tf ET endstream endobj 29 0 obj <> endobj 30 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 211.95 760.60 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 269.46 760.60 Td (AND) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 291.12 760.60 Td ( SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 340.39 760.60 Td (Y) Tj ET Q q 0 0 0 rg BT 346.55 760.60 Td ( COMP) Tj ET Q q 0 0 0 rg BT 373.49 760.60 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 213.05 749.80 Td (CONSOLIDA) Tj ET Q q 0 0 0 rg BT 264.05 749.80 Td (TED ST) Tj ET Q q 0 0 0 rg BT 293.58 749.80 Td (A) Tj ET Q q 0 0 0 rg BT 299.08 749.80 Td (TEMENTS OF INCOME) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 392.08 753.88 Td (\(1\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 739.00 Td (\(UNAUDITED\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 231.25 728.20 Td (\(millions, except per common share data\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 42.60 Td (- 14 -) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 54.5 692.9 m 432.5 692.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 432.5 692.9 m 436.5 692.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 692.9 m 481.5 692.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 677.9 m 481.5 677.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 481.5 692.9 m 485.5 692.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 481.5 677.9 m 485.5 677.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 692.9 m 530.5 692.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 677.9 m 530.5 677.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 530.5 692.9 m 534.5 692.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 534.5 692.9 m 576.5 692.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 677.9 m 481.5 677.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 662.9 m 481.5 662.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 677.9 m 530.5 677.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 662.9 m 530.5 662.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 534.5 662.9 m 576.5 662.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 662.9 m 481.5 662.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 662.9 m 530.5 662.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 534.5 662.9 m 576.5 662.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 542.9 m 481.5 542.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 542.9 m 530.5 542.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 508.9 m 481.5 508.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 508.9 m 530.5 508.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 478.9 m 481.5 478.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 478.9 m 530.5 478.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 448.9 m 481.5 448.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 434.9 m 481.5 434.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 432.9 m 481.5 432.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 448.9 m 530.5 448.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 434.9 m 530.5 434.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 432.9 m 530.5 432.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 432.9 m 481.5 432.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 434.9 m 481.5 434.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 384.9 m 481.5 384.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 370.9 m 481.5 370.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 368.9 m 481.5 368.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 384.9 m 530.5 384.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 370.9 m 530.5 370.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 368.9 m 530.5 368.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 436.5 320.9 m 481.5 320.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 307.9 m 481.5 307.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 305.9 m 481.5 305.9 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 485.5 320.9 m 530.5 320.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 307.9 m 530.5 307.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 305.9 m 530.5 305.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 278.9 m 481.5 278.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 276.9 m 481.5 276.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 278.9 m 530.5 278.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 276.9 m 530.5 276.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 54.5 263.9 m 432.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 54.5 261.9 m 432.5 261.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 432.5 263.9 m 436.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 432.5 261.9 m 436.5 261.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 263.9 m 481.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 436.5 261.9 m 481.5 261.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 481.5 263.9 m 485.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 481.5 261.9 m 485.5 261.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 263.9 m 530.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 485.5 261.9 m 530.5 261.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 530.5 263.9 m 534.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 530.5 261.9 m 534.5 261.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 534.5 263.9 m 576.5 263.9 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 534.5 261.9 m 576.5 261.9 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 683.02 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 458.20 683.16 Td (First-Quarter) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 538.75 683.16 Td (% Incr) Tj ET Q q 0 0 0 rg BT 564.07 683.16 Td (. /) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 57.00 668.02 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 459.00 668.16 Td (2018) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 508.00 668.16 Td (2017) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 541.65 668.16 Td (\(Decr) Tj ET Q q 0 0 0 rg BT 562.75 668.16 Td (.\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 653.16 Td (Revenues) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 439.00 652.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 451.65 652.46 Td (12,906) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 488.00 652.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 500.50 652.46 Td (12,779) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 652.46 Td (1) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 638.16 Td (Costs and expenses:) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 66.00 623.16 Td (Cost of sales) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 114.55 627.47 Td (\(1\), \(2\), \(3\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 622.46 Td (2,563) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 622.46 Td (2,468) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 622.46 Td (4) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 66.00 608.16 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 258.86 612.47 Td (\(1\), \(2\), \(3\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 607.46 Td (3,412) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 607.46 Td (3,315) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 607.46 Td (3) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 66.00 593.16 Td (Research and development expenses) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 205.02 597.47 Td (\(1\), \(2\), \(3\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 592.46 Td (1,743) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 592.46 Td (1,716) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 592.46 Td (2) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 66.00 578.16 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 191.85 582.47 Td (\(3\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 577.46 Td (1,196) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 577.46 Td (1,186) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 577.46 Td (1) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 66.00 563.16 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 136.26 563.16 Td (ges and certain acquisition-related costs) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 287.69 567.47 Td (\(1\), \(4\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 468.30 562.46 Td (43) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 517.15 562.46 Td (84) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 547.05 562.46 Td (\(49\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 66.00 548.16 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 189.20 552.47 Td (\(1\), \(5\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 460.35 547.46 Td (\(178) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 477.80 547.46 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 517.15 547.46 Td (60) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 547.46 Td (*) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 529.16 Td (Income from continuing operations before provision for taxes on income) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 528.46 Td (4,127) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 528.46 Td (3,951) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 528.46 Td (4) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 514.16 Td (Provision for taxes on income) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 170.98 518.47 Td (\(6\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 463.50 513.46 Td (556) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 512.40 513.46 Td (821) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 547.05 513.46 Td (\(32\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 499.16 Td (Income from continuing operations) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 498.46 Td (3,571) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 498.46 Td (3,130) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 498.46 Td (14) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 484.16 Td (Discontinued operationsnet of tax) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 469.85 483.46 Td (\(1) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 477.80 483.46 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 517.15 483.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 483.46 Td (*) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 469.16 Td (Net income before allocation to noncontrolling interests) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 468.46 Td (3,570) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 468.46 Td (3,130) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 468.46 Td (14) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 454.16 Td (Less: Net income attributable to noncontrolling interests) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 473.05 453.46 Td (9) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 521.90 453.46 Td (9) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 552.60 453.46 Td (7) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 439.16 Td (Net income attributable to Pfizer Inc.) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 439.00 438.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 438.46 Td (3,561) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 488.00 438.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 438.46 Td (3,121) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 438.46 Td (14) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 420.16 Td (Earnings per common sharebasic:) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 61.50 405.16 Td (Income from continuing operations attributable to Pfizer Inc. common shareholders) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 439.00 404.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 461.15 404.46 Td (0.60) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 488.00 404.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 510.00 404.46 Td (0.52) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 404.46 Td (15) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 61.50 390.16 Td (Discontinued operationsnet of tax) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 468.30 389.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 517.15 389.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 389.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 61.50 375.16 Td (Net income attributable to Pfizer Inc. common shareholders) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 439.00 374.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 461.15 374.46 Td (0.60) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 488.00 374.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 510.00 374.46 Td (0.52) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 374.46 Td (15) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 356.16 Td (Earnings per common sharediluted:) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 61.50 341.16 Td (Income from continuing operations attributable to Pfizer Inc. common shareholders) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 439.00 340.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 461.15 340.46 Td (0.59) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 488.00 340.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 510.00 340.46 Td (0.51) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 340.46 Td (15) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 61.50 326.16 Td (Discontinued operationsnet of tax) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 468.30 325.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 517.15 325.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 325.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 61.50 311.66 Td (Net income attributable to Pfizer Inc. common shareholders) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 439.00 311.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 461.15 311.46 Td (0.59) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 488.00 311.46 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 510.00 311.46 Td (0.51) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.25 311.46 Td (15) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 57.00 297.46 Td (W) Tj ET Q q 0 0 0 rg BT 65.21 297.46 Td (eighted-average shares used to calculate earnings per common share:) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 573.00 297.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 67.50 283.16 Td (Basic) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 282.46 Td (5,957) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 282.46 Td (6,006) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 573.00 282.46 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 67.50 268.16 Td (Diluted) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 456.40 267.46 Td (6,057) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.25 267.46 Td (6,092) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 573.00 267.46 Td () Tj ET Q BT /F1 11.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 251.40 Td (* ) Tj ET Q q 0 0 0 rg BT 63.00 251.40 Td (Indicates calculation not meaningful or result is equal to or greater than 100%.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 238.40 Td (See end of tables for notes \(1\) through \(6\).) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 225.40 Td (Amounts may not add due to rounding. ) Tj ET Q q 0 0 0 rg BT 212.88 225.40 Td (All percentages have been calculated using unrounded amounts.) Tj ET Q endstream endobj 31 0 obj <> endobj 32 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 765.25 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 765.25 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 765.25 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 765.25 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 765.25 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 193.85 754.45 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 224.94 754.45 Td (T) Tj ET Q q 0 0 0 rg BT 230.27 754.45 Td (O CONSOLIDA) Tj ET Q q 0 0 0 rg BT 290.02 754.45 Td (TED ST) Tj ET Q q 0 0 0 rg BT 319.55 754.45 Td (A) Tj ET Q q 0 0 0 rg BT 325.05 754.45 Td (TEMENTS OF INCOME) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 743.65 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 15 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 713.10 Td (\(1\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (The financial statements present the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 227.33 713.10 Td (three months) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 279.27 713.10 Td ( ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 307.59 713.10 Td (April1, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 361.20 713.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 380.09 713.10 Td (April2, 2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 433.70 713.10 Td (. Subsidiaries operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 701.10 Td (outside the U.S. are included for the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 227.90 701.10 Td (three months) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 279.84 701.10 Td ( ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 308.71 701.10 Td (February25, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 382.31 701.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 401.75 701.10 Td (February26, 2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 475.35 701.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 686.10 Td (The financial results for the three months ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 274.27 686.10 Td (April1, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 327.88 686.10 Td ( are not necessarily indicative of the results that ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 674.10 Td (ultimately could be achieved for the full year) Tj ET Q q 0 0 0 rg BT 260.65 674.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 659.10 Td (The adoption of certain new accounting standards in the first quarter of 2018 impacted our consolidated statements of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 647.10 Td (income as follows:) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 627.90 Td ( ) Tj ET Q BT /F3 10.00 Tf ET 0 0 0 RG /GS0 gs 0.49 w 0 i [] 0 d 1 J 1 j 3 M 99 626.5669921875 m 225.7626953125 626.5669921875 l s q 0 0 0 rg BT 99.00 627.90 Td (Financial ) Tj ET Q q 0 0 0 rg BT 140.20 627.90 Td (Assets and Liabilities) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 225.76 627.90 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 236.76 627.90 Td (W) Tj ET Q q 0 0 0 rg BT 245.40 627.90 Td (e adopted a new accounting standard on January 1, 2018 utilizing the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 615.90 Td (modified retrospective method, and therefore, no adjustments were made to amounts in our prior period financial ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 603.90 Td (statements. ) Tj ET Q q 0 0 0 rg BT 146.03 603.90 Td (The standard requires certain equity investments to be measured at fair value with changes in fair ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 591.90 Td (value now recognized in net income. However) Tj ET Q q 0 0 0 rg BT 284.92 591.90 Td (, equity investments that do not have readily determinable fair ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 579.90 Td (values may be measured at cost minus impairment, if any) Tj ET Q q 0 0 0 rg BT 328.29 579.90 Td (, plus or minus changes resulting from observable price ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 567.90 Td (changes in orderly transactions for the identical or similar investment of the same issuer) Tj ET Q q 0 0 0 rg BT 450.29 567.90 Td (. ) Tj ET Q q 0 0 0 rg BT 455.11 567.90 Td (Therefore, in the first ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 554.70 Td (quarter of 2018, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 165.65 554.70 Td (Other \(income\)/deductions) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 273.12 554.70 Td () Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 284.12 554.70 Td (net) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 296.33 554.70 Td ( includes unrealized net gains on equity securities. See Note \(5\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 542.70 Td (below for additional information.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 526.50 Td ( ) Tj ET Q BT /F3 10.00 Tf ET 0 0 0 RG /GS0 gs 0.49 w 0 i [] 0 d 1 J 1 j 3 M 99 525.1669921875 m 136.75390625 525.1669921875 l s q 0 0 0 rg BT 99.00 526.50 Td (Revenues) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 136.75 526.50 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 147.75 526.50 Td (W) Tj ET Q q 0 0 0 rg BT 156.39 526.50 Td (e adopted a new accounting standard on January 1, 2018 for revenue recognition. Under the new ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 514.50 Td (standard, revenue is recognized upon transfer of control of the product to our customer in an amount that reflects ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 502.50 Td (the consideration we expect to receive in exchange. ) Tj ET Q q 0 0 0 rg BT 307.33 502.50 Td (W) Tj ET Q q 0 0 0 rg BT 315.97 502.50 Td (e adopted the new accounting standard utilizing the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 490.50 Td (modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 478.50 Td (statements. However) Tj ET Q q 0 0 0 rg BT 182.46 478.50 Td (, the adoption of this new standard did impact the timing of recognizing ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 471.84 478.50 Td (Other \(income\)/) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 465.30 Td (deductions) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 142.33 465.30 Td () Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 153.33 465.30 Td (net) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 165.54 465.30 Td (, primarily for upfront and milestone payments on our collaboration arrangements and, to a lesser ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 453.30 Td (extent, product rights and out-licensing arrangements, and the timing of recognizing ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 438.07 453.30 Td (Revenues) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 475.83 453.30 Td ( and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 495.26 453.30 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 546.38 453.30 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 441.30 Td (on certain product shipments. ) Tj ET Q q 0 0 0 rg BT 219.63 441.30 Td (The impact of adoption did not have a material impact to our condensed ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 429.30 Td (consolidated statement of income for the three months ended ) Tj ET Q q 0 0 0 rg BT 344.76 429.30 Td (April 1, 2018. See Note \(5\) below for additional ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 417.30 Td (information.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 401.10 Td ( ) Tj ET Q BT /F3 10.00 Tf ET 0 0 0 RG /GS0 gs 0.49 w 0 i [] 0 d 1 J 1 j 3 M 99 399.7669921875 m 378.3994140625 399.7669921875 l s q 0 0 0 rg BT 99.00 401.10 Td (Pr) Tj ET Q q 0 0 0 rg BT 108.63 401.10 Td (esentation of Net Periodic Pension and Postr) Tj ET Q q 0 0 0 rg BT 289.35 401.10 Td (etir) Tj ET Q q 0 0 0 rg BT 302.86 401.10 Td (ement Benefit Cost) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 378.40 401.10 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 389.40 401.10 Td (W) Tj ET Q q 0 0 0 rg BT 398.04 401.10 Td (e adopted a new accounting standard on ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 389.10 Td (January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than the service costs ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 375.90 Td (be presented in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 162.03 375.90 Td (Other \(income\)/deductions) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 269.50 375.90 Td () Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 280.50 375.90 Td (net, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 297.72 375.90 Td (and that the presentation be applied retrospectively) Tj ET Q q 0 0 0 rg BT 500.88 375.90 Td (. ) Tj ET Q q 0 0 0 rg BT 505.70 375.90 Td (W) Tj ET Q q 0 0 0 rg BT 514.34 375.90 Td (e adopted ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 363.90 Td (the presentation of the net periodic benefit costs other than service costs by reclassifying these costs from ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 523.04 363.90 Td (Cost of ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 351.90 Td (sales, Selling, informational and administrative expenses, Resear) Tj ET Q q 0 0 0 rg BT 359.99 351.90 Td (ch and development expenses ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 480.49 351.90 Td (and) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 494.93 351.90 Td ( Restructuring ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 338.70 Td (char) Tj ET Q q 0 0 0 rg BT 116.96 338.70 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 232.41 338.70 Td (elated costs ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 281.84 338.70 Td (to ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 292.12 338.70 Td (Other \(income\)/deductions) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 399.59 338.70 Td () Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 410.59 338.70 Td (net) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 422.81 338.70 Td (. ) Tj ET Q q 0 0 0 rg BT 427.63 338.70 Td (W) Tj ET Q q 0 0 0 rg BT 436.26 338.70 Td (e have therefore reclassified ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 326.70 Td (the prior period net periodic benefit costs/\(credits\) to apply the retrospective presentation for comparative periods. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 314.70 Td (See Note \(5\) below for additional information.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 297.70 Td (On February 3, 2017, we completed the sale of our global infusion systems net assets, Hospira Infusion Systems ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 285.70 Td (\(HIS\). ) Tj ET Q q 0 0 0 rg BT 108.59 285.70 Td (The operating results of HIS are included in the consolidated statement of income and EH) Tj ET Q q 0 0 0 rg BT 471.26 285.70 Td (s operating results ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 273.70 Td (through February 2, 2017 and, therefore, our financial results, and EH) Tj ET Q q 0 0 0 rg BT 363.70 273.70 Td (s operating results, for first-quarter 2017 reflect ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 261.70 Td (approximately one month of HIS domestic operations and approximately two months of HIS international operations, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 249.70 Td (while financial results for 2018 do not reflect any contribution from HIS global operations.) Tj ET Q BT /F1 10.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 234.70 Td (Certain amounts in the consolidated statements of income and associated notes may not add due to rounding. ) Tj ET Q q 0 0 0 rg BT 518.68 234.70 Td (All ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 222.70 Td (percentages have been calculated using unrounded amounts.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 207.70 Td (\(2\) ) Tj ET Q q 0 0 0 rg BT 81.00 207.70 Td (Exclusive of amortization of intangible assets, except as discussed in footnote \(3\) below) Tj ET Q q 0 0 0 rg BT 432.76 207.70 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 192.70 Td (\(3\) ) Tj ET Q q 0 0 0 rg BT 81.00 192.70 Td (Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 180.70 Td (manufacture, research, market and distribute products, compounds and intellectual property is included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 168.70 Td (Amortization of intangible assets,) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 215.45 168.70 Td ( as these intangible assets benefit multiple business functions. ) Tj ET Q q 0 0 0 rg BT 464.30 168.70 Td (Amortization expense ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 156.70 Td (related to intangible assets that are associated with a single function is included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 410.91 156.70 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 462.03 156.70 Td (,) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 464.53 156.70 Td ( Selling) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 494.80 156.70 Td (,) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 497.30 156.70 Td ( informational ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 144.70 Td (and administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 194.31 144.70 Td ( and/or ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 224.86 144.70 Td (Resear) Tj ET Q q 0 0 0 rg BT 252.25 144.70 Td (ch and development expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 370.26 144.70 Td (, as appropriate.) Tj ET Q endstream endobj 33 0 obj <> endobj 34 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 765.25 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 765.25 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 765.25 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 765.25 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 765.25 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 193.85 754.45 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 224.94 754.45 Td (T) Tj ET Q q 0 0 0 rg BT 230.27 754.45 Td (O CONSOLIDA) Tj ET Q q 0 0 0 rg BT 290.02 754.45 Td (TED ST) Tj ET Q q 0 0 0 rg BT 319.55 754.45 Td (A) Tj ET Q q 0 0 0 rg BT 325.05 754.45 Td (TEMENTS OF INCOME) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 743.65 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 16 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 713.10 Td (\(4\) ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 156.45 713.10 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 271.90 713.10 Td (elated costs ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 321.34 713.10 Td (include the following:) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 702.6 m 441.5 702.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 441.5 702.6 m 446.5 702.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 446.5 702.6 m 498.5 702.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 688.6 m 498.5 688.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 498.5 702.6 m 502.5 702.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 498.5 688.6 m 502.5 688.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 502.5 702.6 m 554.5 702.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 688.6 m 554.5 688.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 664.6 m 441.5 664.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 688.6 m 498.5 688.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 664.6 m 498.5 664.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 688.6 m 554.5 688.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 664.6 m 554.5 664.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 664.6 m 498.5 664.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 664.6 m 554.5 664.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 636.6 m 498.5 636.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 636.6 m 554.5 636.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 636.6 m 498.5 636.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 636.6 m 554.5 636.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 594.6 m 498.5 594.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 594.6 m 554.5 594.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 580.6 m 441.5 580.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 578.6 m 441.5 578.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 441.5 580.6 m 446.5 580.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 441.5 578.6 m 446.5 578.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 446.5 594.6 m 498.5 594.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 446.5 580.6 m 498.5 580.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 446.5 578.6 m 498.5 578.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 498.5 580.6 m 502.5 580.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 498.5 578.6 m 502.5 578.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 502.5 594.6 m 554.5 594.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 502.5 580.6 m 554.5 580.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 502.5 578.6 m 554.5 578.6 l s BT /F1 9.50 Tf ET q 0 0 0 rg BT 84.00 693.16 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 475.20 693.16 Td (First-Quarter) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 668.85 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 475.00 674.22 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 531.00 674.22 Td (2017) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 84.00 655.16 Td (Restructuring \(credits\)/char) Tj ET Q q 0 0 0 rg BT 188.55 655.16 Td (ges) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 201.22 655.16 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 211.22 655.16 Td (acquisition-related costs) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 303.29 659.46 Td (\(a\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 449.00 655.16 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 486.85 655.16 Td (\(8) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 494.80 655.16 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.00 655.16 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 546.05 655.16 Td (8) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 84.00 641.16 Td (Restructuring credits) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 163.41 641.16 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 173.41 641.16 Td (cost reduction initiatives) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 266.81 645.46 Td (\(b\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 486.85 641.16 Td (\(2) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 494.80 641.16 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 538.10 641.16 Td (\(12) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.80 641.16 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 84.00 627.16 Td (Restructuring credits) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 486.85 627.16 Td (\(9) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 494.80 627.16 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 542.85 627.16 Td (\(5) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 550.80 627.16 Td (\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 84.00 613.16 Td (T) Tj ET Q q 0 0 0 rg BT 89.47 613.16 Td (ransaction costs) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 149.89 617.47 Td (\(c\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 485.30 613.16 Td () Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 541.30 613.16 Td (12) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 84.00 599.16 Td (Integration costs) Tj ET Q BT /F1 9.50 Tf ET BT /F1 6.17 Tf ET q 0 0 0 rg BT 147.06 603.47 Td (\(d\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 485.30 599.16 Td (52) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 541.30 599.16 Td (77) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 84.00 584.31 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 159.45 584.31 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 274.90 584.31 Td (elated costs) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 449.00 584.16 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 485.30 584.16 Td (43) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 505.00 584.16 Td ($) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 541.30 584.16 Td (84) Tj ET Q BT /F1 11.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 566.90 Td (\(a\) ) Tj ET Q q 0 0 0 rg BT 99.00 566.90 Td (Restructuring \(credits\)/char) Tj ET Q q 0 0 0 rg BT 209.05 566.90 Td (ges) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 222.38 566.90 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 233.38 566.90 Td (acquisition-related costs include employee termination costs, exit costs and asset ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 554.90 Td (impairments associated with business combinations. Credits for the first quarter of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 431.15 554.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 451.15 554.90 Td ( were primarily associated ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 542.90 Td (with lower exit costs related to our acquisition of Hospira, Inc. \(Hospira\). Restructuring char) Tj ET Q q 0 0 0 rg BT 469.27 542.90 Td (ges for the first ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 530.90 Td (quarter of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 140.65 530.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.65 530.90 Td ( were primarily related to our acquisitions of Medivation, Inc. \(Medivation\) and ) Tj ET Q q 0 0 0 rg BT 482.22 530.90 Td (Anacor ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 518.90 Td (Pharmaceuticals, Inc. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 505.90 Td (\(b\) ) Tj ET Q q 0 0 0 rg BT 99.00 505.90 Td (Restructuring credits) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 182.59 505.90 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 192.59 505.90 Td (cost reduction initiatives relate to employee termination costs, exit costs and asset ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 493.90 Td (impairments not associated with acquisitions. For ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 299.81 493.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 347.56 493.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 350.06 493.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 370.06 493.90 Td (, the credits are mostly related to reserve ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 481.90 Td (releases for cost-reduction programs, partially of) Tj ET Q q 0 0 0 rg BT 293.75 481.90 Td (fset by exit costs. For ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 382.07 481.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 429.83 481.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 432.33 481.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 452.33 481.90 Td (, the credits are mostly ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 469.90 Td (related to reserve releases for cost-reduction programs, partially of) Tj ET Q q 0 0 0 rg BT 365.09 469.90 Td (fset by asset write downs.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 456.90 Td (\(c\) ) Tj ET Q q 0 0 0 rg BT 99.00 456.90 Td (T) Tj ET Q q 0 0 0 rg BT 104.76 456.90 Td (ransaction costs represent external costs for banking, legal, accounting and other similar services, virtually all of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 444.90 Td (which for the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 154.82 444.90 Td (first quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 201.74 444.90 Td ( of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 215.07 444.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 235.07 444.90 Td ( were related to our acquisition of Medivation.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 431.90 Td (\(d\) ) Tj ET Q q 0 0 0 rg BT 99.00 431.90 Td (Integration costs represent external, incremental costs directly related to integrating acquired businesses, and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 418.70 Td (primarily include expenditures for consulting and the integration of systems and processes. In the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 490.85 418.70 Td (first quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 537.77 418.70 Td (s) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 541.66 418.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.41 418.70 Td (of) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 552.74 418.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 406.70 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 119.00 406.70 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 138.44 406.70 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 158.44 406.70 Td (, integration costs primarily relate to our acquisition of Hospira.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 391.70 Td (\(5\)) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 65.66 391.70 Td ( ) Tj ET Q q 0 0 0 rg BT 81.00 391.70 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 210.69 391.70 Td ( includes the following:) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 381.20000000000005 m 447.5 381.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 447.5 381.20000000000005 m 451.5 381.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 451.5 381.20000000000005 m 503.5 381.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 451.5 366.20000000000005 m 503.5 366.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 503.5 381.20000000000005 m 507.5 381.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 366.20000000000005 m 507.5 366.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 507.5 381.20000000000005 m 558.5 381.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 507.5 366.20000000000005 m 558.5 366.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 351.20000000000005 m 447.5 351.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 451.5 366.20000000000005 m 503.5 366.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 451.5 351.20000000000005 m 503.5 351.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 507.5 366.20000000000005 m 558.5 366.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 507.5 351.20000000000005 m 558.5 351.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 451.5 351.20000000000005 m 503.5 351.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 507.5 351.20000000000005 m 558.5 351.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 451.5 323.20000000000005 m 503.5 323.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 507.5 323.20000000000005 m 558.5 323.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 451.5 141.20000000000005 m 503.5 141.20000000000005 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 507.5 141.20000000000005 m 558.5 141.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 128.20000000000005 m 447.5 128.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 126.20000000000005 m 447.5 126.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 447.5 128.20000000000005 m 451.5 128.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 447.5 126.20000000000005 m 451.5 126.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 451.5 128.20000000000005 m 503.5 128.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 451.5 126.20000000000005 m 503.5 126.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 503.5 128.20000000000005 m 507.5 128.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 503.5 126.20000000000005 m 507.5 126.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 507.5 128.20000000000005 m 558.5 128.20000000000005 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 507.5 126.20000000000005 m 558.5 126.20000000000005 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 370.87 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 478.35 371.32 Td (First-Quarter) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 355.45 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 480.00 356.32 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 535.00 356.32 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 341.77 Td (Interest income) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 454.00 341.77 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 486.30 341.82 Td (\(77) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 341.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 510.00 341.77 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 541.30 341.82 Td (\(81) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 554.65 341.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 327.77 Td (Interest expense) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 484.65 327.77 Td (310) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 539.65 327.77 Td (309) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 93.00 313.77 Td (Net interest expense) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 484.65 313.77 Td (233) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 539.65 313.77 Td (228) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 299.77 Td (Royalty-related income) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 486.30 299.82 Td (\(96) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 299.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 541.30 299.82 Td (\(86) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 554.65 299.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 285.77 Td (Net gains on asset disposals) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 195.66 290.30 Td (\(a\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 486.30 285.82 Td (\(19) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 285.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0.17254901960784313 0.17254901960784313 0.17254901960784313 rg BT 541.30 285.82 Td (\(90) Tj ET Q BT /F1 10.00 Tf ET q 0.17254901960784313 0.17254901960784313 0.17254901960784313 rg BT 554.65 285.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 0 rg BT 84.00 270.87 Td (Income from collaborations, out-licensing arrangements and sales of compound/product ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 88.50 258.87 Td (rights) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 111.28 263.40 Td (\(b\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 481.30 258.92 Td (\(142) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 258.87 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 541.30 258.92 Td (\(47) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 554.65 258.87 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 241.87 Td (Net unrealized gains on equity securities) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 246.45 246.40 Td (\(c\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 481.30 241.92 Td (\(1) Tj ET Q q 0 0 0 rg BT 489.63 241.92 Td (1) Tj ET Q q 0 0 0 rg BT 494.63 241.92 Td (1) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 241.87 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 241.87 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 224.87 Td (Net periodic benefit costs/\(credits\) other than service costs) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 318.64 229.40 Td (\(d\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 486.30 224.92 Td (\(82) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 224.87 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 224.87 Td (62) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 207.87 Td (Certain legal matters, net) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 486.30 207.92 Td (\(19) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 207.87 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 549.65 207.87 Td (8) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 190.87 Td (Certain asset impairments) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 489.65 190.87 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 190.87 Td (12) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 173.87 Td (Loss on sale of HIS net assets) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 203.43 178.40 Td (\(e\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 494.65 173.87 Td (3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 173.87 Td (37) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 159.77 Td (Business and legal entity alignment costs) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 248.70 164.30 Td (\(f\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 494.65 159.77 Td (3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 159.77 Td (21) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 145.77 Td (Other) Tj ET Q q 0 0 0 rg BT 106.37 145.77 Td (, net) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 123.58 150.30 Td (\(g\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 489.65 145.77 Td (51) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 541.30 145.82 Td (\(84) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 554.65 145.77 Td (\)) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 93.00 131.76 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 454.00 131.77 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 481.30 131.82 Td (\(178) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.65 131.77 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 510.00 131.77 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 131.77 Td (60) Tj ET Q BT /F1 11.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 115.70 Td (\(a\) ) Tj ET Q q 0 0 0 rg BT 99.00 115.70 Td (In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 109.83 115.70 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 157.58 115.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.08 115.70 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 180.08 115.70 Td (, primarily includes net gains on sales of investments in equity and debt securities ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 103.70 Td (\(approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 162.59 103.70 Td ($12 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 208.98 103.70 Td (\). In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 228.14 103.70 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 275.89 103.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 278.39 103.70 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 298.39 103.70 Td (, primarily includes net gains on sales of investments in equity ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 91.70 Td (and debt securities \(approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 239.51 91.70 Td ($42 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.90 91.70 Td (\) and a gain on sale of property \(approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 476.67 91.70 Td ($48 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 523.06 91.70 Td (\). ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 78.70 Td (\(b\) ) Tj ET Q q 0 0 0 rg BT 99.00 78.70 Td (Includes income from upfront and milestone payments from our collaboration partners and income from out-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 66.70 Td (licensing arrangements and sales of compound/product rights.) Tj ET Q endstream endobj 35 0 obj <> endobj 36 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 765.25 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 765.25 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 765.25 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 765.25 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 765.25 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 193.85 754.45 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 224.94 754.45 Td (T) Tj ET Q q 0 0 0 rg BT 230.27 754.45 Td (O CONSOLIDA) Tj ET Q q 0 0 0 rg BT 290.02 754.45 Td (TED ST) Tj ET Q q 0 0 0 rg BT 319.55 754.45 Td (A) Tj ET Q q 0 0 0 rg BT 325.05 754.45 Td (TEMENTS OF INCOME) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 743.65 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 17 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (\(c\) ) Tj ET Q q 0 0 0 rg BT 99.00 713.10 Td (Represents the unrealized net gains on equity securities reflecting the adoption of a new accounting standard in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 701.10 Td (the first quarter of 2018. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 689.10 Td (readily tradeable equity securities were reported in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 304.19 689.10 Td (Accumulated other compr) Tj ET Q q 0 0 0 rg BT 407.68 689.10 Td (ehensive income.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 676.10 Td (\(d\) ) Tj ET Q q 0 0 0 rg BT 99.00 676.10 Td (Represents the net periodic benefit costs/\(credits\), excluding service costs, as a result of the adoption of a new ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 664.10 Td (accounting standard in the first quarter of 2018. Ef) Tj ET Q q 0 0 0 rg BT 301.26 664.10 Td (fective January 1, 2018, the U.S. Pfizer Consolidated Pension ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 652.10 Td (Plan was frozen to future benefit accruals and for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 298.64 652.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 346.39 652.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 348.89 652.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 368.89 652.10 Td (, resulted in the recognition of net periodic ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 640.10 Td (benefit income due to the extension of the amortization period for the actuarial losses and the elimination of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 628.10 Td (service costs. ) Tj ET Q q 0 0 0 rg BT 154.63 628.10 Td (There was also a greater expected gain on plan assets due to a higher plan asset base compared to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 616.10 Td (the first quarter of 2017. See note \(1\) above for additional information.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 601.90 Td (\(e\) ) Tj ET Q q 0 0 0 rg BT 99.00 601.90 Td (In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 109.83 601.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 157.58 601.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.08 601.90 Td (2018) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 180.08 601.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 182.83 601.90 Td (and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 199.77 601.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 219.77 601.90 Td (, represents an incremental char) Tj ET Q q 0 0 0 rg BT 346.47 601.90 Td (ge to amounts previously recorded in 2016 to write ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 589.90 Td (down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical, Inc. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 577.90 Td (\(ICU Medical\), on February 3, 2017.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 564.90 Td (\(f\) ) Tj ET Q q 0 0 0 rg BT 99.00 564.90 Td (In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 109.83 564.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 157.58 564.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.08 564.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 180.08 564.90 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 199.52 564.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 219.52 564.90 Td (, represents expenses for changes to our infrastructure to align our commercial ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 552.90 Td (operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 540.90 Td (our intercompany supply operations to better support each business.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 527.90 Td (\(g\) ) Tj ET Q q 0 0 0 rg BT 99.00 527.90 Td (In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 109.83 527.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 157.58 527.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.08 527.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 180.08 527.90 Td (, primarily includes, among other things, char) Tj ET Q q 0 0 0 rg BT 362.36 527.90 Td (ges of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 389.02 527.90 Td ($102 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 440.41 527.90 Td (, reflecting the change in the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 515.90 Td (fair value of contingent consideration, partially of) Tj ET Q q 0 0 0 rg BT 297.92 515.90 Td (fset by dividend income of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 407.61 515.90 Td ($59 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 454.00 515.90 Td ( from our investment in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 503.90 Td (V) Tj ET Q q 0 0 0 rg BT 105.62 503.90 Td (iiV) Tj ET Q q 0 0 0 rg BT 118.22 503.90 Td ( Healthcare Limited \(V) Tj ET Q q 0 0 0 rg BT 210.63 503.90 Td (iiV\). In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 242.57 503.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 290.32 503.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 292.82 503.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 312.82 503.90 Td (, primarily includes, among other things, dividend income of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 491.90 Td ($43 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 145.39 491.90 Td ( from our investment in ) Tj ET Q q 0 0 0 rg BT 242.14 491.90 Td (V) Tj ET Q q 0 0 0 rg BT 248.76 491.90 Td (iiV) Tj ET Q q 0 0 0 rg BT 260.25 491.90 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 476.90 Td (\(6\) ) Tj ET Q q 0 0 0 rg BT 81.00 476.90 Td (The) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 96.55 476.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.05 476.90 Td (decrease in the ef) Tj ET Q q 0 0 0 rg BT 168.54 476.90 Td (fective tax rate for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 244.61 476.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 292.36 476.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 294.86 476.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 314.86 476.90 Td ( compared to first-quarter 2017 was primarily due to \(i\) the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 464.90 Td (December 2017 enactment of H.R.1, An ) Tj ET Q q 0 0 0 rg BT 249.00 464.90 Td (Act to provide for reconciliation pursuant to titles II and ) Tj ET Q q 0 0 0 rg BT 475.98 464.90 Td (V) Tj ET Q q 0 0 0 rg BT 483.02 464.90 Td ( of the concurrent ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 452.90 Td (resolution on the budget for fiscal year 2018 \(also known as the T) Tj ET Q q 0 0 0 rg BT 352.45 452.90 Td (ax Cuts and Jobs ) Tj ET Q q 0 0 0 rg BT 421.89 452.90 Td (Act \(TCJA\)\), \(ii\) the favorable ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 440.90 Td (change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, as ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 428.90 Td (well as \(iii\) the non-recurrence of the tax impact on an incremental char) Tj ET Q q 0 0 0 rg BT 367.91 428.90 Td (ge to amounts previously recorded to write ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 416.90 Td (down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. Given the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 404.90 Td (significant changes resulting from and complexities associated with the ) Tj ET Q q 0 0 0 rg BT 368.80 404.90 Td (TCJA, the estimated financial impacts ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 392.90 Td (recorded in 2017 are provisional and are subject to further analysis, interpretation and clarification of the ) Tj ET Q q 0 0 0 rg BT 502.61 392.90 Td (TCJA, which ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 380.90 Td (could result in changes to these estimates during 2018. Under guidance issued by the staf) Tj ET Q q 0 0 0 rg BT 437.12 380.90 Td (f of the U.S. Securities and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 368.90 Td (Exchange Commission, we expect to finalize our accounting related to the tax ef) Tj ET Q q 0 0 0 rg BT 403.21 368.90 Td (fects of the ) Tj ET Q q 0 0 0 rg BT 449.95 368.90 Td (TCJA) Tj ET Q q 0 0 0 rg BT 473.29 368.90 Td ( on deferred taxes, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 356.90 Td (valuation allowances, state tax considerations, the repatriation tax liability) Tj ET Q q 0 0 0 rg BT 376.92 356.90 Td (, global intangible low-taxed income, and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 344.90 Td (any remaining outside basis dif) Tj ET Q q 0 0 0 rg BT 205.79 344.90 Td (ferences in our foreign subsidiaries during 2018 as we complete our analysis, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 332.90 Td (computations and assertions. It is possible that others, applying reasonable judgment to the same facts and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 320.90 Td (circumstances, could develop and support a range of alternative estimated amounts. ) Tj ET Q q 0 0 0 rg BT 417.65 320.90 Td (W) Tj ET Q q 0 0 0 rg BT 426.29 320.90 Td (e will revise these estimates ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 308.90 Td (during 2018 as we gather additional information to complete our tax returns and as any interpretation or clarification ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 296.90 Td (of the ) Tj ET Q q 0 0 0 rg BT 106.37 296.90 Td (TCJA) Tj ET Q q 0 0 0 rg BT 129.71 296.90 Td ( occurs through legislation, U.S. ) Tj ET Q q 0 0 0 rg BT 261.18 296.90 Td (T) Tj ET Q q 0 0 0 rg BT 266.93 296.90 Td (reasury actions or other means.) Tj ET Q endstream endobj 37 0 obj <> endobj 38 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 133.95 755.85 Td (RECONCILIA) Tj ET Q q 0 0 0 rg BT 187.45 755.85 Td (TION OF GAAP) Tj ET Q q 0 0 0 rg BT 249.12 755.85 Td ( REPOR) Tj ET Q q 0 0 0 rg BT 279.84 755.85 Td (TED ) Tj ET Q q 0 0 0 rg BT 299.42 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 304.75 755.85 Td (O NON-GAAP) Tj ET Q q 0 0 0 rg BT 360.17 755.85 Td ( ) Tj ET Q q 0 0 0 rg BT 361.92 755.85 Td (ADJUSTED INFORMA) Tj ET Q q 0 0 0 rg BT 450.18 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 471.67 759.93 Td (\(1\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 227.85 745.05 Td (CER) Tj ET Q q 0 0 0 rg BT 244.81 745.05 Td (T) Tj ET Q q 0 0 0 rg BT 249.59 745.05 Td (AIN LINE ITEMS - \(UNAUDITED\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 213.00 734.25 Td (\(millions of dollars, except per common share data\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 18 -) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 715 m 207.5 715 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 207.5 715 m 211.5 715 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 211.5 715 m 268.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 211.5 701 m 268.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 268.5 715 m 272.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 268.5 701 m 272.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 272.5 715 m 328.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 272.5 701 m 328.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 328.5 715 m 332.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 328.5 701 m 332.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 332.5 715 m 395.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 332.5 701 m 395.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 395.5 715 m 399.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 395.5 701 m 399.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 715 m 454.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 701 m 454.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454.5 715 m 458.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 454.5 701 m 458.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 458.5 715 m 512.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 458.5 701 m 512.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 512.5 715 m 516.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 512.5 701 m 516.5 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 516.5 715 m 576.5 715 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 701 m 576.5 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 211.5 666 m 268.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 272.5 666 m 328.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 332.5 666 m 395.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 701 m 454.5 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 666 m 454.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 458.5 666 m 512.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 701 m 576.5 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 666 m 576.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 211.5 666 m 268.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 272.5 666 m 328.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 332.5 666 m 395.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 666 m 454.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 458.5 666 m 512.5 666 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 666 m 576.5 666 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 421 m 207.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 419 m 207.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 207.5 421 m 211.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 207.5 419 m 211.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 211.5 421 m 268.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 211.5 419 m 268.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 268.5 421 m 272.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 268.5 419 m 272.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 272.5 421 m 328.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 272.5 419 m 328.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 328.5 421 m 332.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 328.5 419 m 332.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 332.5 421 m 395.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 332.5 419 m 395.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 395.5 421 m 399.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 395.5 419 m 399.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 421 m 454.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 419 m 454.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454.5 421 m 458.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454.5 419 m 458.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 458.5 421 m 512.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 458.5 419 m 512.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 512.5 421 m 516.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 512.5 419 m 516.5 419 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 516.5 421 m 576.5 421 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 516.5 419 m 576.5 419 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 705.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 359.85 705.86 Td (First-Quarter 2018) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 681.36 Td () Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 226.95 681.25 Td (GAAP) Tj ET Q q 0 0 0 rg BT 251.95 681.25 Td ( ) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 218.05 670.45 Td (Reported) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 254.04 674.53 Td (\(2\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 283.75 692.01 Td (Purchase) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 279.00 681.21 Td (Accounting) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 277.20 670.46 Td (Adjustments) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 341.00 681.26 Td (Acquisition-) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 335.20 670.46 Td (Related Costs) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 384.95 674.54 Td (\(3\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 681.26 Td (Discontinued) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.75 670.46 Td (Operations) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 471.75 692.01 Td (Certain ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 465.25 681.21 Td (Significant ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 471.55 670.46 Td (Items) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 491.55 674.54 Td (\(4\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 524.65 681.26 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 567.32 681.26 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 526.30 670.46 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 558.80 674.54 Td (\(5\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 656.86 Td (Revenues) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 214.00 656.45 Td ($) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 240.25 656.45 Td (12,906) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.00 656.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 656.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 335.00 656.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 656.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.00 656.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 656.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 461.00 656.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 656.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 519.00 656.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.25 656.46 Td (12,906) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 642.86 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 85.00 646.94 Td (\(6\), \(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 642.45 Td (2,563) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 317.50 642.46 Td (\(1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 642.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 384.50 642.46 Td (\(3) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.00 642.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 642.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 497.00 642.46 Td (\(23) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 642.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 642.46 Td (2,536) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 629.26 Td (Selling, informational and administrative ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 618.46 Td (expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 80.49 622.54 Td (\(6\), \(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 618.45 Td (3,412) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 618.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 618.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 618.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 492.50 618.46 Td (\(126) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 618.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 618.46 Td (3,286) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 604.86 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 170.70 608.94 Td (\(6\), \(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 604.45 Td (1,743) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 320.50 604.46 Td (1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 604.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 604.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 501.50 604.46 Td (\(6) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 604.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 604.46 Td (1,739) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 590.86 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 158.22 594.94 Td (\(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 590.45 Td (1,196) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 301.75 590.46 Td (\(1,126) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 590.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 590.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 590.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 590.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 564.00 590.46 Td (71) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 577.26 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 105.65 577.26 Td (ges and certain) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 566.46 Td (acquisition-related costs) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 256.00 566.45 Td (43) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 566.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 380.00 566.46 Td (\(45) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.00 566.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 566.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 504.50 566.46 Td (2) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 564.00 566.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 552.86 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 248.50 552.45 Td (\(178) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 265.00 552.45 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 313.00 552.46 Td (\(96) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 552.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 552.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 552.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 497.00 552.46 Td (\(47) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 552.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 556.50 552.46 Td (\(322) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 573.00 552.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 539.26 Td (Income from continuing operations before) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 528.46 Td (provision for taxes on income) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 528.45 Td (4,127) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 304.75 528.46 Td (1,221) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 528.46 Td (48) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 528.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 528.46 Td (201) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 528.46 Td (5,597) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 514.86 Td (Provision for taxes on income) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 251.50 514.45 Td (556) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.50 514.46 Td (239) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.50 514.46 Td (8) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 514.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 514.46 Td (1) Tj ET Q q 0 0 0 rg BT 500.00 514.46 Td (17) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 559.50 514.46 Td (920) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 500.86 Td (Income from continuing operations) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 500.45 Td (3,571) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.50 500.46 Td (982) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 500.46 Td (40) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 500.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 500.46 Td (84) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 500.46 Td (4,677) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 486.86 Td (Discontinued operationsnet of tax) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 257.50 486.45 Td (\(1) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 265.00 486.45 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 486.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 486.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 446.50 486.46 Td (1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 486.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 564.00 486.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 473.26 Td (Net income attributable to noncontrolling) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 462.46 Td (interests) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 260.50 462.45 Td (9) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 462.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 462.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 462.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 462.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 568.50 462.46 Td (9) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 448.86 Td (Net income attributable to Pfizer Inc.) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 448.45 Td (3,561) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.50 448.46 Td (982) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 448.46 Td (40) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 446.50 448.46 Td (1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 448.46 Td (84) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 448.46 Td (4,668) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 435.26 Td (Earnings per common share attributable to) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 424.46 Td (Pfizer Inc.diluted) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 249.25 424.45 Td (0.59) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 309.25 424.46 Td (0.16) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 376.25 424.46 Td (0.01) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 424.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 493.25 424.46 Td (0.01) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 557.25 424.46 Td (0.77) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 396 m 207.5 396 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 207.5 396 m 211.5 396 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 211.5 396 m 268.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 211.5 382 m 268.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 268.5 396 m 272.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 268.5 382 m 272.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 272.5 396 m 328.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 272.5 382 m 328.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 328.5 396 m 332.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 328.5 382 m 332.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 332.5 396 m 395.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 332.5 382 m 395.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 395.5 396 m 399.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 395.5 382 m 399.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 396 m 454.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 382 m 454.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454.5 396 m 458.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 454.5 382 m 458.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 458.5 396 m 512.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 458.5 382 m 512.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 512.5 396 m 516.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 512.5 382 m 516.5 382 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 516.5 396 m 576.5 396 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 382 m 576.5 382 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 211.5 347 m 268.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 272.5 347 m 328.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 332.5 347 m 395.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 347 m 454.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 458.5 347 m 512.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 347 m 576.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 211.5 347 m 268.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 272.5 347 m 328.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 332.5 347 m 395.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 347 m 454.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 458.5 347 m 512.5 347 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 516.5 347 m 576.5 347 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 102 m 207.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 100 m 207.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 207.5 102 m 211.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 207.5 100 m 211.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 211.5 102 m 268.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 211.5 100 m 268.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 268.5 102 m 272.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 268.5 100 m 272.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 272.5 102 m 328.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 272.5 100 m 328.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 328.5 102 m 332.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 328.5 100 m 332.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 332.5 102 m 395.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 332.5 100 m 395.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 395.5 102 m 399.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 395.5 100 m 399.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 102 m 454.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 100 m 454.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454.5 102 m 458.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454.5 100 m 458.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 458.5 102 m 512.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 458.5 100 m 512.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 512.5 102 m 516.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 512.5 100 m 516.5 100 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 516.5 102 m 576.5 102 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 516.5 100 m 576.5 100 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 359.85 386.46 Td (First-Quarter 2017) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 362.36 Td () Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 226.95 362.25 Td (GAAP) Tj ET Q q 0 0 0 rg BT 251.95 362.25 Td ( ) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 218.05 351.45 Td (Reported) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 254.04 355.53 Td (\(2\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 283.75 373.01 Td (Purchase) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 279.00 362.21 Td (Accounting) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 277.20 351.46 Td (Adjustments) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 341.00 362.26 Td (Acquisition-) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 335.20 351.46 Td (Related Costs) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 384.95 355.54 Td (\(3\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 362.26 Td (Discontinued) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.75 351.46 Td (Operations) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 471.75 373.01 Td (Certain ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 465.25 362.21 Td (Significant ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 471.55 351.46 Td (Items) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 491.55 355.54 Td (\(4\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 524.65 362.26 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 567.32 362.26 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 526.30 351.46 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 558.80 355.54 Td (\(5\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 337.86 Td (Revenues) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 214.00 337.45 Td ($) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 240.25 337.45 Td (12,779) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.00 337.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 337.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 335.00 337.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 337.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.00 337.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 337.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 461.00 337.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 337.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 519.00 337.46 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.25 337.46 Td (12,779) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 323.86 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 85.00 327.94 Td (\(2\),) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.28 323.86 Td ( ) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 95.53 327.94 Td (\(6\), \(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 323.45 Td (2,468) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 317.50 323.46 Td (\(7) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 323.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 384.50 323.46 Td (\(3) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.00 323.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 323.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 497.00 323.46 Td (\(26) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 323.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 323.46 Td (2,432) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 310.26 Td (Selling, informational and administrative ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 299.46 Td (expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 80.49 303.54 Td (\(2\), \(6\), \(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 299.45 Td (3,315) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 317.50 299.46 Td (\(6) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 299.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 299.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 299.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 497.00 299.46 Td (\(14) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 299.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 299.46 Td (3,295) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 285.86 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 170.70 289.94 Td (\(2\), \(6\), \(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 285.45 Td (1,716) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 320.50 285.46 Td (4) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 285.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 285.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 501.50 285.46 Td (\(7) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 285.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 285.46 Td (1,713) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 271.86 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 158.22 275.94 Td (\(7\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 271.45 Td (1,186) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 301.75 271.46 Td (\(1,151) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 271.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 271.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 271.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 271.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 564.00 271.46 Td (35) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 258.26 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 105.56 258.26 Td (ges and certain ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 247.46 Td (acquisition-related costs) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 135.22 251.54 Td (\(2\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 256.00 247.45 Td (84) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 247.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 380.00 247.46 Td (\(96) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.00 247.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 247.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 247.46 Td (12) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 564.00 247.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 233.86 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 155.71 237.94 Td (\(2\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 256.00 233.45 Td (60) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 313.00 233.46 Td (\(13) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.00 233.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 380.00 233.46 Td (\(25) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.00 233.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 233.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 492.50 233.46 Td (\(122) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 233.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 556.50 233.46 Td (\(100) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 573.00 233.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 220.26 Td (Income from continuing operations before) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 209.46 Td (provision for taxes on income) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 209.45 Td (3,951) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 304.75 209.46 Td (1,172) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 378.50 209.46 Td (124) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 209.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 209.46 Td (157) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 209.46 Td (5,404) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 195.86 Td (Provision for taxes on income) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 251.50 195.45 Td (821) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.50 195.46 Td (340) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 195.46 Td (43) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 195.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 501.50 195.46 Td (\(1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.00 195.46 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 195.46 Td (1,204) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 181.86 Td (Income from continuing operations) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 181.45 Td (3,130) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.50 181.46 Td (832) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 181.46 Td (82) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 181.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 181.46 Td (157) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 181.46 Td (4,201) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 167.86 Td (Discontinued operationsnet of tax) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 256.00 167.45 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 167.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 167.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 167.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 167.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 564.00 167.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 154.26 Td (Net income attributable to noncontrolling) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 143.46 Td (interests) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 260.50 143.45 Td (9) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 316.00 143.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 143.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 143.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.00 143.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 568.50 143.46 Td (9) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 129.86 Td (Net income attributable to Pfizer Inc.) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 244.75 129.45 Td (3,121) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.50 129.46 Td (832) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.00 129.46 Td (82) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 129.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 129.46 Td (157) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 552.75 129.46 Td (4,192) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 116.26 Td (Earnings per common share attributable to) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 105.46 Td (Pfizer Inc.diluted) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 249.25 105.45 Td (0.51) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 309.25 105.46 Td (0.14) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 376.25 105.46 Td (0.01) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 442.00 105.46 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 493.25 105.46 Td (0.03) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 557.25 105.46 Td (0.69) Tj ET Q BT /F1 11.00 Tf ET BT /F1 9.00 Tf ET q 0 0 0 rg BT 36.00 90.70 Td (See end of tables for notes \(1\) through \(7\).) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 36.00 78.95 Td (Amounts may not add due to rounding.) Tj ET Q BT /F1 11.00 Tf ET endstream endobj 39 0 obj <> endobj 40 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 114.55 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 145.64 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 150.97 755.85 Td (O RECONCILIA) Tj ET Q q 0 0 0 rg BT 213.22 755.85 Td (TION OF GAAP) Tj ET Q q 0 0 0 rg BT 274.89 755.85 Td ( REPOR) Tj ET Q q 0 0 0 rg BT 305.61 755.85 Td (TED ) Tj ET Q q 0 0 0 rg BT 325.19 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 330.52 755.85 Td (O NON-GAAP) Tj ET Q q 0 0 0 rg BT 385.94 755.85 Td ( ) Tj ET Q q 0 0 0 rg BT 387.69 755.85 Td (ADJUSTED INFORMA) Tj ET Q q 0 0 0 rg BT 475.95 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 261.10 745.05 Td (CER) Tj ET Q q 0 0 0 rg BT 278.06 745.05 Td (T) Tj ET Q q 0 0 0 rg BT 282.84 745.05 Td (AIN LINE ITEMS) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 734.25 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 19 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 713.10 Td (\(1\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (Certain amounts in the reconciliation of GAAP) Tj ET Q q 0 0 0 rg BT 269.48 713.10 Td ( reported to Non-GAAP) Tj ET Q q 0 0 0 rg BT 365.48 713.10 Td ( adjusted information and associated notes may ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 701.10 Td (not add due to rounding.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 686.10 Td (\(2\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 686.10 Td (The financial statements present the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 227.33 686.10 Td (three months) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 279.27 686.10 Td ( ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 307.59 686.10 Td (April1, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 361.20 686.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 380.09 686.10 Td (April2, 2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 433.70 686.10 Td (. Subsidiaries operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 674.10 Td (outside the U.S. are included for the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 227.90 674.10 Td (three months) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 279.84 674.10 Td ( ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 308.71 674.10 Td (February25, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 382.31 674.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 401.75 674.10 Td (February26, 2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 475.35 674.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 659.10 Td (The adoption of certain new accounting standards in the first quarter of 2018 impacted our consolidated statements of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 647.10 Td (income. ) Tj ET Q q 0 0 0 rg BT 114.88 647.10 Td (Among other items, GAAP) Tj ET Q q 0 0 0 rg BT 223.95 647.10 Td ( Reported and Non-GAAP) Tj ET Q q 0 0 0 rg BT 329.95 647.10 Td ( ) Tj ET Q q 0 0 0 rg BT 331.90 647.10 Td (Adjusted amounts for the first quarter of 2017 have ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 635.10 Td (been revised from previously reported amounts to reflect the retrospective adoption of a new accounting standard in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 623.10 Td (the first quarter of 2018, as of January 1, 2018, requiring the reclassification of the non-service cost components of net ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 611.10 Td (periodic pension and postretirement benefit costs to ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 290.11 611.10 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 419.80 611.10 Td ( from their classification within ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 599.10 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 132.12 599.10 Td (, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 137.12 599.10 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 340.71 599.10 Td (, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 345.71 599.10 Td (Resear) Tj ET Q q 0 0 0 rg BT 373.10 599.10 Td (ch and development expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 491.11 599.10 Td ( and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 587.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 156.45 587.10 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 271.90 587.10 Td (elated costs) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 318.84 587.10 Td (. See Note \(1\) and Note \(5\) to Notes to Consolidated ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 575.10 Td (Statements of Income above and Note \(3\) below for additional information.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 560.10 Td (On February 3, 2017, we completed the sale of our global infusion systems net assets, Hospira Infusion Systems ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 548.10 Td (\(HIS\). ) Tj ET Q q 0 0 0 rg BT 108.59 548.10 Td (The operating results of HIS are included in the consolidated statement of income and EH) Tj ET Q q 0 0 0 rg BT 471.26 548.10 Td (s operating results ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 536.10 Td (through February 2, 2017 and, therefore, our financial results, and EH) Tj ET Q q 0 0 0 rg BT 363.70 536.10 Td (s operating results, for first-quarter 2017 reflect ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 524.10 Td (approximately one month of HIS domestic operations and approximately two months of HIS international operations, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 512.10 Td (while financial results for 2018 do not reflect any contribution from HIS global operations.) Tj ET Q BT /F1 10.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 497.10 Td (\(3\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 497.10 Td (Acquisition-related costs include the following:) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 486.6 m 414.5 486.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 414.5 486.6 m 418.5 486.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 418.5 486.6 m 486.5 486.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 472.6 m 486.5 472.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 486.5 486.6 m 490.5 486.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486.5 472.6 m 490.5 472.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 490.5 486.6 m 558.5 486.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 472.6 m 558.5 472.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 458.6 m 414.5 458.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 472.6 m 486.5 472.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 458.6 m 486.5 458.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 472.6 m 558.5 472.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 458.6 m 558.5 458.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 458.6 m 486.5 458.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 458.6 m 558.5 458.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 388.6 m 486.5 388.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 388.6 m 558.5 388.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 359.6 m 486.5 359.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 359.6 m 558.5 359.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 346.6 m 414.5 346.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 344.6 m 414.5 344.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 414.5 346.6 m 418.5 346.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 414.5 344.6 m 418.5 344.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 418.5 359.6 m 486.5 359.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 418.5 346.6 m 486.5 346.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 418.5 344.6 m 486.5 344.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 486.5 346.6 m 490.5 346.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 486.5 344.6 m 490.5 344.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 490.5 359.6 m 558.5 359.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 490.5 346.6 m 558.5 346.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 490.5 344.6 m 558.5 344.6 l s BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 476.85 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 461.85 477.17 Td (First-Quarter) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 462.85 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 464.00 463.36 Td (2018) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 536.00 463.36 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 449.17 Td (Restructuring \(credits\)/char) Tj ET Q q 0 0 0 rg BT 194.05 449.17 Td (ges) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 207.38 453.70 Td (\(a\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 421.00 449.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 474.30 449.22 Td (\(8) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 482.65 449.17 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 493.00 449.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 549.65 449.17 Td (8) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 435.17 Td (T) Tj ET Q q 0 0 0 rg BT 89.76 435.17 Td (ransaction costs) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 153.35 439.70 Td (\(b\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 472.65 435.17 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 435.17 Td (12) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 421.17 Td (Integration costs) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 150.37 425.70 Td (\(c\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 472.65 421.17 Td (52) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 421.17 Td (77) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 407.17 Td (Net periodic benefit costs other than service costs) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 282.54 411.70 Td (\(d\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 472.65 407.17 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 407.17 Td (25) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 393.17 Td (Additional depreciationasset restructuring) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 261.72 397.70 Td (\(e\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 477.65 393.17 Td (3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 549.65 393.17 Td (3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 97.50 379.17 Td (T) Tj ET Q q 0 0 0 rg BT 103.26 379.17 Td (otal acquisition-related costspre-tax) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 472.65 379.17 Td (48) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 539.65 379.17 Td (124) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 364.72 Td (Income taxes) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 137.03 369.25 Td (\(f\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 474.30 364.77 Td (\(8) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 482.65 364.72 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 541.30 364.77 Td (\(43) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 554.65 364.72 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 97.50 350.17 Td (T) Tj ET Q q 0 0 0 rg BT 102.91 350.17 Td (otal acquisition-related costsnet of tax) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 421.00 350.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 472.65 350.17 Td (40) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 493.00 350.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 544.65 350.17 Td (82) Tj ET Q BT /F1 11.00 Tf ET BT /F1 9.50 Tf ET q 0 0 0 rg BT 81.00 334.10 Td (\(a\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 334.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 172.96 334.10 Td (ges include employee termination costs, asset impairments and other exit costs associated with ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 322.10 Td (business combinations. Credits for the first quarter of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 314.79 322.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 334.79 322.10 Td ( were primarily associated with lower exit costs related ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 310.10 Td (to our acquisition of Hospira, Inc. \(Hospira\). In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 290.90 310.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 338.65 310.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 341.15 310.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 361.15 310.10 Td (, restructuring char) Tj ET Q q 0 0 0 rg BT 436.77 310.10 Td (ges were primarily related to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 298.10 Td (our acquisitions of Medivation, Inc. \(Medivation\) and ) Tj ET Q q 0 0 0 rg BT 316.46 298.10 Td (Anacor Pharmaceuticals, Inc. ) Tj ET Q q 0 0 0 rg BT 436.13 298.10 Td (All of these costs and char) Tj ET Q q 0 0 0 rg BT 541.75 298.10 Td (ges ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 286.10 Td (are included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 160.92 286.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 236.37 286.10 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 351.82 286.10 Td (elated costs) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 398.76 286.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 273.10 Td (\(b\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 273.10 Td (T) Tj ET Q q 0 0 0 rg BT 104.76 273.10 Td (ransaction costs represent external costs for banking, legal, accounting and other similar services, virtually all of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 261.10 Td (which for the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 154.82 261.10 Td (first quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 201.74 261.10 Td ( of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 215.07 261.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 235.07 261.10 Td ( are related to our acquisition of Medivation. ) Tj ET Q q 0 0 0 rg BT 415.85 261.10 Td (All of these costs and char) Tj ET Q q 0 0 0 rg BT 521.47 261.10 Td (ges are ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 249.10 Td (included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.21 249.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 221.67 249.10 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 337.12 249.10 Td (elated costs) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 384.05 249.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 236.10 Td (\(c\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 236.10 Td (Integration costs represent external, incremental costs directly related to integrating acquired businesses, and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 222.90 Td (primarily include expenditures for consulting and the integration of systems and processes. In the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 490.85 222.90 Td (first quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 537.77 222.90 Td (s of) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 552.49 222.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 210.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 119.00 210.90 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 138.44 210.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 158.44 210.90 Td (, integration costs primarily relate to our acquisition of Hospira. ) Tj ET Q q 0 0 0 rg BT 415.60 210.90 Td (All of these costs and char) Tj ET Q q 0 0 0 rg BT 521.22 210.90 Td (ges are ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 198.90 Td (included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.21 198.90 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 221.67 198.90 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 337.12 198.90 Td (elated costs) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 384.05 198.90 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 185.90 Td (\(d\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 185.90 Td (In the first quarter of 2017, this amount represents the net periodic benefit costs, excluding service costs, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 172.70 Td (reclassified to ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 157.31 172.70 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 287.00 172.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 289.75 172.70 Td (as a result of the retrospective adoption of a new accounting ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 160.70 Td (standard in the first quarter of 2018. See Note \(2\) above for additional information. ) Tj ET Q q 0 0 0 rg BT 433.72 160.70 Td (These costs represent ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 148.70 Td (accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 136.70 Td (associated with the Hospira U.S. qualified defined benefit pension plan.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 123.70 Td (\(e\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 123.70 Td (Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.76 123.70 Td (Cost of sales. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 202.88 123.70 Td (Represents the impact of changes in the estimated useful lives of assets involved in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 111.70 Td (restructuring actions related to acquisitions.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 98.70 Td (\(f\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 98.70 Td (Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.76 98.70 Td (Pr) Tj ET Q q 0 0 0 rg BT 156.39 98.70 Td (ovision for taxes on income) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 266.37 98.70 Td (. Income taxes includes the tax ef) Tj ET Q q 0 0 0 rg BT 399.75 98.70 Td (fect of the associated pre-tax amounts, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 86.70 Td (calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction) Tj ET Q q 0 0 0 rg BT 523.05 86.70 Td (s ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 74.70 Td (applicable tax rate. ) Tj ET Q endstream endobj 41 0 obj <> endobj 42 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 114.55 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 145.64 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 150.97 755.85 Td (O RECONCILIA) Tj ET Q q 0 0 0 rg BT 213.22 755.85 Td (TION OF GAAP) Tj ET Q q 0 0 0 rg BT 274.89 755.85 Td ( REPOR) Tj ET Q q 0 0 0 rg BT 305.61 755.85 Td (TED ) Tj ET Q q 0 0 0 rg BT 325.19 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 330.52 755.85 Td (O NON-GAAP) Tj ET Q q 0 0 0 rg BT 385.94 755.85 Td ( ) Tj ET Q q 0 0 0 rg BT 387.69 755.85 Td (ADJUSTED INFORMA) Tj ET Q q 0 0 0 rg BT 475.95 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 261.10 745.05 Td (CER) Tj ET Q q 0 0 0 rg BT 278.06 745.05 Td (T) Tj ET Q q 0 0 0 rg BT 282.84 745.05 Td (AIN LINE ITEMS) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 734.25 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 20 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 713.10 Td (\(4\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (Certain significant items include the following:) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 702.6 m 441.5 702.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 441.5 702.6 m 445.5 702.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 445.5 702.6 m 499.5 702.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 688.6 m 499.5 688.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 499.5 702.6 m 503.5 702.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 499.5 688.6 m 503.5 688.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 503.5 702.6 m 557.5 702.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 688.6 m 557.5 688.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 674.6 m 441.5 674.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 688.6 m 499.5 688.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 674.6 m 499.5 674.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 688.6 m 557.5 688.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 674.6 m 557.5 674.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 674.6 m 441.5 674.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 674.6 m 499.5 674.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 674.6 m 557.5 674.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 586.6 m 499.5 586.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 586.6 m 557.5 586.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 586.6 m 499.5 586.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 586.6 m 557.5 586.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 556.6 m 499.5 556.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 556.6 m 557.5 556.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 543.6 m 441.5 543.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 541.6 m 441.5 541.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 441.5 543.6 m 445.5 543.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 441.5 541.6 m 445.5 541.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 445.5 556.6 m 499.5 556.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 445.5 543.6 m 499.5 543.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 445.5 541.6 m 499.5 541.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 499.5 543.6 m 503.5 543.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 499.5 541.6 m 503.5 541.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 503.5 556.6 m 557.5 556.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 503.5 543.6 m 557.5 543.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 503.5 541.6 m 557.5 541.6 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 693.17 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 474.85 693.17 Td (First-Quarter) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 678.85 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 477.00 679.36 Td (2018) Tj ET Q BT /F1 9.50 Tf ET q 0 0 0 rg BT 535.00 679.36 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 665.17 Td (Restructuring credits) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 167.59 669.70 Td (\(a\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 448.00 665.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 487.30 665.22 Td (\(2) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 495.65 665.17 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 506.00 665.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 540.30 665.22 Td (\(12) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 553.65 665.17 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 650.72 Td (Implementation costs and additional depreciationasset restructuring) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 364.20 655.25 Td (\(b\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 485.65 650.27 Td (53) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 543.65 650.27 Td (42) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 636.17 Td (Certain legal matters, net) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 184.52 640.70 Td (\(c\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 482.30 636.22 Td (\(19) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 495.65 636.17 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 548.65 636.17 Td (8) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 621.27 Td (Loss on sale of HIS net assets) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 203.43 625.80 Td (\(d\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 490.65 621.72 Td (3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 543.65 621.72 Td (37) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 606.27 Td (Business and legal entity alignment costs) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 248.70 610.80 Td (\(e\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 490.65 606.72 Td (3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 543.65 606.72 Td (21) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 591.72 Td (Other) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 106.77 596.25 Td (\(f\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 480.65 591.72 Td (163) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 543.65 591.72 Td (61) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 97.50 576.72 Td (T) Tj ET Q q 0 0 0 rg BT 103.26 576.72 Td (otal certain significant itemspre-tax) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 480.65 576.72 Td (201) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 538.65 576.72 Td (157) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 561.72 Td (Income taxes) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 137.03 566.25 Td (\(g\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 477.30 561.77 Td (\(1) Tj ET Q q 0 0 0 rg BT 485.63 561.77 Td (17) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 495.65 561.72 Td (\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 548.65 561.72 Td (1) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 97.50 547.17 Td (T) Tj ET Q q 0 0 0 rg BT 102.91 547.17 Td (otal certain significant itemsnet of tax) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 448.00 547.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 485.65 547.17 Td (84) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 506.00 547.17 Td ($) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 538.65 547.17 Td (157) Tj ET Q BT /F1 11.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 531.10 Td (\(a\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 531.10 Td (Relates to our cost-reduction and productivity initiatives not associated with acquisitions. Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 519.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 174.45 519.10 Td (ges and certain acquisition-r) Tj ET Q q 0 0 0 rg BT 289.90 519.10 Td (elated costs. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 341.84 519.10 Td (For ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 358.23 519.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 405.98 519.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 408.48 519.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 428.48 519.10 Td (, the credits are mostly related ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 507.10 Td (to reserve releases for cost-reduction programs, partially of) Tj ET Q q 0 0 0 rg BT 335.39 507.10 Td (fset by exit costs. For ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 423.72 507.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 471.47 507.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 473.97 507.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 493.97 507.10 Td (, the credits are ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 495.10 Td (mostly related to reserve releases for cost-reduction programs, partially of) Tj ET Q q 0 0 0 rg BT 394.82 495.10 Td (fset by asset write downs.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 482.10 Td (\(b\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 482.10 Td (Relates to our cost-reduction and productivity initiatives not related to acquisitions. Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 482.80 482.10 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 533.92 482.10 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 539.75 482.10 Td ($30 ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 470.10 Td (million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 127.89 470.10 Td (\), ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 136.22 470.10 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 339.81 470.10 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 345.64 470.10 Td ($17 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 392.03 470.10 Td (\) and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 414.80 470.10 Td (Resear) Tj ET Q q 0 0 0 rg BT 442.20 470.10 Td (ch and development ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 458.10 Td (expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 134.54 458.10 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 140.37 458.10 Td ($6 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 181.76 458.10 Td (\) for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 201.75 458.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 249.50 458.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 252.00 458.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 272.00 458.10 Td (. Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 324.77 458.10 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 375.88 458.10 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 381.71 458.10 Td ($26 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 428.11 458.10 Td (\), ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 436.44 458.10 Td (Selling, informational and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 446.10 Td (administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 194.81 446.10 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 200.64 446.10 Td ($9 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 242.03 446.10 Td (\) and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 264.80 446.10 Td (Resear) Tj ET Q q 0 0 0 rg BT 292.20 446.10 Td (ch and development expenses ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 412.71 446.10 Td (\() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 416.04 446.10 Td ($7 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 457.43 446.10 Td (\) for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 477.42 446.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 525.17 446.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 527.67 446.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 547.67 446.10 Td (. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 433.10 Td (\(c\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 433.10 Td (Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.76 433.10 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 276.45 433.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 420.10 Td (\(d\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 420.10 Td (Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.76 420.10 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 276.45 420.10 Td (. In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 292.28 420.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 340.04 420.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 342.54 420.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 362.54 420.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 381.97 420.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 401.97 420.10 Td (, represents an incremental char) Tj ET Q q 0 0 0 rg BT 528.67 420.10 Td (ge to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 408.10 Td (amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 396.10 Td (sale of HIS net assets to ICU Medical, Inc. on February 3, 2017. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 383.10 Td (\(e\) ) Tj ET Q q 0 0 0 rg BT 99.00 383.10 Td (Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.76 383.10 Td (Other \(income\)/deductionsnet. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 281.45 383.10 Td (In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 292.28 383.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 340.04 383.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 342.54 383.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 362.54 383.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 381.97 383.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 401.97 383.10 Td (, represents expenses for changes to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 371.10 Td (our infrastructure to align our commercial operations, including costs to internally separate our businesses into ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 359.10 Td (distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 344.90 Td (\(f\) ) Tj ET Q q 0 0 0 rg BT 99.00 344.90 Td (In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 109.83 344.90 Td (first-quarter) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 157.58 344.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.33 344.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 180.33 344.90 Td (, included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 232.55 344.90 Td (Cost of sales ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 286.16 344.90 Td (\() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 289.49 344.90 Td ($7 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 330.89 344.90 Td ( income\), ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 371.15 344.90 Td (Selling, informational and administrative ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 332.90 Td (expenses ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 137.04 332.90 Td (\() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 140.37 332.90 Td ($109 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 191.76 332.90 Td (\) and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 214.53 332.90 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 344.21 332.90 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 350.04 332.90 Td ($61 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 396.44 332.90 Td (\). In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 415.60 332.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 463.35 332.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 465.85 332.90 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 485.85 332.90 Td (, primarily ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 320.90 Td (includes ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 134.83 320.90 Td ($108 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 186.22 320.90 Td ( for a special, one-time bonus paid to all non-executive Pfizer colleagues, which was one of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 308.90 Td (several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 296.90 Td (H.R.1, An ) Tj ET Q q 0 0 0 rg BT 146.50 296.90 Td (Act to provide for reconciliation pursuant to titles II and ) Tj ET Q q 0 0 0 rg BT 373.48 296.90 Td (V) Tj ET Q q 0 0 0 rg BT 380.52 296.90 Td ( of the concurrent resolution on the budget ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 284.90 Td (for fiscal year 2018 \(also known as the T) Tj ET Q q 0 0 0 rg BT 271.02 284.90 Td (ax Cuts and Jobs ) Tj ET Q q 0 0 0 rg BT 340.46 284.90 Td (Act \(TCJA\)\) on us. In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 435.45 284.90 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 483.20 284.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 485.70 284.90 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 505.70 284.90 Td (, included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 99.00 272.90 Td (Selling, informational and administrative expenses ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 305.09 272.90 Td (\() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 308.42 272.90 Td ($5 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 349.81 272.90 Td (\) and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 372.58 272.90 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 502.27 272.90 Td ( \() Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 508.10 272.90 Td ($56 ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 260.90 Td (million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 127.89 260.90 Td (\).) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 247.90 Td (\(g\) ) Tj ET Q q 0 0 0 rg BT 99.00 247.90 Td (Included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 146.76 247.90 Td (Pr) Tj ET Q q 0 0 0 rg BT 156.39 247.90 Td (ovision for taxes on income) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 266.37 247.90 Td (. Income taxes includes the tax ef) Tj ET Q q 0 0 0 rg BT 399.75 247.90 Td (fect of the associated pre-tax amounts, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 235.90 Td (calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction) Tj ET Q q 0 0 0 rg BT 523.05 235.90 Td (s ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 223.90 Td (applicable tax rate. First-quarter 2018 was favorably impacted by the December 2017 enactment of the ) Tj ET Q q 0 0 0 rg BT 512.55 223.90 Td (TCJA, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 211.90 Td (primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the ) Tj ET Q q 0 0 0 rg BT 489.24 211.90 Td (TCJA. First-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 199.90 Td (quarter 2017 was unfavorably impacted by the taxes on an incremental char) Tj ET Q q 0 0 0 rg BT 401.76 199.90 Td (ge to amounts previously recorded to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 187.90 Td (write down the HIS net assets to fair value less costs to sell related to the sale of the HIS net assets to ICU ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 175.90 Td (Medical. Given the significant changes resulting from and complexities associated with the ) Tj ET Q q 0 0 0 rg BT 466.22 175.90 Td (TCJA, the estimated ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 163.90 Td (financial impacts recorded in 2017 are provisional and are subject to further analysis, interpretation and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 151.90 Td (clarification of the ) Tj ET Q q 0 0 0 rg BT 175.17 151.90 Td (TCJA, which could result in changes to these estimates during 2018. Under guidance issued by ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 139.90 Td (the staf) Tj ET Q q 0 0 0 rg BT 127.97 139.90 Td (f of the U.S. Securities and Exchange Commission, we expect to finalize our accounting related to the tax ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 127.90 Td (ef) Tj ET Q q 0 0 0 rg BT 106.59 127.90 Td (fects of the ) Tj ET Q q 0 0 0 rg BT 153.33 127.90 Td (TCJA) Tj ET Q q 0 0 0 rg BT 176.67 127.90 Td ( on deferred taxes, valuation allowances, state tax considerations, the repatriation tax liability) Tj ET Q q 0 0 0 rg BT 548.95 127.90 Td (, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 115.90 Td (global intangible low-taxed income, and any remaining outside basis dif) Tj ET Q q 0 0 0 rg BT 387.64 115.90 Td (ferences in our foreign subsidiaries during ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 103.90 Td (2018 as we complete our analysis, computations and assertions. It is possible that others, applying reasonable ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 91.90 Td (judgment to the same facts and circumstances, could develop and support a range of alternative estimated ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 79.90 Td (amounts. ) Tj ET Q q 0 0 0 rg BT 137.71 79.90 Td (W) Tj ET Q q 0 0 0 rg BT 146.34 79.90 Td (e will revise these estimates during 2018 as we gather additional information to complete our tax ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 67.90 Td (returns and as any interpretation or clarification of the ) Tj ET Q q 0 0 0 rg BT 317.34 67.90 Td (TCJA) Tj ET Q q 0 0 0 rg BT 340.68 67.90 Td ( occurs through legislation, U.S. ) Tj ET Q q 0 0 0 rg BT 472.15 67.90 Td (T) Tj ET Q q 0 0 0 rg BT 477.91 67.90 Td (reasury actions or ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 99.00 55.90 Td (other means.) Tj ET Q endstream endobj 43 0 obj <> endobj 44 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 114.55 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 145.64 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 150.97 755.85 Td (O RECONCILIA) Tj ET Q q 0 0 0 rg BT 213.22 755.85 Td (TION OF GAAP) Tj ET Q q 0 0 0 rg BT 274.89 755.85 Td ( REPOR) Tj ET Q q 0 0 0 rg BT 305.61 755.85 Td (TED ) Tj ET Q q 0 0 0 rg BT 325.19 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 330.52 755.85 Td (O NON-GAAP) Tj ET Q q 0 0 0 rg BT 385.94 755.85 Td ( ) Tj ET Q q 0 0 0 rg BT 387.69 755.85 Td (ADJUSTED INFORMA) Tj ET Q q 0 0 0 rg BT 475.95 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 261.10 745.05 Td (CER) Tj ET Q q 0 0 0 rg BT 278.06 745.05 Td (T) Tj ET Q q 0 0 0 rg BT 282.84 745.05 Td (AIN LINE ITEMS) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 734.25 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 33.60 Td (- 21 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 713.10 Td (\(5\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 128.41 713.10 Td ( ) Tj ET Q q 0 0 0 rg BT 130.36 713.10 Td (Adjusted income and its components and Non-GAAP) Tj ET Q q 0 0 0 rg BT 344.96 713.10 Td ( ) Tj ET Q q 0 0 0 rg BT 346.90 713.10 Td (Adjusted diluted EPS are not, and should not be ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 701.10 Td (viewed as, substitutes for U.S. GAAP) Tj ET Q q 0 0 0 rg BT 231.73 701.10 Td ( net income and its components and diluted EPS. Despite the importance of these ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 689.10 Td (measures to management in goal setting and performance measurement \(as described in the Financial ReviewNon-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 677.10 Td (GAAP) Tj ET Q q 0 0 0 rg BT 107.86 677.10 Td ( Financial Measure \(Adjusted Income\) section of Pfizer) Tj ET Q q 0 0 0 rg BT 335.09 677.10 Td () Tj ET Q q 0 0 0 rg BT 337.87 677.10 Td (s 2017 Financial Report, which was filed as Exhibit 13 ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 665.10 Td (to Pfizer) Tj ET Q q 0 0 0 rg BT 115.53 665.10 Td () Tj ET Q q 0 0 0 rg BT 118.30 665.10 Td (s ) Tj ET Q q 0 0 0 rg BT 124.14 665.10 Td (Annual Report on Form 10-K for the fiscal year ended December 31, 2017\), Non-GAAP) Tj ET Q q 0 0 0 rg BT 478.96 665.10 Td ( ) Tj ET Q q 0 0 0 rg BT 480.91 665.10 Td (Adjusted income ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 653.10 Td (and its components and Non-GAAP) Tj ET Q q 0 0 0 rg BT 225.06 653.10 Td ( ) Tj ET Q q 0 0 0 rg BT 227.01 653.10 Td (Adjusted diluted EPS are Non-GAAP) Tj ET Q q 0 0 0 rg BT 377.73 653.10 Td ( financial measures that have no ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 641.10 Td (standardized meaning prescribed by U.S. GAAP) Tj ET Q q 0 0 0 rg BT 274.75 641.10 Td ( and, therefore, have limits in their usefulness to investors.Because of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 629.10 Td (their non-standardized definitions, Non-GAAP) Tj ET Q q 0 0 0 rg BT 268.37 629.10 Td ( ) Tj ET Q q 0 0 0 rg BT 270.32 629.10 Td (Adjusted income and its components and Non-GAAP) Tj ET Q q 0 0 0 rg BT 484.92 629.10 Td ( ) Tj ET Q q 0 0 0 rg BT 486.86 629.10 Td (Adjusted diluted ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 617.10 Td (EPS \(unlike U.S. GAAP) Tj ET Q q 0 0 0 rg BT 178.70 617.10 Td ( net income and its components and diluted EPS\) may not be comparable to the calculation of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 605.10 Td (similar measures of other companies.Non-GAAP) Tj ET Q q 0 0 0 rg BT 280.03 605.10 Td ( ) Tj ET Q q 0 0 0 rg BT 281.98 605.10 Td (Adjusted income and its components and Non-GAAP) Tj ET Q q 0 0 0 rg BT 496.58 605.10 Td ( ) Tj ET Q q 0 0 0 rg BT 498.52 605.10 Td (Adjusted ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 593.10 Td (diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 578.10 Td (\(6\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 578.10 Td (Exclusive of amortization of intangible assets, except as discussed in footnote \(7\) below) Tj ET Q q 0 0 0 rg BT 432.76 578.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 563.10 Td (\(7\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 563.10 Td (Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 551.10 Td (manufacture, research, market and distribute products, compounds and intellectual property is included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 539.10 Td (Amortization of intangible assets) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 212.95 539.10 Td ( as these intangible assets benefit multiple business functions. ) Tj ET Q q 0 0 0 rg BT 461.80 539.10 Td (Amortization expense ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 527.10 Td (related to intangible assets that are associated with a single function is included in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 410.91 527.10 Td (Cost of sales, Selling, informational ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 515.10 Td (and administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 194.31 515.10 Td ( and/or ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 224.86 515.10 Td (Resear) Tj ET Q q 0 0 0 rg BT 252.25 515.10 Td (ch and development expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 370.26 515.10 Td (, as appropriate.) Tj ET Q endstream endobj 45 0 obj <> endobj 46 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 223.40 755.85 Td (OPERA) Tj ET Q q 0 0 0 rg BT 251.91 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 317.99 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 360.75 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 382.24 759.93 Td (\(1\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 270.00 734.25 Td (\(millions of dollars\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 42.60 Td (- 22 -) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 719.5 m 247.5 719.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 247.5 719.5 m 251.5 719.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 251.5 719.5 m 306.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251.5 706.5 m 306.5 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 306.5 719.5 m 310.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 306.5 706.5 m 310.5 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 310.5 719.5 m 371.5 719.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 371.5 719.5 m 375.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 371.5 706.5 m 375.5 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 375.5 719.5 m 419.5 719.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 419.5 719.5 m 423.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 419.5 706.5 m 423.5 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 423.5 719.5 m 472.5 719.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 472.5 719.5 m 476.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 472.5 706.5 m 476.5 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 476.5 719.5 m 526.5 719.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 526.5 719.5 m 530.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 526.5 706.5 m 530.5 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 530.5 719.5 m 575.5 719.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251.5 706.5 m 306.5 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251.5 684.5 m 306.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 310.5 706.5 m 371.5 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 310.5 684.5 m 371.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 375.5 706.5 m 419.5 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 375.5 684.5 m 419.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 423.5 706.5 m 472.5 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 423.5 684.5 m 472.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 476.5 706.5 m 526.5 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 476.5 684.5 m 526.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 530.5 706.5 m 575.5 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 530.5 684.5 m 575.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251.5 684.5 m 306.5 684.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 476.5 684.5 m 526.5 684.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 549.5 m 247.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 547.5 m 247.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 247.5 549.5 m 251.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 247.5 547.5 m 251.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 251.5 549.5 m 306.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 251.5 547.5 m 306.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 306.5 549.5 m 310.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 306.5 547.5 m 310.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 310.5 549.5 m 371.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 310.5 547.5 m 371.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 371.5 549.5 m 375.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 371.5 547.5 m 375.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 375.5 549.5 m 419.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 375.5 547.5 m 419.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 419.5 549.5 m 423.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 419.5 547.5 m 423.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 423.5 549.5 m 472.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 423.5 547.5 m 472.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 472.5 549.5 m 476.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 472.5 547.5 m 476.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 476.5 549.5 m 526.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 476.5 547.5 m 526.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 526.5 549.5 m 530.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 526.5 547.5 m 530.5 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 530.5 549.5 m 575.5 549.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 530.5 547.5 m 575.5 547.5 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 379.35 710.76 Td (First-Quarter 2018) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 259.25 697.76 Td (Innovative ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 254.20 688.76 Td (Health \(IH\)) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 295.93 692.84 Td (\(2\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 324.25 697.76 Td (Essential ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 314.95 688.76 Td (Health \(EH\)) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 359.18 692.84 Td (\(2\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.30 688.96 Td (Other) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 403.79 693.04 Td (\(3\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 426.15 697.76 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 468.82 697.76 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 427.80 688.76 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 460.30 692.84 Td (\(4\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 479.25 697.76 Td (Reconciling ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 487.55 688.76 Td (Items) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 507.55 692.84 Td (\(5\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 539.95 697.90 Td (GAAP) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 534.50 688.90 Td (Reported) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 675.76 Td (Revenues) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 254.00 675.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 278.25 675.76 Td (7,829) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 313.00 675.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.25 675.76 Td (5,077) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 378.00 675.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 407.00 675.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 426.00 675.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 439.75 675.76 Td (12,906) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 479.00 675.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 514.00 675.76 Td () Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 533.00 675.90 Td ($) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 541.25 675.90 Td (12,906) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 662.76 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 285.00 662.76 Td (987) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.25 662.76 Td (1,436) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 662.76 Td (1) Tj ET Q q 0 0 0 rg BT 407.00 662.76 Td (13) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 444.25 662.76 Td (2,536) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 514.00 662.76 Td (27) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 545.75 662.90 Td (2,563) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 45.00 649.76 Td (% of revenue) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 282.75 649.76 Td (12.6) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 298.50 649.76 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 347.75 649.76 Td (28.3) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 363.50 649.76 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 411.50 649.76 Td (*) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 448.75 649.76 Td (19.7) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 464.50 649.76 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 518.50 649.76 Td (*) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 550.25 649.90 Td (19.9) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 566.00 649.90 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 636.76 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 278.25 636.76 Td (1,552) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 350.00 636.76 Td (628) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 395.75 636.76 Td (1,106) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 444.25 636.76 Td (3,286) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.50 636.76 Td (126) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 545.75 636.90 Td (3,412) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 623.76 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 285.00 623.76 Td (587) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 350.00 623.76 Td (221) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 623.76 Td (931) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 444.25 623.76 Td (1,739) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 518.50 623.76 Td (4) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 545.75 623.90 Td (1,743) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 610.76 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 289.50 610.76 Td (51) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 354.50 610.76 Td (19) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 407.00 610.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 455.50 610.76 Td (71) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 502.75 610.76 Td (1,126) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 545.75 610.90 Td (1,196) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 597.76 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 105.65 597.76 Td (ges and certain acquisition-related) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 588.76 Td (costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 289.50 588.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 354.50 588.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 407.00 588.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 455.50 588.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 514.00 588.96 Td (43) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 557.00 588.95 Td (43) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 575.76 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 282.00 575.76 Td (\(279) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 298.50 575.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.50 575.76 Td (\(15) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 363.50 575.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 404.00 575.76 Td (\(28) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 416.00 575.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 448.00 575.76 Td (\(322) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 464.50 575.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 509.50 575.76 Td (144) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 549.50 575.90 Td (\(178) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 566.00 575.90 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 561.96 Td (Income/\(loss\) from continuing operations before) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 552.96 Td (provision for taxes on income) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 278.25 552.96 Td (4,930) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.25 552.96 Td (2,788) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.75 552.96 Td (\(2,121) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 416.00 552.96 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 444.25 552.96 Td (5,597) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 499.75 552.96 Td (\(1,470) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 523.00 552.96 Td (\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 545.75 552.95 Td (4,127) Tj ET Q BT /F1 11.00 Tf ET 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 538.5 m 246.5 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 246.5 538.5 m 250.5 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 250.5 538.5 m 307.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 250.5 525.5 m 307.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 307.5 538.5 m 311.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307.5 525.5 m 311.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 311.5 538.5 m 372.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 311.5 525.5 m 372.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 372.5 538.5 m 376.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 372.5 525.5 m 376.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 376.5 538.5 m 419.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 376.5 525.5 m 419.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 419.5 538.5 m 423.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 419.5 525.5 m 423.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 423.5 538.5 m 473.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 423.5 525.5 m 473.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 473.5 538.5 m 477.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 473.5 525.5 m 477.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 477.5 538.5 m 527.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 477.5 525.5 m 527.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 527.5 538.5 m 531.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 527.5 525.5 m 531.5 525.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 531.5 538.5 m 576.5 538.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 531.5 525.5 m 576.5 525.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 250.5 525.5 m 307.5 525.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 250.5 502.5 m 307.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 311.5 502.5 m 372.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 376.5 502.5 m 419.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 423.5 502.5 m 473.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 477.5 502.5 m 527.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 531.5 502.5 m 576.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 250.5 502.5 m 307.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 376.5 502.5 m 419.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 423.5 502.5 m 473.5 502.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 531.5 502.5 m 576.5 502.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 369.5 m 246.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 36.5 367.5 m 246.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 246.5 369.5 m 250.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 246.5 367.5 m 250.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 250.5 369.5 m 307.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 250.5 367.5 m 307.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 307.5 369.5 m 311.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 307.5 367.5 m 311.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 311.5 369.5 m 372.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 311.5 367.5 m 372.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 372.5 369.5 m 376.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 372.5 367.5 m 376.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 376.5 369.5 m 419.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 376.5 367.5 m 419.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 419.5 369.5 m 423.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 419.5 367.5 m 423.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 423.5 369.5 m 473.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 423.5 367.5 m 473.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 473.5 369.5 m 477.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 473.5 367.5 m 477.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 477.5 369.5 m 527.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 477.5 367.5 m 527.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 527.5 369.5 m 531.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 527.5 367.5 m 531.5 367.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 531.5 369.5 m 576.5 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 531.5 367.5 m 576.5 367.5 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 379.35 529.76 Td (First-Quarter 2017) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 259.25 515.96 Td (Innovative ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 254.20 506.96 Td (Health \(IH\)) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 295.93 511.04 Td (\(2\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 325.25 515.96 Td (Essential ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 315.95 506.96 Td (Health \(EH\)) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 360.18 511.04 Td (\(2\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 383.80 506.96 Td (Other) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 404.29 511.04 Td (\(3\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 426.65 515.96 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 469.32 515.96 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 428.30 506.96 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 460.80 511.04 Td (\(4\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 480.25 515.96 Td (Reconciling ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 488.55 506.96 Td (Items) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 508.55 511.04 Td (\(5\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 540.95 515.95 Td (GAAP) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 535.50 506.95 Td (Reported) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 493.76 Td (Revenues) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 253.00 493.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 279.25 493.76 Td (7,415) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 314.00 493.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 344.25 493.76 Td (5,364) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 379.00 493.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 407.00 493.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 426.00 493.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 440.75 493.76 Td (12,779) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 480.00 493.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 515.00 493.76 Td () Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 534.00 493.90 Td ($) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 542.25 493.90 Td (12,779) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 480.76 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 85.00 484.84 Td (\(6\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 286.00 480.76 Td (849) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 344.25 480.76 Td (1,450) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 480.76 Td (133) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 445.25 480.76 Td (2,432) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 515.00 480.76 Td (36) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 546.75 480.90 Td (2,468) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 45.00 467.76 Td (% of revenue) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 283.75 467.76 Td (1) Tj ET Q q 0 0 0 rg BT 288.25 467.76 Td (1.4) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 299.50 467.76 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 348.75 467.76 Td (27.0) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 364.50 467.76 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 411.50 467.76 Td (*) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 449.75 467.76 Td (19.0) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 465.50 467.76 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 519.50 467.76 Td (*) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 551.25 467.90 Td (19.3) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 567.00 467.90 Td (%) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 454.76 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 221.71 458.84 Td (\(6\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 279.25 454.76 Td (1,425) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 454.76 Td (677) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 395.75 454.76 Td (1,193) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 445.25 454.76 Td (3,295) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 515.00 454.76 Td (20) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 546.75 454.90 Td (3,315) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 441.76 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 170.70 445.84 Td (\(6\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 286.00 441.76 Td (519) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 441.76 Td (253) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 441.76 Td (941) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 445.25 441.76 Td (1,713) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 519.50 441.76 Td (3) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 546.75 441.90 Td (1,716) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 428.76 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 290.50 428.76 Td (26) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 360.00 428.76 Td (9) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 407.00 428.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 456.50 428.76 Td (35) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.75 428.76 Td (1,151) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 546.75 428.90 Td (1,186) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 414.96 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 105.56 414.96 Td (ges and certain acquisition-related ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 405.96 Td (costs) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 66.00 410.04 Td (\(6\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 290.50 405.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 355.50 405.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 407.00 405.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 456.50 405.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 515.00 405.96 Td (84) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 558.00 405.95 Td (84) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 392.76 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 155.71 396.84 Td (\(6\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 283.00 392.76 Td (\(151) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 299.50 392.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 352.50 392.76 Td (\(64) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 364.50 392.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 402.50 392.76 Td (1) Tj ET Q q 0 0 0 rg BT 407.00 392.76 Td (15) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 449.00 392.76 Td (\(100) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 465.50 392.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 510.50 392.76 Td (161) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 558.00 392.90 Td (60) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 39.00 379.76 Td (Income/\(loss\) from continuing operations before) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 48.00 370.81 Td (provision for taxes on income) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 279.25 372.96 Td (4,747) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 344.25 372.96 Td (3,039) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 392.75 372.96 Td (\(2,382) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 416.00 372.96 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 445.25 372.96 Td (5,404) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 500.75 372.96 Td (\(1,453) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 524.00 372.96 Td (\)) Tj ET Q BT /F2 9.00 Tf ET q 0 0 0 rg BT 546.75 372.95 Td (3,951) Tj ET Q BT /F1 11.00 Tf ET BT /F1 9.00 Tf ET q 0 0 0 rg BT 36.00 358.20 Td (See end of tables for notes \(1\) through \(6\).) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 36.00 347.40 Td (Amounts may not add due to rounding.) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 36.00 336.60 Td (* ) Tj ET Q q 0 0 0 rg BT 45.00 336.60 Td (Indicates calculation not meaningful or result is equal to or greater than 100%.) Tj ET Q endstream endobj 47 0 obj <> endobj 48 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 203.95 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 235.04 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 240.37 755.85 Td (O OPERA) Tj ET Q q 0 0 0 rg BT 277.63 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 343.71 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 386.47 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 29.10 Td (- 23 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 722.10 Td (\(1\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 722.10 Td (Certain amounts in the operating segment information and associated notes may not add due to rounding. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 707.10 Td (\(2\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 707.10 Td (Amounts represent the revenues and costs managed by each of our operating segments: Pfizer Innovative Health \(IH\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 695.10 Td (and Pfizer Essential Health \(EH\). ) Tj ET Q q 0 0 0 rg BT 216.88 695.10 Td (The expenses generally include only those costs directly attributable to the operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 683.10 Td (segment. ) Tj ET Q q 0 0 0 rg BT 119.14 683.10 Td (The operating segment information presents the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 312.98 683.10 Td (three months) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 364.91 683.10 Td ( ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 393.24 683.10 Td (April1, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 446.84 683.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 465.73 683.10 Td (April2, 2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 519.34 683.10 Td (. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 671.10 Td (Subsidiaries operating outside the U.S. are included for the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 319.55 671.10 Td (three months) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 371.49 671.10 Td ( ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 400.37 671.10 Td (February25, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 473.96 671.10 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 493.40 671.10 Td (February26, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 659.10 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 101.00 659.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 644.10 Td (The adoption of certain new accounting standards in the first quarter of 2018 impacted our consolidated statements of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 632.10 Td (income. See Note \(1\) and Note \(5\) to Notes to Consolidated Statements of Income, Note \(3\) to Notes to Reconciliation ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 620.10 Td (of GAAP) Tj ET Q q 0 0 0 rg BT 118.69 620.10 Td ( Reported to Non-GAAP) Tj ET Q q 0 0 0 rg BT 218.03 620.10 Td ( ) Tj ET Q q 0 0 0 rg BT 219.97 620.10 Td (Adjusted Information Certain Line Items and Note \(6\) below for additional ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 608.10 Td (information.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 593.10 Td (On February 3, 2017, we completed the sale of our global infusion systems net assets, Hospira Infusion Systems ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 581.10 Td (\(HIS\). ) Tj ET Q q 0 0 0 rg BT 108.59 581.10 Td (The operating results of HIS are included in EH) Tj ET Q q 0 0 0 rg BT 302.98 581.10 Td (s operating results through February 2, 2017 and, therefore, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 569.10 Td (EH) Tj ET Q q 0 0 0 rg BT 97.11 569.10 Td (s operating results for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 186.53 569.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 234.29 569.10 Td ( 2017 reflect approximately one month of legacy HIS domestic operations and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 557.10 Td (approximately two months of legacy HIS international operations, while financial results for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 453.40 557.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 473.40 557.10 Td ( do not reflect any ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 545.10 Td (contribution from HIS global operations.) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 517.6 m 310.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 310.5 517.6 m 314.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 314.5 517.6 m 558.5 517.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 314.5 503.6 m 558.5 503.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 503.6 m 310.5 503.6 l s 81.5 416.6 m 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 82.5 416.6 l 83.5 416.6 m 84.5 416.6 l 85.5 416.6 m 86.5 416.6 l 87.5 416.6 m 88.5 416.6 l 89.5 416.6 m 90.5 416.6 l 91.5 416.6 m 92.5 416.6 l 93.5 416.6 m 94.5 416.6 l 95.5 416.6 m 96.5 416.6 l 97.5 416.6 m 98.5 416.6 l 99.5 416.6 m 100.5 416.6 l 101.5 416.6 m 102.5 416.6 l 103.5 416.6 m 104.5 416.6 l 105.5 416.6 m 106.5 416.6 l 107.5 416.6 m 108.5 416.6 l 109.5 416.6 m 110.5 416.6 l 111.5 416.6 m 112.5 416.6 l 113.5 416.6 m 114.5 416.6 l 115.5 416.6 m 116.5 416.6 l 117.5 416.6 m 118.5 416.6 l 119.5 416.6 m 120.5 416.6 l 121.5 416.6 m 122.5 416.6 l 123.5 416.6 m 124.5 416.6 l 125.5 416.6 m 126.5 416.6 l 127.5 416.6 m 128.5 416.6 l 129.5 416.6 m 130.5 416.6 l 131.5 416.6 m 132.5 416.6 l 133.5 416.6 m 134.5 416.6 l 135.5 416.6 m 136.5 416.6 l 137.5 416.6 m 138.5 416.6 l 139.5 416.6 m 140.5 416.6 l 141.5 416.6 m 142.5 416.6 l 143.5 416.6 m 144.5 416.6 l 145.5 416.6 m 146.5 416.6 l 147.5 416.6 m 148.5 416.6 l 149.5 416.6 m 150.5 416.6 l 151.5 416.6 m 152.5 416.6 l 153.5 416.6 m 154.5 416.6 l 155.5 416.6 m 156.5 416.6 l 157.5 416.6 m 158.5 416.6 l 159.5 416.6 m 160.5 416.6 l 161.5 416.6 m 162.5 416.6 l 163.5 416.6 m 164.5 416.6 l 165.5 416.6 m 166.5 416.6 l 167.5 416.6 m 168.5 416.6 l 169.5 416.6 m 170.5 416.6 l 171.5 416.6 m 172.5 416.6 l 173.5 416.6 m 174.5 416.6 l 175.5 416.6 m 176.5 416.6 l 177.5 416.6 m 178.5 416.6 l 179.5 416.6 m 180.5 416.6 l 181.5 416.6 m 182.5 416.6 l 183.5 416.6 m 184.5 416.6 l 185.5 416.6 m 186.5 416.6 l 187.5 416.6 m 188.5 416.6 l 189.5 416.6 m 190.5 416.6 l 191.5 416.6 m 192.5 416.6 l 193.5 416.6 m 194.5 416.6 l 195.5 416.6 m 196.5 416.6 l 197.5 416.6 m 198.5 416.6 l 199.5 416.6 m 200.5 416.6 l 201.5 416.6 m 202.5 416.6 l 203.5 416.6 m 204.5 416.6 l 205.5 416.6 m 206.5 416.6 l 207.5 416.6 m 208.5 416.6 l 209.5 416.6 m 210.5 416.6 l 211.5 416.6 m 212.5 416.6 l 213.5 416.6 m 214.5 416.6 l 215.5 416.6 m 216.5 416.6 l 217.5 416.6 m 218.5 416.6 l 219.5 416.6 m 220.5 416.6 l 221.5 416.6 m 222.5 416.6 l 223.5 416.6 m 224.5 416.6 l 225.5 416.6 m 226.5 416.6 l 227.5 416.6 m 228.5 416.6 l 229.5 416.6 m 230.5 416.6 l 231.5 416.6 m 232.5 416.6 l 233.5 416.6 m 234.5 416.6 l 235.5 416.6 m 236.5 416.6 l 237.5 416.6 m 238.5 416.6 l 239.5 416.6 m 240.5 416.6 l 241.5 416.6 m 242.5 416.6 l 243.5 416.6 m 244.5 416.6 l 245.5 416.6 m 246.5 416.6 l 247.5 416.6 m 248.5 416.6 l 249.5 416.6 m 250.5 416.6 l 251.5 416.6 m 252.5 416.6 l 253.5 416.6 m 254.5 416.6 l 255.5 416.6 m 256.5 416.6 l 257.5 416.6 m 258.5 416.6 l 259.5 416.6 m 260.5 416.6 l 261.5 416.6 m 262.5 416.6 l 263.5 416.6 m 264.5 416.6 l 265.5 416.6 m 266.5 416.6 l 267.5 416.6 m 268.5 416.6 l 269.5 416.6 m 270.5 416.6 l 271.5 416.6 m 272.5 416.6 l 273.5 416.6 m 274.5 416.6 l 275.5 416.6 m 276.5 416.6 l 277.5 416.6 m 278.5 416.6 l 279.5 416.6 m 280.5 416.6 l 281.5 416.6 m 282.5 416.6 l 283.5 416.6 m 284.5 416.6 l 285.5 416.6 m 286.5 416.6 l 287.5 416.6 m 288.5 416.6 l 289.5 416.6 m 290.5 416.6 l 291.5 416.6 m 292.5 416.6 l 293.5 416.6 m 294.5 416.6 l 295.5 416.6 m 296.5 416.6 l 297.5 416.6 m 298.5 416.6 l 299.5 416.6 m 300.5 416.6 l 301.5 416.6 m 302.5 416.6 l 303.5 416.6 m 304.5 416.6 l 305.5 416.6 m 306.5 416.6 l 307.5 416.6 m 308.5 416.6 l 309.5 416.6 m 310.5 416.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 314.5 503.6 m 558.5 503.6 l s 314.5 416.6 m 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 315.5 416.6 l 316.5 416.6 m 317.5 416.6 l 318.5 416.6 m 319.5 416.6 l 320.5 416.6 m 321.5 416.6 l 322.5 416.6 m 323.5 416.6 l 324.5 416.6 m 325.5 416.6 l 326.5 416.6 m 327.5 416.6 l 328.5 416.6 m 329.5 416.6 l 330.5 416.6 m 331.5 416.6 l 332.5 416.6 m 333.5 416.6 l 334.5 416.6 m 335.5 416.6 l 336.5 416.6 m 337.5 416.6 l 338.5 416.6 m 339.5 416.6 l 340.5 416.6 m 341.5 416.6 l 342.5 416.6 m 343.5 416.6 l 344.5 416.6 m 345.5 416.6 l 346.5 416.6 m 347.5 416.6 l 348.5 416.6 m 349.5 416.6 l 350.5 416.6 m 351.5 416.6 l 352.5 416.6 m 353.5 416.6 l 354.5 416.6 m 355.5 416.6 l 356.5 416.6 m 357.5 416.6 l 358.5 416.6 m 359.5 416.6 l 360.5 416.6 m 361.5 416.6 l 362.5 416.6 m 363.5 416.6 l 364.5 416.6 m 365.5 416.6 l 366.5 416.6 m 367.5 416.6 l 368.5 416.6 m 369.5 416.6 l 370.5 416.6 m 371.5 416.6 l 372.5 416.6 m 373.5 416.6 l 374.5 416.6 m 375.5 416.6 l 376.5 416.6 m 377.5 416.6 l 378.5 416.6 m 379.5 416.6 l 380.5 416.6 m 381.5 416.6 l 382.5 416.6 m 383.5 416.6 l 384.5 416.6 m 385.5 416.6 l 386.5 416.6 m 387.5 416.6 l 388.5 416.6 m 389.5 416.6 l 390.5 416.6 m 391.5 416.6 l 392.5 416.6 m 393.5 416.6 l 394.5 416.6 m 395.5 416.6 l 396.5 416.6 m 397.5 416.6 l 398.5 416.6 m 399.5 416.6 l 400.5 416.6 m 401.5 416.6 l 402.5 416.6 m 403.5 416.6 l 404.5 416.6 m 405.5 416.6 l 406.5 416.6 m 407.5 416.6 l 408.5 416.6 m 409.5 416.6 l 410.5 416.6 m 411.5 416.6 l 412.5 416.6 m 413.5 416.6 l 414.5 416.6 m 415.5 416.6 l 416.5 416.6 m 417.5 416.6 l 418.5 416.6 m 419.5 416.6 l 420.5 416.6 m 421.5 416.6 l 422.5 416.6 m 423.5 416.6 l 424.5 416.6 m 425.5 416.6 l 426.5 416.6 m 427.5 416.6 l 428.5 416.6 m 429.5 416.6 l 430.5 416.6 m 431.5 416.6 l 432.5 416.6 m 433.5 416.6 l 434.5 416.6 m 435.5 416.6 l 436.5 416.6 m 437.5 416.6 l 438.5 416.6 m 439.5 416.6 l 440.5 416.6 m 441.5 416.6 l 442.5 416.6 m 443.5 416.6 l 444.5 416.6 m 445.5 416.6 l 446.5 416.6 m 447.5 416.6 l 448.5 416.6 m 449.5 416.6 l 450.5 416.6 m 451.5 416.6 l 452.5 416.6 m 453.5 416.6 l 454.5 416.6 m 455.5 416.6 l 456.5 416.6 m 457.5 416.6 l 458.5 416.6 m 459.5 416.6 l 460.5 416.6 m 461.5 416.6 l 462.5 416.6 m 463.5 416.6 l 464.5 416.6 m 465.5 416.6 l 466.5 416.6 m 467.5 416.6 l 468.5 416.6 m 469.5 416.6 l 470.5 416.6 m 471.5 416.6 l 472.5 416.6 m 473.5 416.6 l 474.5 416.6 m 475.5 416.6 l 476.5 416.6 m 477.5 416.6 l 478.5 416.6 m 479.5 416.6 l 480.5 416.6 m 481.5 416.6 l 482.5 416.6 m 483.5 416.6 l 484.5 416.6 m 485.5 416.6 l 486.5 416.6 m 487.5 416.6 l 488.5 416.6 m 489.5 416.6 l 490.5 416.6 m 491.5 416.6 l 492.5 416.6 m 493.5 416.6 l 494.5 416.6 m 495.5 416.6 l 496.5 416.6 m 497.5 416.6 l 498.5 416.6 m 499.5 416.6 l 500.5 416.6 m 501.5 416.6 l 502.5 416.6 m 503.5 416.6 l 504.5 416.6 m 505.5 416.6 l 506.5 416.6 m 507.5 416.6 l 508.5 416.6 m 509.5 416.6 l 510.5 416.6 m 511.5 416.6 l 512.5 416.6 m 513.5 416.6 l 514.5 416.6 m 515.5 416.6 l 516.5 416.6 m 517.5 416.6 l 518.5 416.6 m 519.5 416.6 l 520.5 416.6 m 521.5 416.6 l 522.5 416.6 m 523.5 416.6 l 524.5 416.6 m 525.5 416.6 l 526.5 416.6 m 527.5 416.6 l 528.5 416.6 m 529.5 416.6 l 530.5 416.6 m 531.5 416.6 l 532.5 416.6 m 533.5 416.6 l 534.5 416.6 m 535.5 416.6 l 536.5 416.6 m 537.5 416.6 l 538.5 416.6 m 539.5 416.6 l 540.5 416.6 m 541.5 416.6 l 542.5 416.6 m 543.5 416.6 l 544.5 416.6 m 545.5 416.6 l 546.5 416.6 m 547.5 416.6 l 548.5 416.6 m 549.5 416.6 l 550.5 416.6 m 551.5 416.6 l 552.5 416.6 m 553.5 416.6 l 554.5 416.6 m 555.5 416.6 l 556.5 416.6 m 557.5 416.6 l 558.5 416.6 m s 81.5 416.6 m 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 82.5 416.6 l 83.5 416.6 m 84.5 416.6 l 85.5 416.6 m 86.5 416.6 l 87.5 416.6 m 88.5 416.6 l 89.5 416.6 m 90.5 416.6 l 91.5 416.6 m 92.5 416.6 l 93.5 416.6 m 94.5 416.6 l 95.5 416.6 m 96.5 416.6 l 97.5 416.6 m 98.5 416.6 l 99.5 416.6 m 100.5 416.6 l 101.5 416.6 m 102.5 416.6 l 103.5 416.6 m 104.5 416.6 l 105.5 416.6 m 106.5 416.6 l 107.5 416.6 m 108.5 416.6 l 109.5 416.6 m 110.5 416.6 l 111.5 416.6 m 112.5 416.6 l 113.5 416.6 m 114.5 416.6 l 115.5 416.6 m 116.5 416.6 l 117.5 416.6 m 118.5 416.6 l 119.5 416.6 m 120.5 416.6 l 121.5 416.6 m 122.5 416.6 l 123.5 416.6 m 124.5 416.6 l 125.5 416.6 m 126.5 416.6 l 127.5 416.6 m 128.5 416.6 l 129.5 416.6 m 130.5 416.6 l 131.5 416.6 m 132.5 416.6 l 133.5 416.6 m 134.5 416.6 l 135.5 416.6 m 136.5 416.6 l 137.5 416.6 m 138.5 416.6 l 139.5 416.6 m 140.5 416.6 l 141.5 416.6 m 142.5 416.6 l 143.5 416.6 m 144.5 416.6 l 145.5 416.6 m 146.5 416.6 l 147.5 416.6 m 148.5 416.6 l 149.5 416.6 m 150.5 416.6 l 151.5 416.6 m 152.5 416.6 l 153.5 416.6 m 154.5 416.6 l 155.5 416.6 m 156.5 416.6 l 157.5 416.6 m 158.5 416.6 l 159.5 416.6 m 160.5 416.6 l 161.5 416.6 m 162.5 416.6 l 163.5 416.6 m 164.5 416.6 l 165.5 416.6 m 166.5 416.6 l 167.5 416.6 m 168.5 416.6 l 169.5 416.6 m 170.5 416.6 l 171.5 416.6 m 172.5 416.6 l 173.5 416.6 m 174.5 416.6 l 175.5 416.6 m 176.5 416.6 l 177.5 416.6 m 178.5 416.6 l 179.5 416.6 m 180.5 416.6 l 181.5 416.6 m 182.5 416.6 l 183.5 416.6 m 184.5 416.6 l 185.5 416.6 m 186.5 416.6 l 187.5 416.6 m 188.5 416.6 l 189.5 416.6 m 190.5 416.6 l 191.5 416.6 m 192.5 416.6 l 193.5 416.6 m 194.5 416.6 l 195.5 416.6 m 196.5 416.6 l 197.5 416.6 m 198.5 416.6 l 199.5 416.6 m 200.5 416.6 l 201.5 416.6 m 202.5 416.6 l 203.5 416.6 m 204.5 416.6 l 205.5 416.6 m 206.5 416.6 l 207.5 416.6 m 208.5 416.6 l 209.5 416.6 m 210.5 416.6 l 211.5 416.6 m 212.5 416.6 l 213.5 416.6 m 214.5 416.6 l 215.5 416.6 m 216.5 416.6 l 217.5 416.6 m 218.5 416.6 l 219.5 416.6 m 220.5 416.6 l 221.5 416.6 m 222.5 416.6 l 223.5 416.6 m 224.5 416.6 l 225.5 416.6 m 226.5 416.6 l 227.5 416.6 m 228.5 416.6 l 229.5 416.6 m 230.5 416.6 l 231.5 416.6 m 232.5 416.6 l 233.5 416.6 m 234.5 416.6 l 235.5 416.6 m 236.5 416.6 l 237.5 416.6 m 238.5 416.6 l 239.5 416.6 m 240.5 416.6 l 241.5 416.6 m 242.5 416.6 l 243.5 416.6 m 244.5 416.6 l 245.5 416.6 m 246.5 416.6 l 247.5 416.6 m 248.5 416.6 l 249.5 416.6 m 250.5 416.6 l 251.5 416.6 m 252.5 416.6 l 253.5 416.6 m 254.5 416.6 l 255.5 416.6 m 256.5 416.6 l 257.5 416.6 m 258.5 416.6 l 259.5 416.6 m 260.5 416.6 l 261.5 416.6 m 262.5 416.6 l 263.5 416.6 m 264.5 416.6 l 265.5 416.6 m 266.5 416.6 l 267.5 416.6 m 268.5 416.6 l 269.5 416.6 m 270.5 416.6 l 271.5 416.6 m 272.5 416.6 l 273.5 416.6 m 274.5 416.6 l 275.5 416.6 m 276.5 416.6 l 277.5 416.6 m 278.5 416.6 l 279.5 416.6 m 280.5 416.6 l 281.5 416.6 m 282.5 416.6 l 283.5 416.6 m 284.5 416.6 l 285.5 416.6 m 286.5 416.6 l 287.5 416.6 m 288.5 416.6 l 289.5 416.6 m 290.5 416.6 l 291.5 416.6 m 292.5 416.6 l 293.5 416.6 m 294.5 416.6 l 295.5 416.6 m 296.5 416.6 l 297.5 416.6 m 298.5 416.6 l 299.5 416.6 m 300.5 416.6 l 301.5 416.6 m 302.5 416.6 l 303.5 416.6 m 304.5 416.6 l 305.5 416.6 m 306.5 416.6 l 307.5 416.6 m 308.5 416.6 l 309.5 416.6 m 310.5 416.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 310.6 m 310.5 310.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 308.6 m 310.5 308.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 310.5 310.6 m 314.5 310.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 310.5 308.6 m 314.5 308.6 l s 314.5 416.6 m 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 315.5 416.6 l 316.5 416.6 m 317.5 416.6 l 318.5 416.6 m 319.5 416.6 l 320.5 416.6 m 321.5 416.6 l 322.5 416.6 m 323.5 416.6 l 324.5 416.6 m 325.5 416.6 l 326.5 416.6 m 327.5 416.6 l 328.5 416.6 m 329.5 416.6 l 330.5 416.6 m 331.5 416.6 l 332.5 416.6 m 333.5 416.6 l 334.5 416.6 m 335.5 416.6 l 336.5 416.6 m 337.5 416.6 l 338.5 416.6 m 339.5 416.6 l 340.5 416.6 m 341.5 416.6 l 342.5 416.6 m 343.5 416.6 l 344.5 416.6 m 345.5 416.6 l 346.5 416.6 m 347.5 416.6 l 348.5 416.6 m 349.5 416.6 l 350.5 416.6 m 351.5 416.6 l 352.5 416.6 m 353.5 416.6 l 354.5 416.6 m 355.5 416.6 l 356.5 416.6 m 357.5 416.6 l 358.5 416.6 m 359.5 416.6 l 360.5 416.6 m 361.5 416.6 l 362.5 416.6 m 363.5 416.6 l 364.5 416.6 m 365.5 416.6 l 366.5 416.6 m 367.5 416.6 l 368.5 416.6 m 369.5 416.6 l 370.5 416.6 m 371.5 416.6 l 372.5 416.6 m 373.5 416.6 l 374.5 416.6 m 375.5 416.6 l 376.5 416.6 m 377.5 416.6 l 378.5 416.6 m 379.5 416.6 l 380.5 416.6 m 381.5 416.6 l 382.5 416.6 m 383.5 416.6 l 384.5 416.6 m 385.5 416.6 l 386.5 416.6 m 387.5 416.6 l 388.5 416.6 m 389.5 416.6 l 390.5 416.6 m 391.5 416.6 l 392.5 416.6 m 393.5 416.6 l 394.5 416.6 m 395.5 416.6 l 396.5 416.6 m 397.5 416.6 l 398.5 416.6 m 399.5 416.6 l 400.5 416.6 m 401.5 416.6 l 402.5 416.6 m 403.5 416.6 l 404.5 416.6 m 405.5 416.6 l 406.5 416.6 m 407.5 416.6 l 408.5 416.6 m 409.5 416.6 l 410.5 416.6 m 411.5 416.6 l 412.5 416.6 m 413.5 416.6 l 414.5 416.6 m 415.5 416.6 l 416.5 416.6 m 417.5 416.6 l 418.5 416.6 m 419.5 416.6 l 420.5 416.6 m 421.5 416.6 l 422.5 416.6 m 423.5 416.6 l 424.5 416.6 m 425.5 416.6 l 426.5 416.6 m 427.5 416.6 l 428.5 416.6 m 429.5 416.6 l 430.5 416.6 m 431.5 416.6 l 432.5 416.6 m 433.5 416.6 l 434.5 416.6 m 435.5 416.6 l 436.5 416.6 m 437.5 416.6 l 438.5 416.6 m 439.5 416.6 l 440.5 416.6 m 441.5 416.6 l 442.5 416.6 m 443.5 416.6 l 444.5 416.6 m 445.5 416.6 l 446.5 416.6 m 447.5 416.6 l 448.5 416.6 m 449.5 416.6 l 450.5 416.6 m 451.5 416.6 l 452.5 416.6 m 453.5 416.6 l 454.5 416.6 m 455.5 416.6 l 456.5 416.6 m 457.5 416.6 l 458.5 416.6 m 459.5 416.6 l 460.5 416.6 m 461.5 416.6 l 462.5 416.6 m 463.5 416.6 l 464.5 416.6 m 465.5 416.6 l 466.5 416.6 m 467.5 416.6 l 468.5 416.6 m 469.5 416.6 l 470.5 416.6 m 471.5 416.6 l 472.5 416.6 m 473.5 416.6 l 474.5 416.6 m 475.5 416.6 l 476.5 416.6 m 477.5 416.6 l 478.5 416.6 m 479.5 416.6 l 480.5 416.6 m 481.5 416.6 l 482.5 416.6 m 483.5 416.6 l 484.5 416.6 m 485.5 416.6 l 486.5 416.6 m 487.5 416.6 l 488.5 416.6 m 489.5 416.6 l 490.5 416.6 m 491.5 416.6 l 492.5 416.6 m 493.5 416.6 l 494.5 416.6 m 495.5 416.6 l 496.5 416.6 m 497.5 416.6 l 498.5 416.6 m 499.5 416.6 l 500.5 416.6 m 501.5 416.6 l 502.5 416.6 m 503.5 416.6 l 504.5 416.6 m 505.5 416.6 l 506.5 416.6 m 507.5 416.6 l 508.5 416.6 m 509.5 416.6 l 510.5 416.6 m 511.5 416.6 l 512.5 416.6 m 513.5 416.6 l 514.5 416.6 m 515.5 416.6 l 516.5 416.6 m 517.5 416.6 l 518.5 416.6 m 519.5 416.6 l 520.5 416.6 m 521.5 416.6 l 522.5 416.6 m 523.5 416.6 l 524.5 416.6 m 525.5 416.6 l 526.5 416.6 m 527.5 416.6 l 528.5 416.6 m 529.5 416.6 l 530.5 416.6 m 531.5 416.6 l 532.5 416.6 m 533.5 416.6 l 534.5 416.6 m 535.5 416.6 l 536.5 416.6 m 537.5 416.6 l 538.5 416.6 m 539.5 416.6 l 540.5 416.6 m 541.5 416.6 l 542.5 416.6 m 543.5 416.6 l 544.5 416.6 m 545.5 416.6 l 546.5 416.6 m 547.5 416.6 l 548.5 416.6 m 549.5 416.6 l 550.5 416.6 m 551.5 416.6 l 552.5 416.6 m 553.5 416.6 l 554.5 416.6 m 555.5 416.6 l 556.5 416.6 m 557.5 416.6 l 558.5 416.6 m s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 314.5 310.6 m 558.5 310.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 314.5 308.6 m 558.5 308.6 l s BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 522.17 Td (Some additional information about our business segments follows as of the date of the filing of this press release:) Tj ET Q BT /F4 10.00 Tf ET q 0 0 0 rg BT 172.60 508.33 Td (IH Segment) Tj ET Q BT /F4 10.00 Tf ET q 0 0 0 rg BT 409.70 508.28 Td (EH Segment) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 494.17 Td (IH focuses on developing and commercializing novel, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 484.17 Td (value-creating medicines and vaccines that ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 474.17 Td (significantly improve patients) Tj ET Q q 0 0 0 rg BT 206.01 474.17 Td ( lives, as well as ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 464.17 Td (products for consumer healthcare.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 451.17 Td (Key therapeutic areas include internal medicine, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 441.17 Td (vaccines, oncology) Tj ET Q q 0 0 0 rg BT 159.99 441.17 Td (, inflammation & immunology) Tj ET Q q 0 0 0 rg BT 282.11 441.17 Td (, rare ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 431.17 Td (disease and consumer healthcare.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 494.17 Td (EH includes legacy brands that have lost or will soon lose ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 482.17 Td (market exclusivity in both developed and emer) Tj ET Q q 0 0 0 rg BT 504.54 482.17 Td (ging ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 470.17 Td (markets, branded and generic sterile injectable products, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 458.17 Td (biosimilars, and select branded products including anti-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 446.17 Td (infectives. EH also includes an R&D or) Tj ET Q q 0 0 0 rg BT 475.39 446.17 Td (ganization, as well ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 434.17 Td (as our contract manufacturing business.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 422.17 Td (Through February 2, 2017, EH also included HIS. ) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 84.00 404.33 Td (Leading brands include:) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 394.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 394.17 Td (Pr) Tj ET Q q 0 0 0 rg BT 99.46 394.17 Td (evnar 13/Pr) Tj ET Q q 0 0 0 rg BT 147.13 394.17 Td (evenar 13) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 384.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 384.17 Td (Xeljanz) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 374.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 374.17 Td (Eliquis) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 364.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 364.17 Td (L) Tj ET Q q 0 0 0 rg BT 95.09 364.17 Td (yrica) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 115.64 364.17 Td ( \(U.S., Japan and certain other markets\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 354.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 354.17 Td (Enbr) Tj ET Q q 0 0 0 rg BT 109.46 354.17 Td (el ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 119.18 354.17 Td (\(outside the U.S. and Canada\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 344.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 344.17 Td (Ibrance) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 334.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 89.83 334.17 Td (Xtandi) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 84.00 324.17 Td (- Several OTC consumer healthcare products \(e.g., ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 88.50 314.16 Td (Advil) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 109.60 314.16 Td ( and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 129.04 314.16 Td (Centrum) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 164.04 314.16 Td (\)) Tj ET Q BT /F2 10.00 Tf ET q 0 0 0 rg BT 317.00 404.33 Td (Leading brands include:) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 394.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 322.83 394.17 Td (Lipitor) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 317.00 384.16 Td (- Pr) Tj ET Q q 0 0 0 rg BT 332.46 384.16 Td (emarin ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 363.29 384.16 Td (family) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 317.00 374.16 Td (- Norvasc) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 317.00 364.16 Td (- L) Tj ET Q q 0 0 0 rg BT 328.09 364.16 Td (yrica ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 351.14 364.16 Td (\(Europe, Russia, ) Tj ET Q q 0 0 0 rg BT 419.84 364.16 Td (T) Tj ET Q q 0 0 0 rg BT 425.59 364.16 Td (urkey) Tj ET Q q 0 0 0 rg BT 447.71 364.16 Td (, Israel and Central ) Tj ET Q q 0 0 0 rg BT 525.74 364.16 Td (Asia ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 321.50 354.17 Td (countries\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 344.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 322.83 344.17 Td (Celebr) Tj ET Q q 0 0 0 rg BT 349.68 344.17 Td (ex) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 317.00 334.16 Td (- V) Tj ET Q q 0 0 0 rg BT 328.20 334.16 Td (iagra*) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 317.00 324.17 Td (- ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 322.83 324.17 Td (Inflectra/Remsima) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 317.00 314.16 Td (- ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 322.83 314.16 Td (Several sterile injectable products) Tj ET Q BT /F1 11.00 Tf ET BT /F1 8.00 Tf ET q 0 0 0 rg BT 81.00 300.50 Td (* ) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 85.50 300.50 Td (V) Tj ET Q q 0 0 0 rg BT 90.80 300.50 Td (iagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for ) Tj ET Q q 0 0 0 rg BT 363.93 300.50 Td (V) Tj ET Q q 0 0 0 rg BT 369.23 300.50 Td (iagra in the U.S. and Canada, which were reported in IH ) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 85.50 290.90 Td (through 2017, are reported in EH \(which reported all other ) Tj ET Q q 0 0 0 rg BT 274.85 290.90 Td (V) Tj ET Q q 0 0 0 rg BT 280.14 290.90 Td (iagra revenues excluding the U.S. and Canada through 2017\). ) Tj ET Q q 0 0 0 rg BT 479.05 290.90 Td (Therefore, total ) Tj ET Q q 0 0 0 rg BT 530.66 290.90 Td (V) Tj ET Q q 0 0 0 rg BT 535.96 290.90 Td (iagra ) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 85.50 281.30 Td (worldwide revenues are reported in EH from the first quarter of 2018 forward.) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 336.30 281.30 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 85.50 264.30 Td (The following or) Tj ET Q q 0 0 0 rg BT 153.08 264.30 Td (ganizational change impacted our operating segments in 2018:) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 85.50 249.30 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 249.30 Td (Ef) Tj ET Q q 0 0 0 rg BT 103.76 249.30 Td (fective in first-quarter 2018, certain costs for Pfizer) Tj ET Q q 0 0 0 rg BT 309.60 249.30 Td () Tj ET Q q 0 0 0 rg BT 312.38 249.30 Td (s Strategy and Commercial Operations \(StratCO\) group, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 237.30 Td (which were previously reported in the operating results of our operating segments and Corporate, are reported in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 225.30 Td (Other Unallocated. StratCO costs primarily include headcount, vendor costs and data costs lar) Tj ET Q q 0 0 0 rg BT 470.33 225.30 Td (gely in support of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 213.30 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 118.75 213.30 Td () Tj ET Q q 0 0 0 rg BT 121.53 213.30 Td (s commercial operations. ) Tj ET Q q 0 0 0 rg BT 224.09 213.30 Td (The majority of the StratCO costs reflect additional amounts that our operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 201.30 Td (segments would have incurred had each segment operated as a standalone company during the period presented. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 189.30 Td (The reporting change was made to streamline accountability and speed decision making.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 448.83 189.30 Td ( In first-quarter 2017, we ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 177.30 Td (reclassified approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 202.79 177.30 Td ($98 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 249.18 177.30 Td ( of costs from IH, approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 382.76 177.30 Td ($33 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 429.15 177.30 Td ( of costs from EH and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 165.30 Td (approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 154.76 165.30 Td ($9 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 196.15 165.30 Td ( of costs from Corporate to Other unallocated costs to conform to the current period ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 153.30 Td (presentation.) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 54 130.37856445312502 m 114.822265625 130.37856445312502 l s q 0 0 0 rg BT 54.00 132.10 Td (First Quarter) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 114.822265625 130.37856445312502 m 129.4853515625 130.37856445312502 l s q 0 0 0 rg BT 114.82 132.10 Td ( of ) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 129.4853515625 130.37856445312502 m 151.4853515625 130.37856445312502 l s q 0 0 0 rg BT 129.49 132.10 Td (2018) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 151.4853515625 130.37856445312502 m 168.8984375 130.37856445312502 l s q 0 0 0 rg BT 151.49 132.10 Td ( vs. ) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 168.8984375 130.37856445312502 m 229.720703125 130.37856445312502 l s q 0 0 0 rg BT 168.90 132.10 Td (First Quarter) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 229.720703125 130.37856445312502 m 244.3837890625 130.37856445312502 l s q 0 0 0 rg BT 229.72 132.10 Td ( of ) Tj ET Q BT /F4 11.00 Tf ET 0 0 0 RG /GS0 gs 1.05 w 0 i [] 0 d 1 J 1 j 3 M 244.3837890625 130.37856445312502 m 266.3837890625 130.37856445312502 l s q 0 0 0 rg BT 244.38 132.10 Td (2017) Tj ET Q BT /F4 11.00 Tf ET BT /F2 10.00 Tf ET 0 0 0 RG /GS0 gs 0.95 w 0 i [] 0 d 1 J 1 j 3 M 54 110.53505859375002 m 216.4951171875 110.53505859375002 l s q 0 0 0 rg BT 54.00 112.10 Td (Innovative Health Operating Segment) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 54.00 95.10 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 63.00 95.10 Td (Cost of sales ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 116.62 95.10 Td (as a percentage of ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 191.02 95.10 Td (Revenues ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 231.27 95.10 Td (increase) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 264.03 95.10 Td (d ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 271.53 95.10 Td (1.2) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 284.03 95.10 Td ( percentage points ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 359.27 95.10 Td (primarily driven by the unfavorable impact of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 83.10 Td (foreign exchange and an increase in royalty expense, partially of) Tj ET Q q 0 0 0 rg BT 321.04 83.10 Td (fset by a favorable change in product mix, including an ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 71.10 Td (increase in alliance revenues, which have no associated cost of sales.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 338.44 71.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 56.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 56.10 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.05 56.10 Td (increase) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 113.80 56.10 Td ( in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 126.58 56.10 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 177.70 56.10 Td ( of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 191.03 56.10 Td (16%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 209.36 56.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 211.86 56.10 Td (was primarily driven by the unfavorable impact of foreign exchange, an increase in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 44.10 Td (royalty expense, and a favorable change in product mix.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 287.36 44.10 Td ( ) Tj ET Q endstream endobj 49 0 obj <> endobj 50 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 203.95 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 235.04 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 240.37 755.85 Td (O OPERA) Tj ET Q q 0 0 0 rg BT 277.63 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 343.71 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 386.47 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 29.10 Td (- 24 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 722.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 722.10 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.05 722.10 Td (increase) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 113.80 722.10 Td ( in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 126.58 722.10 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 330.17 722.10 Td ( of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 343.50 722.10 Td (9%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 356.83 722.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 359.33 722.10 Td (was primarily driven by additional investment ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 710.10 Td (across several of our key products, primarily Eucrisa, Ibrance, L) Tj ET Q q 0 0 0 rg BT 319.57 710.10 Td (yrica, Prevnar 13/Prevenar 13 \(pediatric indication\) and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 698.10 Td (Xeljanz, partially of) Tj ET Q q 0 0 0 rg BT 143.06 698.10 Td (fset by lower spending on Enbrel.) Tj ET Q BT /F1 10.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 683.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 683.10 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.05 683.10 Td (increase) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 113.80 683.10 Td ( in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 126.58 683.10 Td (Resear) Tj ET Q q 0 0 0 rg BT 153.98 683.10 Td (ch and development) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 233.95 683.10 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 236.45 683.10 Td (expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 271.98 683.10 Td ( of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 285.31 683.10 Td (13%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 303.64 683.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 306.14 683.10 Td (primarily reflects increased costs associated with our Bavencio ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 671.10 Td (collaboration with Merck KGaA) Tj ET Q q 0 0 0 rg BT 192.69 671.10 Td ( as well as initiations of Phase 3 in 2017 \() Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 359.33 671.10 Td (C. difficile) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 401.55 671.10 Td ( vaccine program, which initiated a ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 659.10 Td (Phase 3 clinical study in March 2017 and a JAK1 inhibitor in December 2017\).) Tj ET Q BT /F1 10.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 644.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 644.10 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.05 644.10 Td (favorable) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 118.80 644.10 Td ( change in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 162.39 644.10 Td (Other \(income\)/deductio) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 260.97 644.10 Td (ns) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 269.87 644.10 Td (net) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 292.08 644.10 Td ( primarily reflects: ) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 626.94 cm /I39 Do Q q 0 0 0 rg BT 67.00 629.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 629.10 Td (an increase in milestone income from our collaboration partners and out-licensing arrangements in the first quarter of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 617.10 Td (2018; and ) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 599.94 cm /I40 Do Q q 0 0 0 rg BT 67.00 602.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 602.10 Td (a ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 78.94 602.10 Td ($16 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 125.33 602.10 Td ( increase in dividend income from our investment in ) Tj ET Q q 0 0 0 rg BT 337.04 602.10 Td (V) Tj ET Q q 0 0 0 rg BT 343.66 602.10 Td (iiV) Tj ET Q q 0 0 0 rg BT 356.26 602.10 Td ( Healthcare Limited \(V) Tj ET Q q 0 0 0 rg BT 448.67 602.10 Td (iiV\).) Tj ET Q BT /F2 10.00 Tf ET 0 0 0 RG /GS0 gs 0.95 w 0 i [] 0 d 1 J 1 j 3 M 54 583.53505859375 m 209.2734375 583.53505859375 l s q 0 0 0 rg BT 54.00 585.10 Td (Essential Health Operating Segment) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 568.10 Td (The changes in EH expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. ) Tj ET Q q 0 0 0 rg BT 532.28 568.10 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 556.10 Td (operating results of HIS are included in EH) Tj ET Q q 0 0 0 rg BT 230.34 556.10 Td (s operating results through February 2, 2017 and, therefore, operating results for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 544.10 Td (EH for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 83.99 544.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 131.74 544.10 Td ( 2017 reflect approximately one month of legacy HIS domestic operations and approximately two months ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 532.10 Td (of legacy HIS international operations, while financial results for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 316.70 532.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 336.70 532.10 Td ( do not reflect any contribution from HIS global ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 520.10 Td (operations.) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 54.00 508.10 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 63.00 508.10 Td (Cost of sales ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 116.62 508.10 Td (as a percentage of ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 191.02 508.10 Td (Revenues) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 228.77 508.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 231.27 508.10 Td (increase) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 264.03 508.10 Td (d ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 271.53 508.10 Td (1.3) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 284.03 508.10 Td ( percentage points ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 359.27 508.10 Td (primarily due to the unfavorable impact of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 496.10 Td (foreign exchange and the impact of product losses of exclusivity) Tj ET Q q 0 0 0 rg BT 320.33 496.10 Td (, partially of) Tj ET Q q 0 0 0 rg BT 369.30 496.10 Td (fset by lower volumes driven by the Sterile ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 484.10 Td (Injectable Pharmaceuticals \(SIP\) portfolio, primarily due to legacy Hospira product shortages in the U.S., and generic ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 472.10 Td (competition in developed markets, as well as the non-recurrence of char) Tj ET Q q 0 0 0 rg BT 350.76 472.10 Td (ges related to a product recall that occurred in the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 460.10 Td (first quarter of 2017.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 145.75 460.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 445.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 445.10 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.05 445.10 Td (decrease) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 115.46 445.10 Td ( in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 128.24 445.10 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 179.36 445.10 Td ( of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 192.69 445.10 Td (1%) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 206.02 445.10 Td ( was primarily due to:) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 427.94 cm /I41 Do Q q 0 0 0 rg BT 67.00 430.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 430.10 Td (lower volumes driven by:) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 415.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 415.10 Td (the SIP) Tj ET Q q 0 0 0 rg BT 109.80 415.10 Td ( portfolio, primarily due to legacy Hospira product shortages in the U.S., as well as) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 400.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 400.10 Td (generic competition in developed markets;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 382.94 cm /I42 Do Q q 0 0 0 rg BT 67.00 385.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 385.10 Td (the non-recurrence of char) Tj ET Q q 0 0 0 rg BT 177.59 385.10 Td (ges related to a product recall that occurred in the first quarter of 2017; and) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 367.94 cm /I43 Do Q q 0 0 0 rg BT 67.00 370.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 370.10 Td (the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products,) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 355.10 Td (partially of) Tj ET Q q 0 0 0 rg BT 97.97 355.10 Td (fset by:) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 337.94 cm /I44 Do Q q 0 0 0 rg BT 67.00 340.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 72.00 340.10 Td (the unfavorable impact of foreign exchange.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 323.90 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 63.00 323.90 Td (Selling, informational and administrative) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 228.55 323.90 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 231.05 323.90 Td (expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 266.59 323.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 269.09 323.90 Td (decrease) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 303.50 323.90 Td (d ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 311.00 323.90 Td (7%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 324.33 323.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 327.08 323.90 Td (mainly due to lower advertising, promotional and field ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 311.90 Td (force expenses, reflecting the benefits of cost-reduction and productivity initiatives, and the favorable impact of the sale of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 299.90 Td (HIS) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0.17254901960784313 0.17254901960784313 0.17254901960784313 rg BT 79.11 299.90 Td (, partially of) Tj ET Q q 0.17254901960784313 0.17254901960784313 0.17254901960784313 rg BT 128.08 299.90 Td (fset by the unfavorable impact of foreign exchange) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 0 rg BT 332.17 299.90 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 334.67 299.90 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 283.70 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 63.00 283.70 Td (Resear) Tj ET Q q 0 0 0 rg BT 90.40 283.70 Td (ch and development) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 170.37 283.70 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 172.87 283.70 Td (expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 208.41 283.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 210.91 283.70 Td (decrease) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 245.32 283.70 Td (d ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 252.82 283.70 Td (13%) Tj ET Q BT /F1 11.00 Tf ET q 0 0 0 rg BT 271.15 283.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 273.90 283.70 Td (primarily due to decreased spending for biosimilars and the favorable ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 271.70 Td (impact of the sale of HIS.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 165.75 271.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 256.70 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 256.70 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.05 256.70 Td (unfavorable) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 128.80 256.70 Td ( change in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 172.39 256.70 Td (Other \(income\)/deductio) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 270.97 256.70 Td (ns) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 279.87 256.70 Td (net ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 304.58 256.70 Td (primarily reflects the unfavorable impact of foreign exchange ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 244.70 Td (and the non-recurrence of a gain on the redemption of an acquired bond in the first quarter of 2017.) Tj ET Q BT /F1 10.00 Tf ET endstream endobj 51 0 obj <> endobj 52 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 203.95 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 235.04 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 240.37 755.85 Td (O OPERA) Tj ET Q q 0 0 0 rg BT 277.63 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 343.71 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 386.47 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 29.10 Td (- 25 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 722.10 Td (\(3\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 722.10 Td (Other comprises the costs included in our ) Tj ET Q q 0 0 0 rg BT 249.02 722.10 Td (Adjusted income components) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 367.89 726.63 Td (\(4\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 375.47 722.10 Td ( that are managed outside of our two ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 710.10 Td (operating segments) Tj ET Q BT /F1 10.00 Tf ET BT /F1 6.50 Tf ET q 0 0 0 rg BT 158.48 714.63 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 160.11 710.10 Td (and includes the following: ) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 699.6 m 298.5 699.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 298.5 699.6 m 302.5 699.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 302.5 699.6 m 346.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 685.6 m 346.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346.5 699.6 m 350.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 346.5 685.6 m 350.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 350.5 699.6 m 399.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 685.6 m 399.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 699.6 m 403.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 685.6 m 403.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 403.5 699.6 m 453.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 403.5 685.6 m 453.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 699.6 m 457.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453.5 685.6 m 457.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 699.6 m 515.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 685.6 m 515.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 515.5 699.6 m 519.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 515.5 685.6 m 519.5 685.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519.5 699.6 m 560.5 699.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519.5 685.6 m 560.5 685.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 662.6 m 298.5 662.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 662.6 m 346.5 662.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 346.5 662.6 m 350.5 662.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 662.6 m 399.5 662.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 639.6 m 298.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 639.6 m 346.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 639.6 m 399.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 403.5 639.6 m 453.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 639.6 m 515.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519.5 639.6 m 560.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 639.6 m 346.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 639.6 m 399.5 639.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 541.6 m 346.5 541.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 541.6 m 399.5 541.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 403.5 541.6 m 453.5 541.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 541.6 m 515.5 541.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519.5 541.6 m 560.5 541.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 519.6 m 298.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 517.6 m 298.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 298.5 519.6 m 302.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 298.5 517.6 m 302.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 302.5 519.6 m 346.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 302.5 517.6 m 346.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346.5 519.6 m 350.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346.5 517.6 m 350.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 350.5 519.6 m 399.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 350.5 517.6 m 399.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 519.6 m 403.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 517.6 m 403.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 403.5 519.6 m 453.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 403.5 517.6 m 453.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 519.6 m 457.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 517.6 m 457.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 519.6 m 515.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 517.6 m 515.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 515.5 519.6 m 519.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 515.5 517.6 m 519.5 517.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519.5 519.6 m 560.5 519.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519.5 517.6 m 560.5 517.6 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 397.35 690.46 Td (First-Quarter 2018) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 323.10 676.06 Td (Other Business) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 333.00 667.06 Td (Activities) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 643.85 Td (\(IN MILLIONS\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 310.25 644.06 Td (WRD) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 331.25 648.14 Td (\(a\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 362.05 644.06 Td (GPD) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 380.05 648.14 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.75 644.06 Td (Corporate) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 442.74 648.14 Td (\(c\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 475.75 653.06 Td (Other ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.85 644.06 Td (Unallocated) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 504.33 648.14 Td (\(d\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 530.30 644.06 Td (T) Tj ET Q q 0 0 0 rg BT 535.17 644.06 Td (otal) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 630.06 Td (Revenues) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 305.00 630.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 630.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 353.00 630.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 630.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.00 630.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 630.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.00 630.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 630.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 522.00 630.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.00 630.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 616.06 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 616.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 616.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 616.06 Td (60) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 616.06 Td (53) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 543.50 616.06 Td (1) Tj ET Q q 0 0 0 rg BT 548.00 616.06 Td (13) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 602.06 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 602.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 602.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 602.06 Td (942) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 498.50 602.06 Td (163) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 536.75 602.06 Td (1,106) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 588.06 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 329.50 588.06 Td (553) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 382.50 588.06 Td (190) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 588.06 Td (172) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 588.06 Td (16) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 543.50 588.06 Td (931) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 574.06 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 574.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 574.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 574.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 574.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.00 574.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 560.06 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 150.65 560.06 Td (ges and certain acquisition-related costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 560.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 560.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 560.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 560.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.00 560.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 546.06 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 331.00 546.06 Td (\(17) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.00 546.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 388.50 546.06 Td (\(1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 396.00 546.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 438.00 546.06 Td (\(21) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 546.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 546.06 Td (12) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 545.00 546.06 Td (\(28) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 557.00 546.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 532.06 Td (Loss from continuing operations before provision for) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 523.06 Td (taxes on income) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 305.00 523.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 326.50 523.06 Td (\(536) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.00 523.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 353.00 523.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 379.50 523.06 Td (\(189) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 396.00 523.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.00 523.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 426.75 523.06 Td (\(1,153) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 523.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.00 523.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 523.06 Td (\(244) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 512.00 523.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 522.00 523.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 523.06 Td (\(2,121) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 557.00 523.06 Td (\)) Tj ET Q BT /F1 11.00 Tf ET BT /F1 11.00 Tf ET 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 494.6 m 298.5 494.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 298.5 494.6 m 302.5 494.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 302.5 494.6 m 346.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 481.6 m 346.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346.5 494.6 m 350.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 346.5 481.6 m 350.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 350.5 494.6 m 399.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 481.6 m 399.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 494.6 m 403.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 399.5 481.6 m 403.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 403.5 494.6 m 453.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 403.5 481.6 m 453.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 494.6 m 457.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453.5 481.6 m 457.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 494.6 m 515.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 481.6 m 515.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 515.5 494.6 m 519.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 515.5 481.6 m 519.5 481.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519.5 494.6 m 560.5 494.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519.5 481.6 m 560.5 481.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 460.6 m 298.5 460.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 460.6 m 346.5 460.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 346.5 460.6 m 350.5 460.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 460.6 m 399.5 460.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 81.5 439.6 m 298.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 439.6 m 346.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 439.6 m 399.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 403.5 439.6 m 453.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 439.6 m 515.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519.5 439.6 m 560.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 439.6 m 399.5 439.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 302.5 338.6 m 346.5 338.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 350.5 338.6 m 399.5 338.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 403.5 338.6 m 453.5 338.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 338.6 m 515.5 338.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519.5 338.6 m 560.5 338.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 316.6 m 298.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 81.5 314.6 m 298.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 298.5 316.6 m 302.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 298.5 314.6 m 302.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 302.5 316.6 m 346.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 302.5 314.6 m 346.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346.5 316.6 m 350.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346.5 314.6 m 350.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 350.5 316.6 m 399.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 350.5 314.6 m 399.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 316.6 m 403.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 399.5 314.6 m 403.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 403.5 316.6 m 453.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 403.5 314.6 m 453.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 316.6 m 457.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 314.6 m 457.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 316.6 m 515.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 314.6 m 515.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 515.5 316.6 m 519.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 515.5 314.6 m 519.5 314.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519.5 316.6 m 560.5 316.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519.5 314.6 m 560.5 314.6 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 397.35 485.86 Td (First-Quarter 2017) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 323.10 472.86 Td (Other Business) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 333.00 463.86 Td (Activities) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 84.00 443.85 Td (\(IN MILLIONS\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 310.25 444.06 Td (WRD) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 331.25 448.14 Td (\(a\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 362.05 444.06 Td (GPD) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 380.05 448.14 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.75 444.06 Td (Corporate) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 442.74 448.14 Td (\(c\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 475.75 451.86 Td (Other ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.85 442.86 Td (Unallocated) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 504.33 446.94 Td (\(d\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 530.30 444.06 Td (T) Tj ET Q q 0 0 0 rg BT 535.17 444.06 Td (otal) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 430.86 Td (Revenues) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 305.00 430.86 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 430.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 353.00 430.86 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 430.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.00 430.86 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 430.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.00 430.86 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 430.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 522.00 430.86 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.00 430.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 417.86 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 130.00 421.94 Td (\(e\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 417.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 417.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 438.00 417.86 Td (\(27) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 417.86 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 498.50 417.86 Td (159) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 543.50 417.86 Td (133) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 404.86 Td (Selling, informational and administrative expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 266.71 408.94 Td (\(e\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 404.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 388.50 404.86 Td (\(1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 396.00 404.86 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 429.75 404.86 Td (1,054) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 498.50 404.86 Td (140) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 536.75 404.86 Td (1,193) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 391.86 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 215.70 395.94 Td (\(e\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 329.50 391.86 Td (528) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 382.50 391.86 Td (182) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 391.86 Td (219) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 391.86 Td (1) Tj ET Q q 0 0 0 rg BT 507.50 391.86 Td (1) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 543.50 391.86 Td (941) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 378.86 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 378.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 378.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 378.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 378.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.00 378.86 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 365.06 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 150.56 365.06 Td (ges and certain acquisition-related ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 356.06 Td (costs) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 111.00 360.14 Td (\(e\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 334.00 356.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 387.00 356.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 356.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 356.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 548.00 356.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 342.86 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 200.71 346.94 Td (\(e\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 331.00 342.86 Td (\(21) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.00 342.86 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 388.50 342.86 Td (\(2) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 396.00 342.86 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 342.86 Td (89) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 503.00 342.86 Td (49) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 543.50 342.86 Td (1) Tj ET Q q 0 0 0 rg BT 548.00 342.86 Td (15) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 84.00 329.06 Td (Loss from continuing operations before provision for) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 320.06 Td (taxes on income) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 305.00 320.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 326.50 320.06 Td (\(508) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.00 320.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 353.00 320.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 379.50 320.06 Td (\(180) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 396.00 320.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 406.00 320.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 426.75 320.06 Td (\(1,335) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 320.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.00 320.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.50 320.06 Td (\(359) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 512.00 320.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 522.00 320.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 320.06 Td (\(2,382) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 557.00 320.06 Td (\)) Tj ET Q BT /F1 11.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 304.10 Td (\(a\) ) Tj ET Q q 0 0 0 rg BT 94.50 304.10 Td (WRD) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 117.83 304.10 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 127.83 304.10 Td (the R&D expenses managed by our ) Tj ET Q q 0 0 0 rg BT 272.06 304.10 Td (WRD or) Tj ET Q q 0 0 0 rg BT 306.04 304.10 Td (ganization, which is generally responsible for research ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 292.10 Td (projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 280.10 Td (segment via the GPD or) Tj ET Q q 0 0 0 rg BT 190.41 280.10 Td (ganization for possible clinical and commercial development. R&D spending may include ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 268.10 Td (upfront and milestone payments for intellectual property rights. ) Tj ET Q q 0 0 0 rg BT 350.64 268.10 Td (The ) Tj ET Q q 0 0 0 rg BT 368.51 268.10 Td (WRD or) Tj ET Q q 0 0 0 rg BT 402.49 268.10 Td (ganization also has responsibility for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 256.10 Td (certain science-based and other platform-services or) Tj ET Q q 0 0 0 rg BT 302.83 256.10 Td (ganizations, which provide technical expertise and other ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 244.10 Td (services to the various R&D projects, including EH R&D projects. ) Tj ET Q q 0 0 0 rg BT 363.71 244.10 Td (WRD is also responsible for facilitating all ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 232.10 Td (regulatory submissions and interactions with regulatory agencies, including all safety-event activities.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 219.10 Td (\(b\) ) Tj ET Q q 0 0 0 rg BT 94.50 219.10 Td (GPD) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 114.50 219.10 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 124.50 219.10 Td (the costs associated with our GPD or) Tj ET Q q 0 0 0 rg BT 272.08 219.10 Td (ganization, which is generally responsible for the clinical development ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 207.10 Td (of assets that are in clinical trials for our ) Tj ET Q q 0 0 0 rg BT 257.87 207.10 Td (WRD and Innovative portfolios. GPD also provides technical support and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 195.10 Td (other services to Pfizer R&D projects.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 182.10 Td (\(c\) ) Tj ET Q q 0 0 0 rg BT 94.50 182.10 Td (Corporate) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 134.49 182.10 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 144.49 182.10 Td (the costs associated with Corporate, representing platform functions \(such as worldwide technology) Tj ET Q q 0 0 0 rg BT 543.18 182.10 Td (, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 170.10 Td (global real estate operations, legal, finance, human resources, worldwide public af) Tj ET Q q 0 0 0 rg BT 423.08 170.10 Td (fairs, compliance and worldwide ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 158.10 Td (procurement\), the provision of medical information to healthcare providers, patients and other parties, transparency ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 146.10 Td (and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 134.10 Td (education, and partnerships with global public health and medical associations, as well as certain compensation and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 122.10 Td (other corporate costs, such as interest income and expense, and gains and losses on investments. Ef) Tj ET Q q 0 0 0 rg BT 490.88 122.10 Td (fective in first-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 110.10 Td (quarter 2018, certain costs for StratCO, which were previously reported in the operating results of our operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 98.10 Td (segments and Corporate, are reported in Other Unallocated. For additional information, see note \(d\) below) Tj ET Q q 0 0 0 rg BT 519.55 98.10 Td (. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 83.10 Td (\(d\) ) Tj ET Q q 0 0 0 rg BT 94.50 83.10 Td (Other Unallocated) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 168.08 83.10 Td () Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 178.08 83.10 Td (other unallocated costs, representing overhead expenses associated with our manufacturing ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 71.10 Td (and commercial operations that are not directly assessed to an operating segment, as business unit \(segment\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 59.10 Td (management does not manage these costs \(which include manufacturing variances associated with production\). In ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 47.10 Td (connection with the StratCO reporting change, in first-quarter of 2017 we reclassified approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 499.93 47.10 Td ($98 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 546.32 47.10 Td ( of ) Tj ET Q endstream endobj 53 0 obj <> endobj 54 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 203.95 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 235.04 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 240.37 755.85 Td (O OPERA) Tj ET Q q 0 0 0 rg BT 277.63 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 343.71 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 386.47 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 29.10 Td (- 26 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 722.10 Td (costs from IH, approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 214.75 722.10 Td ($33 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 261.14 722.10 Td ( of costs from EH and approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 411.94 722.10 Td ($9 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 453.33 722.10 Td ( of costs from Corporate ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 710.10 Td (to Other unallocated costs to conform to current period presentation.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 695.10 Td (\(e\) ) Tj ET Q q 0 0 0 rg BT 94.50 695.10 Td (Amounts for first-quarter 2017 have been revised from previously reported amounts to reflect the retrospective ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 683.10 Td (adoption of a new accounting standard in the first quarter of 2018, as of January 1, 2018, requiring) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 1 rg BT 488.84 683.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 0 rg BT 491.34 683.10 Td (the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 671.10 Td (reclassification of the non-service cost components of net periodic pension and postretirement benefit costs to ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 94.50 659.10 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 224.19 659.10 Td ( from their classification within ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 352.77 659.10 Td (Cost of sales, Selling, informational and) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 514.16 659.10 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 94.50 647.10 Td (administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 190.31 647.10 Td (, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 195.31 647.10 Td (Resear) Tj ET Q q 0 0 0 rg BT 222.71 647.10 Td (ch and development expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 340.72 647.10 Td ( and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 360.15 647.10 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 435.61 647.10 Td (ges and certain acquisition-) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 94.50 635.10 Td (r) Tj ET Q q 0 0 0 rg BT 98.02 635.10 Td (elated costs) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 144.95 635.10 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 620.10 Td (For information purposes only) Tj ET Q q 0 0 0 rg BT 215.78 620.10 Td (, the following tables present reconciliations of our segment operating results to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 608.10 Td (segment operating results including estimated Other costs generally associated with each segment. ) Tj ET Q q 0 0 0 rg BT 490.59 608.10 Td (While we do not ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 596.10 Td (manage our segments or have performance goals under such an allocated manner) Tj ET Q q 0 0 0 rg BT 418.69 596.10 Td (, we believe that some investors ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 584.10 Td (may find this information useful in their analyses.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 569.10 Td (The estimated Other costs generally associated with our operating segments do not purport to reflect the additional ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 557.10 Td (amounts that each of our operating segments would have incurred had each segment operated as a standalone ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 94.50 545.10 Td (company during the period presented. ) Tj ET Q BT /F1 11.00 Tf ET BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 519.10 Td (For information purposes only) Tj ET Q q 0 0 0 rg BT 211.28 519.10 Td (, for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 230.44 519.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 278.20 519.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 280.70 519.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 300.70 519.10 Td (, we estimate that Other costs, as described above, for combined ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 507.10 Td (WRD and GPD costs of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 188.60 507.10 Td ($725 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 240.00 507.10 Td (, and combined Corporate and Other Unallocated costs of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 472.70 507.10 Td ($1.3 billion) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 518.81 507.10 Td ( after ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 495.10 Td (excluding \(i\) net interest-related expense not attributable to an operating segment included in Corporate ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 483.10 Td (\(approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 153.59 483.10 Td ($241 million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 204.98 483.10 Td ( for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 221.64 483.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 269.39 483.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 271.89 483.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 291.89 483.10 Td ( in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 304.67 483.10 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 434.36 483.10 Td (\); and \(ii\) net income from ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 471.10 Td (investments and other assets not attributable to an operating segment included in Corporate \(approximately ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 521.00 471.10 Td ($122 ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 459.10 Td (million) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 118.89 459.10 Td ( for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 135.55 459.10 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 183.31 459.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 185.81 459.10 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 205.81 459.10 Td ( in ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 218.58 459.10 Td (Other) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 241.91 459.10 Td ( ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 244.41 459.10 Td (\(income\)/deductionsnet) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 348.27 459.10 Td (\), are generally associated with our operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 90.00 447.10 Td (segments, as follows:) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 90.5 436.6 m 240.5 436.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 240.5 436.6 m 244.5 436.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244.5 436.6 m 299.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244.5 422.6 m 299.5 422.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 299.5 436.6 m 303.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 299.5 422.6 m 303.5 422.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 303.5 436.6 m 363.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 422.6 m 363.5 422.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 363.5 436.6 m 367.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 363.5 422.6 m 367.5 422.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 367.5 436.6 m 453.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 422.6 m 453.5 422.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 436.6 m 457.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453.5 422.6 m 457.5 422.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 436.6 m 557.5 436.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 422.6 m 557.5 422.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 399.6 m 363.5 399.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 363.5 399.6 m 367.5 399.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 399.6 m 453.5 399.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 90.5 349.6 m 240.5 349.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244.5 349.6 m 299.5 349.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 399.6 m 363.5 399.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 349.6 m 363.5 349.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 399.6 m 453.5 399.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 349.6 m 453.5 349.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 349.6 m 557.5 349.6 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244.5 349.6 m 299.5 349.6 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 90.5 214.60000000000002 m 240.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 90.5 212.60000000000002 m 240.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 240.5 214.60000000000002 m 244.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 240.5 212.60000000000002 m 244.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244.5 214.60000000000002 m 299.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244.5 212.60000000000002 m 299.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 299.5 214.60000000000002 m 303.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 299.5 212.60000000000002 m 303.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 303.5 214.60000000000002 m 363.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 303.5 212.60000000000002 m 363.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 363.5 214.60000000000002 m 367.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 363.5 212.60000000000002 m 367.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 367.5 214.60000000000002 m 453.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 367.5 212.60000000000002 m 453.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 214.60000000000002 m 457.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 212.60000000000002 m 457.5 212.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 214.60000000000002 m 557.5 214.60000000000002 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 212.60000000000002 m 557.5 212.60000000000002 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 366.85 427.06 Td (First-Quarter 2018) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 337.50 413.06 Td (Estimated Other Costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 339.80 404.06 Td (Associated with IH) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 409.29 408.14 Td (\(b\)) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 93.00 353.85 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 257.50 381.06 Td (Innovative ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 251.25 372.06 Td (Health Non-) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 271.80 363.06 Td (GAAP) Tj ET Q q 0 0 0 rg BT 295.97 363.06 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 247.55 354.06 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 280.05 358.14 Td (\(a\), \(c\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 324.00 363.06 Td (Estimated ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.65 354.06 Td (WRD/GPD) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 353.15 358.14 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 373.25 363.06 Td (Estimated Corporate/) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 376.95 354.06 Td (Other Unallocated) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 443.17 358.14 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 471.00 390.06 Td (Innovative Health with) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 473.00 381.06 Td (Estimated Other Costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 496.25 372.06 Td (Associated with) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 489.25 363.06 Td (Innovative Health ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.80 354.06 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 503.47 354.06 Td ( ) Tj ET Q q 0 0 0 rg BT 505.22 354.06 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 537.72 358.14 Td (\(b\), \(c\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 340.06 Td (Revenues) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 247.00 340.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.75 340.06 Td (7,829) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 306.00 340.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 340.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 370.00 340.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 340.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.00 340.06 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 340.06 Td (7,829) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 326.06 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 282.50 326.06 Td (987) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 326.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 445.50 326.06 Td (9) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 540.50 326.06 Td (995) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 312.86 Td (Selling, informational and) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 102.00 303.86 Td (administrative expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.75 305.06 Td (1,552) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 305.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 305.06 Td (683) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 305.06 Td (2,235) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 291.86 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 282.50 291.86 Td (587) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 346.50 291.86 Td (735) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 291.86 Td (156) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 291.86 Td (1,478) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 278.06 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 287.00 278.06 Td (51) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 278.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 278.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 545.00 278.06 Td (51) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 264.06 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 159.65 264.06 Td (ges and certain) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 102.00 255.06 Td (acquisition-related costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 287.00 255.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 255.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 255.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 545.00 255.06 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 241.06 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 279.50 241.06 Td (\(279) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 296.00 241.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 348.00 241.06 Td (\(19) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 360.00 241.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 433.50 241.06 Td (\(100) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 241.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 537.50 241.06 Td (\(398) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 554.00 241.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 227.06 Td (Income from continuing operations) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 102.00 218.06 Td (before provision for taxes on income) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.75 218.06 Td (4,930) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 343.50 218.06 Td (\(716) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 360.00 218.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 433.50 218.06 Td (\(747) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 218.06 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 218.06 Td (3,467) Tj ET Q BT /F1 11.00 Tf ET endstream endobj 55 0 obj <> endobj 56 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 203.95 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 235.04 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 240.37 755.85 Td (O OPERA) Tj ET Q q 0 0 0 rg BT 277.63 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 343.71 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 386.47 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 29.10 Td (- 27 -) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 90.5 728.5 m 240.5 728.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 240.5 728.5 m 244.5 728.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244.5 728.5 m 299.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244.5 715.5 m 299.5 715.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 299.5 728.5 m 303.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 299.5 715.5 m 303.5 715.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 303.5 728.5 m 363.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 715.5 m 363.5 715.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 363.5 728.5 m 367.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 363.5 715.5 m 367.5 715.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 367.5 728.5 m 453.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 715.5 m 453.5 715.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 728.5 m 457.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453.5 715.5 m 457.5 715.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 728.5 m 557.5 728.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 715.5 m 557.5 715.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 693.5 m 363.5 693.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 363.5 693.5 m 367.5 693.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 693.5 m 453.5 693.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 90.5 644.5 m 240.5 644.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244.5 644.5 m 299.5 644.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 303.5 644.5 m 363.5 644.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 367.5 644.5 m 453.5 644.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 457.5 644.5 m 557.5 644.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 90.5 644.5 m 240.5 644.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244.5 644.5 m 299.5 644.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 90.5 514.5 m 240.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 90.5 512.5 m 240.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 240.5 514.5 m 244.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 240.5 512.5 m 244.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244.5 514.5 m 299.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244.5 512.5 m 299.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 299.5 514.5 m 303.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 299.5 512.5 m 303.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 303.5 514.5 m 363.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 303.5 512.5 m 363.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 363.5 514.5 m 367.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 363.5 512.5 m 367.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 367.5 514.5 m 453.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 367.5 512.5 m 453.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 514.5 m 457.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453.5 512.5 m 457.5 512.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 514.5 m 557.5 514.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 457.5 512.5 m 557.5 512.5 l s BT /F1 9.00 Tf ET q 0 0 0 rg BT 366.85 719.76 Td (First-Quarter 2018) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 337.50 706.76 Td (Estimated Other Costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 338.55 697.76 Td (Associated with EH) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 410.54 701.84 Td (\(b\)) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 93.00 648.75 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 263.50 675.96 Td (Essential ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 251.25 666.96 Td (Health Non-) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 271.80 657.96 Td (GAAP) Tj ET Q q 0 0 0 rg BT 295.97 657.96 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 247.55 648.96 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 280.05 653.04 Td (\(a\), \(c\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 324.00 657.96 Td (Estimated ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 311.65 648.96 Td (WRD/GPD) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 353.15 653.04 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 373.25 657.96 Td (Estimated Corporate/) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 376.95 648.96 Td (Other Unallocated) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 443.17 653.04 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 477.00 684.76 Td (Essential Health with) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 473.00 675.76 Td (Estimated Other Costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 496.25 666.76 Td (Associated with) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 495.25 657.76 Td (Essential Health ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.80 648.76 Td (Non-GAAP) Tj ET Q q 0 0 0 rg BT 503.47 648.76 Td ( ) Tj ET Q q 0 0 0 rg BT 505.22 648.76 Td (Adjusted) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 537.72 652.84 Td (\(b\), \(c\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 635.76 Td (Revenues) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 247.00 635.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.75 635.76 Td (5,077) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 306.00 635.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 635.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 370.00 635.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 635.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 460.00 635.76 Td ($) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 635.76 Td (5,077) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 622.76 Td (Cost of sales) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.75 622.76 Td (1,436) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 622.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 622.76 Td (104) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 622.76 Td (1,541) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 609.76 Td (Selling, informational and) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 102.00 600.76 Td (administrative expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 282.50 600.96 Td (628) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 600.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 436.50 600.96 Td (423) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 600.96 Td (1,050) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 587.76 Td (Research and development expenses) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 282.50 587.76 Td (221) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 355.50 587.76 Td (8) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 587.76 Td (32) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 540.50 587.76 Td (261) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 574.76 Td (Amortization of intangible assets) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 287.00 574.76 Td (19) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 574.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 574.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 545.00 574.76 Td (19) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 561.76 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 159.65 561.76 Td (ges and certain) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 102.00 552.76 Td (acquisition-related costs) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 287.00 552.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 552.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 441.00 552.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 545.00 552.96 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 539.76 Td (Other \(income\)/deductionsnet) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 284.00 539.76 Td (\(15) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 296.00 539.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 351.00 539.76 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 438.00 539.76 Td (\(28) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 539.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 542.00 539.76 Td (\(43) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 554.00 539.76 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 93.00 526.76 Td (Income from continuing operations) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 102.00 517.76 Td (before provision for taxes on income) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 275.75 517.96 Td (2,788) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 352.50 517.96 Td (\(8) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 360.00 517.96 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 433.50 517.96 Td (\(531) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 450.00 517.96 Td (\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 533.75 517.96 Td (2,249) Tj ET Q BT /F1 11.00 Tf ET BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 90.00 507.28 Td (\(a\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 96.49 503.20 Td ( ) Tj ET Q q 0 0 0 rg BT 99.00 503.20 Td (Amount represents the revenues and costs managed by each of our operating segments. ) Tj ET Q q 0 0 0 rg BT 415.24 503.20 Td (The expenses generally include only ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 99.00 492.40 Td (those costs directly attributable to the operating segment. See note \(2\) above for more information.) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 90.00 485.68 Td (\(b\)) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 96.82 481.60 Td ( ) Tj ET Q q 0 0 0 rg BT 99.00 481.60 Td (Represents costs not assessed to an operating segment, as business unit \(segment\) management does not manage these costs. ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 99.00 470.80 Td (For a description of these other costs and business activities, see above.) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 99.00 457.00 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 457.00 Td (WRD/GPD) Tj ET Q BT /F3 9.00 Tf ET q 0 0 0 rg BT 149.50 457.00 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 158.50 457.00 Td (The information provided for ) Tj ET Q q 0 0 0 rg BT 266.31 457.00 Td (WRD and GPD was substantially all derived from our estimates of the costs ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 446.20 Td (incurred in connection with the R&D projects associated with each operating segment. ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 99.00 432.40 Td ( ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 432.40 Td (Corporate/Other Unallocated) Tj ET Q BT /F3 9.00 Tf ET q 0 0 0 rg BT 212.71 432.40 Td () Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 221.71 432.40 Td (The information provided for Corporate and Other Unallocated was derived mainly using ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 421.60 Td (proportional allocation methods based on global, regional or country revenues or global, regional or country headcount, as ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 410.80 Td (well as certain cost metrics, as appropriate, such as those derived from research and development and manufacturing costs, ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 400.00 Td (and, to a lesser extent, specific identification and estimates. Management believes that the allocations of Corporate and ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 389.20 Td (Other Unallocated costs are reasonable.) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 375.40 Td (The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 364.60 Td (that each of our operating segments would have incurred had each segment operated as a standalone company during the ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 108.00 353.80 Td (period presented.) Tj ET Q BT /F1 9.00 Tf ET BT /F1 5.85 Tf ET q 0 0 0 rg BT 90.00 346.08 Td (\(c\) ) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 99.00 342.00 Td (See note \(4\) below for an explanation of our Non-GAAP) Tj ET Q q 0 0 0 rg BT 303.36 342.00 Td ( ) Tj ET Q q 0 0 0 rg BT 305.12 342.00 Td (Adjusted financial measure.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 327.00 Td (\(4\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 327.00 Td (These Adjusted Income components are defined as the corresponding reported U.S. GAAP) Tj ET Q q 0 0 0 rg BT 453.57 327.00 Td ( components, excluding ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 315.00 Td (purchase accounting adjustments, acquisition-related costs and certain significant items \(some of which may recur) Tj ET Q q 0 0 0 rg BT 537.67 315.00 Td (, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 303.00 Td (such as restructuring or legal char) Tj ET Q q 0 0 0 rg BT 216.04 303.00 Td (ges, but which management does not believe are reflective of our ongoing core ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 291.00 Td (operations\).) Tj ET Q q 0 0 0 rg BT 130.43 291.00 Td (Adjusted Cost of Sales, ) Tj ET Q q 0 0 0 rg BT 226.27 291.00 Td (Adjusted Selling, Informational and ) Tj ET Q q 0 0 0 rg BT 372.08 291.00 Td (Administrative \(SI&A\) expenses, ) Tj ET Q q 0 0 0 rg BT 508.17 291.00 Td (Adjusted ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 279.00 Td (Research and Development \(R&D\) expenses, ) Tj ET Q q 0 0 0 rg BT 264.83 279.00 Td (Adjusted ) Tj ET Q q 0 0 0 rg BT 302.89 279.00 Td (Amortization of Intangible ) Tj ET Q q 0 0 0 rg BT 412.03 279.00 Td (Assets and ) Tj ET Q q 0 0 0 rg BT 457.03 279.00 Td (Adjusted Other ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 267.00 Td (\(Income\)/DeductionsNet are income statement line items prepared on the same basis as, and therefore components ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 255.00 Td (of, the overall adjusted income measure. ) Tj ET Q q 0 0 0 rg BT 244.83 255.00 Td (As described in the Management) Tj ET Q q 0 0 0 rg BT 383.68 255.00 Td (s Discussion and ) Tj ET Q q 0 0 0 rg BT 452.85 255.00 Td (Analysis of Financial ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 243.00 Td (Condition and Results of OperationsNon-GAAP) Tj ET Q q 0 0 0 rg BT 284.51 243.00 Td ( Financial Measure \(Adjusted Income\) section of Pfizer's 2017 ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 231.00 Td (Financial Report, which was filed as Exhibit 13 to Pfizer's ) Tj ET Q q 0 0 0 rg BT 315.81 231.00 Td (Annual Report on Form 10-K for the fiscal year ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 219.00 Td (December 31, 2017, management uses ) Tj ET Q q 0 0 0 rg BT 237.34 219.00 Td (Adjusted income, among other factors, to set performance goals and to measure ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 207.00 Td (the performance of the overall company) Tj ET Q q 0 0 0 rg BT 240.56 207.00 Td (. Because ) Tj ET Q q 0 0 0 rg BT 280.82 207.00 Td (Adjusted income is an important internal measurement for Pfizer) Tj ET Q q 0 0 0 rg BT 540.34 207.00 Td (, we ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 195.00 Td (believe that investors) Tj ET Q q 0 0 0 rg BT 168.56 195.00 Td ( understanding of our performance is enhanced by disclosing this performance measure. ) Tj ET Q q 0 0 0 rg BT 522.99 195.00 Td (W) Tj ET Q q 0 0 0 rg BT 531.63 195.00 Td (e ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 183.00 Td (report ) Tj ET Q q 0 0 0 rg BT 106.83 183.00 Td (Adjusted income and certain components of ) Tj ET Q q 0 0 0 rg BT 285.11 183.00 Td (Adjusted income in order to portray the results of our major ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 171.00 Td (operationsthe discovery) Tj ET Q q 0 0 0 rg BT 185.60 171.00 Td (, development, manufacture, marketing and sale of prescription medicines, vaccines and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 159.00 Td (consumer healthcare \(OTC\) productsprior to considering certain income statement elements. See the accompanying ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 147.00 Td (reconciliations of certain GAAP) Tj ET Q q 0 0 0 rg BT 209.75 147.00 Td ( reported to non-GAAP) Tj ET Q q 0 0 0 rg BT 303.53 147.00 Td ( adjusted information for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 405.73 147.00 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 453.49 147.00 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 455.99 147.00 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 475.99 147.00 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 495.42 147.00 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 515.42 147.00 Td (. ) Tj ET Q q 0 0 0 rg BT 520.24 147.00 Td (The ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 135.00 Td (Adjusted income component measures are not, and should not be viewed as, substitutes for the U.S. GAAP) Tj ET Q q 0 0 0 rg BT 509.44 135.00 Td ( component ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 123.00 Td (measures.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 108.00 Td (\(5\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 108.00 Td (Includes costs associated with \(i\) purchase accounting adjustments; \(ii\) acquisition-related costs; and \(iii\) certain ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 96.00 Td (significant items, which are substantive and/or unusual, and in some cases recurring, items \(such as restructuring or ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 84.00 Td (legal char) Tj ET Q q 0 0 0 rg BT 119.96 84.00 Td (ges\), that are evaluated on an individual basis by management. For additional information about these ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 72.00 Td (reconciling items and/or our non-GAAP) Tj ET Q q 0 0 0 rg BT 241.71 72.00 Td ( adjusted measure of performance, see the accompanying reconciliations of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 60.00 Td (certain GAAP) Tj ET Q q 0 0 0 rg BT 137.56 60.00 Td ( reported to non-GAAP) Tj ET Q q 0 0 0 rg BT 231.34 60.00 Td ( adjusted information for ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 333.53 60.00 Td (first-quarter) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 381.29 60.00 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 383.79 60.00 Td (2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 403.79 60.00 Td ( and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 423.23 60.00 Td (2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 443.23 60.00 Td (.) Tj ET Q endstream endobj 57 0 obj <> endobj 58 0 obj <> stream BT /F1 9.00 Tf ET q 0 0 0 rg BT 215.90 766.65 Td (PFIZER INC. ) Tj ET Q q 0 0 0 rg BT 267.66 766.65 Td (AND SUBSIDIAR) Tj ET Q q 0 0 0 rg BT 336.42 766.65 Td (Y) Tj ET Q q 0 0 0 rg BT 342.59 766.65 Td ( COMP) Tj ET Q q 0 0 0 rg BT 369.52 766.65 Td (ANIES) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 203.95 755.85 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 235.04 755.85 Td (T) Tj ET Q q 0 0 0 rg BT 240.37 755.85 Td (O OPERA) Tj ET Q q 0 0 0 rg BT 277.63 755.85 Td (TING SEGMENT) Tj ET Q q 0 0 0 rg BT 343.71 755.85 Td ( INFORMA) Tj ET Q q 0 0 0 rg BT 386.47 755.85 Td (TION) Tj ET Q BT /F1 9.00 Tf ET q 0 0 0 rg BT 276.50 745.05 Td (\(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 29.10 Td (- 28 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 54.00 722.10 Td (\(6\) ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 722.10 Td (Amounts for IH, EH, Other and Reconciling Items for the first quarter of 2017 have been revised from previously ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 710.10 Td (reported amounts to reflect the retrospective adoption of a new accounting standard in the first quarter of 2018, as of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 698.10 Td (January 1, 2018, requiring) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 1 rg BT 186.25 698.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET 0 Tr /GS0 gs 0 Tw 0 Tc 100 Tz 0 TL q 0 0 0 rg BT 188.75 698.10 Td (the reclassification of the non-service cost components of net periodic pension and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 684.90 Td (postretirement benefit costs to ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 204.30 684.90 Td (Other \(income\)/deductions) Tj ET Q BT /F3 11.00 Tf ET q 0 0 0 rg BT 311.77 684.90 Td () Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 322.77 684.90 Td (net) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 334.99 684.90 Td ( from their classification within ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 463.57 684.90 Td (Cost of sales) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 514.69 684.90 Td (, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 519.69 684.90 Td (Selling, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 672.90 Td (informational and administrative expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 251.82 672.90 Td (, ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 256.82 672.90 Td (Resear) Tj ET Q q 0 0 0 rg BT 284.21 672.90 Td (ch and development expenses) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 402.22 672.90 Td ( and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 421.66 672.90 Td (Restructuring char) Tj ET Q q 0 0 0 rg BT 497.11 672.90 Td (ges and ) Tj ET Q BT /F3 10.00 Tf ET q 0 0 0 rg BT 81.00 660.90 Td (certain acquisition-r) Tj ET Q q 0 0 0 rg BT 163.12 660.90 Td (elated costs) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 210.05 660.90 Td (.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 212.55 660.90 Td ( ) Tj ET Q endstream endobj 59 0 obj <> endobj 60 0 obj <> stream BT /F1 7.50 Tf ET q 0 0 0 rg BT 262.45 774.30 Td (PFIZER INC. - REVENUES) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 226.45 765.30 Td (FIRST) Tj ET Q q 0 0 0 rg BT 246.19 765.30 Td (-QUAR) Tj ET Q q 0 0 0 rg BT 269.49 765.30 Td (TER 2018 and 2017 - \(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 20.10 Td (- 29 -) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 32 751 m 214 751 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 214 751 m 218 751 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 218 751 m 251 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 741 m 251 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 251 751 m 284 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 741 m 284 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 284 751 m 316 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 741 m 316 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 751 m 346 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 751 m 348 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 316 751 m 347 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 741 m 347 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 347 751 m 380 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 741 m 380 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 380 751 m 413 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 741 m 413 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 751 m 452 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 751 m 454 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 413 751 m 453 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 741 m 453 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453 751 m 486 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 741 m 486 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 486 751 m 519 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 741 m 519 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519 751 m 550 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 741 m 550 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 550 751 m 581 751 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 741 m 581 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 741 m 251 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 741 m 284 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 741 m 316 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 731 m 316 731 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 741 m 347 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 731 m 347 731 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 741 m 348 731 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 741 m 346 731 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 741 m 380 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 741 m 413 741 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 741 m 452 731 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 741 m 454 731 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 731 m 453 731 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 741 m 486 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 741 m 519 741 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 731 m 550 731 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 731 m 581 731 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 721 m 218 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 721 m 251 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 721 m 284 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 721 m 316 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 721 m 347 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 731 m 348 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 731 m 346 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 731 m 452 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 731 m 454 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 721 m 214 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 711 m 214 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 711 m 218 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 721 m 251 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 721 m 284 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 721 m 316 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 721 m 346 711 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 721 m 348 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 721 m 347 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 711 m 347 711 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 721 m 348 711 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 721 m 346 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 721 m 380 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 721 m 413 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 721 m 452 711 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 721 m 454 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 721 m 453 721 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 721 m 454 711 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 721 m 452 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 721 m 486 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 711 m 486 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 721 m 519 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 721 m 550 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 721 m 581 721 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 711 m 214 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 701 m 214 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 701 m 218 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 711 m 251 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 711 m 284 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 701 m 284 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 711 m 316 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 701 m 316 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 711 m 346 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 711 m 348 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 711 m 347 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 701 m 347 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 711 m 348 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 711 m 346 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 711 m 380 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 701 m 380 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 711 m 413 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 701 m 413 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 711 m 452 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 711 m 454 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 711 m 453 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 701 m 453 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 711 m 454 701 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 711 m 452 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 711 m 486 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 701 m 486 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 711 m 519 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 701 m 519 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 711 m 550 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 701 m 550 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 711 m 581 711 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 701 m 581 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 701 m 214 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 691 m 214 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 691 m 218 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 701 m 251 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 691 m 251 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 701 m 284 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 691 m 284 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 701 m 316 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 691 m 316 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 701 m 346 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 701 m 348 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 701 m 347 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 691 m 347 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 701 m 348 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 701 m 346 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 701 m 380 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 691 m 380 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 701 m 413 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 691 m 413 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 701 m 452 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 701 m 454 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 701 m 453 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 691 m 453 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 701 m 454 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 701 m 452 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 701 m 486 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 691 m 486 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 701 m 519 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 691 m 519 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 701 m 550 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 691 m 550 691 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 701 m 581 701 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 691 m 581 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 691 m 346 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 691 m 348 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 691 m 348 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 691 m 346 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 691 m 452 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 691 m 454 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 691 m 454 681 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 691 m 452 681 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 691 m 581 691 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 681 m 346 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 681 m 348 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 681 m 348 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 681 m 346 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 681 m 452 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 681 m 454 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 681 m 454 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 681 m 452 671 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 671 m 346 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 671 m 348 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 671 m 348 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 671 m 346 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 671 m 452 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 671 m 454 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 671 m 454 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 671 m 452 661 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 661 m 346 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 661 m 348 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 661 m 348 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 661 m 346 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 661 m 452 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 661 m 454 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 661 m 454 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 661 m 452 651 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 651 m 346 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 651 m 348 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 651 m 348 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 651 m 346 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 651 m 452 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 651 m 454 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 651 m 454 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 651 m 452 641 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 641 m 346 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 641 m 348 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 641 m 348 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 641 m 346 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 641 m 452 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 641 m 454 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 641 m 454 631 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 641 m 452 631 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 622 m 251 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 622 m 284 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 622 m 316 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 631 m 346 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 631 m 348 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 622 m 347 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 631 m 348 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 631 m 346 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 622 m 380 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 622 m 413 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 631 m 452 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 631 m 454 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 622 m 453 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 631 m 454 622 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 631 m 452 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 622 m 486 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 622 m 519 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 622 m 550 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 622 m 581 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 622 m 214 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 612 m 214 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 622 m 218 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 612 m 218 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 622 m 251 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 612 m 251 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 612 m 284 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 612 m 316 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 622 m 346 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 622 m 348 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 612 m 347 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 622 m 348 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 622 m 346 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 612 m 380 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 612 m 413 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 622 m 452 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 622 m 454 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 622 m 453 622 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 612 m 453 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 622 m 454 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 622 m 452 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 612 m 486 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 612 m 519 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 612 m 550 612 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 612 m 581 612 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 612 m 346 603 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 612 m 348 603 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 612 m 348 603 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 612 m 346 603 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 612 m 454 603 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 612 m 452 603 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 594 m 214 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 594 m 251 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 594 m 284 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 594 m 316 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 603 m 346 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 603 m 348 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 594 m 347 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 603 m 348 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 603 m 346 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 594 m 380 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 594 m 413 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 603 m 452 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 603 m 454 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 594 m 453 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 603 m 454 594 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 603 m 452 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 594 m 486 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 594 m 519 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 594 m 550 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 594 m 581 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 584 m 214 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 594 m 218 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 584 m 218 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 594 m 251 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 584 m 251 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 584 m 284 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 584 m 316 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 594 m 346 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 594 m 348 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 584 m 347 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 594 m 348 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 594 m 346 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 584 m 380 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 584 m 413 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 594 m 452 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 594 m 454 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 584 m 453 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 594 m 454 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 594 m 452 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 584 m 486 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 594 m 519 594 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 584 m 519 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 584 m 550 584 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 584 m 581 584 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 584 m 346 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 584 m 348 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 584 m 348 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 584 m 346 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 584 m 452 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 584 m 454 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 584 m 454 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 584 m 452 575 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 575 m 346 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 575 m 348 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 575 m 348 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 575 m 346 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 575 m 452 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 575 m 454 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 575 m 454 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 575 m 452 566 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 566 m 346 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 566 m 348 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 566 m 348 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 566 m 346 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 566 m 452 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 566 m 454 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 566 m 454 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 566 m 452 557 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 557 m 346 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 557 m 348 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 557 m 348 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 557 m 346 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 557 m 452 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 557 m 454 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 557 m 454 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 557 m 452 548 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 548 m 346 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 548 m 348 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 548 m 348 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 548 m 346 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 548 m 452 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 548 m 454 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 548 m 454 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 548 m 452 539 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 539 m 346 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 539 m 348 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 539 m 348 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 539 m 346 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 539 m 452 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 539 m 454 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 539 m 454 530 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 539 m 452 530 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 521 m 214 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 521 m 251 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 521 m 284 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 521 m 316 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 530 m 346 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 530 m 348 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 521 m 347 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 530 m 348 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 530 m 346 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 521 m 380 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 521 m 413 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 530 m 452 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 530 m 454 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 530 m 454 521 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 530 m 452 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 521 m 486 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 521 m 519 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 521 m 550 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 521 m 581 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 521 m 214 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 511 m 214 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 521 m 218 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 511 m 218 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 521 m 251 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 511 m 251 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 521 m 284 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 511 m 284 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 521 m 316 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 511 m 316 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 521 m 346 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 521 m 348 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 521 m 347 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 511 m 347 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 521 m 348 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 521 m 346 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 521 m 380 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 511 m 380 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 521 m 413 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 511 m 413 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 521 m 452 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 521 m 454 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 521 m 453 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 511 m 453 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 521 m 454 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 521 m 452 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 521 m 486 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 511 m 486 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 521 m 519 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 511 m 519 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 521 m 550 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 511 m 550 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 521 m 581 521 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 511 m 581 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 511 m 251 511 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 511 m 284 511 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 511 m 346 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 511 m 348 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 511 m 348 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 511 m 346 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 511 m 452 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 511 m 454 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 511 m 454 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 511 m 452 502 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 502 m 346 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 502 m 348 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 502 m 348 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 502 m 346 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 502 m 452 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 502 m 454 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 502 m 454 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 502 m 452 493 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 493 m 346 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 493 m 348 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 493 m 348 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 493 m 346 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 493 m 452 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 493 m 454 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 493 m 454 484 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 493 m 452 484 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 475 m 214 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 475 m 251 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 475 m 284 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 475 m 316 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 484 m 346 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 484 m 348 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 475 m 347 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 484 m 348 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 484 m 346 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 475 m 380 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 475 m 413 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 484 m 452 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 484 m 454 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 475 m 453 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 484 m 454 475 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 484 m 452 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 475 m 486 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 475 m 519 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 475 m 550 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 475 m 581 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 465 m 214 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 475 m 218 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 465 m 218 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 475 m 251 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 465 m 251 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 475 m 284 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 465 m 284 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 475 m 316 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 465 m 316 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 475 m 346 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 475 m 348 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 475 m 347 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 465 m 347 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 475 m 348 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 475 m 346 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 475 m 380 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 465 m 380 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 475 m 413 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 465 m 413 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 475 m 452 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 475 m 454 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 475 m 453 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 465 m 453 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 475 m 454 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 475 m 452 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 475 m 486 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 465 m 486 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 475 m 519 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 465 m 519 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 475 m 550 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 465 m 550 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 475 m 581 475 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 465 m 581 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 465 m 214 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 465 m 251 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 465 m 284 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 465 m 316 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 465 m 346 456 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 465 m 348 456 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 465 m 347 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 465 m 348 456 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 465 m 346 456 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 465 m 380 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 465 m 413 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 465 m 452 456 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 465 m 454 456 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 465 m 453 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 465 m 454 456 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 465 m 452 456 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 465 m 486 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 465 m 519 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 465 m 550 465 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 465 m 581 465 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 456 m 346 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 456 m 348 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 456 m 348 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 456 m 346 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 456 m 452 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 456 m 454 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 456 m 454 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 456 m 452 447 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 447 m 346 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 447 m 348 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 447 m 348 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 447 m 346 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 447 m 452 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 447 m 454 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 447 m 454 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 447 m 452 438 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 438 m 346 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 438 m 348 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 438 m 348 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 438 m 346 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 438 m 452 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 438 m 454 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 438 m 454 429 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 438 m 452 429 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 420 m 214 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 420 m 251 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 420 m 284 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 420 m 316 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 429 m 346 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 429 m 348 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 420 m 347 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 429 m 348 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 429 m 346 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 420 m 380 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 420 m 413 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 429 m 452 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 429 m 454 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 420 m 453 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 429 m 454 420 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 429 m 452 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 420 m 486 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 420 m 519 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 420 m 550 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 420 m 581 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 410 m 214 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 420 m 218 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 410 m 251 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 410 m 284 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 420 m 316 420 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 410 m 316 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 420 m 346 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 420 m 348 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 410 m 347 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 420 m 348 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 420 m 346 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 410 m 380 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 410 m 413 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 420 m 452 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 420 m 454 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 410 m 453 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 420 m 454 410 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 420 m 452 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 410 m 486 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 410 m 519 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 410 m 550 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 410 m 581 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 410 m 214 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 400 m 214 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 410 m 218 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 410 m 251 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 400 m 251 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 410 m 284 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 400 m 284 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 410 m 316 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 400 m 316 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 410 m 346 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 410 m 348 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 410 m 347 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 400 m 347 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 410 m 348 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 410 m 346 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 410 m 380 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 400 m 380 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 410 m 413 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 400 m 413 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 410 m 452 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 410 m 454 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 410 m 453 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 400 m 453 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 410 m 454 400 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 410 m 452 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 410 m 486 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 400 m 486 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 410 m 519 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 400 m 519 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 410 m 550 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 400 m 550 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 410 m 581 410 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 400 m 581 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 400 m 214 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 390 m 214 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 400 m 218 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 390 m 218 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 400 m 251 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 390 m 251 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 400 m 284 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 390 m 284 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 400 m 316 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 390 m 316 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 400 m 346 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 400 m 348 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 400 m 347 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 390 m 347 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 400 m 348 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 400 m 346 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 400 m 380 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 390 m 380 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 400 m 413 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 390 m 413 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 400 m 452 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 400 m 454 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 400 m 453 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 390 m 453 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 400 m 454 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 400 m 452 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 400 m 486 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 390 m 486 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 400 m 519 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 390 m 519 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 400 m 550 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 390 m 550 390 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 400 m 581 400 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 390 m 581 390 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 390 m 346 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 390 m 348 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 390 m 348 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 390 m 346 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 390 m 452 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 390 m 454 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 390 m 454 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 390 m 452 380 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 380 m 346 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 380 m 348 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 380 m 348 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 380 m 346 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 380 m 452 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 380 m 454 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 380 m 454 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 380 m 452 370 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 370 m 346 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 370 m 348 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 370 m 348 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 370 m 346 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 370 m 452 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 370 m 454 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 370 m 454 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 370 m 452 360 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 360 m 346 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 360 m 348 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 360 m 348 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 360 m 346 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 360 m 452 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 360 m 454 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 360 m 454 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 360 m 452 350 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 350 m 346 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 350 m 348 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 350 m 348 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 350 m 346 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 350 m 452 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 350 m 454 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 350 m 454 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 350 m 452 340 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 340 m 346 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 340 m 348 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 340 m 348 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 340 m 346 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 340 m 452 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 340 m 454 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 340 m 454 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 340 m 452 330 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 330 m 346 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 330 m 348 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 330 m 348 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 330 m 346 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 330 m 452 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 330 m 454 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 330 m 454 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 330 m 452 320 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 320 m 346 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 320 m 348 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 320 m 348 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 320 m 346 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 320 m 452 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 320 m 454 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 320 m 454 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 320 m 452 310 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 310 m 346 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 310 m 348 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 310 m 348 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 310 m 346 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 310 m 452 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 310 m 454 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 310 m 454 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 310 m 452 300 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 300 m 346 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 300 m 348 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 300 m 348 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 300 m 346 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 300 m 452 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 300 m 454 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 300 m 454 291 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 300 m 452 291 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 282 m 214 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 291 m 346 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 291 m 348 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 291 m 348 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 291 m 346 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 291 m 452 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 291 m 454 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 291 m 454 282 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 291 m 452 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 282 m 214 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 272 m 214 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 282 m 218 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 272 m 218 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 282 m 251 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 272 m 251 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 282 m 284 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 272 m 284 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 282 m 316 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 272 m 316 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 282 m 346 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 282 m 348 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 282 m 347 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 272 m 347 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 282 m 348 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 282 m 346 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 282 m 380 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 272 m 380 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 282 m 413 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 272 m 413 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 282 m 452 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 282 m 454 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 282 m 453 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 272 m 453 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 282 m 454 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 282 m 452 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 282 m 486 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 272 m 486 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 282 m 519 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 272 m 519 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 282 m 550 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 272 m 550 272 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 282 m 581 282 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 272 m 581 272 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 272 m 346 262 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 272 m 348 262 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 272 m 348 262 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 272 m 346 262 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 272 m 454 262 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 272 m 452 262 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 262 m 346 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 262 m 348 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 262 m 348 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 262 m 346 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 262 m 452 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 262 m 454 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 262 m 454 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 262 m 452 252 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 252 m 346 242 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 252 m 348 242 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 252 m 348 242 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 252 m 346 242 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 252 m 454 242 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 252 m 452 242 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 242 m 346 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 242 m 348 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 242 m 348 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 242 m 346 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 242 m 452 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 242 m 454 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 242 m 454 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 242 m 452 232 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 232 m 346 222 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 232 m 348 222 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 232 m 348 222 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 232 m 346 222 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 232 m 454 222 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 232 m 452 222 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 222 m 346 212 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 222 m 348 212 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 222 m 348 212 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 222 m 346 212 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 222 m 454 212 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 222 m 452 212 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 202 m 214 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 202 m 251 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 202 m 284 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 202 m 316 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 212 m 346 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 212 m 348 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 202 m 347 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 212 m 348 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 212 m 346 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 202 m 380 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 202 m 413 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 212 m 452 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 212 m 454 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 202 m 453 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 212 m 454 202 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 212 m 452 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 202 m 486 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 202 m 519 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 202 m 550 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 202 m 581 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 202 m 214 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 192 m 214 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 202 m 218 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 192 m 218 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 202 m 251 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 192 m 251 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 202 m 284 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 192 m 284 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 202 m 316 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 192 m 316 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 202 m 346 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 202 m 348 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 202 m 347 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 192 m 347 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 202 m 348 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 202 m 346 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 202 m 380 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 192 m 380 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 202 m 413 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 192 m 413 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 202 m 452 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 202 m 454 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 202 m 453 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 192 m 453 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 202 m 454 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 202 m 452 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 202 m 486 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 192 m 486 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 202 m 519 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 192 m 519 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 202 m 550 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 192 m 550 192 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 202 m 581 202 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 192 m 581 192 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 192 m 346 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 192 m 348 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 192 m 348 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 192 m 346 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 192 m 452 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 192 m 454 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 192 m 454 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 192 m 452 182 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 182 m 346 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 182 m 348 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 182 m 348 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 182 m 346 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 182 m 452 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 182 m 454 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 182 m 454 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 182 m 452 173 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 173 m 346 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 173 m 348 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 173 m 348 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 173 m 346 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 173 m 452 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 173 m 454 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 173 m 454 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 173 m 452 164 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 164 m 346 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 164 m 348 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 164 m 348 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 164 m 346 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 164 m 452 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 164 m 454 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 164 m 454 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 164 m 452 154 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 154 m 346 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 154 m 348 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 154 m 348 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 154 m 346 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 154 m 452 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 154 m 454 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 154 m 454 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 154 m 452 145 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 145 m 346 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 145 m 348 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 145 m 348 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 145 m 346 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 145 m 452 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 145 m 454 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 145 m 454 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 145 m 452 136 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 136 m 346 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 136 m 348 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 136 m 348 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 136 m 346 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 136 m 452 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 136 m 454 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 136 m 454 127 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 136 m 452 127 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 118 m 214 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 118 m 218 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 118 m 251 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 118 m 284 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 118 m 316 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 127 m 346 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 127 m 348 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 118 m 347 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 127 m 348 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 127 m 346 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 118 m 380 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 118 m 413 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 127 m 452 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 127 m 454 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 127 m 454 118 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 127 m 452 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 118 m 486 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 118 m 519 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 118 m 581 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 108 m 214 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 108 m 218 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 118 m 251 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 108 m 251 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 118 m 284 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 108 m 284 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 118 m 316 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 108 m 316 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 118 m 346 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 118 m 348 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 108 m 347 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 118 m 348 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 118 m 346 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 118 m 380 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 108 m 380 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 118 m 413 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 108 m 413 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 118 m 452 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 118 m 454 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 118 m 453 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 108 m 453 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 108 m 486 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 118 m 519 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 108 m 519 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 118 m 550 118 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 108 m 550 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 108 m 581 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 108 m 251 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 108 m 284 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 108 m 316 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 108 m 346 99 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 108 m 348 99 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 108 m 347 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 108 m 348 99 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 108 m 346 99 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 108 m 380 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 108 m 413 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 108 m 452 99 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 108 m 454 99 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 108 m 453 108 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 108 m 454 99 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 108 m 452 99 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 108 m 486 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 108 m 519 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 108 m 550 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 108 m 581 108 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 90 m 214 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 90 m 251 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 90 m 284 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 90 m 316 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 99 m 346 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 99 m 348 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 90 m 347 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 99 m 348 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 99 m 346 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 90 m 380 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 90 m 413 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 99 m 452 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 99 m 454 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 90 m 453 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 99 m 454 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 99 m 452 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 90 m 486 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 90 m 519 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 90 m 550 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 90 m 581 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 90 m 214 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 90 m 218 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 90 m 251 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 90 m 284 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 90 m 316 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 90 m 346 80 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 90 m 348 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 90 m 347 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 90 m 348 80 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 90 m 346 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 90 m 380 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 90 m 413 90 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 90 m 452 80 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 90 m 454 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 90 m 453 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 90 m 486 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 90 m 519 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 90 m 550 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 90 m 581 90 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 80 m 214 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 70 m 214 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 80 m 218 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 214 70 m 218 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 80 m 251 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 218 70 m 251 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 80 m 284 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 251 70 m 284 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 80 m 316 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 284 70 m 316 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 80 m 346 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 80 m 348 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 80 m 347 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 316 70 m 347 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 80 m 348 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 80 m 346 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 80 m 380 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 347 70 m 380 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 80 m 413 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 380 70 m 413 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 80 m 452 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 80 m 454 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 80 m 453 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 413 70 m 453 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 80 m 486 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 453 70 m 486 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 80 m 519 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 486 70 m 519 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 80 m 550 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 519 70 m 550 70 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 80 m 581 80 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 550 70 m 581 70 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 70 m 346 60 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 70 m 348 60 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 70 m 348 60 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 70 m 346 60 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 70 m 452 60 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 70 m 454 60 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 60 m 346 50 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 60 m 348 50 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 60 m 348 50 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 60 m 346 50 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 60 m 452 50 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 60 m 454 50 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 32 41 m 214 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 32 39 m 214 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 214 41 m 218 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 214 39 m 218 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 218 41 m 251 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 218 39 m 251 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 251 41 m 284 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 251 39 m 284 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 284 41 m 316 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 284 39 m 316 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 50 m 346 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 50 m 348 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 316 41 m 346 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 316 39 m 347 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 50 m 348 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 346 50 m 346 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 348 41 m 380 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 347 39 m 380 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 380 41 m 413 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 380 39 m 413 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 452 50 m 452 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 50 m 454 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 413 41 m 452 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 413 39 m 453 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 454 41 m 486 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 453 39 m 486 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 486 41 m 519 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 486 39 m 519 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519 41 m 550 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 519 39 m 550 39 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 550 41 m 581 41 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 550 39 m 581 39 l s BT /F1 7.50 Tf ET q 0 0 0 rg BT 34.50 743.30 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 256.95 743.42 Td (WORLDWIDE) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 370.10 743.42 Td (UNITED ST) Tj ET Q q 0 0 0 rg BT 410.04 743.42 Td (A) Tj ET Q q 0 0 0 rg BT 414.90 743.42 Td (TES) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 468.25 743.42 Td (T) Tj ET Q q 0 0 0 rg BT 473.12 743.42 Td (OT) Tj ET Q q 0 0 0 rg BT 483.40 743.42 Td (AL) Tj ET Q q 0 0 0 rg BT 493.40 743.42 Td ( INTERNA) Tj ET Q q 0 0 0 rg BT 529.31 743.42 Td (TIONAL) Tj ET Q BT /F1 8.00 Tf ET BT /F1 5.20 Tf ET q 0 0 0 rg BT 558.90 747.05 Td (\(a\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 34.50 733.30 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 226.50 729.27 Td (2018) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 259.50 729.27 Td (2017) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 298.00 733.42 Td (% Change) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 355.50 729.27 Td (2018) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 388.50 729.27 Td (2017) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 415.50 733.42 Td (% Change) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 461.50 729.27 Td (2018) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 494.50 729.27 Td (2017) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 532.50 733.42 Td (% Change) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 34.50 723.65 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 291.30 723.42 Td (T) Tj ET Q q 0 0 0 rg BT 295.96 723.42 Td (otal) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.05 723.42 Td (Oper) Tj ET Q q 0 0 0 rg BT 338.37 723.42 Td (.) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 424.30 723.42 Td (T) Tj ET Q q 0 0 0 rg BT 428.96 723.42 Td (otal) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 525.80 723.42 Td (T) Tj ET Q q 0 0 0 rg BT 530.46 723.42 Td (otal) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 556.05 723.42 Td (Oper) Tj ET Q q 0 0 0 rg BT 572.03 723.42 Td (.) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 713.42 Td (T) Tj ET Q q 0 0 0 rg BT 39.43 713.42 Td (OT) Tj ET Q q 0 0 0 rg BT 49.93 713.42 Td (AL) Tj ET Q q 0 0 0 rg BT 59.86 713.42 Td ( REVENUES) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 713.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 227.35 713.42 Td (12,906) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 713.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.35 713.42 Td (12,779) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 293.85 713.42 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 713.42 Td (\(2%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 713.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 360.10 713.42 Td (6,275) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 713.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 393.10 713.42 Td (6,637) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 424.35 713.42 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 713.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 466.10 713.42 Td (6,631) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 713.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 499.10 713.42 Td (6,142) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 528.35 713.42 Td (8%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.35 713.42 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 39.00 703.42 Td (PFIZER INNOV) Tj ET Q q 0 0 0 rg BT 92.41 703.42 Td (A) Tj ET Q q 0 0 0 rg BT 97.27 703.42 Td (TIVE HEAL) Tj ET Q q 0 0 0 rg BT 138.06 703.42 Td (TH \(IH\)) Tj ET Q BT /F1 8.00 Tf ET BT /F1 5.20 Tf ET q 0 0 0 rg BT 164.52 707.05 Td (\(b\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 703.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 703.42 Td (7,829) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 703.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 703.42 Td (7,415) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 293.85 703.42 Td (6%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 325.35 703.42 Td (3%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 703.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 360.10 703.42 Td (4,544) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 703.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 393.10 703.42 Td (4,493) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 426.85 703.42 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 703.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 466.10 703.42 Td (3,285) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 703.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 499.10 703.42 Td (2,922) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 703.42 Td (12%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.35 703.42 Td (5%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 693.42 Td (Internal Medicine) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 693.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 693.42 Td (2,347) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 693.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 693.42 Td (2,377) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 291.35 693.42 Td (\(1%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 693.42 Td (\(3%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 693.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 360.10 693.42 Td (1,641) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 693.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 393.10 693.42 Td (1,770) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 424.35 693.42 Td (\(7%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 693.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 693.42 Td (706) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 693.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 693.42 Td (608) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 693.42 Td (16%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.35 693.42 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 683.30 Td (L) Tj ET Q q 0 0 0 rg BT 49.17 683.30 Td (yrica IH) Tj ET Q BT /F1 8.00 Tf ET BT /F1 5.20 Tf ET q 0 0 0 rg BT 73.95 686.92 Td (\(c\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 231.10 683.30 Td (1,131) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.10 683.30 Td (1,131) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 295.75 683.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 683.30 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 683.30 Td (907) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 683.30 Td (891) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 427.50 683.30 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 683.30 Td (225) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 683.30 Td (240) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 683.30 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 683.30 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 673.30 Td (Eliquis alliance revenues and direct sales) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 673.30 Td (765) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 673.30 Td (564) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 673.30 Td (35%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 673.30 Td (30%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 673.30 Td (435) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 673.30 Td (342) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 673.30 Td (27%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 673.30 Td (330) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 673.30 Td (223) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 673.30 Td (48%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 673.30 Td (35%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 663.30 Td (Chantix/Champix) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 663.30 Td (251) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 663.30 Td (239) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 294.50 663.30 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 663.30 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 663.30 Td (188) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 663.30 Td (179) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 427.50 663.30 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 663.30 Td (64) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 663.30 Td (61) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 663.30 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 663.30 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 653.30 Td (BMP2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 653.30 Td (73) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 653.30 Td (62) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 653.30 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 653.30 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 653.30 Td (73) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 653.30 Td (62) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 653.30 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 653.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 653.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 530.25 653.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.25 653.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 643.30 Td (T) Tj ET Q q 0 0 0 rg BT 49.32 643.30 Td (oviaz) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 643.30 Td (60) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 643.30 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 643.30 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 643.30 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 643.30 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 643.30 Td (24) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 643.30 Td (\(25%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 643.30 Td (42) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 643.30 Td (39) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 643.30 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 643.30 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 633.30 Td (V) Tj ET Q q 0 0 0 rg BT 49.97 633.30 Td (iagra IH) Tj ET Q BT /F1 7.50 Tf ET BT /F1 4.87 Tf ET q 0 0 0 rg BT 74.74 636.70 Td (\(d\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 633.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 633.30 Td (249) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 297.60 633.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 329.10 633.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 633.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 633.30 Td (242) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 633.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 633.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 512.25 633.30 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 532.10 633.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.10 633.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 623.35 Td (All other Internal Medicine) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 623.35 Td (66) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 623.35 Td (69) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 623.35 Td (\(4%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 623.35 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 623.35 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 623.35 Td (30) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 623.35 Td (\(33%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 623.35 Td (46) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 623.35 Td (39) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 623.35 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 623.35 Td (12%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 614.42 Td (V) Tj ET Q q 0 0 0 rg BT 45.57 614.42 Td (accines) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 614.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 614.42 Td (1,463) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 614.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 614.42 Td (1,465) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 295.75 614.42 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 614.42 Td (\(3%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 614.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 614.42 Td (837) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 614.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 614.42 Td (951) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 422.50 614.42 Td (\(12%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 614.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 614.42 Td (626) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 614.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 614.42 Td (515) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 614.42 Td (22%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 557.50 614.42 Td (15%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 604.35 Td (Prevnar 13/Prevenar 13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 231.10 604.35 Td (1,380) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.10 604.35 Td (1,392) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 604.35 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 604.35 Td (\(3%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 604.35 Td (826) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 604.35 Td (938) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 604.35 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 604.35 Td (555) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 604.35 Td (454) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 604.35 Td (22%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 604.35 Td (16%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 595.35 Td (All other ) Tj ET Q q 0 0 0 rg BT 73.68 595.35 Td (V) Tj ET Q q 0 0 0 rg BT 78.61 595.35 Td (accines) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 595.35 Td (83) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 595.35 Td (73) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 595.35 Td (13%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 595.35 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 595.35 Td (1) Tj ET Q q 0 0 0 rg BT 373.25 595.35 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 595.35 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.00 595.35 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 595.35 Td (71) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 595.35 Td (61) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 595.35 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 595.35 Td (5%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 586.42 Td (Oncology) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 586.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 586.42 Td (1,697) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 586.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 586.42 Td (1,347) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 292.00 586.42 Td (26%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 323.50 586.42 Td (23%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 586.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 360.10 586.42 Td (1,133) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 586.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 586.42 Td (953) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 425.00 586.42 Td (19%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 586.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 586.42 Td (564) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 586.42 Td (394) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 586.42 Td (43%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 557.50 586.42 Td (33%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 576.35 Td (Ibrance) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 576.35 Td (933) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 576.35 Td (679) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 576.35 Td (37%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 576.35 Td (35%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 576.35 Td (726) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 576.35 Td (608) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 576.35 Td (19%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 576.35 Td (207) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 576.35 Td (71) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 532.10 576.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.10 576.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 567.35 Td (Sutent) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 567.35 Td (262) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 567.35 Td (250) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 294.50 567.35 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 567.35 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 567.35 Td (88) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 567.35 Td (85) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 427.50 567.35 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 567.35 Td (174) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 567.35 Td (165) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 567.35 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 567.35 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 558.35 Td (Xtandi alliance revenues) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 558.35 Td (159) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 558.35 Td (131) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 558.35 Td (21%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 558.35 Td (21%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 558.35 Td (159) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 558.35 Td (131) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 558.35 Td (21%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 558.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 558.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 530.25 558.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.25 558.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 549.35 Td (Xalkori) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 549.35 Td (153) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 549.35 Td (142) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 294.50 549.35 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 549.35 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 549.35 Td (42) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 549.35 Td (57) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 549.35 Td (\(26%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 549.35 Td (1) Tj ET Q q 0 0 0 rg BT 475.50 549.35 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 549.35 Td (85) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 549.35 Td (31%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 549.35 Td (21%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 540.35 Td (Inlyta) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 540.35 Td (74) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 540.35 Td (85) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 540.35 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 540.35 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 540.35 Td (28) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 540.35 Td (30) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.00 540.35 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 540.35 Td (46) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 540.35 Td (54) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 540.35 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 540.35 Td (\(20%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 531.35 Td (Bosulif) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 531.35 Td (60) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 531.35 Td (47) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 531.35 Td (29%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 531.35 Td (26%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 531.35 Td (41) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 531.35 Td (32) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 531.35 Td (26%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 531.35 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 531.35 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 531.35 Td (36%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 531.35 Td (25%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 522.35 Td (All other Oncology) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 522.35 Td (57) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 522.35 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 297.60 522.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 329.10 522.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 522.35 Td (50) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 522.35 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 522.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.25 522.35 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 512.25 522.35 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 522.35 Td (33%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 522.35 Td (22%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 513.42 Td (Inflammation & Immunology \(I&I\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 513.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 513.42 Td (869) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 513.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 513.42 Td (871) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 295.75 513.42 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 513.42 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 513.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 513.42 Td (283) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 513.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 513.42 Td (234) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 425.00 513.42 Td (21%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 513.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 513.42 Td (585) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 513.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 513.42 Td (637) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 525.85 513.42 Td (\(8%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 555.00 513.42 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 503.35 Td (Enbrel \(Outside the U.S. and Canada\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 503.35 Td (506) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 503.35 Td (588) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 503.35 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 503.35 Td (\(21%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 503.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 503.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 428.75 503.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 503.35 Td (506) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 503.35 Td (588) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 503.35 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 503.35 Td (\(21%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 494.35 Td (Xeljanz) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 494.35 Td (326) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 494.35 Td (250) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 494.35 Td (30%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 494.35 Td (29%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 494.35 Td (253) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 494.35 Td (212) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 494.35 Td (19%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 494.35 Td (72) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 494.35 Td (38) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 494.35 Td (89%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 494.35 Td (82%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 485.35 Td (Eucrisa) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 485.35 Td (26) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 277.25 485.35 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 297.60 485.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 327.25 485.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 485.35 Td (26) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 485.35 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 485.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 485.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 485.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 530.25 485.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.25 485.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 476.35 Td (All other I&I) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 476.35 Td (1) Tj ET Q q 0 0 0 rg BT 244.25 476.35 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 476.35 Td (24) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 476.35 Td (\(53%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 476.35 Td (\(52%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 476.35 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 476.35 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 476.35 Td (\(67%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.25 476.35 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 476.35 Td (1) Tj ET Q q 0 0 0 rg BT 512.25 476.35 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 476.35 Td (\(36%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 476.35 Td (\(34%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 467.42 Td (Rar) Tj ET Q q 0 0 0 rg BT 52.93 467.42 Td (e Disease) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 467.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 467.42 Td (549) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 467.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 467.42 Td (507) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 293.85 467.42 Td (8%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 325.35 467.42 Td (2%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 467.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 467.42 Td (172) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 467.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 467.42 Td (126) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 425.00 467.42 Td (36%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 467.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 467.42 Td (377) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 467.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 467.42 Td (381) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 525.85 467.42 Td (\(1%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 556.85 467.42 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 457.35 Td (BeneFIX) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 457.35 Td (147) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 457.35 Td (149) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 457.35 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 457.35 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 457.35 Td (68) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 457.35 Td (59) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 457.35 Td (16%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 457.35 Td (79) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 457.35 Td (91) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 457.35 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 457.35 Td (\(20%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 448.35 Td (Genotropin) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 448.35 Td (132) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 448.35 Td (104) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 448.35 Td (28%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 448.35 Td (21%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 448.35 Td (31) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 448.35 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 448.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 448.35 Td (101) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 448.35 Td (99) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 448.35 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 448.35 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 439.35 Td (Refacto ) Tj ET Q q 0 0 0 rg BT 69.99 439.35 Td (AF/Xyntha) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 439.35 Td (130) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 439.35 Td (130) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 295.75 439.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 439.35 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 439.35 Td (30) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 439.35 Td (26) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 439.35 Td (14%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 439.35 Td (100) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 439.35 Td (104) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 439.35 Td (\(4%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 439.35 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 430.35 Td (Somavert) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 430.35 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 430.35 Td (56) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 430.35 Td (12%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 430.35 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 430.35 Td (24) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 430.35 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 430.35 Td (22%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 430.35 Td (39) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 430.35 Td (36) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 430.35 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 430.35 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 421.35 Td (All other Rare Disease) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 421.35 Td (76) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 421.35 Td (67) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 421.35 Td (13%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 421.35 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 421.35 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 421.35 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 427.50 421.35 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 421.35 Td (58) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 421.35 Td (50) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 421.35 Td (16%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 421.35 Td (7%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 412.42 Td (Consumer) Tj ET Q q 0 0 0 rg BT 73.70 412.42 Td ( Healthcar) Tj ET Q q 0 0 0 rg BT 107.51 412.42 Td (e) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 412.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 412.42 Td (905) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 412.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 412.42 Td (848) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 293.85 412.42 Td (7%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 325.35 412.42 Td (4%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 412.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 412.42 Td (479) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 412.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 412.42 Td (460) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 426.85 412.42 Td (4%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 412.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 412.42 Td (427) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 412.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 412.42 Td (388) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 412.42 Td (10%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.35 412.42 Td (3%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 39.00 402.42 Td (PFIZER ESSENTIAL) Tj ET Q q 0 0 0 rg BT 110.07 402.42 Td ( HEAL) Tj ET Q q 0 0 0 rg BT 132.51 402.42 Td (TH \(EH\)) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 161.05 406.05 Td (\(e\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 402.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 402.42 Td (5,077) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 402.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 402.42 Td (5,364) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 291.35 402.42 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 402.42 Td (\(9%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 402.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 360.10 402.42 Td (1,731) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 402.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 393.10 402.42 Td (2,144) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 422.50 402.42 Td (\(19%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 402.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 466.10 402.42 Td (3,347) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 402.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 499.10 402.42 Td (3,220) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 528.35 402.42 Td (4%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 556.85 402.42 Td (\(2%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 392.42 Td (Legacy Established Pr) Tj ET Q q 0 0 0 rg BT 112.03 392.42 Td (oducts \(LEP\)) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 154.33 395.82 Td (\(f\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 392.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 392.42 Td (2,636) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 392.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 392.42 Td (2,606) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 293.85 392.42 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 392.42 Td (\(3%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 392.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 392.42 Td (740) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 392.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 392.42 Td (846) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 422.50 392.42 Td (\(13%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 392.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 466.10 392.42 Td (1,896) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 392.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 499.10 392.42 Td (1,760) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 528.35 392.42 Td (8%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.35 392.42 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 382.30 Td (Lipitor) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 382.30 Td (51) Tj ET Q q 0 0 0 rg BT 244.25 382.30 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 382.30 Td (404) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 382.30 Td (27%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 382.30 Td (19%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 382.30 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 382.30 Td (30) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.00 382.30 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 382.30 Td (483) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 382.30 Td (374) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 382.30 Td (29%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 382.30 Td (21%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 372.30 Td (Norvasc) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 372.30 Td (254) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 372.30 Td (228) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 372.30 Td (12%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 372.30 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 372.30 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 372.30 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.00 372.30 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 372.30 Td (245) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 372.30 Td (218) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 372.30 Td (12%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 372.30 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 362.30 Td (Premarin family) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 362.30 Td (191) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 362.30 Td (228) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 362.30 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 362.30 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 362.30 Td (180) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 362.30 Td (214) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 362.30 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 362.30 Td (1) Tj ET Q q 0 0 0 rg BT 479.25 362.30 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 362.30 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 362.30 Td (\(19%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 362.30 Td (\(24%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 352.30 Td (Zithromax) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 352.30 Td (90) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 352.30 Td (79) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 352.30 Td (14%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 352.30 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 352.30 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 352.30 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 352.30 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 352.30 Td (89) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 352.30 Td (78) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 352.30 Td (14%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 352.30 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 342.30 Td (Zoloft) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 342.30 Td (74) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 342.30 Td (68) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 294.50 342.30 Td (9%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 342.30 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 342.30 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 342.30 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 342.30 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 342.30 Td (59) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 342.30 Td (55) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 342.30 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 342.30 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 332.30 Td (Xalatan/Xalacom) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 332.30 Td (72) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 332.30 Td (77) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 332.30 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 332.30 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 332.30 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 332.30 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.00 332.30 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 332.30 Td (67) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 332.30 Td (72) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 332.30 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 332.30 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 322.30 Td (Ef) Tj ET Q q 0 0 0 rg BT 50.51 322.30 Td (fexor) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 322.30 Td (71) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 322.30 Td (66) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 294.50 322.30 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 326.00 322.30 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 322.30 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 322.30 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.00 322.30 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 322.30 Td (53) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 322.30 Td (48) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 322.30 Td (1) Tj ET Q q 0 0 0 rg BT 530.85 322.30 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 322.30 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 312.30 Td (Sildenafil Citrate) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 312.30 Td (62) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 312.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 297.60 312.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 329.10 312.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 312.30 Td (62) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 312.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 312.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 312.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 312.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 530.25 312.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.25 312.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 302.30 Td (Xanax) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 302.30 Td (54) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 302.30 Td (55) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 295.75 302.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 302.30 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 302.30 Td (1) Tj ET Q q 0 0 0 rg BT 373.25 302.30 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 302.30 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 302.30 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 302.30 Td (44) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 302.30 Td (42) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 302.30 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 302.30 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 292.35 Td (EpiPen) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 292.35 Td (52) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 292.35 Td (81) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 292.35 Td (\(36%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 292.35 Td (\(36%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 292.35 Td (45) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 292.35 Td (69) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 292.35 Td (\(35%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.25 292.35 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 292.35 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 292.35 Td (\(36%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 292.35 Td (\(39%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 283.35 Td (All other LEP) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 231.10 283.35 Td (1,203) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.10 283.35 Td (1,321) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 283.35 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 283.35 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 283.35 Td (365) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 283.35 Td (473) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 283.35 Td (\(23%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 283.35 Td (838) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 283.35 Td (848) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 283.35 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 283.35 Td (\(7%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 274.42 Td (Sterile Injectable Pharmaceuticals \(SIP\)) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 169.02 277.82 Td (\(g\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 274.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 274.42 Td (1,360) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 274.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 274.42 Td (1,552) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 289.50 274.42 Td (\(12%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 321.00 274.42 Td (\(15%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 274.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 274.42 Td (670) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 274.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 274.42 Td (925) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 422.50 274.42 Td (\(28%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 274.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 274.42 Td (689) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 274.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 274.42 Td (627) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 274.42 Td (10%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.35 274.42 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 264.30 Td (Sulperazon) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 264.30 Td (168) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 264.30 Td (122) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 264.30 Td (38%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 264.30 Td (29%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 264.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 264.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 428.75 264.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 264.30 Td (168) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 264.30 Td (122) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 264.30 Td (38%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 264.30 Td (29%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 254.30 Td (Medrol) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 254.30 Td (120) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 254.30 Td (120) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 295.75 254.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 254.30 Td (\(3%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 254.30 Td (83) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 254.30 Td (82) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 427.50 254.30 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 254.30 Td (36) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 254.30 Td (38) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 254.30 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 254.30 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 244.30 Td (Fragmin) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 244.30 Td (70) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 244.30 Td (71) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 244.30 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 244.30 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 244.30 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 244.30 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 428.75 244.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 244.30 Td (66) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 244.30 Td (67) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 244.30 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 244.30 Td (\(10%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 234.30 Td (T) Tj ET Q q 0 0 0 rg BT 47.82 234.30 Td (ygacil) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 234.30 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 234.30 Td (74) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 234.30 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 234.30 Td (\(21%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 234.30 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 234.30 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 234.30 Td (\(68%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 234.30 Td (56) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 234.30 Td (53) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 234.30 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 234.30 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 224.30 Td (Zosyn/T) Tj ET Q q 0 0 0 rg BT 68.65 224.30 Td (azocin) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 224.30 Td (61) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 224.30 Td (37) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 224.30 Td (63%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 224.30 Td (62%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 224.30 Td (43) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 224.30 Td (34) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 224.30 Td (25%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 224.30 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 512.25 224.30 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 532.10 224.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.10 224.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 214.30 Td (Precedex) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 214.30 Td (55) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 214.30 Td (64) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 214.30 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 214.30 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 214.30 Td (27) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 214.30 Td (38) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 214.30 Td (\(29%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 214.30 Td (28) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 214.30 Td (26) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 214.30 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 214.30 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 204.30 Td (All other SIP) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 204.30 Td (823) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.10 204.30 Td (1,063) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 204.30 Td (\(23%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 204.30 Td (\(24%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 365.75 204.30 Td (506) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 398.75 204.30 Td (746) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 204.30 Td (\(32%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 204.30 Td (317) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 204.30 Td (317) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 530.25 204.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 204.30 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 194.42 Td (Peri-LOE Pr) Tj ET Q q 0 0 0 rg BT 81.81 194.42 Td (oducts) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 102.65 197.82 Td (\(h\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 194.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 194.42 Td (737) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 194.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 194.42 Td (822) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 289.50 194.42 Td (\(10%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 321.00 194.42 Td (\(15%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 194.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 194.42 Td (170) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 194.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 194.42 Td (155) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 425.00 194.42 Td (10%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 194.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 194.42 Td (567) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 194.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 194.42 Td (668) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 524.00 194.42 Td (\(15%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 555.00 194.42 Td (\(20%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 184.30 Td (V) Tj ET Q q 0 0 0 rg BT 48.47 184.30 Td (iagra EH) Tj ET Q BT /F1 7.50 Tf ET BT /F1 4.87 Tf ET q 0 0 0 rg BT 75.33 187.70 Td (\(d\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 184.30 Td (187) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 184.30 Td (89) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 297.60 184.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 329.10 184.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 184.30 Td (88) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 184.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 184.30 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 184.30 Td (99) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 184.30 Td (89) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 184.30 Td (10%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 560.00 184.30 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 174.35 Td (Celebrex) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 174.35 Td (145) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 174.35 Td (175) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 174.35 Td (\(17%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 174.35 Td (\(21%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 174.35 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 174.35 Td (30) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 174.35 Td (\(49%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 471.75 174.35 Td (129) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 174.35 Td (144) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 174.35 Td (\(1) Tj ET Q q 0 0 0 rg BT 530.85 174.35 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 174.35 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 165.35 Td (Vfend) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 165.35 Td (98) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 165.35 Td (107) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 165.35 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 165.35 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 165.35 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 165.35 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 165.35 Td (\(57%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 165.35 Td (96) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 165.35 Td (102) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 165.35 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 165.35 Td (\(1) Tj ET Q q 0 0 0 rg BT 561.85 165.35 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 156.30 Td (L) Tj ET Q q 0 0 0 rg BT 47.67 156.30 Td (yrica EH) Tj ET Q BT /F1 7.50 Tf ET BT /F1 4.87 Tf ET q 0 0 0 rg BT 74.53 159.70 Td (\(c\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 156.30 Td (82) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 156.30 Td (141) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 156.30 Td (\(42%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 156.30 Td (\(48%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 156.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 156.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 428.75 156.30 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 156.30 Td (82) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 504.75 156.30 Td (141) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 156.30 Td (\(42%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 156.30 Td (\(48%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 146.35 Td (Zyvox) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 146.35 Td (68) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 146.35 Td (77) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 146.35 Td (\(1) Tj ET Q q 0 0 0 rg BT 296.35 146.35 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 146.35 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 146.35 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 146.35 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 146.35 Td (\(40%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 146.35 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 146.35 Td (68) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 146.35 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 146.35 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 137.35 Td (Revatio) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 137.35 Td (56) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 137.35 Td (65) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 137.35 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 137.35 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 137.35 Td (33) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 137.35 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 425.60 137.35 Td (17%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 137.35 Td (22) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 137.35 Td (36) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 137.35 Td (\(38%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 137.35 Td (\(43%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 128.35 Td (Pristiq) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 128.35 Td (53) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 269.75 128.35 Td (1) Tj ET Q q 0 0 0 rg BT 273.50 128.35 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 290.10 128.35 Td (\(54%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 128.35 Td (\(56%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 128.35 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 128.35 Td (74) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 128.35 Td (\(71%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 128.35 Td (32) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 128.35 Td (41) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 524.60 128.35 Td (\(24%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 555.60 128.35 Td (\(28%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 119.35 Td (All other Peri-LOE Products) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 119.35 Td (49) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 119.35 Td (53) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.00 119.35 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 321.60 119.35 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 373.25 119.35 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.25 119.35 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 423.10 119.35 Td (\(54%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 119.35 Td (45) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 119.35 Td (46) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 526.50 119.35 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 119.35 Td (\(7%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 110.42 Td (Biosimilars) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 76.75 113.82 Td (\(i\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 110.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 110.42 Td (173) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 110.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 110.42 Td (105) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 292.00 110.42 Td (66%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 323.50 110.42 Td (53%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 110.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 369.50 110.42 Td (55) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 110.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 402.50 110.42 Td (17) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 430.60 110.42 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 110.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 110.42 Td (1) Tj ET Q q 0 0 0 rg BT 475.50 110.42 Td (19) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 110.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 508.50 110.42 Td (88) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 110.42 Td (36%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 557.50 110.42 Td (20%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 100.35 Td (Inflectra/Remsima) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 236.75 100.35 Td (145) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 100.35 Td (78) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 292.60 100.35 Td (86%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 324.10 100.35 Td (73%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 100.35 Td (55) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 100.35 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 430.60 100.35 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 100.35 Td (90) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 100.35 Td (61) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 527.10 100.35 Td (48%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 558.10 100.35 Td (32%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 91.35 Td (All other Biosimilars) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 240.50 91.35 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 273.50 91.35 Td (27) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 294.50 91.35 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 323.50 91.35 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 369.50 91.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 402.50 91.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 428.75 91.35 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 475.50 91.35 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 508.50 91.35 Td (27) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.00 91.35 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 557.50 91.35 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 82.42 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 59.51 82.42 Td ( Centr) Tj ET Q q 0 0 0 rg BT 80.00 82.42 Td (eOne) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 96.66 85.82 Td (\(j\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 82.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 82.42 Td (171) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 82.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 82.42 Td (182) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 291.35 82.42 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 82.42 Td (\(7%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 82.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 369.50 82.42 Td (96) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 82.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 82.42 Td (137) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 422.50 82.42 Td (\(30%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 82.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 475.50 82.42 Td (75) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 82.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 508.50 82.42 Td (45) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 82.42 Td (69%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 557.50 82.42 Td (63%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 72.42 Td (Hospira Infusion Systems \(HIS\)) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 142.40 75.82 Td (\(k\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 72.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 240.50 72.42 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 72.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 273.50 72.42 Td (97) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 297.60 72.42 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 329.10 72.42 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 72.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 369.50 72.42 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 72.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 402.50 72.42 Td (64) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 430.60 72.42 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 72.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 475.50 72.42 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 72.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 508.50 72.42 Td (33) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 532.10 72.42 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 563.10 72.42 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 62.42 Td (T) Tj ET Q q 0 0 0 rg BT 38.81 62.42 Td (otal L) Tj ET Q q 0 0 0 rg BT 57.36 62.42 Td (yrica) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 73.60 66.05 Td (\(c\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 62.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 231.10 62.42 Td (1,213) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 62.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.10 62.42 Td (1,271) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 291.35 62.42 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 322.85 62.42 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 62.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 62.42 Td (907) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 62.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 62.42 Td (891) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 426.85 62.42 Td (2%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 62.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 62.42 Td (307) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 62.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 62.42 Td (380) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 524.00 62.42 Td (\(19%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 555.00 62.42 Td (\(24%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 52.42 Td (T) Tj ET Q q 0 0 0 rg BT 38.81 52.42 Td (otal ) Tj ET Q q 0 0 0 rg BT 52.64 52.42 Td (V) Tj ET Q q 0 0 0 rg BT 57.77 52.42 Td (iagra) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 74.44 56.05 Td (\(d\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 52.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 52.42 Td (187) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 52.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 52.42 Td (339) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 289.50 52.42 Td (\(45%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 321.00 52.42 Td (\(46%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 52.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 369.50 52.42 Td (88) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 52.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 52.42 Td (242) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 422.50 52.42 Td (\(63%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 52.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 475.50 52.42 Td (99) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 52.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 508.50 52.42 Td (97) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 528.35 52.42 Td (2%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 556.85 52.42 Td (\(4%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 42.42 Td (T) Tj ET Q q 0 0 0 rg BT 38.81 42.42 Td (otal ) Tj ET Q q 0 0 0 rg BT 52.36 42.42 Td (Alliance r) Tj ET Q q 0 0 0 rg BT 83.67 42.42 Td (evenues) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 42.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 236.75 42.42 Td (855) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 253.50 42.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 269.75 42.42 Td (656) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 292.00 42.42 Td (30%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 323.50 42.42 Td (27%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.50 42.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 365.75 42.42 Td (602) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 382.50 42.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 398.75 42.42 Td (474) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 425.00 42.42 Td (27%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 455.50 42.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 471.75 42.42 Td (253) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 488.50 42.42 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.75 42.42 Td (182) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 526.50 42.42 Td (39%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 557.50 42.42 Td (26%) Tj ET Q BT /F1 11.00 Tf ET BT /F1 7.00 Tf ET q 0 0 0 rg BT 31.50 32.10 Td (See end of tables for notes.) Tj ET Q BT /F1 7.00 Tf ET endstream endobj 61 0 obj <> endobj 62 0 obj <> stream BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.15 774.30 Td (PFIZER INC.) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 209.40 765.30 Td (INTERNA) Tj ET Q q 0 0 0 rg BT 241.48 765.30 Td (TIONAL) Tj ET Q q 0 0 0 rg BT 269.11 765.30 Td ( REVENUES BY) Tj ET Q q 0 0 0 rg BT 322.17 765.30 Td ( GEOGRAPHIC REGION) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 226.45 756.30 Td (FIRST) Tj ET Q q 0 0 0 rg BT 246.19 756.30 Td (-QUAR) Tj ET Q q 0 0 0 rg BT 269.49 756.30 Td (TER 2018 and 2017 - \(UNAUDITED\)) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 15.60 Td (- 30 -) Tj ET Q 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 32 746.5 m 209 746.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 209 746.5 m 213 746.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 213 746.5 m 244 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 736.5 m 244 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244 746.5 m 275 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 736.5 m 275 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 275 746.5 m 307 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 736.5 m 307 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 746.5 m 337 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 746.5 m 339 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 307 746.5 m 338 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 736.5 m 338 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 338 746.5 m 369 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 736.5 m 369 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 369 746.5 m 401 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 736.5 m 401 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 401 746.5 m 432 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 736.5 m 432 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 746.5 m 462 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 746.5 m 464 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 432 746.5 m 463 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 736.5 m 463 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 463 746.5 m 494 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 736.5 m 494 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 494 746.5 m 524 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 736.5 m 524 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 524 746.5 m 554 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 736.5 m 554 736.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 554 746.5 m 584 746.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 736.5 m 584 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 736.5 m 244 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 736.5 m 275 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 736.5 m 307 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 726.5 m 307 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 736.5 m 337 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 736.5 m 339 726.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 736.5 m 338 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 726.5 m 338 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 736.5 m 339 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 736.5 m 337 726.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 736.5 m 369 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 736.5 m 401 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 736.5 m 432 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 726.5 m 432 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 736.5 m 462 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 736.5 m 464 726.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 736.5 m 463 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 726.5 m 463 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 736.5 m 464 726.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 736.5 m 462 726.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 736.5 m 494 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 736.5 m 524 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 736.5 m 554 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 726.5 m 554 726.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 736.5 m 584 736.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 726.5 m 584 726.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 716.5 m 209 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 716.5 m 244 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 716.5 m 275 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 716.5 m 307 716.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 726.5 m 337 716.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 726.5 m 339 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 716.5 m 338 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 716.5 m 369 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 716.5 m 401 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 716.5 m 432 716.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 726.5 m 462 716.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 726.5 m 464 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 716.5 m 463 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 716.5 m 494 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 716.5 m 524 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 716.5 m 554 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 716.5 m 584 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 716.5 m 209 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 716.5 m 213 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 716.5 m 244 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 716.5 m 275 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 716.5 m 307 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 706.5 m 307 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 716.5 m 337 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 716.5 m 339 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 716.5 m 338 716.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 716.5 m 339 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 716.5 m 337 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 716.5 m 369 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 716.5 m 401 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 716.5 m 432 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 706.5 m 432 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 716.5 m 462 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 716.5 m 464 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 716.5 m 463 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 716.5 m 494 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 716.5 m 524 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 716.5 m 554 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 706.5 m 554 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 716.5 m 584 716.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 706.5 m 209 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 696.5 m 209 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 706.5 m 213 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 706.5 m 244 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 706.5 m 275 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 706.5 m 307 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 706.5 m 337 696.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 706.5 m 339 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 706.5 m 338 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 706.5 m 339 696.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 706.5 m 337 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 706.5 m 369 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 706.5 m 401 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 706.5 m 432 706.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 706.5 m 462 696.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 706.5 m 464 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 706.5 m 463 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 706.5 m 494 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 706.5 m 524 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 706.5 m 554 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 706.5 m 584 706.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 696.5 m 209 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 686.5 m 209 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 696.5 m 213 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 686.5 m 213 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 696.5 m 244 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 686.5 m 244 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 696.5 m 275 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 686.5 m 275 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 696.5 m 307 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 686.5 m 307 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 696.5 m 337 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 696.5 m 339 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 696.5 m 338 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 686.5 m 338 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 696.5 m 339 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 696.5 m 337 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 696.5 m 369 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 686.5 m 369 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 696.5 m 401 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 686.5 m 401 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 696.5 m 432 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 686.5 m 432 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 696.5 m 462 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 696.5 m 464 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 696.5 m 463 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 686.5 m 463 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 696.5 m 464 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 696.5 m 462 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 696.5 m 494 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 686.5 m 494 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 696.5 m 524 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 686.5 m 524 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 696.5 m 554 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 686.5 m 554 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 696.5 m 584 696.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 686.5 m 584 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 686.5 m 337 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 686.5 m 339 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 686.5 m 339 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 686.5 m 337 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 686.5 m 462 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 686.5 m 464 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 686.5 m 464 676.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 686.5 m 462 676.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 686.5 m 554 686.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 686.5 m 584 686.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 676.5 m 337 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 676.5 m 339 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 676.5 m 339 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 676.5 m 337 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 676.5 m 462 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 676.5 m 464 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 676.5 m 464 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 676.5 m 462 667.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 667.5 m 337 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 667.5 m 339 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 667.5 m 339 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 667.5 m 337 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 667.5 m 462 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 667.5 m 464 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 667.5 m 464 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 667.5 m 462 658.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 658.5 m 337 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 658.5 m 339 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 658.5 m 339 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 658.5 m 337 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 658.5 m 462 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 658.5 m 464 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 658.5 m 464 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 658.5 m 462 649.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 649.5 m 337 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 649.5 m 339 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 649.5 m 339 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 649.5 m 337 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 649.5 m 462 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 649.5 m 464 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 649.5 m 464 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 649.5 m 462 640.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 640.5 m 337 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 640.5 m 339 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 640.5 m 339 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 640.5 m 337 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 640.5 m 462 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 640.5 m 464 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 640.5 m 464 630.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 640.5 m 462 630.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 621.5 m 209 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 621.5 m 244 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 621.5 m 275 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 621.5 m 307 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 630.5 m 337 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 630.5 m 339 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 621.5 m 338 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 630.5 m 339 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 630.5 m 337 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 621.5 m 369 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 621.5 m 401 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 621.5 m 432 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 630.5 m 462 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 630.5 m 464 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 621.5 m 463 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 630.5 m 464 621.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 630.5 m 462 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 621.5 m 494 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 621.5 m 524 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 621.5 m 554 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 621.5 m 584 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 611.5 m 209 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 621.5 m 213 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 611.5 m 213 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 611.5 m 244 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 611.5 m 275 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 611.5 m 307 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 621.5 m 337 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 621.5 m 339 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 611.5 m 338 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 621.5 m 339 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 621.5 m 337 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 611.5 m 369 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 611.5 m 401 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 611.5 m 432 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 621.5 m 462 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 621.5 m 464 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 611.5 m 463 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 621.5 m 464 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 621.5 m 462 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 621.5 m 494 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 611.5 m 494 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 611.5 m 524 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 621.5 m 554 621.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 611.5 m 554 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 611.5 m 584 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 611.5 m 244 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 611.5 m 275 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 611.5 m 307 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 611.5 m 337 602.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 611.5 m 339 602.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 611.5 m 338 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 611.5 m 339 602.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 611.5 m 337 602.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 611.5 m 369 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 611.5 m 401 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 611.5 m 432 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 611.5 m 462 602.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 611.5 m 464 602.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 611.5 m 463 611.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 611.5 m 464 602.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 611.5 m 462 602.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 611.5 m 494 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 611.5 m 524 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 611.5 m 554 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 611.5 m 584 611.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 593.5 m 209 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 593.5 m 244 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 593.5 m 275 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 593.5 m 307 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 602.5 m 337 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 602.5 m 339 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 593.5 m 338 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 602.5 m 339 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 602.5 m 337 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 593.5 m 369 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 593.5 m 401 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 593.5 m 432 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 602.5 m 462 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 602.5 m 464 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 593.5 m 463 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 602.5 m 464 593.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 602.5 m 462 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 593.5 m 494 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 593.5 m 524 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 593.5 m 554 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 593.5 m 584 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 583.5 m 209 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 593.5 m 213 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 583.5 m 213 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 583.5 m 244 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 583.5 m 275 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 583.5 m 307 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 593.5 m 337 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 593.5 m 339 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 583.5 m 338 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 593.5 m 339 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 593.5 m 337 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 583.5 m 369 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 583.5 m 401 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 583.5 m 432 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 593.5 m 462 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 593.5 m 464 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 583.5 m 463 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 593.5 m 464 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 593.5 m 462 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 593.5 m 494 593.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 583.5 m 494 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 583.5 m 524 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 583.5 m 554 583.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 583.5 m 584 583.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 583.5 m 337 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 583.5 m 339 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 583.5 m 339 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 583.5 m 337 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 583.5 m 462 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 583.5 m 464 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 583.5 m 464 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 583.5 m 462 574.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 574.5 m 337 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 574.5 m 339 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 574.5 m 339 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 574.5 m 337 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 574.5 m 462 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 574.5 m 464 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 574.5 m 464 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 574.5 m 462 565.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 565.5 m 337 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 565.5 m 339 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 565.5 m 339 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 565.5 m 337 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 565.5 m 462 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 565.5 m 464 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 565.5 m 464 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 565.5 m 462 556.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 556.5 m 337 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 556.5 m 339 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 556.5 m 339 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 556.5 m 337 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 556.5 m 462 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 556.5 m 464 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 556.5 m 464 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 556.5 m 462 547.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 547.5 m 337 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 547.5 m 339 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 547.5 m 339 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 547.5 m 337 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 547.5 m 462 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 547.5 m 464 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 547.5 m 464 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 547.5 m 462 538.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 538.5 m 337 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 538.5 m 339 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 538.5 m 339 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 538.5 m 337 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 538.5 m 462 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 538.5 m 464 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 538.5 m 464 529.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 538.5 m 462 529.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 520.5 m 209 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 520.5 m 244 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 520.5 m 275 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 520.5 m 307 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 529.5 m 337 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 529.5 m 339 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 520.5 m 338 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 529.5 m 339 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 529.5 m 337 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 520.5 m 369 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 520.5 m 401 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 520.5 m 432 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 529.5 m 462 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 529.5 m 464 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 520.5 m 463 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 529.5 m 464 520.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 529.5 m 462 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 520.5 m 494 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 520.5 m 524 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 520.5 m 554 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 520.5 m 584 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 520.5 m 209 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 510.5 m 209 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 520.5 m 213 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 510.5 m 213 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 520.5 m 244 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 510.5 m 244 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 520.5 m 275 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 510.5 m 275 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 520.5 m 307 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 510.5 m 307 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 520.5 m 337 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 520.5 m 339 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 520.5 m 338 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 510.5 m 338 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 520.5 m 339 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 520.5 m 337 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 520.5 m 369 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 510.5 m 369 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 520.5 m 401 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 510.5 m 401 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 520.5 m 432 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 510.5 m 432 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 520.5 m 462 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 520.5 m 464 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 520.5 m 463 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 510.5 m 463 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 520.5 m 464 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 520.5 m 462 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 520.5 m 494 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 510.5 m 494 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 520.5 m 524 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 510.5 m 524 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 520.5 m 554 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 510.5 m 554 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 520.5 m 584 520.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 510.5 m 584 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 510.5 m 244 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 510.5 m 275 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 510.5 m 307 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 510.5 m 337 501.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 510.5 m 339 501.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 510.5 m 338 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 510.5 m 339 501.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 510.5 m 337 501.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 510.5 m 369 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 510.5 m 401 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 510.5 m 432 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 510.5 m 462 501.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 510.5 m 464 501.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 510.5 m 463 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 510.5 m 464 501.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 510.5 m 462 501.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 510.5 m 494 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 510.5 m 524 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 510.5 m 554 510.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 510.5 m 584 510.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 501.5 m 337 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 501.5 m 339 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 501.5 m 339 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 501.5 m 337 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 501.5 m 462 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 501.5 m 464 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 501.5 m 464 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 501.5 m 462 492.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 492.5 m 337 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 492.5 m 339 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 492.5 m 339 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 492.5 m 337 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 492.5 m 462 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 492.5 m 464 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 492.5 m 464 483.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 492.5 m 462 483.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 474.5 m 244 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 474.5 m 275 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 474.5 m 307 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 483.5 m 337 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 483.5 m 339 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 474.5 m 338 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 483.5 m 339 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 483.5 m 337 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 474.5 m 369 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 474.5 m 401 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 474.5 m 432 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 483.5 m 462 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 483.5 m 464 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 474.5 m 463 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 483.5 m 464 474.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 483.5 m 462 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 474.5 m 494 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 474.5 m 524 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 474.5 m 554 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 474.5 m 584 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 474.5 m 209 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 464.5 m 209 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 474.5 m 213 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 464.5 m 213 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 474.5 m 244 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 464.5 m 244 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 474.5 m 275 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 464.5 m 275 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 474.5 m 307 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 464.5 m 307 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 474.5 m 337 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 474.5 m 339 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 474.5 m 338 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 464.5 m 338 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 474.5 m 339 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 474.5 m 337 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 474.5 m 369 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 464.5 m 369 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 474.5 m 401 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 464.5 m 401 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 474.5 m 432 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 464.5 m 432 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 474.5 m 462 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 474.5 m 464 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 474.5 m 463 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 464.5 m 463 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 474.5 m 464 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 474.5 m 462 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 474.5 m 494 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 464.5 m 494 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 474.5 m 524 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 464.5 m 524 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 474.5 m 554 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 464.5 m 554 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 474.5 m 584 474.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 464.5 m 584 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 464.5 m 244 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 464.5 m 275 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 464.5 m 307 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 464.5 m 337 455.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 464.5 m 339 455.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 464.5 m 338 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 464.5 m 339 455.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 464.5 m 337 455.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 464.5 m 369 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 464.5 m 401 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 464.5 m 432 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 464.5 m 462 455.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 464.5 m 464 455.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 464.5 m 463 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 464.5 m 464 455.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 464.5 m 462 455.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 464.5 m 494 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 464.5 m 524 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 464.5 m 554 464.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 464.5 m 584 464.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 455.5 m 337 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 455.5 m 339 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 455.5 m 339 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 455.5 m 337 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 455.5 m 462 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 455.5 m 464 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 455.5 m 464 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 455.5 m 462 446.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 446.5 m 337 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 446.5 m 339 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 446.5 m 339 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 446.5 m 337 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 446.5 m 462 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 446.5 m 464 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 446.5 m 464 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 446.5 m 462 437.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 437.5 m 337 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 437.5 m 339 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 437.5 m 339 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 437.5 m 337 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 437.5 m 462 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 437.5 m 464 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 437.5 m 464 428.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 437.5 m 462 428.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 419.5 m 209 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 419.5 m 244 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 419.5 m 275 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 419.5 m 307 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 428.5 m 337 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 428.5 m 339 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 419.5 m 338 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 428.5 m 339 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 428.5 m 337 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 419.5 m 369 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 419.5 m 401 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 419.5 m 432 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 428.5 m 462 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 428.5 m 464 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 419.5 m 463 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 428.5 m 464 419.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 428.5 m 462 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 419.5 m 494 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 419.5 m 524 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 419.5 m 554 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 419.5 m 584 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 409.5 m 209 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 419.5 m 213 419.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 409.5 m 244 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 409.5 m 275 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 409.5 m 307 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 419.5 m 337 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 419.5 m 339 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 409.5 m 338 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 419.5 m 339 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 419.5 m 337 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 409.5 m 369 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 409.5 m 401 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 409.5 m 432 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 419.5 m 462 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 419.5 m 464 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 409.5 m 463 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 419.5 m 464 409.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 419.5 m 462 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 409.5 m 494 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 409.5 m 524 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 409.5 m 554 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 409.5 m 584 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 399.5 m 209 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 409.5 m 213 409.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 399.5 m 244 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 399.5 m 275 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 399.5 m 307 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 409.5 m 337 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 409.5 m 339 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 399.5 m 338 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 409.5 m 339 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 409.5 m 337 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 399.5 m 369 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 399.5 m 401 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 399.5 m 432 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 409.5 m 462 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 409.5 m 464 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 399.5 m 463 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 409.5 m 464 399.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 409.5 m 462 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 399.5 m 494 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 399.5 m 524 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 399.5 m 554 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 399.5 m 584 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 399.5 m 209 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 389.5 m 209 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 399.5 m 213 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 389.5 m 213 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 399.5 m 244 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 389.5 m 244 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 399.5 m 275 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 389.5 m 275 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 399.5 m 307 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 389.5 m 307 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 399.5 m 337 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 399.5 m 339 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 399.5 m 338 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 389.5 m 338 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 399.5 m 339 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 399.5 m 337 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 399.5 m 369 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 389.5 m 369 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 399.5 m 401 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 389.5 m 401 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 399.5 m 432 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 389.5 m 432 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 399.5 m 462 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 399.5 m 464 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 399.5 m 463 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 389.5 m 463 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 399.5 m 464 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 399.5 m 462 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 399.5 m 494 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 389.5 m 494 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 399.5 m 524 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 389.5 m 524 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 399.5 m 554 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 389.5 m 554 389.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 399.5 m 584 399.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 389.5 m 584 389.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 389.5 m 337 379.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 389.5 m 339 379.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 389.5 m 339 379.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 389.5 m 337 379.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 389.5 m 462 379.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 389.5 m 464 379.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 379.5 m 337 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 379.5 m 339 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 379.5 m 339 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 379.5 m 337 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 379.5 m 462 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 379.5 m 464 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 379.5 m 464 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 379.5 m 462 369.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 369.5 m 337 359.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 369.5 m 339 359.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 369.5 m 339 359.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 369.5 m 337 359.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 369.5 m 462 359.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 369.5 m 464 359.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 359.5 m 337 349.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 359.5 m 339 349.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 359.5 m 339 349.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 359.5 m 337 349.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 359.5 m 462 349.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 359.5 m 464 349.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 349.5 m 337 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 349.5 m 339 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 349.5 m 339 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 349.5 m 337 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 349.5 m 462 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 349.5 m 464 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 349.5 m 464 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 349.5 m 462 339.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 339.5 m 337 329.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 339.5 m 339 329.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 339.5 m 339 329.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 339.5 m 337 329.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 339.5 m 462 329.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 339.5 m 464 329.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 329.5 m 337 319.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 329.5 m 339 319.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 329.5 m 339 319.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 329.5 m 337 319.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 329.5 m 462 319.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 329.5 m 464 319.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 319.5 m 337 309.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 319.5 m 339 309.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 319.5 m 339 309.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 319.5 m 337 309.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 319.5 m 462 309.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 319.5 m 464 309.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 309.5 m 337 299.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 309.5 m 339 299.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 309.5 m 339 299.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 309.5 m 337 299.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 309.5 m 462 299.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 309.5 m 464 299.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 299.5 m 337 289.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 299.5 m 339 289.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 299.5 m 339 289.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 299.5 m 337 289.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 299.5 m 462 289.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 299.5 m 464 289.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 289.5 m 337 279.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 289.5 m 339 279.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 289.5 m 339 279.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 289.5 m 337 279.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 289.5 m 462 279.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 289.5 m 464 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 279.5 m 209 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 269.5 m 209 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 279.5 m 213 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 269.5 m 213 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 279.5 m 244 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 269.5 m 244 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 279.5 m 275 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 269.5 m 275 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 279.5 m 307 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 269.5 m 307 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 279.5 m 337 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 279.5 m 339 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 279.5 m 338 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 269.5 m 338 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 279.5 m 339 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 279.5 m 337 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 279.5 m 369 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 269.5 m 369 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 279.5 m 401 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 269.5 m 401 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 279.5 m 432 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 269.5 m 432 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 279.5 m 462 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 279.5 m 464 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 279.5 m 463 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 269.5 m 463 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 279.5 m 464 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 279.5 m 462 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 279.5 m 494 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 269.5 m 494 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 279.5 m 524 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 269.5 m 524 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 279.5 m 554 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 269.5 m 554 269.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 279.5 m 584 279.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 269.5 m 584 269.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 269.5 m 337 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 269.5 m 339 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 269.5 m 339 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 269.5 m 337 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 269.5 m 462 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 269.5 m 464 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 269.5 m 464 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 269.5 m 462 259.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 259.5 m 337 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 259.5 m 339 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 259.5 m 339 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 259.5 m 337 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 259.5 m 462 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 259.5 m 464 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 259.5 m 464 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 259.5 m 462 249.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 249.5 m 337 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 249.5 m 339 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 249.5 m 339 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 249.5 m 337 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 249.5 m 462 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 249.5 m 464 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 249.5 m 464 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 249.5 m 462 239.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 239.5 m 337 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 239.5 m 339 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 239.5 m 339 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 239.5 m 337 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 239.5 m 462 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 239.5 m 464 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 239.5 m 464 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 239.5 m 462 229.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 229.5 m 337 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 229.5 m 339 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 229.5 m 339 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 229.5 m 337 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 229.5 m 462 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 229.5 m 464 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 229.5 m 464 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 229.5 m 462 219.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 219.5 m 337 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 219.5 m 339 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 219.5 m 339 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 219.5 m 337 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 219.5 m 462 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 219.5 m 464 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 219.5 m 464 209.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 219.5 m 462 209.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 199.5 m 209 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 199.5 m 244 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 199.5 m 275 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 199.5 m 307 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 209.5 m 337 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 209.5 m 339 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 199.5 m 338 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 209.5 m 339 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 209.5 m 337 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 199.5 m 369 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 199.5 m 401 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 199.5 m 432 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 209.5 m 462 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 209.5 m 464 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 199.5 m 463 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 209.5 m 464 199.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 209.5 m 462 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 199.5 m 494 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 199.5 m 524 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 199.5 m 554 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 199.5 m 584 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 199.5 m 209 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 189.5 m 209 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 199.5 m 213 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 189.5 m 213 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 199.5 m 244 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 189.5 m 244 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 199.5 m 275 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 189.5 m 275 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 199.5 m 307 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 189.5 m 307 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 199.5 m 337 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 199.5 m 339 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 199.5 m 338 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 189.5 m 338 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 199.5 m 339 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 199.5 m 337 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 199.5 m 369 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 189.5 m 369 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 199.5 m 401 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 189.5 m 401 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 199.5 m 432 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 189.5 m 432 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 199.5 m 462 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 199.5 m 464 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 199.5 m 463 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 189.5 m 463 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 199.5 m 464 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 199.5 m 462 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 199.5 m 494 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 189.5 m 494 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 199.5 m 524 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 189.5 m 524 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 199.5 m 554 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 189.5 m 554 189.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 199.5 m 584 199.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 189.5 m 584 189.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 189.5 m 337 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 189.5 m 339 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 189.5 m 339 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 189.5 m 337 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 189.5 m 462 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 189.5 m 464 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 189.5 m 464 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 189.5 m 462 179.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 179.5 m 337 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 179.5 m 339 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 179.5 m 339 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 179.5 m 337 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 179.5 m 462 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 179.5 m 464 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 179.5 m 464 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 179.5 m 462 169.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 169.5 m 337 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 169.5 m 339 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 169.5 m 339 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 169.5 m 337 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 169.5 m 462 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 169.5 m 464 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 169.5 m 464 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 169.5 m 462 159.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 159.5 m 337 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 159.5 m 339 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 159.5 m 339 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 159.5 m 337 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 159.5 m 462 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 159.5 m 464 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 159.5 m 464 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 159.5 m 462 149.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 149.5 m 337 139.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 149.5 m 339 139.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 149.5 m 339 139.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 149.5 m 337 139.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 149.5 m 462 139.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 149.5 m 464 139.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 139.5 m 337 129.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 139.5 m 339 129.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 139.5 m 339 129.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 139.5 m 337 129.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 139.5 m 462 129.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 139.5 m 464 129.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 129.5 m 337 119.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 129.5 m 339 119.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 129.5 m 339 119.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 129.5 m 337 119.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 129.5 m 462 119.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 129.5 m 464 119.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 109.5 m 209 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 109.5 m 244 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 109.5 m 275 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 109.5 m 307 109.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 119.5 m 337 109.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 119.5 m 339 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 109.5 m 338 109.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 119.5 m 339 109.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 119.5 m 337 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 109.5 m 369 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 109.5 m 401 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 109.5 m 432 109.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 119.5 m 462 109.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 119.5 m 464 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 109.5 m 463 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 109.5 m 494 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 109.5 m 524 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 109.5 m 554 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 109.5 m 584 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 109.5 m 209 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 99.5 m 209 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 109.5 m 213 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 109.5 m 244 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 99.5 m 244 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 109.5 m 275 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 99.5 m 275 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 109.5 m 307 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 99.5 m 307 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 109.5 m 337 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 109.5 m 339 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 109.5 m 338 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 99.5 m 338 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 109.5 m 339 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 109.5 m 337 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 109.5 m 369 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 99.5 m 369 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 109.5 m 401 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 99.5 m 401 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 109.5 m 432 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 99.5 m 432 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 109.5 m 462 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 109.5 m 464 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 109.5 m 463 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 99.5 m 463 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 109.5 m 464 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 109.5 m 462 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 109.5 m 494 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 99.5 m 494 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 109.5 m 524 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 99.5 m 524 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 109.5 m 554 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 99.5 m 554 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 109.5 m 584 109.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 99.5 m 584 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 99.5 m 213 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 99.5 m 244 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 99.5 m 275 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 99.5 m 307 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 99.5 m 337 89.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 99.5 m 339 89.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 99.5 m 338 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 99.5 m 339 89.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 99.5 m 337 89.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 99.5 m 369 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 99.5 m 401 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 99.5 m 432 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 99.5 m 462 89.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 99.5 m 464 89.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 99.5 m 463 99.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 99.5 m 464 89.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 99.5 m 462 89.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 99.5 m 494 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 99.5 m 524 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 99.5 m 554 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 99.5 m 584 99.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 79.5 m 213 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 79.5 m 244 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 79.5 m 275 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 79.5 m 307 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 89.5 m 337 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 89.5 m 339 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 79.5 m 338 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 89.5 m 339 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 89.5 m 337 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 79.5 m 369 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 79.5 m 401 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 79.5 m 432 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 89.5 m 462 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 89.5 m 464 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 79.5 m 463 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 89.5 m 464 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 89.5 m 462 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 79.5 m 494 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 79.5 m 524 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 79.5 m 554 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 79.5 m 584 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 79.5 m 209 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 79.5 m 213 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 79.5 m 244 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 79.5 m 275 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 79.5 m 307 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 79.5 m 337 69.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 79.5 m 339 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 79.5 m 338 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 79.5 m 339 69.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 79.5 m 337 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 79.5 m 369 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 79.5 m 401 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 79.5 m 432 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 79.5 m 462 69.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 79.5 m 464 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 79.5 m 463 79.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 79.5 m 464 69.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 79.5 m 462 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 79.5 m 494 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 79.5 m 524 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 79.5 m 554 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 79.5 m 584 79.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 69.5 m 209 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 32 59.5 m 209 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 69.5 m 213 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 209 59.5 m 213 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 69.5 m 244 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 213 59.5 m 244 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 69.5 m 275 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 244 59.5 m 275 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 69.5 m 307 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 275 59.5 m 307 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 69.5 m 337 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 69.5 m 339 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 69.5 m 338 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 307 59.5 m 338 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 69.5 m 339 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 69.5 m 337 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 69.5 m 369 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 338 59.5 m 369 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 69.5 m 401 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 369 59.5 m 401 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 69.5 m 432 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 401 59.5 m 432 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 69.5 m 462 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 69.5 m 464 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 69.5 m 463 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 432 59.5 m 463 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 69.5 m 464 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 69.5 m 462 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 69.5 m 494 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 463 59.5 m 494 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 69.5 m 524 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 494 59.5 m 524 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 69.5 m 554 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 524 59.5 m 554 59.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 69.5 m 584 69.5 l s 0 0 0 RG /GS0 gs 0.50 w 0 i [] 0 d 0 J 0 j 3 M 554 59.5 m 584 59.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 59.5 m 337 49.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 59.5 m 339 49.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 59.5 m 339 49.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 59.5 m 337 49.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 59.5 m 462 49.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 59.5 m 464 49.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 49.5 m 337 39.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 49.5 m 339 39.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 49.5 m 462 39.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 49.5 m 464 39.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 32 30.5 m 209 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 32 28.5 m 209 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 209 30.5 m 213 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 209 28.5 m 213 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 213 30.5 m 244 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 213 28.5 m 244 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244 30.5 m 275 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 244 28.5 m 275 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 275 30.5 m 307 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 275 28.5 m 307 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 307 30.5 m 337 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 307 28.5 m 338 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 39.5 m 339 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 337 39.5 m 337 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 339 30.5 m 369 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 338 28.5 m 369 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 369 30.5 m 401 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 369 28.5 m 401 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 401 30.5 m 432 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 401 28.5 m 432 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 432 30.5 m 462 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 432 28.5 m 463 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 39.5 m 464 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 462 39.5 m 462 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 464 30.5 m 494 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 463 28.5 m 494 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 494 30.5 m 524 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 494 28.5 m 524 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 524 30.5 m 554 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 524 28.5 m 554 28.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 554 30.5 m 584 30.5 l s 0 0 0 RG /GS0 gs 1.00 w 0 i [] 0 d 0 J 0 j 3 M 554 28.5 m 584 28.5 l s BT /F1 7.50 Tf ET q 0 0 0 rg BT 40.50 738.80 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 232.75 738.92 Td (DEVELOPED EUROPE) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 312.55 742.32 Td (\(l\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.85 738.92 Td (DEVELOPED REST) Tj ET Q q 0 0 0 rg BT 408.86 738.92 Td ( OF) Tj ET Q q 0 0 0 rg BT 420.87 738.92 Td ( ) Tj ET Q q 0 0 0 rg BT 422.61 738.92 Td (WORLD) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 451.78 742.32 Td (\(m\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 478.85 738.92 Td (EMERGING MARKETS) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 561.15 742.32 Td (\(n\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 34.50 728.80 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 220.50 724.77 Td (2018) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 251.50 724.77 Td (2017) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 289.00 728.92 Td (% Change) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 345.50 724.77 Td (2018) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 377.00 724.77 Td (2017) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 414.50 728.92 Td (% Change) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 470.50 724.77 Td (2018) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 501.00 724.77 Td (2017) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 536.50 728.92 Td (% Change) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 34.50 719.15 Td (\(MILLIONS OF DOLLARS\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 282.30 718.92 Td (T) Tj ET Q q 0 0 0 rg BT 286.96 718.92 Td (otal) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 313.05 718.92 Td (Oper) Tj ET Q q 0 0 0 rg BT 329.37 718.92 Td (.) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.80 718.92 Td (T) Tj ET Q q 0 0 0 rg BT 412.46 718.92 Td (otal) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 438.05 718.92 Td (Oper) Tj ET Q q 0 0 0 rg BT 454.37 718.92 Td (.) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 530.30 718.92 Td (T) Tj ET Q q 0 0 0 rg BT 534.96 718.92 Td (otal) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 559.55 718.92 Td (Oper) Tj ET Q q 0 0 0 rg BT 575.53 718.92 Td (.) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 708.92 Td (T) Tj ET Q q 0 0 0 rg BT 39.37 708.92 Td (OT) Tj ET Q q 0 0 0 rg BT 49.65 708.92 Td (AL) Tj ET Q q 0 0 0 rg BT 59.65 708.92 Td ( INTERNA) Tj ET Q q 0 0 0 rg BT 95.56 708.92 Td (TIONAL) Tj ET Q q 0 0 0 rg BT 124.74 708.92 Td ( REVENUES) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 708.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 224.10 708.92 Td (2,092) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 708.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 255.10 708.92 Td (2,021) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 284.85 708.92 Td (4%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 313.85 708.92 Td (\(8%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 708.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 349.10 708.92 Td (1,461) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 708.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 381.10 708.92 Td (1,554) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.85 708.92 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 708.92 Td (\(10%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 708.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 474.10 708.92 Td (3,078) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 708.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.10 708.92 Td (2,567) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 708.92 Td (20%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 708.92 Td (15%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 39.00 698.92 Td (PFIZER INNOV) Tj ET Q q 0 0 0 rg BT 92.41 698.92 Td (A) Tj ET Q q 0 0 0 rg BT 97.27 698.92 Td (TIVE HEAL) Tj ET Q q 0 0 0 rg BT 138.06 698.92 Td (TH \(IH\)) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 164.52 702.55 Td (\(b\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 698.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 224.10 698.92 Td (1,314) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 698.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 255.10 698.92 Td (1,190) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 283.00 698.92 Td (10%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 313.85 698.92 Td (\(2%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 698.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 698.92 Td (812) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 698.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 698.92 Td (799) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 410.35 698.92 Td (2%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 438.85 698.92 Td (\(3%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 698.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 474.10 698.92 Td (1,158) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 698.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 698.92 Td (933) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 698.92 Td (24%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 698.92 Td (20%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 688.92 Td (Internal Medicine) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 688.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 688.92 Td (231) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 688.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 688.92 Td (158) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 283.00 688.92 Td (46%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 314.50 688.92 Td (29%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 688.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 688.92 Td (295) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 688.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 688.92 Td (319) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.85 688.92 Td (\(8%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 688.92 Td (\(1) Tj ET Q q 0 0 0 rg BT 443.25 688.92 Td (1%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 688.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 688.92 Td (180) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 688.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 688.92 Td (130) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 688.92 Td (38%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 688.92 Td (32%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 678.80 Td (L) Tj ET Q q 0 0 0 rg BT 49.17 678.80 Td (yrica IH) Tj ET Q BT /F1 8.00 Tf ET BT /F1 5.20 Tf ET q 0 0 0 rg BT 73.95 682.42 Td (\(c\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 678.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 678.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 678.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 678.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 354.75 678.80 Td (169) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 386.75 678.80 Td (188) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 678.80 Td (\(10%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 678.80 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 678.80 Td (56) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 678.80 Td (52) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 678.80 Td (9%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 678.80 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 668.85 Td (Eliquis alliance revenues and direct sales) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 229.75 668.85 Td (191) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 260.75 668.85 Td (124) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 668.85 Td (54%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 668.85 Td (36%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 668.85 Td (68) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 668.85 Td (61) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 668.85 Td (10%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 442.00 668.85 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 668.85 Td (71) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 668.85 Td (37) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 668.85 Td (91%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 668.85 Td (79%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 659.85 Td (Chantix/Champix) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 659.85 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 659.85 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 659.85 Td (14%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 317.00 659.85 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 659.85 Td (28) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 659.85 Td (32) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 659.85 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 659.85 Td (\(19%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 659.85 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 659.85 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 659.85 Td (53%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 659.85 Td (51%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 650.85 Td (BMP2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 412.25 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 443.25 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 650.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 641.85 Td (T) Tj ET Q q 0 0 0 rg BT 49.06 641.85 Td (oviaz) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 641.85 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 641.85 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 641.85 Td (18%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 317.00 641.85 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 641.85 Td (22) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 641.85 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 411.00 641.85 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 439.50 641.85 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 641.85 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 641.85 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 641.85 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 641.85 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 632.80 Td (V) Tj ET Q q 0 0 0 rg BT 49.97 632.80 Td (iagra IH) Tj ET Q BT /F1 7.50 Tf ET BT /F1 4.87 Tf ET q 0 0 0 rg BT 74.74 636.20 Td (\(d\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 632.80 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 414.10 632.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 445.10 632.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 632.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 622.85 Td (All other Internal Medicine) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 622.85 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 622.85 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 622.85 Td (25%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 622.85 Td (17%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 622.85 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 622.85 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 411.00 622.85 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 442.00 622.85 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 622.85 Td (35) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 622.85 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 622.85 Td (20%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 622.85 Td (13%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 613.92 Td (V) Tj ET Q q 0 0 0 rg BT 45.23 613.92 Td (accines) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 613.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 613.92 Td (198) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 613.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 613.92 Td (191) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 284.85 613.92 Td (4%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 313.85 613.92 Td (\(8%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 613.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 613.92 Td (106) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 613.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 613.92 Td (107) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.85 613.92 Td (\(1%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 438.85 613.92 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 613.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 613.92 Td (322) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 613.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 613.92 Td (216) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 613.92 Td (49%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 613.92 Td (45%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 603.85 Td (Prevnar 13/Prevenar 13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 229.75 603.85 Td (141) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 260.75 603.85 Td (139) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 603.85 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 603.85 Td (\(10%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 354.75 603.85 Td (103) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 386.75 603.85 Td (106) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 603.85 Td (\(3%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 439.50 603.85 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 603.85 Td (310) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 603.85 Td (210) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 603.85 Td (48%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 603.85 Td (45%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 594.85 Td (All other ) Tj ET Q q 0 0 0 rg BT 73.61 594.85 Td (V) Tj ET Q q 0 0 0 rg BT 78.19 594.85 Td (accines) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 594.85 Td (57) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 594.85 Td (52) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 594.85 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 594.85 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 594.85 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 594.85 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 414.10 594.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 440.10 594.85 Td (96%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 594.85 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 594.85 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 594.85 Td (75%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 594.85 Td (63%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 585.92 Td (Oncology) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 585.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 585.92 Td (268) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 585.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 585.92 Td (187) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 283.00 585.92 Td (44%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 314.50 585.92 Td (27%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 585.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 585.92 Td (1) Tj ET Q q 0 0 0 rg BT 358.50 585.92 Td (10) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 585.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 390.50 585.92 Td (76) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 408.50 585.92 Td (44%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 439.50 585.92 Td (38%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 585.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 585.92 Td (186) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 585.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 585.92 Td (131) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 585.92 Td (42%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 585.92 Td (39%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 575.85 Td (Ibrance) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 229.75 575.85 Td (1) Tj ET Q q 0 0 0 rg BT 233.50 575.85 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 575.85 Td (43) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 288.60 575.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 320.10 575.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 575.85 Td (41) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 575.85 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 414.10 575.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 445.10 575.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 575.85 Td (49) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 575.85 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 536.60 575.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 566.60 575.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 566.85 Td (Sutent) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 566.85 Td (80) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 566.85 Td (75) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 566.85 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 566.85 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 566.85 Td (27) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 566.85 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 566.85 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 566.85 Td (\(1) Tj ET Q q 0 0 0 rg BT 443.85 566.85 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 566.85 Td (67) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 566.85 Td (60) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 566.85 Td (1) Tj ET Q q 0 0 0 rg BT 535.35 566.85 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 566.85 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 557.85 Td (Xtandi alliance revenues) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 412.25 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 443.25 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 557.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 548.85 Td (Xalkori) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 548.85 Td (46) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 548.85 Td (40) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 548.85 Td (15%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 317.00 548.85 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 548.85 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 548.85 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 548.85 Td (15%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 442.00 548.85 Td (9%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 548.85 Td (50) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 548.85 Td (32) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 548.85 Td (56%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 548.85 Td (49%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 539.85 Td (Inlyta) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 539.85 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 539.85 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 539.85 Td (\(31%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 539.85 Td (\(38%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 539.85 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 539.85 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 539.85 Td (\(19%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 539.85 Td (\(21%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 539.85 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 539.85 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 539.85 Td (10%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 539.85 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 530.85 Td (Bosulif) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 530.85 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 530.85 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 530.85 Td (38%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 530.85 Td (22%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 530.85 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 530.85 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 530.85 Td (20%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 440.10 530.85 Td (16%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 530.85 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 530.85 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 536.60 530.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 566.60 530.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 521.85 Td (All other Oncology) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 521.85 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 521.85 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 521.85 Td (73%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 521.85 Td (51%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 521.85 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 521.85 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 521.85 Td (\(27%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 521.85 Td (\(31%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 521.85 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 521.85 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 521.85 Td (69%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 521.85 Td (58%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 512.92 Td (Inflammation & Immunology \(I&I\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 512.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 512.92 Td (305) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 512.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 512.92 Td (351) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 280.50 512.92 Td (\(13%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 512.92 Td (\(23%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 512.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 512.92 Td (130) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 512.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 512.92 Td (128) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 410.35 512.92 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 438.85 512.92 Td (\(3%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 512.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 512.92 Td (150) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 512.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 512.92 Td (158) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 530.35 512.92 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 560.35 512.92 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 502.85 Td (Enbrel \(Outside the U.S. and Canada\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 229.75 502.85 Td (290) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 260.75 502.85 Td (348) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 502.85 Td (\(17%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 502.85 Td (\(27%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 502.85 Td (89) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 502.85 Td (95) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 502.85 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 439.50 502.85 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 502.85 Td (126) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 502.85 Td (145) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.10 502.85 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 502.85 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 493.85 Td (Xeljanz) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 493.85 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 493.85 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 288.60 493.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 320.10 493.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 493.85 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 493.85 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 493.85 Td (44%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 440.10 493.85 Td (38%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 493.85 Td (24) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 493.85 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 493.85 Td (83%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 493.85 Td (87%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 484.85 Td (Eucrisa) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 412.25 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 443.25 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 484.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 475.85 Td (All other I&I) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 234.75 475.85 Td (\(4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 241.00 475.85 Td (\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 265.75 475.85 Td (\(2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 272.00 475.85 Td (\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 288.60 475.85 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 475.85 Td (77%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 475.85 Td (1) Tj ET Q q 0 0 0 rg BT 362.25 475.85 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 475.85 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 475.85 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 475.85 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 475.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 475.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 475.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 475.85 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 466.92 Td (Rar) Tj ET Q q 0 0 0 rg BT 52.86 466.92 Td (e Disease) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 466.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 466.92 Td (207) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 466.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 466.92 Td (208) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 286.75 466.92 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 466.92 Td (\(12%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 466.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 358.50 466.92 Td (87) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 466.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 390.50 466.92 Td (94) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.85 466.92 Td (\(8%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 466.92 Td (\(12%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 466.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 466.92 Td (83) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 466.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 513.50 466.92 Td (78) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 532.85 466.92 Td (7%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 562.85 466.92 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 456.85 Td (BeneFIX) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 456.85 Td (40) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 456.85 Td (48) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 456.85 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 456.85 Td (\(26%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 456.85 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 456.85 Td (27) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 456.85 Td (\(22%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 456.85 Td (\(27%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 456.85 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 456.85 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 456.85 Td (12%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 456.85 Td (10%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 447.85 Td (Genotropin) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 447.85 Td (44) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 447.85 Td (40) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 447.85 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 447.85 Td (\(4%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 447.85 Td (35) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 447.85 Td (37) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 447.85 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 447.85 Td (\(10%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 447.85 Td (22) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 447.85 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 447.85 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 447.85 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 438.85 Td (Refacto ) Tj ET Q q 0 0 0 rg BT 69.78 438.85 Td (AF/Xyntha) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 438.85 Td (64) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 438.85 Td (68) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.00 438.85 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 438.85 Td (\(17%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 438.85 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 438.85 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 411.00 438.85 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 442.00 438.85 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 438.85 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 438.85 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 438.85 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.00 438.85 Td (\(4%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 429.85 Td (Somavert) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 429.85 Td (31) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 429.85 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 429.85 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 429.85 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 429.85 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 429.85 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 429.85 Td (12%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 442.00 429.85 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 429.85 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 429.85 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 429.85 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.00 429.85 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 45.00 420.85 Td (All other Rare Disease) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 420.85 Td (28) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 420.85 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 420.85 Td (23%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 317.00 420.85 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 420.85 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 420.85 Td (13) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 420.85 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 439.50 420.85 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 420.85 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 420.85 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 420.85 Td (23%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 420.85 Td (20%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 411.92 Td (Consumer) Tj ET Q q 0 0 0 rg BT 73.70 411.92 Td ( Healthcar) Tj ET Q q 0 0 0 rg BT 107.51 411.92 Td (e) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 411.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 411.92 Td (105) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 411.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.50 411.92 Td (95) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 283.00 411.92 Td (1) Tj ET Q q 0 0 0 rg BT 286.75 411.92 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 313.85 411.92 Td (\(2%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 411.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 358.50 411.92 Td (85) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 411.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 390.50 411.92 Td (74) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 408.50 411.92 Td (15%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 441.35 411.92 Td (9%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 411.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 411.92 Td (237) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 411.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 411.92 Td (219) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 532.85 411.92 Td (8%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 562.85 411.92 Td (3%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 39.00 401.92 Td (PFIZER ESSENTIAL) Tj ET Q q 0 0 0 rg BT 110.07 401.92 Td ( HEAL) Tj ET Q q 0 0 0 rg BT 132.51 401.92 Td (TH \(EH\)) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 161.05 405.55 Td (\(e\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 401.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 401.92 Td (778) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 401.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 401.92 Td (831) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 282.35 401.92 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 401.92 Td (\(17%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 401.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 401.92 Td (648) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 401.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 401.92 Td (755) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 406.00 401.92 Td (\(14%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 401.92 Td (\(18%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 401.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 474.10 401.92 Td (1,920) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 401.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 504.10 401.92 Td (1,634) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 401.92 Td (18%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 401.92 Td (12%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 391.92 Td (Legacy Established Pr) Tj ET Q q 0 0 0 rg BT 112.03 391.92 Td (oducts \(LEP\)) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 154.33 395.32 Td (\(f\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 391.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 391.92 Td (371) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 391.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 391.92 Td (373) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 286.75 391.92 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 391.92 Td (\(12%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 391.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 391.92 Td (400) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 391.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 391.92 Td (452) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 406.00 391.92 Td (\(12%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 391.92 Td (\(16%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 391.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 474.10 391.92 Td (1,125) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 391.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 391.92 Td (935) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 391.92 Td (20%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 391.92 Td (15%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 381.80 Td (Lipitor) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 381.80 Td (44) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 381.80 Td (42) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 381.80 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 381.80 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 381.80 Td (46) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 381.80 Td (53) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 381.80 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 381.80 Td (\(21%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 381.80 Td (393) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 381.80 Td (279) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 381.80 Td (41%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 381.80 Td (33%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 371.80 Td (Norvasc) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 371.80 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 371.80 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 371.80 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 371.80 Td (\(10%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 371.80 Td (43) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 371.80 Td (50) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 371.80 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 371.80 Td (\(18%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 371.80 Td (184) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 371.80 Td (151) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 371.80 Td (22%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 371.80 Td (16%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 361.80 Td (Premarin family) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 361.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 361.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 361.80 Td (\(38%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 361.80 Td (\(44%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 361.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 361.80 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 361.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 361.80 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 361.80 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 361.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.10 361.80 Td (\(26%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 361.80 Td (\(30%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 351.80 Td (Zithromax) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 351.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 351.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 351.80 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 351.80 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 351.80 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 351.80 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 351.80 Td (\(27%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 351.80 Td (\(30%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 351.80 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 351.80 Td (49) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 351.80 Td (29%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 351.80 Td (23%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 341.80 Td (Zoloft) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 341.80 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 341.80 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 341.80 Td (13%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 341.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 341.80 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 341.80 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 341.80 Td (\(19%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 341.80 Td (\(22%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 341.80 Td (35) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 341.80 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 341.80 Td (20%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 341.80 Td (15%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 331.80 Td (Xalatan/Xalacom) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 331.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 331.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.00 331.80 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 331.80 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 331.80 Td (29) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 331.80 Td (34) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 331.80 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 331.80 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 331.80 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 331.80 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 331.80 Td (\(1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.00 331.80 Td (\(6%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 321.80 Td (Ef) Tj ET Q q 0 0 0 rg BT 50.44 321.80 Td (fexor) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 321.80 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 321.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.00 321.80 Td (\(3%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 321.80 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 321.80 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 321.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 321.80 Td (31%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 440.10 321.80 Td (26%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 321.80 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 321.80 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 321.80 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 321.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 311.80 Td (Sildenafil Citrate) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 412.25 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 443.25 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 311.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 301.80 Td (Xanax) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 301.80 Td (22) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 301.80 Td (22) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 301.80 Td (2%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 301.80 Td (\(1) Tj ET Q q 0 0 0 rg BT 318.85 301.80 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 301.80 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 301.80 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 301.80 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 301.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 301.80 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 301.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 301.80 Td (10%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 301.80 Td (4%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 291.80 Td (EpiPen) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 291.80 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 291.80 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 291.80 Td (\(36%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 291.80 Td (\(39%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 534.75 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 564.75 291.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 281.80 Td (All other LEP) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 229.75 281.80 Td (233) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 260.75 281.80 Td (238) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.00 281.80 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 281.80 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 354.75 281.80 Td (221) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 386.75 281.80 Td (246) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 281.80 Td (\(1) Tj ET Q q 0 0 0 rg BT 412.85 281.80 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 281.80 Td (\(14%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 281.80 Td (384) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 281.80 Td (363) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 281.80 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 281.80 Td (2%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 271.92 Td (Sterile Injectable Pharmaceuticals \(SIP\)) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 169.02 275.32 Td (\(g\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 271.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 271.92 Td (157) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 271.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 271.92 Td (149) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 284.85 271.92 Td (6%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 313.85 271.92 Td (\(6%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 271.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 271.92 Td (103) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 271.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 271.92 Td (131) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 406.00 271.92 Td (\(21%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 271.92 Td (\(24%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 271.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 271.92 Td (429) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 271.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 271.92 Td (348) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 271.92 Td (23%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 271.92 Td (17%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 261.80 Td (Sulperazon) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 261.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 261.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 261.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 261.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 261.80 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 261.80 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 261.80 Td (\(19%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 261.80 Td (\(22%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 261.80 Td (166) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 261.80 Td (1) Tj ET Q q 0 0 0 rg BT 513.50 261.80 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 261.80 Td (39%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 261.80 Td (31%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 251.80 Td (Medrol) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 251.80 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 251.80 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 251.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 251.80 Td (\(1) Tj ET Q q 0 0 0 rg BT 318.85 251.80 Td (1%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 251.80 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 251.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 251.80 Td (\(13%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 251.80 Td (\(17%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 251.80 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 251.80 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 251.80 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 251.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 241.80 Td (Fragmin) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 241.80 Td (37) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 241.80 Td (35) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 241.80 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 241.80 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 241.80 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 241.80 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 241.80 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 241.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 241.80 Td (1) Tj ET Q q 0 0 0 rg BT 487.25 241.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 241.80 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 241.80 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 241.80 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 231.80 Td (T) Tj ET Q q 0 0 0 rg BT 47.56 231.80 Td (ygacil) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 231.80 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 231.80 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 231.80 Td (15%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 317.00 231.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 231.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 231.80 Td (2) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 231.80 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 231.80 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 231.80 Td (35) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 231.80 Td (35) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 231.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.00 231.80 Td (\(4%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 221.80 Td (Zosyn/T) Tj ET Q q 0 0 0 rg BT 68.39 221.80 Td (azocin) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 221.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 221.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 288.60 221.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 320.10 221.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 221.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 221.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 414.10 221.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 445.10 221.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 221.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 221.80 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 536.60 221.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 566.60 221.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 211.80 Td (Precedex) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 211.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 211.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 286.75 211.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 318.25 211.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 211.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 211.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 411.00 211.80 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 443.25 211.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 211.80 Td (1) Tj ET Q q 0 0 0 rg BT 487.25 211.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 211.80 Td (1) Tj ET Q q 0 0 0 rg BT 517.25 211.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 211.80 Td (8%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 211.80 Td (5%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 201.80 Td (All other SIP) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 201.80 Td (87) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 201.80 Td (85) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 285.50 201.80 Td (3%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 201.80 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 201.80 Td (59) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 201.80 Td (85) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 201.80 Td (\(31%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 201.80 Td (\(34%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 479.75 201.80 Td (170) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 509.75 201.80 Td (147) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 201.80 Td (16%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.60 201.80 Td (1) Tj ET Q q 0 0 0 rg BT 565.35 201.80 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 191.92 Td (Peri-LOE Pr) Tj ET Q q 0 0 0 rg BT 81.81 191.92 Td (oducts) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 102.65 195.32 Td (\(h\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 191.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 191.92 Td (127) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 191.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 191.92 Td (203) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 280.50 191.92 Td (\(37%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 191.92 Td (\(44%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 191.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 191.92 Td (139) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 191.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 191.92 Td (153) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.85 191.92 Td (\(9%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 191.92 Td (\(13%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 191.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 479.75 191.92 Td (301) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 191.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 509.75 191.92 Td (312) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 530.35 191.92 Td (\(4%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 560.35 191.92 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 181.80 Td (V) Tj ET Q q 0 0 0 rg BT 48.47 181.80 Td (iagra EH) Tj ET Q BT /F1 7.50 Tf ET BT /F1 4.87 Tf ET q 0 0 0 rg BT 75.33 185.20 Td (\(d\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 181.80 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 181.80 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 181.80 Td (\(20%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 181.80 Td (\(29%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 181.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 181.80 Td (9) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 181.80 Td (77%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 440.10 181.80 Td (68%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 181.80 Td (73) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 181.80 Td (69) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 181.80 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 181.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 171.80 Td (Celebrex) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 171.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 171.80 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.00 171.80 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 171.80 Td (\(19%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 171.80 Td (60) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 171.80 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 171.80 Td (\(5%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 439.50 171.80 Td (\(9%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 171.80 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 171.80 Td (74) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.10 171.80 Td (\(16%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 171.80 Td (\(20%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 161.80 Td (Vfend) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 161.80 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 161.80 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 161.80 Td (\(43%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 161.80 Td (\(50%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 161.80 Td (20) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 161.80 Td (26) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 161.80 Td (\(23%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 161.80 Td (\(26%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 161.80 Td (66) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 161.80 Td (59) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.60 161.80 Td (12%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 161.80 Td (7%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 151.80 Td (L) Tj ET Q q 0 0 0 rg BT 47.67 151.80 Td (yrica EH) Tj ET Q BT /F1 7.50 Tf ET BT /F1 4.87 Tf ET q 0 0 0 rg BT 74.53 155.20 Td (\(c\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 151.80 Td (63) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 260.75 151.80 Td (1) Tj ET Q q 0 0 0 rg BT 264.50 151.80 Td (17) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 151.80 Td (\(46%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 151.80 Td (\(52%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 151.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 151.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 412.25 151.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 443.25 151.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 151.80 Td (18) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 151.80 Td (23) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.10 151.80 Td (\(23%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 151.80 Td (\(28%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 141.80 Td (Zyvox) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 141.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 141.80 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 141.80 Td (\(40%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 141.80 Td (\(47%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 141.80 Td (12) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 141.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 141.80 Td (\(25%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 141.80 Td (\(28%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 141.80 Td (45) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 141.80 Td (43) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 533.50 141.80 Td (6%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 563.50 141.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 131.80 Td (Revatio) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 131.80 Td (10) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 131.80 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 281.10 131.80 Td (\(52%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 312.60 131.80 Td (\(57%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 131.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 131.80 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 131.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 131.80 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 131.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 131.80 Td (8) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.10 131.80 Td (\(24%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 131.80 Td (\(29%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 121.80 Td (Pristiq) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 237.25 121.80 Td (7) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 268.25 121.80 Td (6) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 121.80 Td (28%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 121.80 Td (13%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 121.80 Td (1) Tj ET Q q 0 0 0 rg BT 362.25 121.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 121.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 121.80 Td (\(34%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 121.80 Td (\(37%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 121.80 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 121.80 Td (19) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 529.10 121.80 Td (\(30%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 121.80 Td (\(31%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 111.80 Td (All other Peri-LOE Products) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 111.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 111.80 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 111.80 Td (1) Tj ET Q q 0 0 0 rg BT 287.35 111.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 111.80 Td (\(2%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 111.80 Td (14) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 111.80 Td (15) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 406.60 111.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 111.80 Td (\(15%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 111.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 513.50 111.80 Td (16) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 111.80 Td (\(3%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 561.00 111.80 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 101.92 Td (Biosimilars) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 76.75 105.32 Td (\(i\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 101.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 233.50 101.92 Td (99) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 101.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.50 101.92 Td (75) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 283.00 101.92 Td (31%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 314.50 101.92 Td (15%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 101.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 362.25 101.92 Td (4) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 101.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 394.25 101.92 Td (3) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 408.50 101.92 Td (41%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 439.50 101.92 Td (34%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 101.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 101.92 Td (16) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 101.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 517.25 101.92 Td (9) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 531.00 101.92 Td (71%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 561.00 101.92 Td (56%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 91.80 Td (Inflectra/Remsima) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 91.80 Td (75) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 91.80 Td (54) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 91.80 Td (39%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 315.10 91.80 Td (23%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 362.25 91.80 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 394.25 91.80 Td (3) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 409.10 91.80 Td (47%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 440.10 91.80 Td (40%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 483.50 91.80 Td (1) Tj ET Q q 0 0 0 rg BT 487.25 91.80 Td (1) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 91.80 Td (4) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 536.60 91.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 566.60 91.80 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 43.50 81.80 Td (All other Biosimilars) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 233.50 81.80 Td (24) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 264.50 81.80 Td (21) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 283.60 81.80 Td (1) Tj ET Q q 0 0 0 rg BT 287.35 81.80 Td (1%) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 314.50 81.80 Td (\(3%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 358.50 81.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 390.50 81.80 Td () Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 408.50 81.80 Td (\(8%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 437.60 81.80 Td (\(12%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 487.25 81.80 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 517.25 81.80 Td (5) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 531.00 81.80 Td (\(7%\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 559.10 81.80 Td (\(16%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 71.92 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 59.51 71.92 Td ( Centr) Tj ET Q q 0 0 0 rg BT 80.00 71.92 Td (eOne) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 96.66 75.32 Td (\(j\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 71.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 233.50 71.92 Td (24) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 71.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.50 71.92 Td (31) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 280.50 71.92 Td (\(22%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 71.92 Td (\(24%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 71.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 362.25 71.92 Td (2) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 71.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 394.25 71.92 Td (4) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 406.00 71.92 Td (\(38%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 71.92 Td (\(39%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 71.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 71.92 Td (49) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 71.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 513.50 71.92 Td (10) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 536.60 71.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 566.60 71.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 40.50 61.92 Td (Hospira Infusion Systems \(HIS\)) Tj ET Q BT /F2 7.50 Tf ET BT /F2 4.87 Tf ET q 0 0 0 rg BT 142.40 65.32 Td (\(k\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 61.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 233.50 61.92 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 61.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 268.25 61.92 Td (1) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 288.60 61.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 320.10 61.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 61.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 358.50 61.92 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 61.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 390.50 61.92 Td (12) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 414.10 61.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 445.10 61.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 61.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 61.92 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 61.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 513.50 61.92 Td (19) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 536.60 61.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 566.60 61.92 Td (*) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 51.92 Td (T) Tj ET Q q 0 0 0 rg BT 38.81 51.92 Td (otal L) Tj ET Q q 0 0 0 rg BT 57.36 51.92 Td (yrica) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 73.60 55.55 Td (\(c\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 51.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 233.50 51.92 Td (63) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 51.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 51.92 Td (1) Tj ET Q q 0 0 0 rg BT 264.50 51.92 Td (17) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 280.50 51.92 Td (\(46%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 51.92 Td (\(52%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 51.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 354.75 51.92 Td (169) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 51.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 386.75 51.92 Td (188) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 406.00 51.92 Td (\(10%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 437.00 51.92 Td (\(14%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 51.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 51.92 Td (74) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 51.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 513.50 51.92 Td (75) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 530.35 51.92 Td (\(1%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 560.35 51.92 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 41.92 Td (T) Tj ET Q q 0 0 0 rg BT 38.81 41.92 Td (otal ) Tj ET Q q 0 0 0 rg BT 52.64 41.92 Td (V) Tj ET Q q 0 0 0 rg BT 57.77 41.92 Td (iagra) Tj ET Q BT /F2 8.00 Tf ET BT /F2 5.20 Tf ET q 0 0 0 rg BT 74.44 45.55 Td (\(d\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 41.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 237.25 41.92 Td (9) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 41.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 264.50 41.92 Td (12) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 280.50 41.92 Td (\(20%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 312.00 41.92 Td (\(29%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 41.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 358.50 41.92 Td (16) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 41.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 390.50 41.92 Td (17) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 407.85 41.92 Td (\(5%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 438.85 41.92 Td (\(9%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 41.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 41.92 Td (73) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 41.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 513.50 41.92 Td (69) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 532.85 41.92 Td (7%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 562.85 41.92 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 34.50 31.92 Td (T) Tj ET Q q 0 0 0 rg BT 38.81 31.92 Td (otal ) Tj ET Q q 0 0 0 rg BT 52.36 31.92 Td (Alliance r) Tj ET Q q 0 0 0 rg BT 83.67 31.92 Td (evenues) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 215.50 31.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 229.75 31.92 Td (179) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 246.50 31.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 260.75 31.92 Td (1) Tj ET Q q 0 0 0 rg BT 264.50 31.92 Td (16) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 283.00 31.92 Td (54%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 314.50 31.92 Td (36%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 340.50 31.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 358.50 31.92 Td (73) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 371.50 31.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 390.50 31.92 Td (66) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 408.50 31.92 Td (1) Tj ET Q q 0 0 0 rg BT 412.25 31.92 Td (1%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 441.35 31.92 Td (7%) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 465.50 31.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 483.50 31.92 Td () Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 496.50 31.92 Td ($) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 514.75 31.92 Td (\(1) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 521.00 31.92 Td (\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 528.50 31.92 Td (\(73%\)) Tj ET Q BT /F2 7.50 Tf ET q 0 0 0 rg BT 558.50 31.92 Td (\(67%\)) Tj ET Q BT /F1 11.00 Tf ET endstream endobj 63 0 obj <> endobj 64 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 31.60 Td (- 31 -) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 283.75 743.50 Td (PFIZER INC.) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 222.95 733.90 Td (NOTES ) Tj ET Q q 0 0 0 rg BT 250.58 733.90 Td (T) Tj ET Q q 0 0 0 rg BT 255.32 733.90 Td (O REVENUES ) Tj ET Q q 0 0 0 rg BT 306.74 733.90 Td (T) Tj ET Q q 0 0 0 rg BT 310.98 733.90 Td (ABLE INFORMA) Tj ET Q q 0 0 0 rg BT 369.88 733.90 Td (TION) Tj ET Q BT /F1 8.00 Tf ET q 0 0 0 rg BT 279.75 724.30 Td (\(UNAUDITED\)) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 688.45 Td (\(a\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 688.10 Td (T) Tj ET Q q 0 0 0 rg BT 60.32 688.10 Td (otal International represents Developed Europe region + Developed Rest of ) Tj ET Q q 0 0 0 rg BT 288.32 688.10 Td (W) Tj ET Q q 0 0 0 rg BT 295.03 688.10 Td (orld region + Emer) Tj ET Q q 0 0 0 rg BT 352.00 688.10 Td (ging Markets region. Details for these regions are described in footnotes) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 679.10 Td (\(l\) to \(n\) below) Tj ET Q q 0 0 0 rg BT 101.37 679.10 Td (, respectively) Tj ET Q q 0 0 0 rg BT 140.87 679.10 Td (, and the product revenues from these regions are described on page 30.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 668.45 Td (\(b\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 668.10 Td (The Pfizer Innovative Health business encompasses Internal Medicine, ) Tj ET Q q 0 0 0 rg BT 270.67 668.10 Td (V) Tj ET Q q 0 0 0 rg BT 275.60 668.10 Td (accines, Oncology) Tj ET Q q 0 0 0 rg BT 330.34 668.10 Td (, Inflammation & Immunology) Tj ET Q q 0 0 0 rg BT 422.76 668.10 Td (, Rare Disease and Consumer Healthcare.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 656.45 Td (\(c\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 656.10 Td (L) Tj ET Q q 0 0 0 rg BT 60.37 656.10 Td (yrica revenues from all of Europe, Russia, ) Tj ET Q q 0 0 0 rg BT 188.60 656.10 Td (T) Tj ET Q q 0 0 0 rg BT 192.99 656.10 Td (urkey) Tj ET Q q 0 0 0 rg BT 209.69 656.10 Td (, Israel and Central ) Tj ET Q q 0 0 0 rg BT 268.17 656.10 Td (Asia countries are included in L) Tj ET Q q 0 0 0 rg BT 363.77 656.10 Td (yrica EH. ) Tj ET Q q 0 0 0 rg BT 393.97 656.10 Td (All other L) Tj ET Q q 0 0 0 rg BT 426.89 656.10 Td (yrica revenues are included in L) Tj ET Q q 0 0 0 rg BT 522.89 656.10 Td (yrica IH. ) Tj ET Q q 0 0 0 rg BT 551.14 656.10 Td (T) Tj ET Q q 0 0 0 rg BT 555.39 656.10 Td (otal) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 647.10 Td (L) Tj ET Q q 0 0 0 rg BT 60.37 647.10 Td (yrica revenues represent the aggregate of worldwide revenues from L) Tj ET Q q 0 0 0 rg BT 268.42 647.10 Td (yrica IH and L) Tj ET Q q 0 0 0 rg BT 311.94 647.10 Td (yrica EH.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 636.45 Td (\(d\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 636.10 Td (V) Tj ET Q q 0 0 0 rg BT 61.19 636.10 Td (iagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for ) Tj ET Q q 0 0 0 rg BT 317.10 636.10 Td (V) Tj ET Q q 0 0 0 rg BT 322.23 636.10 Td (iagra in the U.S. and Canada, which were reported in IH through 2017, are reported) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 627.10 Td (in EH \(which reported all other ) Tj ET Q q 0 0 0 rg BT 151.74 627.10 Td (V) Tj ET Q q 0 0 0 rg BT 156.86 627.10 Td (iagra revenues excluding the U.S. and Canada through 2017\). ) Tj ET Q q 0 0 0 rg BT 343.19 627.10 Td (Therefore, total ) Tj ET Q q 0 0 0 rg BT 391.57 627.10 Td (V) Tj ET Q q 0 0 0 rg BT 396.69 627.10 Td (iagra revenues in 2018 are reported in EH. ) Tj ET Q q 0 0 0 rg BT 525.73 627.10 Td (T) Tj ET Q q 0 0 0 rg BT 529.98 627.10 Td (otal ) Tj ET Q q 0 0 0 rg BT 542.77 627.10 Td (V) Tj ET Q q 0 0 0 rg BT 547.89 627.10 Td (iagra) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 618.10 Td (revenues in 2017 represent the aggregate of worldwide revenues from ) Tj ET Q q 0 0 0 rg BT 267.52 618.10 Td (V) Tj ET Q q 0 0 0 rg BT 272.65 618.10 Td (iagra IH and ) Tj ET Q q 0 0 0 rg BT 311.71 618.10 Td (V) Tj ET Q q 0 0 0 rg BT 316.84 618.10 Td (iagra EH.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 607.45 Td (\(e\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 607.10 Td (The Pfizer Essential Health business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 598.10 Td (Hospira Infusion Systems \(HIS\) \(through February 2, 2017\). On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS. ) Tj ET Q q 0 0 0 rg BT 515.04 598.10 Td (The operating) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 589.10 Td (results of HIS are included in EH) Tj ET Q q 0 0 0 rg BT 158.27 589.10 Td (s operating results through February 2, 2017 and, therefore, EH) Tj ET Q q 0 0 0 rg BT 350.73 589.10 Td (s operating results for first-quarter 2017 reflect approximately one month) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 580.10 Td (of legacy HIS domestic operations and approximately two months of legacy HIS international operations, while EH) Tj ET Q q 0 0 0 rg BT 405.72 580.10 Td (s operating results for first-quarter 2018 do not reflect) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 571.10 Td (any contribution from HIS global operations.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 559.45 Td (\(f\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 559.10 Td (Legacy Established Products primarily include products that have lost patent protection \(excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products\). In fourth-) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 550.10 Td (quarter 2017, we sold our equity share in Hisun Pfizer) Tj ET Q q 0 0 0 rg BT 218.26 550.10 Td (. ) Tj ET Q q 0 0 0 rg BT 221.60 550.10 Td (As a result, ef) Tj ET Q q 0 0 0 rg BT 262.98 550.10 Td (fective in first-quarter 2018, Hisun Pfizer) Tj ET Q q 0 0 0 rg BT 386.97 550.10 Td (-related revenues, previous reported in emer) Tj ET Q q 0 0 0 rg BT 519.27 550.10 Td (ging markets) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 541.10 Td (within ) Tj ET Q q 0 0 0 rg BT 76.84 541.10 Td (All Other LEP) Tj ET Q q 0 0 0 rg BT 120.24 541.10 Td ( and ) Tj ET Q q 0 0 0 rg BT 134.47 541.10 Td (All Other SIP) Tj ET Q q 0 0 0 rg BT 175.10 541.10 Td (, are reported in emer) Tj ET Q q 0 0 0 rg BT 238.96 541.10 Td (ging markets within Pfizer CentreOne.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 530.45 Td (\(g\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 530.10 Td (Sterile Injectable Pharmaceuticals includes branded and generic injectables \(excluding Peri-LOE Products\). In fourth-quarter 2017, we sold our equity share in Hisun Pfizer) Tj ET Q q 0 0 0 rg BT 572.10 530.10 Td (.) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 521.10 Td (As a result, ef) Tj ET Q q 0 0 0 rg BT 97.59 521.10 Td (fective in first-quarter 2018, Hisun Pfizer) Tj ET Q q 0 0 0 rg BT 221.58 521.10 Td (-related revenues, previous reported in emer) Tj ET Q q 0 0 0 rg BT 353.88 521.10 Td (ging markets within ) Tj ET Q q 0 0 0 rg BT 415.47 521.10 Td (All Other LEP) Tj ET Q q 0 0 0 rg BT 458.87 521.10 Td ( and ) Tj ET Q q 0 0 0 rg BT 473.11 521.10 Td (All Other SIP) Tj ET Q q 0 0 0 rg BT 513.74 521.10 Td (, are reported in) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 512.10 Td (emer) Tj ET Q q 0 0 0 rg BT 70.92 512.10 Td (ging markets within Pfizer CentreOne.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 501.45 Td (\(h\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 501.10 Td (Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. ) Tj ET Q q 0 0 0 rg BT 383.56 501.10 Td (These products primarily include: L) Tj ET Q q 0 0 0 rg BT 491.18 501.10 Td (yrica in Europe, Russia,) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 492.10 Td (T) Tj ET Q q 0 0 0 rg BT 60.45 492.10 Td (urkey) Tj ET Q q 0 0 0 rg BT 77.15 492.10 Td (, Israel and Central ) Tj ET Q q 0 0 0 rg BT 135.64 492.10 Td (Asia; worldwide revenues for Celebrex, Pristiq, Zyvox ) Tj ET Q q 0 0 0 rg BT 301.79 492.10 Td (Vfend, Revatio and Inspra; and beginning in 2018, ) Tj ET Q q 0 0 0 rg BT 455.79 492.10 Td (V) Tj ET Q q 0 0 0 rg BT 460.92 492.10 Td (iagra revenues for all countries \(and) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 483.10 Td (V) Tj ET Q q 0 0 0 rg BT 61.19 483.10 Td (iagra revenues for all countries other than the U.S. and Canada in 2017, see note \(d\) above\).) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 471.45 Td (\(i\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 471.10 Td (Biosimilars includes Inflectra/Remsima \(biosimilar infliximab\) in the U.S. and certain international markets, Nivestim \(biosimilar filgrastim\) in certain European, ) Tj ET Q q 0 0 0 rg BT 543.61 471.10 Td (Asian and) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 462.10 Td (Africa/Middle Eastern markets and Retacrit \(biosimilar epoetin zeta\) in certain European and ) Tj ET Q q 0 0 0 rg BT 337.36 462.10 Td (Africa/Middle Eastern markets.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 451.45 Td (\(j\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 451.10 Td (Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 442.10 Td (manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In fourth-quarter 2017, we sold our equity share in Hisun) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 433.10 Td (Pfizer) Tj ET Q q 0 0 0 rg BT 73.70 433.10 Td (. ) Tj ET Q q 0 0 0 rg BT 77.04 433.10 Td (As a result, ef) Tj ET Q q 0 0 0 rg BT 118.42 433.10 Td (fective in first-quarter 2018, Hisun Pfizer) Tj ET Q q 0 0 0 rg BT 242.41 433.10 Td (-related revenues, previous reported in emer) Tj ET Q q 0 0 0 rg BT 374.71 433.10 Td (ging markets within ) Tj ET Q q 0 0 0 rg BT 436.31 433.10 Td (All Other LEP) Tj ET Q q 0 0 0 rg BT 479.71 433.10 Td ( and ) Tj ET Q q 0 0 0 rg BT 493.94 433.10 Td (All Other SIP) Tj ET Q q 0 0 0 rg BT 534.57 433.10 Td (, are reported) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 424.10 Td (in emer) Tj ET Q q 0 0 0 rg BT 78.63 424.10 Td (ging markets within Pfizer CentreOne.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 413.45 Td (\(k\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 413.10 Td (HIS \(through February 2, 2017\) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV) Tj ET Q q 0 0 0 rg BT 542.85 413.10 Td ( Infusion) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 405.60 Td (Products, including lar) Tj ET Q q 0 0 0 rg BT 123.98 405.60 Td (ge volume IV) Tj ET Q q 0 0 0 rg BT 165.09 405.60 Td ( solutions and their associated administration sets.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 394.45 Td (\(l\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 394.10 Td (Developed Europe region includes the following markets: ) Tj ET Q q 0 0 0 rg BT 231.45 394.10 Td (W) Tj ET Q q 0 0 0 rg BT 237.93 394.10 Td (estern Europe, Scandinavian countries and Finland.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 383.45 Td (\(m\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 383.10 Td (Developed Rest of ) Tj ET Q q 0 0 0 rg BT 113.56 383.10 Td (W) Tj ET Q q 0 0 0 rg BT 120.04 383.10 Td (orld region includes the following markets: Japan, Canada, ) Tj ET Q q 0 0 0 rg BT 298.33 383.10 Td (Australia, South Korea and New Zealand.) Tj ET Q BT /F1 7.00 Tf ET q 0 0 0 rg BT 39.00 372.45 Td (\(n\)) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 372.10 Td (Emer) Tj ET Q q 0 0 0 rg BT 72.11 372.10 Td (ging Markets region includes, but is not limited to, the following markets: ) Tj ET Q q 0 0 0 rg BT 295.42 372.10 Td (Asia \(excluding Japan and South Korea\), Latin ) Tj ET Q q 0 0 0 rg BT 437.89 372.10 Td (America, Eastern Europe, ) Tj ET Q q 0 0 0 rg BT 516.82 372.10 Td (Africa, the Middle) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 363.10 Td (East, Central Europe and ) Tj ET Q q 0 0 0 rg BT 132.72 363.10 Td (T) Tj ET Q q 0 0 0 rg BT 137.03 363.10 Td (urkey) Tj ET Q q 0 0 0 rg BT 153.62 363.10 Td (.) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 39.00 352.10 Td (*) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 352.10 Td (Indicates calculation not meaningful or result is equal to or greater than 100%.) Tj ET Q BT /F1 7.50 Tf ET q 0 0 0 rg BT 56.00 341.10 Td (Amounts may not add due to rounding. ) Tj ET Q q 0 0 0 rg BT 175.16 341.10 Td (All percentages have been calculated using unrounded amounts.) Tj ET Q BT /F1 11.00 Tf ET endstream endobj 65 0 obj <> endobj 66 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 31.60 Td (- 32 -) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 742.10 Td (DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this earnings release and the related ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 730.10 Td (attachments is as of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 144.09 730.10 Td (May1, 2018) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 194.92 730.10 Td (. ) Tj ET Q q 0 0 0 rg BT 199.74 730.10 Td (W) Tj ET Q q 0 0 0 rg BT 208.38 730.10 Td (e assume no obligation to update any forward-looking statements contained in this ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 718.10 Td (earnings release and the related attachments as a result of new information or future events or developments.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 700.10 Td (This earnings release and the related attachments contain forward-looking statements about our anticipated future operating ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 688.10 Td (and financial performance, business plans and prospects, in-line products and product candidates, including anticipated ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 676.10 Td (regulatory submissions, data read-outs, approvals, performance, timing of exclusivity and potential benefits of Pfizer) Tj ET Q q 0 0 0 rg BT 530.74 676.10 Td () Tj ET Q q 0 0 0 rg BT 533.52 676.10 Td (s ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 664.10 Td (products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 652.10 Td (from our acquisitions and other business development activities, manufacturing and product supply and plans relating to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 640.10 Td (share repurchases and dividends, among other things, that involve substantial risks and uncertainties.) Tj ET Q q 0 0 0 rg BT 468.64 640.10 Td (Y) Tj ET Q q 0 0 0 rg BT 474.87 640.10 Td (ou can identify these ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 628.10 Td (statements by the fact that they use future dates or use words such as will, may) Tj ET Q q 0 0 0 rg BT 390.58 628.10 Td (, could, likely) Tj ET Q q 0 0 0 rg BT 462.68 628.10 Td (, ongoing, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 616.10 Td (anticipate, estimate, expect, project, intend, plan, believe, assume, tar) Tj ET Q q 0 0 0 rg BT 415.39 616.10 Td (get, forecast, guidance, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 604.10 Td (goal, objective, aim and other words and terms of similar meaning. ) Tj ET Q q 0 0 0 rg BT 359.56 604.10 Td (Among the factors that could cause actual results ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 592.10 Td (to dif) Tj ET Q q 0 0 0 rg BT 84.21 592.10 Td (fer materially from past results and future plans and projected future results are the following:) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 572.94 cm /I45 Do Q q 0 0 0 rg BT 67.00 575.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 575.10 Td (the outcome of research and development activities, including, without limitation, the ability to meet anticipated pre-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 563.10 Td (clinical and clinical trial commencement and completion dates, regulatory submission and approval dates, and launch ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 551.10 Td (dates for product candidates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 539.10 Td (unfavorable new clinical data and additional analyses of existing clinical data;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 519.94 cm /I46 Do Q q 0 0 0 rg BT 67.00 522.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 522.10 Td (decisions by regulatory authorities regarding whether and when to approve our drug applications, which will depend ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 510.10 Td (on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the ef) Tj ET Q q 0 0 0 rg BT 513.21 510.10 Td (ficacy and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 498.10 Td (safety information submitted; decisions by regulatory authorities regarding labeling, ingredients and other matters that ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 486.10 Td (could af) Tj ET Q q 0 0 0 rg BT 113.30 486.10 Td (fect the availability or commercial potential of our products; and uncertainties regarding our ability to address ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 474.10 Td (the comments received by us from regulatory authorities such as the U.S. Food and Drug ) Tj ET Q q 0 0 0 rg BT 438.98 474.10 Td (Administration \(FDA\) and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 462.10 Td (the European Medicines ) Tj ET Q q 0 0 0 rg BT 180.14 462.10 Td (Agency with respect to certain of our drug applications to the satisfaction of those authorities;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 442.94 cm /I47 Do Q q 0 0 0 rg BT 67.00 445.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 445.10 Td (the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 425.94 cm /I48 Do Q q 0 0 0 rg BT 67.00 428.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 428.10 Td (the outcome of post-approval clinical trials, which could result in the loss of marketing approval for a product or ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 416.10 Td (changes in the labeling for) Tj ET Q q 0 0 0 rg BT 186.67 416.10 Td (, and/or increased or new concerns about the safety or ef) Tj ET Q q 0 0 0 rg BT 412.23 416.10 Td (ficacy of, a product that could af) Tj ET Q q 0 0 0 rg BT 542.27 416.10 Td (fect ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 404.10 Td (its availability or commercial potential;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 384.94 cm /I49 Do Q q 0 0 0 rg BT 67.00 387.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 387.10 Td (risks associated with preliminary) Tj ET Q q 0 0 0 rg BT 212.26 387.10 Td (, early stage or interim data, including the risk that final results of studies for which ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 375.10 Td (preliminary) Tj ET Q q 0 0 0 rg BT 127.00 375.10 Td (, early stage or interim data have been provided and/or additional clinical trials may be dif) Tj ET Q q 0 0 0 rg BT 487.25 375.10 Td (ferent from ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 363.10 Td (\(including less favorable than\) the preliminary) Tj ET Q q 0 0 0 rg BT 266.12 363.10 Td (, early stage or interim data results and may not support further clinical ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 351.10 Td (development of the applicable product candidate or indication;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 331.94 cm /I50 Do Q q 0 0 0 rg BT 67.00 334.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 334.10 Td (the success of external business-development activities, including the ability to satisfy the conditions to closing of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 322.10 Td (announced transactions in the anticipated time frame or at all or to realize the anticipated benefits of such transactions;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 302.94 cm /I51 Do Q q 0 0 0 rg BT 67.00 305.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 305.10 Td (competitive developments, including the impact on our competitive position of new product entrants, in-line branded ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 293.10 Td (products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 281.10 Td (similar to those treated by our in-line drugs and drug candidates;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 261.94 cm /I52 Do Q q 0 0 0 rg BT 67.00 264.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 264.10 Td (the implementation by the FDA) Tj ET Q q 0 0 0 rg BT 207.65 264.10 Td ( and regulatory authorities in certain other countries of an abbreviated legal pathway to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 252.10 Td (approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 240.10 Td (attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 220.94 cm /I53 Do Q q 0 0 0 rg BT 67.00 223.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 223.10 Td (risks related to our ability to develop and launch biosimilars, including risks associated with at risk launches, defined ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 211.10 Td (as the marketing of a product by Pfizer before the final resolution of litigation \(including any appeals\) brought by a ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 199.10 Td (third party alleging that such marketing would infringe one or more patents owned or controlled by the third party;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 179.94 cm /I54 Do Q q 0 0 0 rg BT 67.00 182.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 182.10 Td (the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 170.10 Td (protection for our products or competitor products;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 150.94 cm /I55 Do Q q 0 0 0 rg BT 67.00 153.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 153.10 Td (the ability to successfully market both new and existing products domestically and internationally;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 133.94 cm /I56 Do Q q 0 0 0 rg BT 67.00 136.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 136.10 Td (dif) Tj ET Q q 0 0 0 rg BT 91.93 136.10 Td (ficulties or delays in manufacturing, including delays caused by natural events, such as hurricanes; supply shortages ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 124.10 Td (at our facilities; and legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 112.10 Td (product, debarment, injunctions or voluntary recall of a product;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 92.94 cm /I57 Do Q q 0 0 0 rg BT 67.00 95.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 95.10 Td (trade buying patterns;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 75.94 cm /I58 Do Q q 0 0 0 rg BT 67.00 78.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 78.10 Td (the impact of existing and future legislation and regulatory provisions on product exclusivity;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 58.94 cm /I59 Do Q q 0 0 0 rg BT 67.00 61.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 61.10 Td (trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 49.10 Td (pricing or formulary placement for our products;) Tj ET Q endstream endobj 67 0 obj <> endobj 68 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 31.60 Td (- 33 -) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 739.94 cm /I60 Do Q q 0 0 0 rg BT 67.00 742.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 742.10 Td (the impact of any significant spending reductions or cost controls af) Tj ET Q q 0 0 0 rg BT 352.42 742.10 Td (fecting Medicare, Medicaid or other publicly ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 730.10 Td (funded or subsidized health programs or changes in the tax treatment of employer) Tj ET Q q 0 0 0 rg BT 407.92 730.10 Td (-sponsored health insurance that may ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 718.10 Td (be implemented;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 698.94 cm /I61 Do Q q 0 0 0 rg BT 67.00 701.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 701.10 Td (the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 689.10 Td (of some or all of the provisions of the U.S. Patient Protection and ) Tj ET Q q 0 0 0 rg BT 344.57 689.10 Td (Af) Tj ET Q q 0 0 0 rg BT 354.95 689.10 Td (fordable Care ) Tj ET Q q 0 0 0 rg BT 411.59 689.10 Td (Act, as amended by the Health Care ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 677.10 Td (and Education Reconciliation ) Tj ET Q q 0 0 0 rg BT 201.24 677.10 Td (Act;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 657.94 cm /I62 Do Q q 0 0 0 rg BT 67.00 660.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 660.10 Td (U.S. federal or state legislation or regulatory action and/or policy ef) Tj ET Q q 0 0 0 rg BT 351.84 660.10 Td (forts af) Tj ET Q q 0 0 0 rg BT 380.26 660.10 Td (fecting, among other things, pharmaceutical ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 648.10 Td (product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 636.10 Td (subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases that ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 624.10 Td (could result in new mandatory rebates and discounts or other pricing restrictions; the importation of prescription drugs ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 612.10 Td (from outside the U.S. at prices that are regulated by governments of various foreign countries; restrictions on direct-to-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 600.10 Td (consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative ef) Tj ET Q q 0 0 0 rg BT 512.64 600.10 Td (fectiveness ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 588.10 Td (methodologies that could be implemented in a manner that focuses primarily on the cost dif) Tj ET Q q 0 0 0 rg BT 447.39 588.10 Td (ferences and minimizes the ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 576.10 Td (therapeutic dif) Tj ET Q q 0 0 0 rg BT 138.85 576.10 Td (ferences among pharmaceutical products and restricts access to innovative medicines; as well as pricing ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 564.10 Td (pressures for our products as a result of highly competitive insurance markets;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 544.94 cm /I63 Do Q q 0 0 0 rg BT 67.00 547.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 547.10 Td (legislation or regulatory action in markets outside the U.S. af) Tj ET Q q 0 0 0 rg BT 324.93 547.10 Td (fecting pharmaceutical product pricing, reimbursement or ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 535.10 Td (access, including, in particular) Tj ET Q q 0 0 0 rg BT 202.50 535.10 Td (, continued government-mandated reductions in prices and access restrictions for certain ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 523.10 Td (biopharmaceutical products to control costs in those markets;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 503.94 cm /I64 Do Q q 0 0 0 rg BT 67.00 506.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 506.10 Td (the exposure of our operations outside the U.S. to possible capital and exchange controls, expropriation and other ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 494.10 Td (restrictive government actions, changes in intellectual property legal protections and remedies, as well as political ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 482.10 Td (unrest, unstable governments and legal systems and inter) Tj ET Q q 0 0 0 rg BT 308.52 482.10 Td (-governmental disputes;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 462.94 cm /I65 Do Q q 0 0 0 rg BT 67.00 465.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 465.10 Td (contingencies related to actual or alleged environmental contamination;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 445.94 cm /I66 Do Q q 0 0 0 rg BT 67.00 448.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 448.10 Td (claims and concerns that may arise regarding the safety or ef) Tj ET Q q 0 0 0 rg BT 323.50 448.10 Td (ficacy of in-line products and product candidates;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 428.94 cm /I67 Do Q q 0 0 0 rg BT 67.00 431.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 431.10 Td (any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 411.94 cm /I68 Do Q q 0 0 0 rg BT 67.00 414.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 414.10 Td (legal defense costs, insurance expenses and settlement costs; ) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 394.94 cm /I69 Do Q q 0 0 0 rg BT 67.00 397.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 397.10 Td (the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 385.10 Td (litigation, product liability and other product-related litigation, including personal injury) Tj ET Q q 0 0 0 rg BT 433.32 385.10 Td (, consumer) Tj ET Q q 0 0 0 rg BT 476.80 385.10 Td (, of) Tj ET Q q 0 0 0 rg BT 489.95 385.10 Td (f-label ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 373.10 Td (promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 361.10 Td (employment and other legal proceedings, including various means for resolving asbestos litigation, as well as tax ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 349.10 Td (issues;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 329.94 cm /I70 Do Q q 0 0 0 rg BT 67.00 332.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 332.10 Td (the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 320.10 Td (timely basis, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 303.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 303.10 Td (our ability to protect our patents and other intellectual property) Tj ET Q q 0 0 0 rg BT 332.22 303.10 Td (, both domestically and internationally;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 283.94 cm /I71 Do Q q 0 0 0 rg BT 67.00 286.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 286.10 Td (interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 274.10 Td (countries experiencing high inflation rates;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 254.94 cm /I72 Do Q q 0 0 0 rg BT 67.00 257.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 257.10 Td (governmental laws and regulations af) Tj ET Q q 0 0 0 rg BT 230.77 257.10 Td (fecting domestic and foreign operations, including, without limitation, tax ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 245.10 Td (obligations and changes af) Tj ET Q q 0 0 0 rg BT 187.18 245.10 Td (fecting the tax treatment by the U.S. of income earned outside the U.S. that may result from ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 233.10 Td (pending and possible future proposals, including further clarifications and/or interpretations of the recently passed ) Tj ET Q q 0 0 0 rg BT 539.85 233.10 Td (T) Tj ET Q q 0 0 0 rg BT 545.26 233.10 Td (ax ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 221.10 Td (Cuts and Jobs ) Tj ET Q q 0 0 0 rg BT 138.51 221.10 Td (Act;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 201.94 cm /I73 Do Q q 0 0 0 rg BT 67.00 204.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 204.10 Td (any significant issues involving our lar) Tj ET Q q 0 0 0 rg BT 236.07 204.10 Td (gest wholesale distributors, which account for a substantial portion of our ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 192.10 Td (revenues;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 172.94 cm /I74 Do Q q 0 0 0 rg BT 67.00 175.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 175.10 Td (the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 163.10 Td (revenues and on patient confidence in the integrity of our medicines;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 143.94 cm /I75 Do Q q 0 0 0 rg BT 67.00 146.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 146.10 Td (the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.) Tj ET Q q 0 0 0 rg BT 514.76 146.10 Td (s exit ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 134.10 Td (from the EU, which could have implications on our research, commercial and general business operations in the U.K. ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 122.10 Td (and the EU, including the approval and supply of our products; ) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 102.94 cm /I76 Do Q q 0 0 0 rg BT 67.00 105.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 105.10 Td (any significant issues that may arise related to the outsourcing of certain operational and staf) Tj ET Q q 0 0 0 rg BT 451.25 105.10 Td (f functions to third parties, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 93.10 Td (including with regard to quality) Tj ET Q q 0 0 0 rg BT 206.99 93.10 Td (, timeliness and compliance with applicable legal requirements and industry standards;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 73.94 cm /I77 Do Q q 0 0 0 rg BT 67.00 76.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 76.10 Td (any significant issues that may arise related to our joint ventures and other third-party business arrangements;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 56.94 cm /I78 Do Q q 0 0 0 rg BT 67.00 59.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 59.10 Td (changes in U.S. generally accepted accounting principles;) Tj ET Q endstream endobj 69 0 obj <> endobj 70 0 obj <> stream BT /F1 10.00 Tf ET q 0 0 0 rg BT 295.15 31.60 Td (- 34 -) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 739.94 cm /I79 Do Q q 0 0 0 rg BT 67.00 742.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 742.10 Td (further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 730.10 Td (regulations, in the U.S. and other countries;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 710.94 cm /I80 Do Q q 0 0 0 rg BT 67.00 713.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 713.10 Td (uncertainties related to general economic, political, business, industry) Tj ET Q q 0 0 0 rg BT 359.15 713.10 Td (, regulatory and market conditions including, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 701.10 Td (without limitation, uncertainties related to the impact on Pfizer) Tj ET Q q 0 0 0 rg BT 331.92 701.10 Td (, our customers, suppliers and lenders and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 689.10 Td (counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 677.10 Td (recent and possible future changes in global financial markets; the related risk that our allowance for doubtful accounts ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 665.10 Td (may not be adequate; and the risks related to volatility of our income due to changes in the market value of equity ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 653.10 Td (investments;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 633.94 cm /I81 Do Q q 0 0 0 rg BT 67.00 636.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 636.10 Td (any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 624.10 Td (other parts of the world, and related U.S. military action overseas;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 604.94 cm /I82 Do Q q 0 0 0 rg BT 67.00 607.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 607.10 Td (growth in costs and expenses;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 587.94 cm /I83 Do Q q 0 0 0 rg BT 67.00 590.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 590.10 Td (changes in our product, segment and geographic mix; ) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 570.94 cm /I84 Do Q q 0 0 0 rg BT 67.00 573.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 573.10 Td (the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 561.10 Td (significant items;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 541.94 cm /I85 Do Q q 0 0 0 rg BT 67.00 544.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 544.10 Td (the impact of acquisitions, divestitures, restructurings, internal reor) Tj ET Q q 0 0 0 rg BT 349.08 544.10 Td (ganizations, product recalls, withdrawals and other ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 532.10 Td (unusual items, including our ability to realize the projected benefits of our cost-reduction and productivity initiatives ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 520.10 Td (and of the internal separation of our commercial operations into our current operating structure; ) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 500.94 cm /I86 Do Q q 0 0 0 rg BT 67.00 503.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 503.10 Td (the risk of an impairment char) Tj ET Q q 0 0 0 rg BT 201.61 503.10 Td (ge related to our intangible assets, goodwill or equity-method investments;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 483.94 cm /I87 Do Q q 0 0 0 rg BT 67.00 486.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 486.10 Td (risks related to internal control over financial reporting;) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 466.94 cm /I88 Do Q q 0 0 0 rg BT 67.00 469.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 469.10 Td (risks and uncertainties related to our acquisitions of Hospira, Inc. \(Hospira\), ) Tj ET Q q 0 0 0 rg BT 387.03 469.10 Td (Anacor Pharmaceuticals, Inc. \(Anacor\), ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 457.10 Td (Medivation, Inc. \(Medivation\) and ) Tj ET Q q 0 0 0 rg BT 221.52 457.10 Td (AstraZeneca) Tj ET Q q 0 0 0 rg BT 274.82 457.10 Td (s small molecule anti-infectives business, including, among other ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 445.10 Td (things, the ability to realize the anticipated benefits of those acquisitions, including the possibility that expected cost ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 433.10 Td (savings related to the acquisition of Hospira and accretion related to the acquisitions of Hospira, ) Tj ET Q q 0 0 0 rg BT 467.56 433.10 Td (Anacor and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 421.10 Td (Medivation will not be realized or will not be realized within the expected time frame; the risk that the businesses will ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 409.10 Td (not be integrated successfully; disruption from the transactions making it more dif) Tj ET Q q 0 0 0 rg BT 409.35 409.10 Td (ficult to maintain business and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 397.10 Td (operational relationships; risks related to our ability to grow revenues for Xtandi and expand Xtandi into the non-) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 385.10 Td (metastatic castration-resistant prostate cancer setting; significant transaction costs; and unknown liabilities; and) Tj ET Q BT /F1 10.00 Tf ET /GS0 gs q 4.00 0 0 10.09 63.00 365.94 cm /I89 Do Q q 0 0 0 rg BT 67.00 368.10 Td ( ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 368.10 Td (risks and uncertainties related to our evaluation of strategic alternatives for our Consumer Healthcare business, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 356.10 Td (including, among other things, the ability to realize the anticipated benefits of any strategic alternatives we may pursue ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 344.10 Td (for our Consumer Healthcare business, the potential for disruption to our business and diversion of management) Tj ET Q q 0 0 0 rg BT 532.57 344.10 Td (s ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 332.10 Td (attention from other aspects of our business, the possibility that such strategic alternatives will not be completed on ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 320.10 Td (terms that are advantageous to Pfizer) Tj ET Q q 0 0 0 rg BT 228.60 320.10 Td (, the possibility that we may be unable to realize a higher value for Pfizer ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 81.00 308.10 Td (Consumer Healthcare through strategic alternatives and unknown liabilities.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 291.10 Td (W) Tj ET Q q 0 0 0 rg BT 71.64 291.10 Td (e cannot guarantee that any forward-looking statement will be realized. ) Tj ET Q q 0 0 0 rg BT 358.47 291.10 Td (Achievement of anticipated results is subject to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 279.10 Td (substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 267.10 Td (should underlying assumptions prove inaccurate, actual results could vary materially from past results and those ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 255.10 Td (anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 243.10 Td (cautioned not to put undue reliance on forward-looking statements. ) Tj ET Q q 0 0 0 rg BT 333.48 243.10 Td (A) Tj ET Q q 0 0 0 rg BT 340.15 243.10 Td ( further list and description of risks, uncertainties and ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 231.10 Td (other matters can be found in our ) Tj ET Q q 0 0 0 rg BT 197.68 231.10 Td (Annual Report on Form 10-K for the fiscal year ended ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 418.18 231.10 Td (December31, 2017) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 496.76 231.10 Td ( and in our ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 219.10 Td (subsequent reports on Form 10-Q, in each case including in the sections thereof captioned Forward-Looking Information ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 207.10 Td (and Factors ) Tj ET Q q 0 0 0 rg BT 111.70 207.10 Td (That May ) Tj ET Q q 0 0 0 rg BT 152.80 207.10 Td (Af) Tj ET Q q 0 0 0 rg BT 163.17 207.10 Td (fect Future Results and Item 1A. Risk Factors, and in our subsequent reports on Form 8-K.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 190.10 Td (The operating segment information provided in this earnings release and the related attachments does not purport to ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 178.10 Td (represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 166.10 Td (operating segments would have recorded had each segment operated as a standalone company during the periods ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 154.10 Td (presented.) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 137.10 Td (This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 125.10 Td (candidates. ) Tj ET Q q 0 0 0 rg BT 110.02 125.10 Td (These studies typically are part of a lar) Tj ET Q q 0 0 0 rg BT 265.06 125.10 Td (ger body of clinical data relating to such products or product candidates, ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 113.10 Td (and the discussion herein should be considered in the context of the lar) Tj ET Q q 0 0 0 rg BT 346.08 113.10 Td (ger body of data. In addition, clinical trial data are ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 101.10 Td (subject to dif) Tj ET Q q 0 0 0 rg BT 115.03 101.10 Td (fering interpretations, and, even when we view data as suf) Tj ET Q q 0 0 0 rg BT 347.27 101.10 Td (ficient to support the safety and/or ef) Tj ET Q q 0 0 0 rg BT 494.82 101.10 Td (fectiveness of a ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 89.10 Td (product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may ) Tj ET Q BT /F1 10.00 Tf ET q 0 0 0 rg BT 63.00 77.10 Td (require additional data or may deny approval altogether) Tj ET Q q 0 0 0 rg BT 284.86 77.10 Td (.) Tj ET Q endstream endobj 71 0 obj <> /View <>>>>> endobj 72 0 obj <> /View <>>>>> endobj 73 0 obj <> endobj 74 0 obj <> stream xy\E7~n{{w'd'52 HaGPPA!"" b-&h,+TLy?:uk?uΩoH""?W~.Xv3&rm 2\jMgwm'CڴzlycǏ\ rBjx\DsV@{twocmC{Iwl11z:1m!t-\q3D.:yz'Wɨp[_F=>E"ǢӦ/|K&_~=!wn-az3¦h$7,ؑ2Oo_eSFLlk}Fg[F>|;